pert_iname	classes
goserelin	hormones, hormone substitutes, and hormone antagonists|amino acids, peptides, and proteins|antineoplastic and immunomodulating agents|adrenal cortex hormones|miscellaneous therapeutic agents|antineoplastic agents|drugs that are mainly renally excreted|gonadotropin releasing hormone receptor agonists|gonadotropin releasing hormone agonist|peptides|gonadotropins and antigonadotropins|hormones and related agents|antineoplastic agents, hormonal|qtc prolonging agents|peptide hormones|hypothalamic hormones|hyperglycemia associated agents|oligopeptides|moderate risk qtc prolonging agents|neuropeptides|gonadotropin releasing hormone receptor agonist|nerve tissue proteins|pituitary hormone releasing hormones|endocrine therapy|hormones|proteins
cyclosporin a	amino acids, peptides, and proteins|oatp1b3 inhibitors|bcrp/abcg2 inhibitors|agents that produce neuromuscular block (indirect)|ophthalmologicals|cytochrome p 450 cyp3a4 substrates|calcineurin inhibitor immunosuppressant|nephrotoxic agents|p glycoprotein inhibitors|oat1/slc22a6 substrates|p glycoprotein substrates|peptides|agents that produce hypertension|oatp1b1/slco1b1 inhibitors|cytochrome p 450 cyp2d6 inhibitors|oatp1b1/slco1b1 substrates|cyclosporins|agents that reduce seizure threshold|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|calcineurin inhibitors|anti inflammatory agents|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a4 inhibitors (moderate)|peptides, cyclic|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|bsep/abcb11 substrates with a narrow therapeutic index|enzyme inhibitors|oat1/slc22a6 inhibitors|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|antirheumatic agents|immunosuppressive agents|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2d6 inhibitors (moderate)|cytochrome p 450 cyp3a5 substrates|neurotoxic agents|dermatologicals|agents causing hyperkalemia|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|bsep/abcb11 substrates|bsep/abcb11 inhibitors|immunologic factors
pdgfb	amino acids, peptides, and proteins|neoplasm proteins|acids|phosphoric acids|stomatological preparations|angiogenesis modulating agents|phosphorus acids|dna binding proteins|calcium compounds|electrolytes|ions|peptides|anions|proto oncogene proteins|cicatrizants|angiogenesis inducing agents|preparations for treatment of wounds and ulcers|human platelet derived growth factor|hematologic agents|intercellular signaling peptides and proteins|acids, noncarboxylic|biological factors|platelet derived growth factor|growth substances|blood proteins|dermatologicals|alimentary tract and metabolism|proto oncogene proteins c sis|oncogene proteins|proteins|phosphorus compounds
cyanocobalamin	growth substances|vitamin b12 and folic acid|iron preparations|antianemic preparations|heterocyclic compounds, fused ring|micronutrients|corrinoids|drugs that are mainly renally excreted|vitamin b 12, biosynthesis|food|vitamin b complex|diet, food, and nutrition|blood and blood forming organs|vitamins|food and beverages
biotin	vitamins|growth substances|supplements|enzymes and coenzymes|imidazoles|alimentary tract and metabolism|micronutrients|coenzymes|food|vitamin b complex|diet, food, and nutrition|dietary supplements|food and beverages|physiological phenomena
ascorbic acid	acids, acyclic|carbohydrates|micronutrients|ophthalmologicals|food|vitamin c and analogues|food and beverages|organic acids|gastrointestinal acidifying agents|protective agents|sugar acids|gynecological antiinfectives and antiseptics|diet, food, and nutrition|physiological phenomena|antioxidants|growth substances|compounds used in a research, industrial, or household setting|hydroxy acids|alimentary tract and metabolism|genito urinary system and sex hormones|sensory organs|urinary acidifying agents|vitamins
glutamine	amino acids, peptides, and proteins|supplements|amino acids and derivatives|amino acids, neutral|alimentary tract and metabolism|amino acids, diamino|amino acids|amino acids, basic|glutamine|dietary supplements
adenosine phosphate	carbohydrates|supplements|nucleotides|purine nucleotides|ribonucleotides|heterocyclic compounds, fused ring|glycosides|purines|nucleic acids, nucleotides, and nucleosides|adenine nucleotides|dietary supplements
alpha linolenic acid	dietary fats, unsaturated|linolenic acids|supplements|fatty acids, essential|dietary fats|fatty acids, omega 3|fatty acids|fish oils|lipids|food|oils|fats|diet, food, and nutrition|dietary supplements|fatty acids, unsaturated|food and beverages|physiological phenomena
met	amino acids, peptides, and proteins|supplements|amino acids, neutral|antidotes|amino acids, sulfur|amino acids|sulfur compounds|dietary supplements|amino acids, essential
calcitriol	antipsoriatics|membrane transport modulators|micronutrients|calcium regulating hormones and agents|food|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|food and beverages|cholestenes|antipsoriatics for topical use|vitamin d and analogues|vitamins (fat soluble)|cytochrome p 450 substrates|cytochrome p 450 cyp3a inducers|diet, food, and nutrition|bone density conservation agents|vitamins|physiological phenomena|growth substances|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|alimentary tract and metabolism|steroids|lipids|cholestanes|misc. skin and mucous membrane agents|secosteroids|sterols|membrane lipids
riboflavin	micronutrients|ophthalmologicals|food|food and beverages|photosensitizing agents|pteridines|flavins|enzymes and coenzymes|oat1/slc22a6 inhibitors|coenzymes|pigments, biological|vitamin b complex|diet, food, and nutrition|heterocyclic compounds, fused ring|biological factors|physiological phenomena|growth substances|radiation sensitizing agents|dermatologicals|alimentary tract and metabolism|sensory organs|vitamins
calcifediol	micronutrients|food|fused ring compounds|food and beverages|cholestenes|vitamin d and analogues|vitamins (fat soluble)|diet, food, and nutrition|bone density conservation agents|physiological phenomena|growth substances|steroids|alimentary tract and metabolism|lipids|cholestanes|vitamins|secosteroids|sterols|membrane lipids
tryptophan	amino acids, aromatic|amino acids, peptides, and proteins|nervous system|supplements|amino acids, cyclic|antidepressive agents, second generation|miscellaneous antidepressants|psychoanaleptics|central nervous system agents|psychotropic drugs|serotonergic drugs shown to increase risk of serotonin syndrome|tryptophan|amino acids|central nervous system depressants|antidepressive agents|dietary supplements|amino acids, essential
thiamine	growth substances|thiazoles|alimentary tract and metabolism|micronutrients|pyrimidines|sulfur compounds|oct2 inhibitors|oct1 substrates|food|vitamin b complex|diet, food, and nutrition|vitamins|food and beverages|physiological phenomena
dihomo gamma linolenic acid	supplements|eicosanoids|biological factors|fatty acids|inflammation mediators|lipids|dietary supplements|fatty acids, unsaturated|autacoids
cit	acids, acyclic|amino acids, peptides, and proteins|supplements|hydroxy acids|oat1/slc22a6 substrates|amino acids, diamino|amino acids|proteins|dicarboxylic acids|dietary supplements|oat3/slc22a8 substrates
folic acid	vitamin b12 and folic acid|diagnostic agents|micronutrients|drugs that are mainly renally excreted|food|dietary supplements|food and beverages|supplements|pterins|pteridines|hematinics|bcrp/abcg2 substrates|autacoids|folic acid and derivatives|hematologic agents|oat1/slc22a6 inhibitors|vitamin b complex|diet, food, and nutrition|biological factors|heterocyclic compounds, fused ring|growth substances|antianemic preparations|vitamins
icosapent	dietary fats, unsaturated|fatty acids, omega 3|anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|fish oils|food|oils|dietary supplements|food and beverages|nephrotoxic agents|supplements|dietary fats|fatty acids|agents that produce hypertension|non cox 2 selective nsaids|autacoids|anti inflammatory agents|fats|diet, food, and nutrition|biological factors|physiological phenomena|hypolipidemic agents|eicosanoids|agents causing hyperkalemia|inflammation mediators|lipids|fatty acids, unsaturated
retinol	adjuvants, immunologic|cyclohexanes|diagnostic agents|cyclohexenes|micronutrients|ophthalmologicals|food|polyenes|food and beverages|tests for fat absorption|anti acne preparations for topical use|anticarcinogenic agents|cycloparaffins|alkenes|protective agents|vitamin a|vitamins (fat soluble)|carotenoids|anti acne preparations|retinoids for topical use in acne|retinoids|pigments, biological|diet, food, and nutrition|biological factors|physiological phenomena|antioxidants|growth substances|compounds used in a research, industrial, or household setting|nasal preparations|dermatologicals|alimentary tract and metabolism|sensory organs|terpenes|vitamins|immunologic factors
alpha tocopherol	micronutrients|food|cytochrome p 450 cyp3a4 inducers|dietary supplements|cytochrome p 450 cyp3a4 substrates|food and beverages|vitamin e, analogs & derivatives|supplements|protective agents|benzopyrans|vitamins (fat soluble)|basic ointments and protectants|cytochrome p 450 substrates|vitamin e|cytochrome p 450 cyp3a inducers|diet, food, and nutrition|heterocyclic compounds, fused ring|physiological phenomena|antioxidants|growth substances|compounds used in a research, industrial, or household setting|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|pyrans|vitamins
pyridoxine	picolines|pyridines|antiinfectives for systemic use|alimentary tract and metabolism|drugs for treatment of tuberculosis|antimycobacterials|micronutrients|drugs that are mainly renally excreted|food|analogs/derivatives|diet, food, and nutrition|vitamins|food and beverages|vitamin b complex
menadione	quinones|micronutrients|cytochrome p 450 cyp1a2 inducers (strength unknown)|food|dietary supplements|food and beverages|supplements|cytochrome p 450 cyp1a2 inducers|cytochrome p 450 cyp2a6 inhibitors (strength unknown)|phytol|blood and blood forming organs|naphthoquinones|vitamins (fat soluble)|cytochrome p 450 enzyme inhibitors|coagulants|hematologic agents|hemostatics|vitamins|diet, food, and nutrition|physiological phenomena|growth substances|cytochrome p 450 enzyme inducers|diterpenes|antifibrinolytic agents|terpenes|cytochrome p 450 cyp2a6 inhibitors|vitamin k|naphthalenes|fibrin modulating agents
pravastatin	drugs causing inadvertant photosensitivity|oatp1b3 substrates|hydroxymethylglutaryl coa reductase inhibitors|bcrp/abcg2 inhibitors|lipid regulating agents|p glycoprotein substrates|photosensitizing agents|oat3/slc22a8 inhibitors|lipid modifying agents|bcrp/abcg2 substrates|hypolipidemic agents indicated for hyperlipidemia|oatp1b1/slco1b1 substrates|agents causing muscle toxicity|enzyme inhibitors|oat1/slc22a6 inhibitors|noxae|lipid modifying agents, plain|hypolipidemic agents|bsep/abcb11 substrates|anticholesteremic agents|toxic actions|oat3/slc22a8 substrates
fluvoxamine	membrane transport modulators|cytochrome p 450 cyp2c8 inhibitors|cytochrome p 450 cyp2b6 inhibitors (strength unknown)|psychoanaleptics|central nervous system agents|tranquilizing agents|drugs that are mainly renally excreted|amines|cytochrome p 450 cyp3a4 substrates|hypoglycemia associated agents|p glycoprotein inhibitors|selective serotonin reuptake inhibitors|antidepressive agents, second generation|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|serotonin modulators|central nervous system depressants|neurotransmitter agents|antidepressive agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 cyp2b6 inhibitors|hydroxylamines|nervous system|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a4 inhibitors (moderate)|cytochrome p 450 cyp1a2 inhibitors (strong)|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp3a inhibitors|chemically induced disorders|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp1a2 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strong)|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a7 inhibitors (moderate)|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a7 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2d6 inhibitors (moderate)|neurotransmitter uptake inhibitors|psychotropic drugs|cytochrome p 450 cyp1a2 substrates|bsep/abcb11 substrates|cytochrome p 450 cyp2c9 inhibitors (moderate)|oximes|anti anxiety agents
valsartan	oatp1b3 substrates|angiotensin ii receptor blockers (arbs), plain|angiotensin ii antagonists and diuretics|angiotensin 2 receptor blocker|antihypertensive agents indicated for hypertension|hypotensive agents|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|oatp1b1/slco1b1 inhibitors|cardiovascular agents|oatp1b1/slco1b1 substrates|cytochrome p 450 enzyme inhibitors|agents causing angioedema|angiotensin ii receptor blockers (arbs) and diuretics|angiotensin ii type 2 receptor blockers|cytochrome p 450 substrates|angiotensin ii receptor blockers (arbs) and calcium channel blockers|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp2c9 inhibitors|agents acting on the renin angiotensin system|antihypertensive agents|agents causing hyperkalemia|angiotensin ii antagonists and calcium channel blockers|angiotensin receptor antagonists|angiotensin ii type 1 receptor blockers
ramipril	ace inhibitors and diuretics|agents acting on the renin angiotensin system|cholinesterase inhibitors|agents causing angioedema|angiotensin converting enzyme inhibitors|antihypertensive agents|agents causing hyperkalemia|drugs causing inadvertant photosensitivity|heterocyclic compounds, fused ring|photosensitizing agents|protease inhibitors|hypotensive agents|ace inhibitors and calcium channel blockers|enzyme inhibitors|lipid modifying agents|cardiovascular agents|antihypertensive agents indicated for hypertension
flunisolide	corticosteroids for systemic use|anti asthmatic agents|adrenal cortex hormones|agents to treat airway disease|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|corticosteroids|steroids, fluorinated|anti inflammatory agents|pregnanes|cytochrome p 450 substrates|cytochrome p 450 cyp3a inducers|immunosuppressive agents|corticosteroid hormone receptor agonists|adrenals|drugs for obstructive airway diseases|respiratory system agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|nasal preparations|cytochrome p 450 enzyme inducers|steroids|pregnadienes
baclofen	amino acids, peptides, and proteins|gaba agonists|muscle relaxants|central nervous system agents|drugs that are mainly renally excreted|musculo skeletal system|butyrates|muscle relaxants, centrally acting agents|gaba derivative skeletal muscle relaxants|amino acids|central nervous system depressants|neurotransmitter agents|agents causing muscle toxicity|gamma aminobutyric acid ergic agonist|gaba b receptor agonists|gaba agents|muscle relaxants, peripherally acting agents|aminobutyrates
nicotine	agents producing tachycardia|ganglionic stimulants|cholinergic nicotinic agonist|ganglion blockers|cytochrome p 450 cyp2e1 inducers (strength unknown)|drugs used in addictive disorders|cytochrome p 450 cyp1a2 inducers (strength unknown)|cytochrome p 450 cyp2a6 substrates|cytochrome p 450 cyp3a4 substrates|miscellaneous autonomic drugs|cytochrome p 450 cyp1a2 inducers|nicotine, metabolism|cytochrome p 450 cyp2c19 substrates|cholinergic agonists|cytochrome p 450 cyp2b6 substrates|cytochrome p 450 cyp2e1 inhibitors|cytochrome p 450 cyp2a6 inhibitors (strength unknown)|oct2 inhibitors|neurotransmitter agents|nicotine, antagonists & inhibitors|pyridines|nicotinic agonists|nervous system|cholinergic agents|cytochrome p 450 enzyme inhibitors|smoking cessation agents|alkaloids|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|monoamine oxidase a inhibitors  for interaction with monoamine oxidase a substrates|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp2e1 inducers|oct1 inhibitors|cytochrome p 450 cyp3a substrates|drugs used in nicotine dependence|peripheral nervous system agents|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 enzyme inducers|solanaceous alkaloids|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|cytochrome p 450 cyp1a2 substrates|cytochrome p 450 cyp2a6 inhibitors|autonomic agents|cytochrome p 450 cyp2c8 substrates
lorazepam	hypnotics and sedatives|muscle relaxants|central nervous system agents|tranquilizing agents|drugs that are mainly renally excreted|psycholeptics|cytochrome p 450 cyp3a4 substrates|benzodiazepine hypnotics and sedatives|muscle relaxants, centrally acting agents|benzazepines|anticonvulsants|central nervous system depressants|neurotransmitter agents|benzodiazepines and benzodiazepine derivatives|nervous system|anti anxiety agents|gaba modulators|gastrointestinal agents|cytochrome p 450 substrates|gaba agents|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|peripheral nervous system agents|psychotropic drugs|antiemetics|autonomic agents|benzodiazepinones|cytochrome p 450 cyp3a4 substrates (strength unknown)
esmolol	adrenergic agents|beta blockers (beta1 selective)|antihypertensive agents indicated for hypertension|amines|bradycardia causing agents|beta blocking agents, selective|adrenergic antagonists|hypotensive agents|antiarrhythmic agents|neurotransmitter agents|qtc prolonging agents|adrenergic beta 1 receptor antagonists|propanols|adrenergic beta antagonists|cytochrome p 450 substrates|potential qtc prolonging agents|cytochrome p 450 cyp2d6 substrates|antihypertensive agents|agents causing hyperkalemia|amino alcohols|alcohols
bortezomib	cytochrome p 450 cyp2c19 substrates with a narrow therapeutic index|pyrazines|antineoplastic and immunomodulating agents|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|oatp1b3 inhibitors|acids|antineoplastic agents|hepatotoxic agents|cytochrome p 450 cyp3a4 substrates|p glycoprotein substrates|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp2d6 substrates with a narrow therapeutic index|hypotensive agents|cytochrome p 450 cyp2c19 inhibitors (weak)|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|cytochrome p 450 cyp1a2 inhibitors (moderate)|myelosuppressive agents|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp1a2 inhibitors|acids, noncarboxylic|immunosuppressive agents|potential qtc prolonging agents|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|cardiotoxic antineoplastic agents|cytochrome p 450 cyp1a2 substrates|boron compounds|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|cytochrome p 450 cyp2c9 substrates with a narrow therapeutic index|proteasome inhibitors|boronic acids
carbidopa	aromatic l amino acid decarboxylase inhibitors|phenols|aromatic amino acid decarboxylase inhibitors|central nervous system agents|hydrazines|anti parkinson drugs|anti dyskinesia agents|catechols|biogenic amines|biogenic monoamines|drugs that are mainly renally excreted|enzyme inhibitors|benzene derivatives|amines|catecholamines
phentermine	appetite depressants|agents producing tachycardia|central nervous system agents|adrenergic agents|increased sympathetic activity|centrally acting antiobesity products|amines|cytochrome p 450 cyp3a4 substrates|serotonergic drugs shown to increase risk of serotonin syndrome|agents that produce hypertension|neurotransmitter agents|antiobesity preparations, excl. diet products|anti obesity agents|sympathomimetics|cytochrome p 450 substrates|monoamine oxidase a inhibitors  for interaction with monoamine oxidase a substrates|appetite suppression|cytochrome p 450 cyp3a substrates|amphetamines|peripheral nervous system agents|alimentary tract and metabolism|autonomic agents|phenethylamines|sympathomimetic amine anorectic|cytochrome p 450 cyp3a4 substrates (strength unknown)
tramadol	opiate agonists|agents producing tachycardia|dimethylamines|sensory system agents|central nervous system agents|cyclohexanes|serotonin receptor antagonists|opioids|drugs that are mainly renally excreted|amines|cytochrome p 450 cyp3a4 substrates|narcotics|opioid agonist|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|analgesics|anticholinergic agents|cycloparaffins|cytochrome p 450 cyp2b6 substrates|serotonin modulators|central nervous system depressants|antidepressive agents|nmda receptor antagonists|nervous system|agents that reduce seizure threshold|cyclohexanols|cytochrome p 450 substrates|serotonin 5 ht2 receptor antagonists|serotonin 5 ht2c receptor antagonists|muscarinic antagonists|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|combined inhibitors of serotonin/norepinephrine reuptake|peripheral nervous system agents|ugt1a1 substrates|alcohols
vidarabine	carbohydrates|ophthalmologicals|nucleosides|antivirals for systemic use|ribonucleosides|nucleosides and nucleotides excl. reverse transcriptase inhibitors|glycosides|anti infective agents|antiviral agents|nucleic acids, nucleotides, and nucleosides|noxae|heterocyclic compounds, fused ring|purine nucleosides|antiinfectives for systemic use|antimetabolites|sensory organs|direct acting antivirals|purines|toxic actions|arabinonucleosides
betaxolol	propanolamines|adrenergic agents|ophthalmologicals|beta blockers (beta1 selective)|phenoxypropanolamines|antihypertensive agents indicated for hypertension|amines|bradycardia causing agents|beta blocking agents, selective|adrenergic antagonists|hypotensive agents|antiarrhythmic agents|neurotransmitter agents|antiglaucoma preparations and miotics|cardiovascular agents|qtc prolonging agents|adrenergic beta 1 receptor antagonists|propanols|moderate risk qtc prolonging agents|adrenergic beta antagonists|cytochrome p 450 substrates|cytochrome p 450 cyp2d6 substrates|beta adrenergic agents|antihypertensive agents|peripheral nervous system agents|agents causing hyperkalemia|cytochrome p 450 cyp1a2 substrates|sensory organs|amino alcohols|autonomic agents|sympatholytics|alcohols
fluconazole	antifungal agents|hormones, hormone substitutes, and hormone antagonists|hormone antagonists|triazoles|drugs that are mainly renally excreted|cytochrome p 450 cyp3a5 inhibitors (weak)|antifungals for dermatological use|p glycoprotein inhibitors|cytochrome p 450 cyp3a5 inhibitors|antimycotics for systemic use|qtc prolonging agents|steroid synthesis inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2c9 inhibitors (strong)|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 inhibitors (moderate)|antifungals for topical use|enzyme inhibitors|imidazole and triazole derivatives|14 alpha demethylase inhibitors|anti infective agents|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2c9 inhibitors|potential qtc prolonging agents|azole antifungals|triazole derivatives|cytochrome p 450 cyp2c19 inhibitors|antiinfectives for systemic use|dermatologicals|agents causing hyperkalemia
troglitazone	ugt1a3 substrates|cytochrome p 450 cyp2c8 inhibitors|thiazoles|drugs used in diabetes|cytochrome p 450 cyp2b6 inducers (strength unknown)|ugt2b7 substrates|cytochrome p 450 cyp3a4 inducers|chromans|cytochrome p 450 cyp3a7 inhibitors (strength unknown)|cytochrome p 450 cyp2c8 inhibitors (moderate)|cytochrome p 450 cyp3a5 inhibitors|ugt1a6 inhibitors|blood glucose lowering agents|oatp1b1/slco1b1 inhibitors|cytochrome p 450 cyp2b6 inducers|benzopyrans|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|thiazolidinediones|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2c9 inhibitors|heterocyclic compounds, fused ring|ugt1a6 substrate|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a7 inhibitors|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|alimentary tract and metabolism|ugt1a9 substrates|pyrans|sulfur compounds|cytochrome p 450 cyp3a5 inhibitors (strength unknown)|cytochrome p 450 cyp2c9 inhibitors (moderate)|bsep/abcb11 inhibitors|ugt1a1 substrates|ugt1a4 substrates|cytochrome p 450 cyp2c8 substrates
erythromycin	oatp1b3 substrates|antibacterials for systemic use|anti bacterial agents|oatp1b3 inhibitors|erythromycin and similars|ophthalmologicals|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp3a7 inhibitors (strength unknown)|p glycoprotein inhibitors|anti acne preparations for topical use|p glycoprotein substrates|cytochrome p 450 cyp3a5 inhibitors|macrolides, lincosamides and streptogramins|oatp1b1/slco1b1 inhibitors|antiinfectives for treatment of acne|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|oatp1b1/slco1b1 substrates|macrolide antimicrobial|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|anti acne preparations|cytochrome p 450 cyp3a4 inhibitors (moderate)|gastrointestinal agents|moderate risk qtc prolonging agents|cytochrome p 450 substrates|enzyme inhibitors|anti infective agents|cytochrome p 450 cyp3a inhibitors|macrolides|cytochrome p 450 cyp3a7 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|antiinfectives for systemic use|dermatologicals|protein synthesis inhibitors|erythromycins|cytochrome p 450 cyp3a5 inhibitors (strength unknown)|bsep/abcb11 substrates|bsep/abcb11 inhibitors|lactones
caffeine	purinergic antagonists|central nervous system stimulants|caffeine and caffeine containing products|psychoanaleptics|central nervous system agents|diagnostic agents|bcrp/abcg2 inhibitors|phosphodiesterase inhibitors|purinergic agents|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|purinones|tests for gastric secretion|neurotransmitter agents|cytochrome p 450 cyp1a2 inhibitors (moderate)|respiratory and cns stimulants|nervous system|cytochrome p 450 enzyme inhibitors|alkaloids|psychostimulants, agents used for adhd and nootropics|cytochrome p 450 substrates|anorexigenic agents & respiratory and cns stimulants|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|xanthine derivatives|cytochrome p 450 cyp1a2 inhibitors|heterocyclic compounds, fused ring|drugs for obstructive airway diseases|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|central nervous system stimulation|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 cyp1a2 substrates|purines|tricarboxylic acids|cytochrome p 450 cyp2c8 substrates
sildenafil	urological agents|cytochrome p 450 cyp2c9 inhibitors (weak)|piperazines|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp2c19 substrates|sulfones|cytochrome p 450 cyp2e1 inhibitors|cytochrome p 450 cyp2c19 inhibitors (weak)|oatp1b1/slco1b1 inhibitors|cardiovascular agents|cytochrome p 450 cyp3a7 substrates|phosphodiesterase 5 inhibitors|amides|urologicals|cytochrome p 450 enzyme inhibitors|drugs used in erectile dysfunction|agents causing muscle toxicity|sulfonamides|vasodilating agents|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp2c9 inhibitors|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|sulfur compounds|purines
dofetilide	membrane transport modulators|amines|cytochrome p 450 cyp3a4 substrates|antiarrhythmics, class iii|oct2 substrates|sulfones|antiarrhythmic agents|cardiovascular agents|qtc prolonging agents|amides|cytochrome p 450 substrates|ethylamines|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a substrates|highest risk qtc prolonging agents|narrow therapeutic index drugs|sulfur compounds|cardiac therapy|potassium channel blockers|oct2 substrates with a narrow therapeutic index
pyrimethamine	folic acid antagonists|mate inhibitors|cytochrome p 450 cyp2c8 inhibitors|cytochrome p 450 enzyme inhibitors|antibiotics for pneumocystis pneumonia|cytochrome p 450 cyp2c8 inhibitors (weak)|pyrimidines|diaminopyrimidines|enzyme inhibitors|mate 2 inhibitors|antimalarials|anti infective agents|antiprotozoals|mate 1 inhibitors|antiparasitic agents|antiparasitic products, insecticides and repellents
reserpine	adrenergic uptake inhibitors|membrane transport modulators|central nervous system agents|adrenergic agents|tranquilizing agents|drugs that are mainly renally excreted|antihypertensive agents indicated for hypertension|p glycoprotein inhibitors|p glycoprotein substrates|catecholamine depleting sympatholytic|indoles|oct2 substrates|gastrointestinal acidifying agents|hypotensive agents|antipsychotic agents|p glycoprotein inducers|cytochrome p 450 cyp3a5 inducers (strength unknown)|indole alkaloids|central nervous system depressants|neurotransmitter agents|oatp1b1/slco1b1 inhibitors|antidepressive agents|cardiovascular agents|alkaloids|decreased sympathetic activity|cytochrome p 450 cyp3a inducers|heterocyclic compounds, fused ring|oct1 inhibitors|neurotoxic agents|antihypertensive agents|neurotransmitter uptake inhibitors|cytochrome p 450 enzyme inducers|psychotropic drugs|bsep/abcb11 inhibitors|cytochrome p 450 cyp3a5 inducers|antiadrenergic agents, centrally acting|secologanin tryptamine alkaloids
azithromycin	drugs causing inadvertant photosensitivity|antibacterials for systemic use|anti bacterial agents|ophthalmologicals|experimental unapproved treatments for covid 19|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|p glycoprotein substrates|photosensitizing agents|cytochrome p 450 cyp2a6 inhibitors (strength unknown)|macrolides, lincosamides and streptogramins|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|qtc prolonging agents|macrolide antimicrobial|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|moderate risk qtc prolonging agents|cytochrome p 450 substrates|anti infective agents|cytochrome p 450 cyp3a inhibitors|macrolides|cytochrome p 450 cyp3a substrates|antiinfectives for systemic use|polyketides|cytochrome p 450 cyp2a6 inhibitors|lactones|cytochrome p 450 cyp3a4 substrates (strength unknown)
ticlopidine	antiplatelet agents|purinergic antagonists|cytochrome p 450 cyp2c8 inhibitors|cytochrome p 450 cyp2c9 inhibitors (weak)|purinergic p2y receptor antagonists|thiophenes|drugs that are mainly renally excreted|purinergic agents|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp2e1 inhibitors (weak)|thienopyridines|cytochrome p 450 cyp2c19 inhibitors (moderate)|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|cytochrome p 450 cyp2b6 inhibitors (moderate)|cytochrome p 450 cyp2c19 substrates|decreased platelet aggregation|cytochrome p 450 cyp2e1 inhibitors|neurotransmitter agents|cardiovascular agents|blood and blood forming organs|pyridines|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 cyp2b6 inhibitors|cytochrome p 450 enzyme inhibitors|purinergic p2 receptor antagonists|fibrin modulating agents|hematologic agents|cytochrome p 450 cyp2b6 inhibitors (strong)|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|platelet aggregation inhibitors excl. heparin|enzyme inhibitors|chemically induced disorders|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strong)|cytochrome p 450 cyp1a2 inhibitors|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2c8 inhibitors (weak)|sulfur compounds|cytochrome p 450 cyp3a4 substrates (strength unknown)
adapalene	anti acne preparations for topical use|dermatologicals|anti inflammatory agents|anti acne preparations|retinoids for topical use in acne|retinoids|misc. skin and mucous membrane agents|naphthalenes
midodrine	agents producing tachycardia|adrenergic agents|amines|bradycardia causing agents|vasoconstrictor agents|agents that produce hypertension|adrenergic alpha 1 receptor agonists|neurotransmitter agents|cardiovascular agents|cardiac stimulants excl. cardiac glycosides|sympathomimetics|adrenergic agonists|cytochrome p 450 substrates|adrenergic alpha agonists|cytochrome p 450 cyp2d6 substrates|ethanolamines|peripheral nervous system agents|adrenergic and dopaminergic agents|amino alcohols|autonomic agents|cardiac therapy|alcohols
pantoprazole	gastric acid lowering agents|bcrp/abcg2 inhibitors|drugs that are mainly renally excreted|acid reducers|anti ulcer agents|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp2c19 substrates|oat3/slc22a8 inhibitors|cytochrome p 450 cyp2c19 inhibitors (weak)|oatp1b1/slco1b1 inhibitors|bcrp/abcg2 substrates|drugs for peptic ulcer and gastro oesophageal reflux disease (gord)|pyridines|drugs for acid related disorders|cytochrome p 450 enzyme inhibitors|benzimidazoles|gastrointestinal agents|cytochrome p 450 substrates|enzyme inhibitors|heterocyclic compounds, fused ring|2 pyridinylmethylsulfinylbenzimidazoles|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|alimentary tract and metabolism|proton pump inhibitors|sulfur compounds|sulfoxides
torasemide	membrane transport modulators|antihypertensive agents indicated for hypertension|increased diuresis at loop of henle|sulfones|hypotensive agents|sodium potassium chloride symporter inhibitors|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|cardiovascular agents|high ceiling diuretics|ototoxic agents|oatp1b1/slco1b1 substrates|pyridines|cytochrome p 450 enzyme inhibitors|sulfonamides|hyperglycemia associated agents|diuretics|natriuretic agents|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp2c9 inhibitors|antihypertensive agents|sulfur compounds|non potassium sparing diuretics|cytochrome p 450 cyp2c8 substrates
citalopram	psychoanaleptics|central nervous system agents|serotonin receptor antagonists|cytochrome p 450 cyp3a4 inhibitors (weak)|amines|cytochrome p 450 cyp3a4 substrates|hypoglycemia associated agents|p glycoprotein inhibitors|p glycoprotein substrates|selective serotonin reuptake inhibitors|antidepressive agents, second generation|cytochrome p 450 cyp2c19 substrates|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|serotonin modulators|cytochrome p 450 cyp2c19 inhibitors (weak)|central nervous system depressants|neurotransmitter agents|antidepressive agents|qtc prolonging agents|propylamines|cytochrome p 450 cyp2d6 inhibitors|benzofurans|cytochrome p 450 cyp2b6 inhibitors|nervous system|cytochrome p 450 enzyme inhibitors|vasodilating agents|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp1a2 inhibitors (weak)|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|serotonin 5 ht2 receptor antagonists|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp1a2 inhibitors|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|combined inhibitors of serotonin/norepinephrine reuptake|neurotransmitter uptake inhibitors|psychotropic drugs|nitriles|highest risk qtc prolonging agents
moxifloxacin	topoisomerase inhibitors|antibacterials for systemic use|anti bacterial agents|ophthalmologicals|quinolone antimicrobial|fluoroquinolones|cytochrome p 450 cyp1a2 inhibitors (moderate)|quinolines|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|moderate risk qtc prolonging agents|quinolones|enzyme inhibitors|anti infective agents|cytochrome p 450 cyp1a2 inhibitors|heterocyclic compounds, fused ring|antiinfectives for systemic use|topoisomerase ii inhibitors|sensory organs
oxyphenonium	drugs for functional gastrointestinal disorders|agents producing tachycardia|cholinergic agents|mydriatics|parasympatholytics|peripheral nervous system agents|quaternary ammonium compounds|onium compounds|alimentary tract and metabolism|anticholinergic agents|nitrogen compounds|ammonium compounds|autonomic agents|neurotransmitter agents|synthetic anticholinergics, quaternary ammonium compounds|amines|muscarinic antagonists
nelfinavir	hiv protease inhibitors|cytochrome p 450 cyp2b6 inhibitors (strength unknown)|oatp1b3 inhibitors|bcrp/abcg2 inhibitors|cytochrome p 450 cyp3a4 inhibitors (strong)|cytochrome p 450 cyp3a4 substrates|antivirals for systemic use|p glycoprotein inhibitors|ugt1a1 inducers|p glycoprotein substrates|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp3a5 inhibitors|cytochrome p 450 cyp2c19 inducers|p glycoprotein inducers|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|oatp1b1/slco1b1 inhibitors|anti retroviral agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 cyp2b6 inhibitors|cytochrome p 450 enzyme inhibitors|hyperglycemia associated agents|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|enzyme inhibitors|anti infective agents|antiviral agents|cytochrome p 450 cyp3a inhibitors|isoquinolines|cytochrome p 450 cyp2c9 inhibitors|potential qtc prolonging agents|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a7 inhibitors|cytochrome p 450 cyp3a7 inhibitors (strong)|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2c19 inducers (strength unknown)|cytochrome p 450 cyp3a5 inhibitors (strong)|antiinfectives for systemic use|oct1 inhibitors|cytochrome p 450 enzyme inducers|protease inhibitors|anti hiv agents|bsep/abcb11 substrates|direct acting antivirals
glimepiride	drugs used in diabetes|alimentary tract and metabolism|sulfones|immunosuppressive agents|sulfonylureas|sulfur compounds|cytochrome p 450 substrates|bsep/abcb11 substrates|blood glucose lowering agents|antiarrhythmic agents|cytochrome p 450 cyp2c9 substrates|cardiovascular agents|hypoglycemia associated agents
diflorasone	hormones, hormone substitutes, and hormone antagonists|steroids, fluorinated|dermatologicals|anti inflammatory agents|adrenal cortex hormones|corticosteroids, dermatological preparations|hormones|pregnanes|corticosteroids, potent (group iii)|steroids|corticosteroids|pregnadienes|pregnadienetriols|immunosuppressive agents|fused ring compounds|corticosteroid hormone receptor agonists
indinavir	hiv protease inhibitors|cytochrome p 450 cyp3a4 inhibitors (strong)|cytochrome p 450 cyp3a5 inhibitors (weak)|cytochrome p 450 cyp3a4 substrates|antivirals for systemic use|p glycoprotein inhibitors|ugt1a1 inhibitors|p glycoprotein substrates|cytochrome p 450 cyp3a5 inhibitors|p glycoprotein inducers|oatp1b1/slco1b1 inhibitors|anti retroviral agents|pyridines|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|hyperglycemia associated agents|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|enzyme inhibitors|anti infective agents|antiviral agents|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a7 inhibitors (weak)|cytochrome p 450 cyp3a7 inhibitors|oct1 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|protease inhibitors|antiinfectives for systemic use|anti hiv agents|bsep/abcb11 substrates|direct acting antivirals
guanadrel	amidines|adrenergic antagonists|antihypertensive agents|cardiovascular agents
lovastatin	ugt1a3 substrates|cytochrome p 450 cyp2c8 inhibitors|drugs causing inadvertant photosensitivity|hydroxymethylglutaryl coa reductase inhibitors|lipid regulating agents|ugt2b7 substrates|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|cytochrome p 450 cyp2d6 inhibitors (weak)|photosensitizing agents|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp2c8 inhibitors (moderate)|lipid modifying agents|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|oatp1b1/slco1b1 inhibitors|hypolipidemic agents indicated for hyperlipidemia|cytochrome p 450 cyp3a7 substrates|cytochrome p 450 cyp2d6 inhibitors|oatp1b1/slco1b1 substrates|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a4 inhibitors (moderate)|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2c9 inhibitors|hypolipidemic agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|bsep/abcb11 substrates|anticholesteremic agents|ugt1a1 substrates|cytochrome p 450 cyp2c8 substrates
cefotiam	thiazines|antibacterials for systemic use|anti bacterial agents|nephrotoxic agents|oat1/slc22a6 substrates|oat3/slc22a8 inhibitors|second generation cephalosporins|beta lactams|amides|cephacetrile|cephalosporins|oat1/slc22a6 inhibitors|anti infective agents|heterocyclic compounds, fused ring|antiinfectives for systemic use|sulfur compounds|lactams|oat3/slc22a8 substrates
aminosalicylic acid	salicylates|phenols|hydroxy acids|para aminobenzoates|antiinfectives for systemic use|anti bacterial agents|drugs for treatment of tuberculosis|antimycobacterials|antituberculosis agents|benzoates|aminosalicylic acids|acids, carbocyclic|hydroxybenzoates|anti infective agents|benzene derivatives|aminosalicylic acid and derivatives|aminobenzoates
reboxetine	adrenergic uptake inhibitors|membrane transport modulators|psychoanaleptics|central nervous system agents|adrenergic agents|oxazines|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|cytochrome p 450 cyp2d6 inhibitors (weak)|central nervous system depressants|neurotransmitter agents|antidepressive agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 cyp2d6 inhibitors|nervous system|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a substrates|neurotransmitter uptake inhibitors|psychotropic drugs|morpholines
milrinone	cardiac stimulants excl. cardiac glycosides|phosphodiesterase 5 inhibitors|phosphodiesterase 3 inhibitors|compounds used in a research, industrial, or household setting|aminopyridines|pyridines|vasodilating agents|hematologic agents|protective agents|cardiotonic agents|drugs that are mainly renally excreted|enzyme inhibitors|cardiac therapy|cardiovascular agents|phosphodiesterase inhibitors|amines
nevirapine	human immunodeficiency virus 1 non nucleoside analog reverse transcriptase inhibitor|cytochrome p 450 cyp2a6 substrates|hepatotoxic agents|cytochrome p 450 cyp2b6 inducers (strong)|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|antivirals for systemic use|cytochrome p 450 cyp2d6 inhibitors (weak)|cytochrome p 450 cyp2b6 substrates|cytochrome p 450 cyp2c9 inducers (strength unknown)|non nucleoside reverse transcriptase inhibitors|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 inducers (weak)|anti retroviral agents|nonnucleoside reverse transcriptase inhibitors|cytochrome p 450 cyp2b6 inducers|cytochrome p 450 cyp3a7 substrates|pyridines|cytochrome p 450 cyp2d6 inhibitors|reverse transcriptase inhibitors|cytochrome p 450 enzyme inhibitors|nucleic acid synthesis inhibitors|cytochrome p 450 cyp1a2 inhibitors (weak)|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|anti infective agents|antiviral agents|cytochrome p 450 cyp3a inducers|chemically induced disorders|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp1a2 inhibitors|cytochrome p 450 cyp2d6 substrates|oct1 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|antiinfectives for systemic use|cytochrome p 450 enzyme inducers|anti hiv agents|direct acting antivirals|cytochrome p 450 cyp2c9 inducers|inducers of drug clearance
oxiconazole	antifungal agents|cytochrome p 450 cyp3a4 inducers (strength unknown)|dermatologicals|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 enzyme inducers|genito urinary system and sex hormones|antifungals for topical use|azole antifungals|cytochrome p 450 substrates|imidazole derivatives|imidazole and triazole derivatives|anti infective agents|cytochrome p 450 cyp3a inducers|gynecological antiinfectives and antiseptics|cytochrome p 450 cyp3a4 inducers|antifungals for dermatological use
alclometasone	hormones, hormone substitutes, and hormone antagonists|adrenal cortex hormones|ophthalmologicals|cytochrome p 450 cyp3a4 substrates|fused ring compounds|corticosteroids|anti inflammatory agents|corticosteroids, moderately potent (group ii)|pregnanes|cytochrome p 450 substrates|pregnadienetriols|immunosuppressive agents|corticosteroid hormone receptor agonists|cytochrome p 450 cyp3a substrates|dermatologicals|steroids|corticosteroids, dermatological preparations|hormones|sensory organs|pregnadienes
butalbital	hypnotics and sedatives|nervous system|nicotinic antagonists|cytochrome p 450 cyp3a4 inducers (strength unknown)|methemoglobinemia associated agents|cytochrome p 450 enzyme inducers|anticholinergic agents|pyrimidines|anticonvulsants|central nervous system depressants|cytochrome p 450 cyp3a inducers|psycholeptics|cytochrome p 450 cyp3a4 inducers|pyrimidinones|barbiturates
cladribine	carbohydrates|antineoplastic and immunomodulating agents|2 chloroadenosine|deoxyadenosines|antineoplastic agents|purine antimetabolite|nucleosides|bcrp/abcg2 substrates|ribonucleosides|agents causing muscle toxicity|selective immunosuppressants|glycosides|nucleic acids, nucleotides, and nucleosides|heterocyclic compounds, fused ring|immunosuppressive agents|purine nucleosides|deoxyribonucleosides|antimetabolites|cardiotoxic antineoplastic agents|purine analogues|narrow therapeutic index drugs|purines|immunologic factors
ranolazine	membrane transport modulators|piperazines|drugs that are mainly renally excreted|mate 2 inhibitors|cytochrome p 450 cyp3a4 inhibitors (weak)|mate 1 inhibitors|cytochrome p 450 cyp3a4 substrates|acetamides|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp2d6 inhibitors (weak)|antianginal agents|oct2 inhibitors|cardiovascular agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|vasodilating agents|cytochrome p 450 cyp3a4 inhibitors|moderate risk qtc prolonging agents|cytochrome p 450 substrates|cytochrome p 450 cyp3a inhibitors|mate inhibitors|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|bsep/abcb11 substrates|cardiac therapy|sodium channel blockers
mesalazine	salicylates|nephrotoxic agents|phenols|aminosalicylate|anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|intestinal antiinflammatory agents|agents causing hyperkalemia|anti inflammatory agents|analgesics|aminosalicylic acids|agents that produce hypertension|hydroxybenzoates|non cox 2 selective nsaids|benzene derivatives|analgesics, non narcotic
benzatropine	agents producing tachycardia|membrane transport modulators|central nervous system agents|anti dyskinesia agents|aza compounds|drugs that are mainly renally excreted|anticholinergic agents|tropanes|neurotransmitter agents|qtc prolonging agents|dopamine uptake inhibitors|nervous system|cholinergic agents|alkaloids|anti parkinson drugs|cytochrome p 450 substrates|histamine receptor antagonists|ethers of tropine or tropine derivatives|potential qtc prolonging agents|muscarinic antagonists|cytochrome p 450 cyp2d6 substrates|peripheral nervous system agents|neurotransmitter uptake inhibitors|dopamine agents|histamine antagonists|histamine h1 antagonists
ziprasidone	serotonin 5 ht1 receptor agonists|central nervous system agents|serotonin receptor antagonists|tranquilizing agents|adrenergic alpha 1 receptor antagonists|psycholeptics|cytochrome p 450 cyp3a4 substrates|adrenergic antagonists|cytochrome p 450 cyp2d6 inhibitors (weak)|serotonin 5 ht1 receptor antagonists|serotonin 5 ht1d receptor antagonists|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|anticholinergic agents|antipsychotic agents|agents that produce hypertension|indole derivatives|central nervous system depressants|neurotransmitter agents|antidepressive agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|nervous system|cytochrome p 450 enzyme inhibitors|hyperglycemia associated agents|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a4 inhibitors (moderate)|cytochrome p 450 substrates|serotonin 5 ht2 receptor antagonists|cytochrome p 450 cyp3a inhibitors|antipsychotic agents (second generation [atypical])|dopamine d2 receptor antagonists|serotonin 5 ht2c receptor antagonists|muscarinic antagonists|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|cytochrome p 450 cyp3a5 substrates|neurotoxic agents|serotonin 5 ht2a receptor antagonists|psychotropic drugs|dopamine agents|highest risk qtc prolonging agents|sulfur compounds|histamine antagonists|dopamine antagonists|serotonin receptor agonists|histamine h1 antagonists|cytochrome p 450 cyp3a4 substrates (strength unknown)
methysergide	antimigraine preparations|serotonin receptor antagonists|cytochrome p 450 cyp3a4 substrates|ergolines|serotonin agents|vasoconstrictor agents|analgesics|agents that produce hypertension|central nervous system depressants|neurotransmitter agents|antidepressive agents|cardiovascular agents|nervous system|alkaloids|cytochrome p 450 substrates|serotonin 5 ht2 receptor antagonists|heterocyclic compounds, fused ring|serotonin 5 ht2c receptor antagonists|ergot alkaloids and derivatives|cytochrome p 450 cyp3a substrates|serotonin 5 ht2a receptor antagonists|lysergic acid|cytochrome p 450 cyp3a4 substrates (strength unknown)
cabergoline	serotonin 5 ht1 receptor agonists|central nervous system agents|anti dyskinesia agents|antineoplastic agents|cytochrome p 450 cyp3a4 substrates|p glycoprotein substrates|ergolines|ergot derivative dopamine receptor agonists|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|serotonin modulators|agents that produce hypertension|central nervous system depressants|neurotransmitter agents|antidepressive agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|nervous system|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|alkaloids|anti parkinson drugs|cytochrome p 450 substrates|serotonin 5 ht2 receptor agonists|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a inhibitors|heterocyclic compounds, fused ring|ergot alkaloids and derivatives|cytochrome p 450 cyp3a substrates|prolactine inhibitors|dopamine agents|genito urinary system and sex hormones|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|dopamine agonists|serotonin receptor agonists
idoxuridine	carbohydrates|pyrimidines|ophthalmologicals|nucleosides|antivirals for systemic use|deoxyuridine|ribonucleosides|nucleic acid synthesis inhibitors|nucleosides and nucleotides excl. reverse transcriptase inhibitors|glycosides|enzyme inhibitors|nucleoside analog antiviral|anti infective agents|antiviral agents|nucleic acids, nucleotides, and nucleosides|deoxyribonucleosides|pyrimidine nucleosides|antiinfectives for systemic use|dermatologicals|sensory organs|direct acting antivirals
dapsone	drugs causing inadvertant photosensitivity|antibiotics for pneumocystis pneumonia|anti bacterial agents|leprostatic agents|cytochrome p 450 cyp2c18 substrates|cytochrome p 450 cyp3a4 substrates|folic acid antagonists|anti acne preparations for topical use|photosensitizing agents|cytochrome p 450 cyp2c19 substrates|antimycobacterials|miscellaneous local anti infectives|sulfones|cytochrome p 450 cyp2c9 inducers (strength unknown)|antiparasitic agents|cytochrome p 450 cyp3a7 substrates|anti acne preparations|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|anti infective agents|antimalarials|drugs for treatment of lepra|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|methemoglobinemia associated agents|antiinfectives for systemic use|dermatologicals|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 enzyme inducers|sulfur compounds|miscellaneous antimycobacterials|antiprotozoals|cytochrome p 450 cyp2c9 inducers|cytochrome p 450 cyp2c8 substrates
terconazole	antifungal agents|antifungal agents (vaginal)|genito urinary system and sex hormones|anti infective agents|gynecological antiinfectives and antiseptics|triazole derivatives|azole antifungals
phenytoin	cytochrome p 450 cyp3a7 substrates with a narrow therapeutic index|cytochrome p 450 cyp2a6 substrates|cytochrome p 450 cyp2b6 inducers (strength unknown)|phenytoin and prodrugs|decreased central nervous system disorganized electrical activity|cytochrome p 450 cyp3a inducers (strong)|cytochrome p 450 cyp2c9 inducers (strength unknown)|cytochrome p 450 cyp2c18 substrates with a narrow therapeutic index|cytochrome p 450 cyp2c8 inducers (strong)|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|ugt1a9 substrates with a narrow therapeutic index|ugt1a1 substrates with a narrow therapeutic index|hydantoins|cytochrome p 450 cyp3a7 substrates|nervous system|cytochrome p 450 cyp2d6 substrates|narrow therapeutic index drugs|enzyme inducing antiepileptic drugs|cytochrome p 450 cyp3a7 inducers|ugt1a4 substrates|cytochrome p 450 cyp2c19 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp2b6 substrates|cytochrome p 450 cyp3a4 inducers (strong)|cytochrome p 450 enzyme inhibitors|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 inhibitors|ugt1a6 substrate|p glycoprotein substrates with a narrow therapeutic index|cytochrome p 450 cyp2c8 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a5 inducers|imidazolidines|inducers of drug clearance|membrane transport modulators|central nervous system agents|ugt1a6 substrates with a narrow therapeutic index|cytochrome p 450 cyp1a2 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp1a2 inducers|cytochrome p 450 cyp2c19 inducers|central nervous system depressants|cytochrome p 450 cyp2a6 substrates with a narrow therapeutic index|cytochrome p 450 cyp2b6 substrates with a narrow therapeutic index|ugt1a9 inhibitors|voltage gated sodium channel blockers|comt substrates|cytochrome p 450 cyp2b6 inducers|thyroxine binding globulin substrates|cytochrome p 450 cyp2c8 inducers|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 cyp2c19 inducers (moderate)|cytochrome p 450 cyp2c9 inducers|cytochrome p 450 cyp3a7 inducers (weak)|sodium channel blockers|cytochrome p 450 cyp2b6 inducers (strong)|anti epileptic agent|ugt1a1 inducers|p glycoprotein substrates|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp2d6 substrates with a narrow therapeutic index|ugt1a6 inhibitors|cytochrome p 450 cyp3a5 inducers (strength unknown)|anticonvulsants|agents causing muscle toxicity|imidazoles|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp2e1 substrates with a narrow therapeutic index|methemoglobinemia associated agents|cytochrome p 450 enzyme inducers|ugt1a9 substrates|cytochrome p 450 cyp2c9 substrates with a narrow therapeutic index|cytochrome p 450 cyp2c18 substrates|ugt1a1 substrates|cytochrome p 450 cyp2c8 substrates
medrysone	hormones, hormone substitutes, and hormone antagonists|adrenal cortex hormones|ophthalmologicals|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|p glycoprotein substrates|corticosteroids|cytochrome p 450 cyp3a5 inducers (strength unknown)|hyperglycemia associated agents|anti inflammatory agents|pregnanes|cytochrome p 450 substrates|cytochrome p 450 cyp3a inducers|corticosteroid hormone receptor agonists|immunosuppressive agents|cytochrome p 450 cyp3a substrates|glucocorticoids|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|pregnenes|hormones|steroids|sensory organs|thyroxine binding globulin inhibitors|cytochrome p 450 cyp3a5 inducers|oat3/slc22a8 substrates
doxycycline	drugs causing inadvertant photosensitivity|antibacterials for systemic use|anti bacterial agents|agents that produce neuromuscular block (indirect)|drugs that are mainly renally excreted|stomatological preparations|cytochrome p 450 cyp3a4 substrates|tetracyclines|photosensitizing agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|antiparasitic agents|cytochrome p 450 enzyme inhibitors|naphthacenes|antiinfectives and antiseptics for local oral treatment|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|oat1/slc22a6 inhibitors|anti infective agents|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a substrates|antiinfectives for systemic use|alimentary tract and metabolism|antiprotozoals
diethylstilbestrol	cytochrome p 450 cyp2e1 inhibitors (strong)|hormones, hormone substitutes, and hormone antagonists|cytochrome p 450 cyp2c8 inhibitors|antineoplastic and immunomodulating agents|adrenal cortex hormones|thyroxine binding globulin inducers|bcrp/abcg2 inhibitors|contraceptive agents, male|estrogen contraceptives|contraceptives, postcoital|estrogens, non steroidal|carcinogens|synthetic estrogens, plain|cytochrome p 450 cyp3a4 substrates|hormonal contraceptives for systemic use|p glycoprotein substrates|cytochrome p 450 cyp2e1 inhibitors|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|sex hormones and modulators of the genital system|oatp1b1/slco1b1 inhibitors|hormones and related agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|comt substrates|antineoplastic agents, hormonal|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|stilbenes|estrogens|cytochrome p 450 substrates|contraceptive agents, female|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp3a inhibitors|noxae|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp3a substrates|endocrine therapy|hormones|genito urinary system and sex hormones|bsep/abcb11 substrates|benzene derivatives|toxic actions|cytochrome p 450 cyp2c8 substrates|benzylidene compounds
lymecycline	tetracyclines|naphthacenes|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|agents that produce neuromuscular block (indirect)|anti infective agents
clotrimazole	antifungal agents|hormones, hormone substitutes, and hormone antagonists|hormone antagonists|cytochrome p 450 cyp2c8 inhibitors|antifungal agents (vaginal)|stomatological preparations|cytochrome p 450 cyp2b6 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|antifungals for dermatological use|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp2c8 inhibitors (moderate)|cytochrome p 450 cyp3a inducers (strong)|cytochrome p 450 cyp2e1 inhibitors|cytochrome p 450 cyp2a6 inhibitors (strong)|anti infective agents, local|p glycoprotein inducers|oatp1b3 inducers|oatp1b1/slco1b1 inhibitors|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|imidazole derivatives|cytochrome p 450 cyp2b6 inducers|steroid synthesis inhibitors|cytochrome p 450 cyp2d6 inhibitors|oatp1b1/slco1b1 substrates|cytochrome p 450 cyp2b6 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2c9 inhibitors (strong)|imidazoles|antiinfectives and antiseptics for local oral treatment|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2b6 inhibitors (strong)|antifungals for topical use|cytochrome p 450 substrates|enzyme inhibitors|imidazole and triazole derivatives|anti infective agents|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a inhibitors|gynecological antiinfectives and antiseptics|cytochrome p 450 cyp2c9 inhibitors|azole antifungals|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2d6 inhibitors (moderate)|cytochrome p 450 cyp3a4 inducers (strength unknown)|dermatologicals|cytochrome p 450 enzyme inducers|cytochrome p 450 cyp2e1 inhibitors (moderate)|bsep/abcb11 substrates|cytochrome p 450 cyp2c9 inhibitors (moderate)|cytochrome p 450 cyp2a6 inhibitors|bsep/abcb11 inhibitors|cytochrome p 450 cyp2c8 inhibitors (strong)|cytochrome p 450 cyp3a7 inducers|cytochrome p 450 cyp3a7 inducers (weak)
cycloserine	amino acids, peptides, and proteins|anti bacterial agents|anti infective agents, urinary|antituberculosis agents|oxazoles|oxazolidinones|antimycobacterials|amino acids|isoxazoles|anti infective agents|noxae|neurotoxic agents|amino acids, neutral|antiinfectives for systemic use|antimetabolites|drugs for treatment of tuberculosis|renal agents|antibiotics, antitubercular|toxic actions
anagrelide	antiplatelet agents|agents producing tachycardia|antineoplastic and immunomodulating agents|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|antineoplastic agents|decreased platelet production|phosphodiesterase inhibitors|phosphodiesterase 3 inhibitors|cardiovascular agents|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|vasodilating agents|hematologic agents|platelet reducing agents|cytochrome p 450 cyp1a2 inhibitors (weak)|cytochrome p 450 substrates|thrombocytosis|cytochrome p 450 cyp1a2 inhibitors|heterocyclic compounds, fused ring|highest risk qtc prolonging agents|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs
sulfafurazole	drugs causing inadvertant photosensitivity|antibacterials for systemic use|anti bacterial agents|sulfonamides and trimethoprim|ophthalmologicals|sulfanilamides|amines|hypoglycemia associated agents|short acting sulfonamides|sulfonamide antibacterial|photosensitizing agents|sulfones|blood glucose lowering agents|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|qtc prolonging agents|amides|cytochrome p 450 enzyme inhibitors|sulfonamides|moderate risk qtc prolonging agents|anti infective agents|gynecological antiinfectives and antiseptics|cytochrome p 450 cyp2c9 inhibitors|aniline compounds|antiinfectives for systemic use|genito urinary system and sex hormones|sensory organs|sulfur compounds
metoprolol	propanolamines|drugs causing inadvertant photosensitivity|adrenergic agents|drugs that are mainly renally excreted|beta blockers (beta1 selective)|antihypertensive agents indicated for hypertension|amines|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|beta blocking agents, selective|adrenergic antagonists|photosensitizing agents|hypotensive agents|oct2 inhibitors|antiarrhythmic agents|cardiovascular agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|adrenergic beta 1 receptor antagonists|adrenergic beta antagonists|cytochrome p 450 substrates|beta blocking agents and thiazides|beta blocking agents and calcium channel blockers|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2d6 inhibitors (moderate)|antihypertensive agents|agents causing hyperkalemia|amino alcohols|alcohols|cytochrome p 450 cyp3a4 substrates (strength unknown)
crotamiton	aniline compounds|compounds used in a research, industrial, or household setting|agrochemicals|toxic actions|pesticides|scabicides and pediculicides|benzene derivatives|amines
dicoumarol	4 hydroxycoumarins|benzopyrans|fibrinolytic agents|anticoagulants|vitamin k antagonists|heterocyclic compounds, fused ring|hematologic agents|pyrans|narrow therapeutic index drugs|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates with a narrow therapeutic index|cytochrome p 450 cyp2c9 substrates|enzyme inhibitors|uncoupling agents|coumarins|blood and blood forming organs
ropinirole	nervous system|nonergot derivative dopamine receptor agonists|heterocyclic compounds, fused ring|anti parkinson agents (dopamine agonist)|central nervous system agents|dopamine agents|hypotensive agents|anti parkinson drugs|anti dyskinesia agents|cytochrome p 450 cyp1a2 substrates|cytochrome p 450 substrates|dopamine agonists|central nervous system depressants|neurotransmitter agents|antidepressive agents
chlorotrianisene	hormones, hormone substitutes, and hormone antagonists|natural and semisynthetic estrogens, plain|hormones|stilbenes|antineoplastic agents|estrogens|genito urinary system and sex hormones|estrogens, non steroidal|sex hormones and modulators of the genital system|benzene derivatives|antineoplastic agents, hormonal|benzylidene compounds
isradipine	membrane transport modulators|calcium regulating hormones and agents|drugs that are mainly renally excreted|antihypertensive agents indicated for hypertension|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|p glycoprotein inhibitors|hypotensive agents|antiarrhythmic agents|calcium channel blockers|selective calcium channel blockers with mainly vascular effects|cardiovascular agents|qtc prolonging agents|pyridines|calcium channel blockers (dihydropyridine)|cytochrome p 450 enzyme inhibitors|vasodilating agents|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a4 inhibitors (moderate)|cytochrome p 450 substrates|cytochrome p 450 cyp3a inhibitors|potential qtc prolonging agents|cytochrome p 450 cyp3a substrates|antihypertensive agents|agents causing hyperkalemia|dihydropyridines|bsep/abcb11 substrates|dihydropyridine derivatives
betazole	histamine agents|pyrazoles|diagnostic agents|gastrointestinal agents|tests for gastric secretion|neurotransmitter agents|histamine agonists
topiramate	carbohydrates|central nervous system agents|drugs that are mainly renally excreted|cytochrome p 450 cyp3a4 inducers|decreased central nervous system disorganized electrical activity|p glycoprotein substrates|anticonvulsants|central nervous system depressants|cytochrome p 450 cyp3a4 inducers (weak)|miscellaneous anticonvulsants|anti obesity agents|nervous system|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 substrates|hexoses|cytochrome p 450 cyp3a inducers|monosaccharides|cytochrome p 450 cyp2c19 inhibitors|neuroprotective agents|cytochrome p 450 cyp3a4 inducers (strength unknown)|ketoses|cytochrome p 450 enzyme inducers|enzyme inducing antiepileptic drugs|fructose
cefmetazole	amides|nephrotoxic agents|thiazines|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|cephalosporins|heterocyclic compounds, fused ring|sulfur compounds|second generation cephalosporins|beta lactams|anti infective agents|cephamycins|lactams
olmesartan	agents acting on the renin angiotensin system|oatp1b3 substrates|antihypertensive agents|imidazoles|tetrazoles|agents causing hyperkalemia|angiotensin ii antagonists and calcium channel blockers|angiotensin ii receptor blockers (arbs) and diuretics|angiotensin ii receptor blockers (arbs), plain|hypotensive agents|angiotensin ii receptor blockers (arbs) and calcium channel blockers|bsep/abcb11 inhibitors|angiotensin 2 receptor blocker|cardiovascular agents|antihypertensive agents indicated for hypertension|angiotensin receptor antagonists|oatp1b1/slco1b1 substrates
amsacrine	aminoacridines|laboratory chemicals|compounds used in a research, industrial, or household setting|p glycoprotein inhibitors|antineoplastic and immunomodulating agents|heterocyclic compounds, fused ring|myelosuppressive agents|cardiotoxic antineoplastic agents|immunosuppressive agents|antineoplastic agents|intercalating agents|narrow therapeutic index drugs|indicators and reagents|acridines
theophylline	purinergic antagonists|anti asthmatic agents|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|xanthines and adrenergics|phosphodiesterase inhibitors|purinergic agents|cytochrome p 450 cyp3a4 substrates|purinergic p1 receptor antagonists|respiratory smooth muscle relaxants|purinones|cytochrome p 450 cyp2d6 substrates with a narrow therapeutic index|neurotransmitter agents|cardiovascular agents|phosphodiesterase 5 inhibitors|agents that reduce seizure threshold|vasodilating agents|alkaloids|cytochrome p 450 substrates|enzyme inhibitors|xanthine derivatives|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|heterocyclic compounds, fused ring|drugs for obstructive airway diseases|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp2e1 substrates with a narrow therapeutic index|respiratory system agents|cytochrome p 450 cyp3a substrates|peripheral nervous system agents|cytochrome p 450 cyp2e1 substrates|bronchodilator agents|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs|purines|autonomic agents|cytochrome p 450 cyp2c8 substrates
argatroban	antithrombins|cytochrome p 450 cyp3a4 substrates|fibrinolytic agents|blood and blood forming organs|anticoagulants|hematologic agents|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|piperidines|enzyme inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|protease inhibitors|narrow therapeutic index drugs|serine protease inhibitors|thrombin inhibitors|cytochrome p 450 cyp3a4 substrates (strength unknown)
liothyronine	thyroxine binding globulin substrates|hormones, hormone substitutes, and hormone antagonists|triiodothyronine|l triiodothyronine|oatp1b3 substrates|oat3/slc22a8 inhibitors|hormones|thyronines|p glycoprotein inducers|agents used to treat hypothyroidism|drugs that are mainly renally excreted|ugt1a1 substrates|thyroid products|systemic hormonal preparations, excl. sex hormones and insulins|oatp1b1/slco1b1 substrates
disopyramide	agents producing tachycardia|membrane transport modulators|drugs that are mainly renally excreted|hypoglycemia associated agents|cytochrome p 450 cyp3a4 substrates|anticholinergic agents|oct2 inhibitors|antiarrhythmic agents|blood glucose lowering agents|voltage gated sodium channel blockers|cardiovascular agents|qtc prolonging agents|pyridines|antiarrhythmics, class ia|cytochrome p 450 substrates|muscarinic antagonists|oct1 inhibitors|cytochrome p 450 cyp3a substrates|antiarrhythmics, class i|highest risk qtc prolonging agents|cytochrome p 450 cyp1a2 substrates|cardiac therapy|sodium channel blockers
lidocaine	anesthetics, local|membrane transport modulators|sensory system agents|central nervous system agents|ophthalmologicals|cytochrome p 450 cyp2c18 substrates|cytochrome p 450 cyp2a6 substrates|amines|cytochrome p 450 cyp3a4 substrates|local anesthesia|antipruritics, incl. antihistamines, anesthetics, etc.|neuraxial anesthetics|antipruritics and local anesthetics|p glycoprotein inhibitors|antiarrhythmics, class ib|cytochrome p 450 cyp2b6 substrates|local anesthetics (amide)|antiarrhythmic agents|central nervous system depressants|voltage gated sodium channel blockers|cytochrome p 450 cyp1a2 inhibitors (moderate)|cardiovascular agents|cytochrome p 450 cyp3a7 substrates|cytochrome p 450 cyp2d6 inhibitors|amides|agents that reduce seizure threshold|nervous system|cytochrome p 450 enzyme inhibitors|throat preparations|anilides|anesthetics for topical use|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|vasoprotectives|anesthetics|cytochrome p 450 cyp1a2 inhibitors|otologicals|cytochrome p 450 cyp2d6 substrates|aniline compounds|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|methemoglobinemia associated agents|peripheral nervous system agents|antiarrhythmics, class i|dermatologicals|cytochrome p 450 cyp1a2 substrates|agents for treatment of hemorrhoids and anal fissures for topical use|cardiac therapy|sodium channel blockers|analgesics and anesthetics|cytochrome p 450 cyp2c8 substrates
clemastine	antipruritics, incl. antihistamines, anesthetics, etc.|antihistamines for topical use|histamine agents|photosensitizing agents|central nervous system depressants|antihistamines for systemic use|neurotransmitter agents|pyrrolidines|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|anti allergic agents|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|antipruritics|dermatologicals|highest risk qtc prolonging agents|histamine antagonists|aminoalkyl ethers|histamine h1 antagonists
acarbose	carbohydrates|polysaccharides|trisaccharides|drugs used in diabetes|alimentary tract and metabolism|drugs that are mainly renally excreted|enzyme inhibitors|blood glucose lowering agents|oligosaccharides|glycoside hydrolase inhibitors|hypoglycemia associated agents
venlafaxine	agents producing tachycardia|membrane transport modulators|psychoanaleptics|central nervous system agents|cyclohexanes|drugs that are mainly renally excreted|amines|cytochrome p 450 cyp3a4 substrates|hypoglycemia associated agents|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp2d6 inhibitors (weak)|antidepressive agents, second generation|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|cycloparaffins|serotonin modulators|fatty alcohols|norepinephrine uptake inhibitors|central nervous system depressants|neurotransmitter agents|antidepressive agents|serotonin and noradrenaline reuptake inhibitors|qtc prolonging agents|hexanols|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 cyp2b6 inhibitors|agents that reduce seizure threshold|nervous system|cytochrome p 450 enzyme inhibitors|cyclohexanols|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|ethylamines|potential qtc prolonging agents|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2d6 inhibitors (moderate)|combined inhibitors of serotonin/norepinephrine reuptake|neurotransmitter uptake inhibitors|psychotropic drugs|lipids|phenethylamines|bcrp/abcg2 inducers|alcohols
amcinonide	hormones, hormone substitutes, and hormone antagonists|adrenal cortex hormones|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|corticosteroids, potent (group iii)|corticosteroids|cytochrome p 450 cyp3a5 inducers (strength unknown)|steroids, fluorinated|hyperglycemia associated agents|anti inflammatory agents|pregnanes|cytochrome p 450 substrates|cytochrome p 450 cyp3a inducers|corticosteroid hormone receptor agonists|immunosuppressive agents|cytochrome p 450 cyp3a substrates|glucocorticoids|cytochrome p 450 cyp3a4 inducers (strength unknown)|dermatologicals|cytochrome p 450 enzyme inducers|steroids|corticosteroids, dermatological preparations|hormones|thyroxine binding globulin inhibitors|pregnadienes|cytochrome p 450 cyp3a5 inducers
atomoxetine	agents producing tachycardia|membrane transport modulators|adrenergic agents|drugs that are mainly renally excreted|amines|cytochrome p 450 cyp2c19 substrates|agents that produce hypertension|norepinephrine uptake inhibitors|central nervous system depressants|neurotransmitter agents|miscellaneous central nervous system agents|qtc prolonging agents|propylamines|norepinephrine reuptake inhibitor|nervous system|cytochrome p 450 enzyme inhibitors|psychostimulants, agents used for adhd and nootropics|cytochrome p 450 substrates|potential qtc prolonging agents|cytochrome p 450 cyp2d6 substrates|neurotransmitter uptake inhibitors
chlorambucil	nitrogen mustard compounds|agents that reduce seizure threshold|antineoplastic and immunomodulating agents|alkylating drugs|hydrocarbons, halogenated|nitrogen mustard analogues|myelosuppressive agents|antineoplastic agents|antineoplastic agents, alkylating|alkylating activity|narrow therapeutic index drugs|immunosuppressive agents|noxae|toxic actions|mustard compounds
etomidate	hypnotics and sedatives|agents producing tachycardia|nervous system|imidazoles|adrenergic agonists|anesthetics, general|central nervous system agents|miscellaneous general anesthetics|agents that produce hypertension|drugs that are mainly renally excreted|central nervous system depressants|adrenergic alpha 2 receptor agonists|adrenergic alpha agonists|anesthetics|anesthetics, intravenous
raltitrexed	folic acid antagonists|folic acid analogues|antimetabolites|heterocyclic compounds, fused ring|myelosuppressive agents|antineoplastic agents|narrow therapeutic index drugs|sulfur compounds|enzyme inhibitors|thymidylate synthase, antagonists & inhibitors|immunosuppressive agents|noxae|toxic actions
ropivacaine	anesthetics, local|sensory system agents|central nervous system agents|drugs that are mainly renally excreted|amines|cytochrome p 450 cyp3a4 substrates|local anesthesia|neuraxial anesthetics|cytochrome p 450 cyp2b6 substrates|hypotensive agents|local anesthetics (amide)|central nervous system depressants|amides|nervous system|anilides|cytochrome p 450 substrates|anesthetics|aniline compounds|cytochrome p 450 cyp3a substrates|peripheral nervous system agents|cytochrome p 450 cyp1a2 substrates
bupivacaine	anesthetics, local|sensory system agents|central nervous system agents|amines|cytochrome p 450 cyp3a4 substrates|local anesthesia|neuraxial anesthetics|cytochrome p 450 cyp2c19 substrates|hypotensive agents|local anesthetics (amide)|central nervous system depressants|amides|agents that reduce seizure threshold|nervous system|anilides|cytochrome p 450 substrates|anesthetics|cytochrome p 450 cyp2d6 substrates|aniline compounds|cytochrome p 450 cyp3a substrates|peripheral nervous system agents
penciclovir	reverse transcriptase inhibitors|nucleic acid synthesis inhibitors|antiinfectives for systemic use|dermatologicals|heterocyclic compounds, fused ring|nucleosides and nucleotides excl. reverse transcriptase inhibitors|purinones|cytochrome p 450 cyp1a2 substrates|cytochrome p 450 substrates|herpesvirus nucleoside analog dna polymerase inhibitor|direct acting antivirals|purines|anti infective agents|antiviral agents|antivirals for systemic use
flucloxacillin	antibacterials for systemic use|anti bacterial agents|beta lactam antibacterials|cytochrome p 450 cyp3a4 substrates|beta lactams|amides|beta lactamase resistant penicillins|cytochrome p 450 substrates|anti infective agents|cytochrome p 450 cyp3a inducers|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|antiinfectives for systemic use|cytochrome p 450 enzyme inducers|sulfur compounds|bsep/abcb11 substrates|penicillins|lactams
tranexamic acid	decreased fibrinolysis|coagulants|hematologic agents|cyclohexanes|cycloparaffins|hemostatics|amino acids|acids, carbocyclic|antifibrinolytic agents|blood and blood forming organs|cyclohexanecarboxylic acids|fibrin modulating agents
mitomycin c	antineoplastic and immunomodulating agents|alkylating drugs|azirines|antineoplastic agents|indolequinones|indoles|cross linking reagents|alkylating activity|cytotoxic antibiotics and related substances|myelosuppressive agents|nucleic acid synthesis inhibitors|mitomycins|indicators and reagents|enzyme inhibitors|noxae|heterocyclic compounds, fused ring|immunosuppressive agents|compounds used in a research, industrial, or household setting|antibiotics, antineoplastic|cardiotoxic antineoplastic agents|narrow therapeutic index drugs|toxic actions
ibutilide	amides|highest risk qtc prolonging agents|sulfones|sulfur compounds|drugs that are mainly renally excreted|antiarrhythmic agents|cardiac therapy|cardiovascular agents|qtc prolonging agents|antiarrhythmics, class iii
vindesine	antineoplastic and immunomodulating agents|antineoplastic agents|cytochrome p 450 cyp3a4 substrates|indoles|indole alkaloids|vinca alkaloids|myelosuppressive agents|antineoplastic agents, phytogenic|antimitotic agents|alkaloids|cytochrome p 450 substrates|tubulin modulators|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|heterocyclic compounds, fused ring|immunosuppressive agents|cytochrome p 450 cyp3a substrates|mitosis modulators|cardiotoxic antineoplastic agents|narrow therapeutic index drugs|secologanin tryptamine alkaloids
chlorthalidone	membrane transport modulators|drugs causing inadvertant photosensitivity|phthalimides|antihypertensive agents indicated for hypertension|thiazide like diuretic|photosensitizing agents|sulfones|hypotensive agents|low ceiling diuretics and potassium sparing agents|cardiovascular agents|isoindoles|phthalic acids|amides|increased diuresis|sulfonamides|hyperglycemia associated agents|diuretics|low ceiling diuretics, excl. thiazides|natriuretic agents|ketones|heterocyclic compounds, fused ring|antihypertensive agents|sodium chloride symporter inhibitors|acids, carbocyclic|sulfur compounds|non potassium sparing diuretics|benzene derivatives|imides|benzophenones
pentobarbital	hypnotics and sedatives|nicotinic antagonists|central nervous system agents|pyrimidines|drugs that are mainly renally excreted|psycholeptics|cytochrome p 450 cyp3a4 inducers|adjuvants, anesthesia|barbiturates, plain|cytochrome p 450 cyp2a6 inducers|cytochrome p 450 cyp2c19 substrates|anticholinergic agents|cytochrome p 450 cyp3a inducers (strong)|anticonvulsants|central nervous system depressants|neurotransmitter agents|pyrimidinones|barbiturates|cytochrome p 450 cyp3a4 inducers (strong)|nervous system|gaba modulators|cytochrome p 450 substrates|gaba agents|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp2a6 inducers (strong)|cytochrome p 450 enzyme inducers
valproic acid	cytochrome p 450 cyp2c19 substrates with a narrow therapeutic index|acids, acyclic|ugt1a3 substrates|cytochrome p 450 cyp2c8 inhibitors|drugs causing inadvertant photosensitivity|ugt2b7 substrates with a narrow therapeutic index|central nervous system agents|fatty acid derivatives|tranquilizing agents|ugt1a6 substrates with a narrow therapeutic index|antineoplastic agents|cytochrome p 450 cyp2a6 substrates|hepatotoxic agents|ugt2b7 substrates|anti epileptic agent|decreased central nervous system disorganized electrical activity|ugt1a1 inhibitors|photosensitizing agents|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|cytochrome p 450 cyp2a6 inducers|cytochrome p 450 cyp2c19 substrates|oat3/slc22a8 inhibitors|serotonergic drugs shown to increase risk of serotonin syndrome|cytochrome p 450 cyp2b6 substrates|fatty acids|anticonvulsants|central nervous system depressants|cytochrome p 450 cyp2a6 substrates with a narrow therapeutic index|cytochrome p 450 cyp2b6 substrates with a narrow therapeutic index|neurotransmitter agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|miscellaneous anticonvulsants|oat3/slc22a8 substrates with a narrow therapeutic index|qtc prolonging agents|ugt1a1 substrates with a narrow therapeutic index|ugt1a3 substrates with a narrow therapeutic index|ugt1a9 substrates with a narrow therapeutic index|nervous system|valerates|cytochrome p 450 enzyme inhibitors|antimanic agents|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 inhibitors|fatty acids, volatile|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|gaba agents|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|mood stabilizer|oat1/slc22a6 inhibitors|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp1a2 inhibitors|cytochrome p 450 cyp2c9 inhibitors|pentanoic acids|ugt1a6 substrate|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|histone deacetylase inhibitors|methemoglobinemia associated agents|cytochrome p 450 enzyme inducers|psychotropic drugs|ugt1a9 substrates|highest risk qtc prolonging agents|narrow therapeutic index drugs|lipids|cytochrome p 450 cyp2c9 inhibitors (moderate)|cytochrome p 450 cyp2c9 substrates with a narrow therapeutic index|ugt1a1 substrates|ugt1a4 substrates|oat3/slc22a8 substrates
zolmitriptan	serotonin 1b and serotonin 1d receptor agonist|serotonin 5 ht1 receptor agonists|antimigraine preparations|serotonin 1b receptor agonists|oxazoles|amines|indoles|selective serotonin 5 ht1 receptor agonists|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|analgesics|serotonin modulators|agents that produce hypertension|central nervous system depressants|neurotransmitter agents|antidepressive agents|serotonin 1d receptor agonists|monoamine oxidase a substrates|nervous system|selective serotonin agonists|cytochrome p 450 substrates|biogenic monoamines|triptans|heterocyclic compounds, fused ring|cytochrome p 450 cyp1a2 substrates|biogenic amines|serotonin receptor agonists
paracetamol	sensory system agents|central nervous system agents|drugs that are mainly renally excreted|cytochrome p 450 cyp3a4 inhibitors (weak)|cytochrome p 450 cyp2a6 substrates|cytochrome p 450 cyp3a4 inducers|amines|cytochrome p 450 cyp3a4 substrates|miscellaneous analgesics and antipyretics|p glycoprotein inhibitors|p glycoprotein substrates|analgesics|acetaminophen and prodrugs|amides|nervous system|cytochrome p 450 enzyme inhibitors|anilides|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a inhibitors|analgesics, non narcotic|cytochrome p 450 cyp2d6 substrates|ugt1a6 substrate|aniline compounds|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|methemoglobinemia associated agents|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 enzyme inducers|ugt1a9 substrates|cytochrome p 450 cyp1a2 substrates|antipyretics|ugt1a1 substrates
gefitinib	antineoplastic and immunomodulating agents|bcrp/abcg2 inhibitors|antineoplastic agents|kinase inhibitor|cytochrome p 450 cyp3a4 substrates|tyrosine kinase inhibitors|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp2d6 inhibitors (weak)|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|bcrp/abcg2 substrates|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp3a inhibitors|protein kinase inhibitors|cytochrome p 450 cyp2c9 inhibitors|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|quinazolines|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates
piperacillin	antibacterials for systemic use|anti bacterial agents|extended spectrum penicillins|penicillin g|agents that produce neuromuscular block (indirect)|drugs that are mainly renally excreted|beta lactam antibacterials|penicillins with extended spectrum|beta lactams|amides|oat1/slc22a6 inhibitors|anti infective agents|heterocyclic compounds, fused ring|antiinfectives for systemic use|sulfur compounds|penicillins|lactams|oat3/slc22a8 substrates
dihydroergotamine	serotonin 5 ht1 receptor agonists|sensory system agents|antimigraine preparations|central nervous system agents|adrenergic alpha 1 receptor antagonists|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|adrenergic antagonists|ergot derivative dopamine receptor agonists|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|analgesics|vasoconstrictor agents|serotonin modulators|agents that produce hypertension|central nervous system depressants|neurotransmitter agents|antidepressive agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cardiovascular agents|sympatholytic (adrenergic blocking) agents|ergotamines|nervous system|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|alkaloids|serotonin 5 ht2 receptor agonists|cytochrome p 450 substrates|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a inhibitors|analgesics, non narcotic|heterocyclic compounds, fused ring|ergot alkaloids and derivatives|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|peripheral nervous system agents|dopamine agents|narrow therapeutic index drugs|ergotamine derivative|dopamine agonists|serotonin receptor agonists
amitriptyline	adrenergic uptake inhibitors|cytochrome p 450 cyp2c19 substrates with a narrow therapeutic index|agents producing tachycardia|membrane transport modulators|cytochrome p 450 cyp2c8 inhibitors|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|sensory system agents|central nervous system agents|serotonin receptor antagonists|drugs that are mainly renally excreted|adrenergic alpha 1 receptor antagonists|cytochrome p 450 cyp3a4 substrates|ugt1a1 inhibitors|p glycoprotein substrates|adrenergic antagonists|cytochrome p 450 cyp2d6 inhibitors (weak)|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp2c8 inhibitors (moderate)|histamine h1 antagonists|analgesics|anticholinergic agents|cytochrome p 450 cyp2b6 substrates|cytochrome p 450 cyp2d6 substrates with a narrow therapeutic index|agents that produce hypertension|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|serotonin modulators|central nervous system depressants|cytochrome p 450 cyp2b6 substrates with a narrow therapeutic index|neurotransmitter agents|tertiary amine tricyclic antidepressants|antidepressive agents|ugt1a4 substrates|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|agents that reduce seizure threshold|antidepressive agents, tricyclic|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|moderate risk qtc prolonging agents|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|non selective monoamine reuptake inhibitors|serotonin 5 ht2 receptor antagonists|analgesics, non narcotic|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|serotonin 5 ht2c receptor antagonists|muscarinic antagonists|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|combined inhibitors of serotonin/norepinephrine reuptake|cytochrome p 450 cyp3a5 substrates|neurotoxic agents|neurotransmitter uptake inhibitors|psychotropic drugs|serotonin 5 ht2a receptor antagonists|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|cytochrome p 450 cyp2c9 substrates with a narrow therapeutic index|cytochrome p 450 cyp2c8 substrates with a narrow therapeutic index|histamine antagonists|ugt1a1 substrates|tricyclics and other norepinephrine reuptake inhibitors|cytochrome p 450 cyp2c8 substrates
floxuridine	carbohydrates|antineoplastic and immunomodulating agents|pyrimidines|thyroxine binding globulin inducers|antineoplastic agents|drugs that are mainly renally excreted|nucleosides|myelosuppressive agents|deoxyuridine|ribonucleosides|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2c9 inhibitors (strong)|glycosides|nucleic acids, nucleotides, and nucleosides|noxae|cytochrome p 450 cyp2c9 inhibitors|immunosuppressive agents|pyrimidine analogues|deoxyribonucleosides|pyrimidine nucleosides|antimetabolites|narrow therapeutic index drugs|drugs that are mainly renally excreted with a narrow therapeutic index|toxic actions
tolcapone	central nervous system agents|anti dyskinesia agents|drugs that are mainly renally excreted|comt inhibitors|hypotensive agents|central nervous system depressants|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|nervous system|phenols|cytochrome p 450 enzyme inhibitors|anti parkinson drugs|enzyme inhibitors|cytochrome p 450 cyp2c9 inhibitors|ketones|nitro compounds|dopamine agents|nitrophenols|benzene derivatives|benzophenones
fluorometholone	hormones, hormone substitutes, and hormone antagonists|adrenal cortex hormones|ophthalmologicals|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|anti acne preparations for topical use|corticosteroids|cytochrome p 450 cyp3a5 inducers (strength unknown)|steroids, fluorinated|hyperglycemia associated agents|anti inflammatory agents|anti acne preparations|corticosteroids, moderately potent (group ii)|pregnanes|anti allergic agents|cytochrome p 450 substrates|vasoprotectives|pregnadienediols|cytochrome p 450 cyp3a inducers|corticosteroid hormone receptor agonists|immunosuppressive agents|cytochrome p 450 cyp3a substrates|glucocorticoids|cytochrome p 450 cyp3a4 inducers (strength unknown)|dermatologicals|cytochrome p 450 enzyme inducers|steroids|corticosteroids, dermatological preparations|hormones|sensory organs|thyroxine binding globulin inhibitors|pregnadienes|agents for treatment of hemorrhoids and anal fissures for topical use|cytochrome p 450 cyp3a5 inducers
indometacin	anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|antiinflammatory preparations, non steroids for topical use|central nervous system agents|sensory system agents|ophthalmologicals|other nonsteroidal anti inflammatory agents|ugt2b7 substrates|tocolytic agents|musculo skeletal system|hypoglycemia associated agents|nephrotoxic agents|p glycoprotein inhibitors|oat1/slc22a6 substrates|p glycoprotein substrates|indoles|ugt1a1 inhibitors|cytochrome p 450 cyp2c19 substrates|oat3/slc22a8 inhibitors|analgesics|agents that produce hypertension|non cox 2 selective nsaids|acetic acid derivatives and related substances|oatp1b1/slco1b1 inhibitors|cardiovascular agents|antigout preparations|antiinflammatory and antirheumatic products, non steroids|myelosuppressive agents|topical products for joint and muscular pain|cytochrome p 450 enzyme inhibitors|anti inflammatory agents|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|oat1/slc22a6 inhibitors|analgesics, non narcotic|antirheumatic agents|heterocyclic compounds, fused ring|immunosuppressive agents|cytochrome p 450 cyp2c19 inhibitors|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|ugt1a9 substrates|ugt2b7 inhibitors|sensory organs|bsep/abcb11 substrates|cardiac therapy|ugt1a1 substrates|oat3/slc22a8 substrates|cyclooxygenase inhibitors
ethambutol	diamines|antiinfectives for systemic use|anti bacterial agents|drugs for treatment of tuberculosis|antimycobacterials|antituberculosis agents|drugs that are mainly renally excreted|polyamines|anti infective agents|ethylenediamines|amines
metformin	amidines|guanidines|biguanides|drugs used in diabetes|alimentary tract and metabolism|oct2 substrates|mate substrates|mate 1 substrates|drugs that are mainly renally excreted|oct1 substrates|blood glucose lowering agents|oct2 inhibitors|mate 2 substrates
ipratropium	agents producing tachycardia|anti asthmatic agents|aza compounds|azabicyclo compounds|belladonna alkaloids|agents to treat airway disease|anticholinergic agents|tropanes|neurotransmitter agents|cholinergic agents|alkaloids|adrenergics, inhalants|atropine derivatives|muscarinic antagonists|drugs for obstructive airway diseases|respiratory system agents|antimuscarinics antispasmodics|peripheral nervous system agents|nasal preparations|bronchodilator agents|solanaceous alkaloids|autonomic agents
olanzapine	agents producing tachycardia|central nervous system agents|serotonin receptor antagonists|cytochrome p 450 cyp2c9 inhibitors (weak)|tranquilizing agents|adrenergic alpha 1 receptor antagonists|cytochrome p 450 cyp3a4 inhibitors (weak)|diazepines, oxazepines, thiazepines and oxepines|psycholeptics|p glycoprotein substrates|adrenergic antagonists|benzazepines|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|anticholinergic agents|hypotensive agents|antipsychotic agents|cytochrome p 450 cyp2c19 inhibitors (weak)|central nervous system depressants|neurotransmitter agents|antidepressive agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|nervous system|cytochrome p 450 enzyme inhibitors|hyperglycemia associated agents|cytochrome p 450 cyp3a4 inhibitors|gastrointestinal agents|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|serotonin 5 ht2 receptor antagonists|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2c9 inhibitors|antipsychotic agents (second generation [atypical])|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|muscarinic antagonists|cytochrome p 450 cyp2d6 substrates|potential qtc prolonging agents|cytochrome p 450 cyp2c19 inhibitors|serotonin 5 ht2c receptor antagonists|adrenergic alpha antagonists|peripheral nervous system agents|serotonin 5 ht2a receptor antagonists|psychotropic drugs|cytochrome p 450 cyp1a2 substrates|antiemetics|histamine h2 antagonists|autonomic agents|histamine antagonists|dopamine antagonists|ugt1a4 substrates|histamine h1 antagonists
atenolol	beta blocking agents, selective, and thiazides|adrenergic agents|beta blockers (beta1 selective)|antihypertensive agents indicated for hypertension|amines|bradycardia causing agents|beta blocking agents, selective|adrenergic antagonists|hypotensive agents|qtc shortening agents|antiarrhythmic agents|cardiovascular agents|adrenergic beta 1 receptor antagonists|adrenergic beta antagonists|cytochrome p 450 substrates|beta blocking agents and thiazides|beta blocking agents and calcium channel blockers|cytochrome p 450 cyp2d6 substrates|antihypertensive agents|peripheral nervous system agents|agents causing hyperkalemia|bsep/abcb11 substrates|amino alcohols|autonomic agents|sympatholytics|alcohols
nitrofural	medicated dressings|ophthalmologicals|agents against leishmaniasis and trypanosomiasis|antiparasitic products, insecticides and repellents|blood and blood forming organs|furans|blood substitutes and perfusion solutions|nitrofurans|anti infective agents|otologicals|antiseptics and disinfectants|irrigating solutions|nitrofuran derivatives|nitro compounds|dermatologicals|sensory organs|antiprotozoals|medicated dressings with antiinfectives
omeprazole	gastric acid lowering agents|bcrp/abcg2 inhibitors|cytochrome p 450 cyp1a2 inducers (strength unknown)|acid reducers|anti ulcer agents|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp1a2 inducers|cytochrome p 450 cyp2d6 inhibitors (weak)|photosensitizing agents|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp2c19 inhibitors (weak)|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|drugs for peptic ulcer and gastro oesophageal reflux disease (gord)|pyridines|cytochrome p 450 cyp2d6 inhibitors|drugs for acid related disorders|cytochrome p 450 enzyme inhibitors|benzimidazoles|cytochrome p 450 cyp3a4 inhibitors|gastrointestinal agents|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp1a2 inhibitors|heterocyclic compounds, fused ring|2 pyridinylmethylsulfinylbenzimidazoles|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|alimentary tract and metabolism|proton pump inhibitors|sulfur compounds|cytochrome p 450 cyp2c18 substrates|sulfoxides|cytochrome p 450 cyp2c8 substrates
pyrazinamide	cytochrome p 450 cyp3a substrates|drugs causing inadvertant photosensitivity|photosensitizing agents|antiinfectives for systemic use|pyrazines|anti bacterial agents|drugs for treatment of tuberculosis|antimycobacterials|cytochrome p 450 substrates|drugs that are mainly renally excreted|anti infective agents|hepatotoxic agents
metixene	agents producing tachycardia|nervous system|anticholinergic agents|anti parkinson drugs|sulfur compounds|xanthenes|tertiary amines|heterocyclic compounds, fused ring|muscarinic antagonists
cetirizine	p glycoprotein inhibitors|histamine agents|p glycoprotein substrates|anti allergic agents|piperazine derivatives|histamine h1 antagonists, non sedating|drugs that are mainly renally excreted|piperazines|central nervous system depressants|antihistamines for systemic use|histamine antagonists|potential qtc prolonging agents|qtc prolonging agents|histamine h1 antagonists
terfenadine	cytochrome p 450 cyp2c8 inhibitors|cytochrome p 450 cyp3a4 inhibitors (strong)|histamine h1 antagonists, non sedating|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|histamine agents|p glycoprotein substrates|cytochrome p 450 cyp2d6 inhibitors (weak)|anticholinergic agents|antihistamines for systemic use|neurotransmitter agents|benzhydryl compounds|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|piperidines|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a inducers|muscarinic antagonists|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2d6 inhibitors (moderate)|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 enzyme inducers|highest risk qtc prolonging agents|bsep/abcb11 substrates|benzene derivatives|histamine antagonists|histamine h1 antagonists|cytochrome p 450 cyp3a4 substrates (strength unknown)
diltiazem	membrane transport modulators|cytochrome p 450 cyp2c8 inhibitors|drugs causing inadvertant photosensitivity|cytochrome p 450 cyp3a5 inhibitors (moderate)|cytochrome p 450 cyp3a4 inhibitors (strong)|benzothiazepine derivatives|calcium regulating hormones and agents|antihypertensive agents indicated for hypertension|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|p glycoprotein inhibitors|p glycoprotein substrates|photosensitizing agents|benzazepines|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp2c8 inhibitors (moderate)|cytochrome p 450 cyp3a5 inhibitors|hypotensive agents|antiarrhythmic agents|calcium channel blockers|selective calcium channel blockers with direct cardiac effects|cardiovascular agents|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|vasodilating agents|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a4 inhibitors (moderate)|calcium channel blockers (nondihydropyridine)|moderate risk qtc prolonging agents|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|miscellaneous calcium channel blocking agents|vasoprotectives|cytochrome p 450 cyp3a inhibitors|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a7 inhibitors (moderate)|cytochrome p 450 cyp3a7 inhibitors|cytochrome p 450 cyp3a7 inhibitors (strong)|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|antihypertensive agents|agents causing hyperkalemia|agents for treatment of hemorrhoids and anal fissures for topical use|cytochrome p 450 cyp2c8 substrates
protriptyline	adrenergic uptake inhibitors|membrane transport modulators|psychoanaleptics|central nervous system agents|adrenergic agents|benzocycloheptenes|p glycoprotein inhibitors|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|serotonin modulators|agents that produce hypertension|central nervous system depressants|neurotransmitter agents|antidepressive agents|qtc prolonging agents|dibenzocycloheptenes|nervous system|agents that reduce seizure threshold|antidepressive agents, tricyclic|cytochrome p 450 substrates|non selective monoamine reuptake inhibitors|potential qtc prolonging agents|cytochrome p 450 cyp2d6 substrates|neurotoxic agents|combined inhibitors of serotonin/norepinephrine reuptake|neurotransmitter uptake inhibitors|psychotropic drugs|narrow therapeutic index drugs
aminohippuric acid	diagnostic agents|benzoates|aminobenzoates|oat1/slc22a6 substrates|keto acids|oat3/slc22a8 inhibitors|oct2 inhibitors|oatp1b1/slco1b1 inhibitors|amides|laboratory chemicals|para aminobenzoates|indicators and reagents|oat1/slc22a6 inhibitors|tests for renal function and ureteral injuries|aminohippuric acids|hippurates|compounds used in a research, industrial, or household setting|benzamides and benzamide derivatives|acids, carbocyclic|benzene derivatives|oat3/slc22a8 substrates
pah	diagnostic agents|benzoates|aminobenzoates|oat1/slc22a6 substrates|keto acids|oat3/slc22a8 inhibitors|oct2 inhibitors|oatp1b1/slco1b1 inhibitors|amides|laboratory chemicals|para aminobenzoates|indicators and reagents|oat1/slc22a6 inhibitors|tests for renal function and ureteral injuries|aminohippuric acids|hippurates|compounds used in a research, industrial, or household setting|benzamides and benzamide derivatives|acids, carbocyclic|benzene derivatives|oat3/slc22a8 substrates
alfuzosin	urological agents|adrenergic agents|drugs used in benign prostatic hypertrophy|adrenergic alpha 1 receptor antagonists|cytochrome p 450 cyp3a4 substrates|adrenergic antagonists|neurotransmitter agents|qtc prolonging agents|prostatic hyperplasia|selective alfa 1 adrenergic blocking agents|urologicals|cytochrome p 450 substrates|potential qtc prolonging agents|heterocyclic compounds, fused ring|peripheral alpha 1 blockers|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|genito urinary system and sex hormones
trimethadione	oxazolidine derivatives|central nervous system agents|oxazoles|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|anti epileptic agent|decreased central nervous system disorganized electrical activity|cytochrome p 450 cyp2c19 substrates|anticonvulsants|antiarrhythmic agents|central nervous system depressants|calcium channel blockers|qtc prolonging agents|nervous system|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|potential qtc prolonging agents|cytochrome p 450 cyp3a substrates|agents causing hyperkalemia|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 cyp2c8 substrates
minoxidil	antihypertensive agents|vasodilating agents|dermatologicals|pyrimidines|arteriolar vasodilation|arteriolar vasodilator|hypotensive agents|pyrimidine derivatives|direct vasodilators|piperidines|cardiovascular agents|arteriolar smooth muscle, agents acting on|misc. skin and mucous membrane agents|ugt1a1 substrates|antihypertensive agents indicated for hypertension
megestrol acetate	central nervous system stimulants|antineoplastic and immunomodulating agents|adrenal cortex hormones|central nervous system agents|antineoplastic agents|drugs that are mainly renally excreted|pregnadien derivatives|cytochrome p 450 cyp3a4 substrates|fused ring compounds|hormonal contraceptives for systemic use|p glycoprotein inhibitors|megestrol|progestogens and estrogens, sequential preparations|contraceptives, oral, synthetic|sex hormones and modulators of the genital system|hormones and related agents|antineoplastic agents, hormonal|hyperglycemia associated agents|pregnanes|appetite stimulants|progestins|contraceptives, oral|cytochrome p 450 substrates|contraceptive agents, female|combination contraceptives (with estrogen and derivatives)|cytochrome p 450 cyp3a substrates|progestin contraceptives|steroids|reproductive control agents|endocrine therapy|genito urinary system and sex hormones|pregnadienes
tioguanine	antineoplastic and immunomodulating agents|antimetabolites|myelosuppressive agents|purine analogues|antineoplastic agents|narrow therapeutic index drugs|thiopurine analogs|purines|immunosuppressive agents|noxae|toxic actions|heterocyclic compounds, fused ring
methylergometrine	ergot alkaloids and derivatives|cytochrome p 450 cyp3a substrates|cytochrome p 450 enzyme inhibitors|ergonovine|ergolines|cytochrome p 450 cyp3a4 inhibitors|heterocyclic compounds, fused ring|alkaloids|reproductive control agents|uterotonic agents|genito urinary system and sex hormones|agents that produce hypertension|cytochrome p 450 substrates|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 substrates|dopamine antagonists
aztreonam	amides|monobactam antibacterial|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|heterocyclic compounds, fused ring|sulfur compounds|drugs that are mainly renally excreted|beta lactams|anti infective agents|monobactams|lactams
chlorzoxazone	oxazol, thiazine, and triazine derivatives|muscle relaxants|central nervous system agents|drugs that are mainly renally excreted|cytochrome p 450 cyp3a4 inhibitors (weak)|cytochrome p 450 cyp2a6 substrates|musculo skeletal system|cytochrome p 450 cyp3a4 substrates|muscle relaxants, centrally acting agents|cytochrome p 450 cyp2e1 inhibitors|central nervous system depressants|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|centrally mediated muscle relaxation|cytochrome p 450 cyp3a inhibitors|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|peripheral nervous system agents|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|cytochrome p 450 cyp1a2 substrates|benzoxazoles
aminoglutethimide	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|antineoplastic and immunomodulating agents|estrogen antagonists|antineoplastic agents|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp2c19 inducers|antineoplastic agents, hormonal|steroid synthesis inhibitors|aromatase inhibitors|piperidines|enzyme inhibitors|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp2c19 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|endocrine therapy|hormone antagonists and related agents|narrow therapeutic index drugs|piperidones
mefloquine	aminoquinolines|cytochrome p 450 cyp3a4 substrates|antiparasitic products, insecticides and repellents|p glycoprotein inhibitors|p glycoprotein substrates|cholinesterase inhibitors|cytochrome p 450 cyp2d6 inhibitors (weak)|quinolines|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|antiparasitic agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|agents that reduce seizure threshold|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|anti infective agents|antimalarials|cytochrome p 450 cyp3a inhibitors|potential qtc prolonging agents|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|antiprotozoals|methanolquinolines
sulfadiazine	antibacterials for systemic use|anti bacterial agents|sulfonamides and trimethoprim|drugs that are mainly renally excreted|sulfanilamides|amines|cytochrome p 450 cyp3a4 substrates|hypoglycemia associated agents|intermediate acting sulfonamides|sulfonamide antibacterial|sulfones|blood glucose lowering agents|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|coccidiostats|antiparasitic agents|amides|cytochrome p 450 enzyme inhibitors|sulfonamides|cytochrome p 450 substrates|anti infective agents|gynecological antiinfectives and antiseptics|cytochrome p 450 cyp2c9 inhibitors|aniline compounds|cytochrome p 450 cyp3a substrates|methemoglobinemia associated agents|antiinfectives for systemic use|genito urinary system and sex hormones|sulfur compounds|antiprotozoals|cytochrome p 450 cyp2c8 substrates
tetrahydrobiopterin	various alimentary tract and metabolism products|dietary supplements|amines|phenylalanine hydroxylase activators|p glycoprotein inhibitors|supplements|pterins|pteridines|other miscellaneous therapeutic agents|nitric oxide synthase|enzymes and coenzymes|ethylamines|coenzymes|pigments, biological|heterocyclic compounds, fused ring|phenylalanine hydroxylase activator|biological factors|alimentary tract and metabolism|phenethylamines|breast cancer resistance protein inhibitors
vinorelbine	antineoplastic and immunomodulating agents|antineoplastic agents|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp2d6 inhibitors (weak)|indoles|indole alkaloids|vinca alkaloids|myelosuppressive agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|antineoplastic agents, phytogenic|antimitotic agents|alkaloids|cytochrome p 450 substrates|tubulin modulators|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|heterocyclic compounds, fused ring|immunosuppressive agents|cytochrome p 450 cyp3a substrates|neurotoxic agents|mitosis modulators|cardiotoxic antineoplastic agents|narrow therapeutic index drugs|secologanin tryptamine alkaloids
clozapine	agents producing tachycardia|drugs causing inadvertant photosensitivity|serotonin 5 ht1d receptor antagonists|central nervous system agents|serotonin receptor antagonists|tranquilizing agents|drugs that are mainly renally excreted|adrenergic alpha 1 receptor antagonists|cytochrome p 450 cyp2a6 substrates|diazepines, oxazepines, thiazepines and oxepines|psycholeptics|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|p glycoprotein substrates|adrenergic antagonists|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|photosensitizing agents|cytochrome p 450 cyp2c19 substrates|histamine h1 antagonists|serotonin 5 ht1 receptor antagonists|anticholinergic agents|serotonin 5 ht1a receptor antagonists|hypotensive agents|antipsychotic agents|agents that produce hypertension|serotonin agents|cytochrome p 450 cyp2c19 inhibitors (weak)|central nervous system depressants|neurotransmitter agents|antidepressive agents|dibenzazepines|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|gaba antagonists|nervous system|agents that reduce seizure threshold|cytochrome p 450 enzyme inhibitors|hyperglycemia associated agents|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 inhibitors (moderate)|moderate risk qtc prolonging agents|cytochrome p 450 substrates|gaba agents|cytochrome p 450 cyp2c9 substrates|serotonin 5 ht2 receptor antagonists|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp1a2 inhibitors|antipsychotic agents (second generation [atypical])|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|muscarinic antagonists|cytochrome p 450 cyp2d6 substrates|serotonin 5 ht2c receptor antagonists|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|cytochrome p 450 cyp2d6 inhibitors (moderate)|cytochrome p 450 cyp3a4 inducers (strength unknown)|neurotoxic agents|cytochrome p 450 enzyme inducers|psychotropic drugs|serotonin 5 ht2a receptor antagonists|cytochrome p 450 cyp1a2 substrates|histamine antagonists|dopamine antagonists|ugt1a4 substrates|cytochrome p 450 cyp2c8 substrates
doxylamine	agents producing tachycardia|ethanolamine derivatives|central nervous system agents|histamine agents|anticholinergic agents|central nervous system depressants|antihistamines for systemic use|neurotransmitter agents|qtc prolonging agents|pyridines|gastrointestinal agents|histamine receptor antagonists|potential qtc prolonging agents|muscarinic antagonists|peripheral nervous system agents|antiemetics|autonomic agents|histamine antagonists|aminoalkyl ethers|histamine h1 antagonists
levonorgestrel	norsteroids|inhibit ovum fertilization|adrenal cortex hormones|contraceptives, postcoital|cytochrome p 450 cyp3a4 substrates|hormonal contraceptives for systemic use|fused ring compounds|progestogens and estrogens, sequential preparations|contraceptives, oral, synthetic|sex hormones and modulators of the genital system|norpregnenes|hyperglycemia associated agents|norpregnanes|progestins|contraceptives, oral|cytochrome p 450 substrates|contraceptive agents, female|combination contraceptives (with estrogen and derivatives)|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|progestin contraceptives|progestin containing intrauterine device|reproductive control agents|steroids|genito urinary system and sex hormones
norepinephrine	agents producing tachycardia|adrenergic agents|catechols|amines|norepinephrine, antagonists & inhibitors|adrenergic beta 2 receptor agonists|epinephrine and similars|oct2 substrates|vasoconstrictor agents|agents that produce hypertension|oct2 inhibitors|oct1 substrates|adrenergic alpha 1 receptor agonists|adrenergic alpha 2 receptor agonists|neurotransmitter agents|cardiovascular agents|comt substrates|cardiac stimulants excl. cardiac glycosides|sympathomimetics|phenols|alpha and beta adrenergic agonists|adrenergic agonists|adrenergic beta 1 receptor agonists|biogenic monoamines|cardiac therapy|adrenergic alpha agonists|adrenergic beta agonists|catecholamines|ethanolamines|peripheral nervous system agents|adrenergic and dopaminergic agents|biogenic amines|amino alcohols|adrenergic beta 3 receptor agonists|autonomic agents|benzene derivatives|alcohols
mirtazapine	miscellaneous antidepressants|psychoanaleptics|central nervous system agents|adrenergic agents|serotonin receptor antagonists|tranquilizing agents|cytochrome p 450 cyp3a4 inhibitors (weak)|cytochrome p 450 cyp3a4 substrates|histamine agents|adrenergic antagonists|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|serotonin modulators|adrenergic alpha 2 receptor antagonists|agents that produce hypertension|central nervous system depressants|neurotransmitter agents|antidepressive agents|qtc prolonging agents|nervous system|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|antidepressive agents, tetracyclic|cytochrome p 450 substrates|serotonin 5 ht2 receptor antagonists|serotonin 5 ht3 receptor antagonists|cytochrome p 450 cyp3a inhibitors|potential qtc prolonging agents|heterocyclic compounds, fused ring|serotonin 5 ht2c receptor antagonists|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|serotonin 5 ht2a receptor antagonists|psychotropic drugs|cytochrome p 450 cyp1a2 substrates|histamine antagonists|histamine h1 antagonists|anti anxiety agents
thiethylperazine	phenothiazines|central nervous system agents|piperazines|drugs that are mainly renally excreted|antipsychotic agents|central nervous system depressants|antihistamines for systemic use|neurotransmitter agents|phenothiazine derivatives|gastrointestinal agents|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|neurotoxic agents|peripheral nervous system agents|dopamine agents|sulfur compounds|antiemetics|autonomic agents|dopamine antagonists
timolol	propanolamines|thiazoles|thiadiazoles|beta blocking agents, non selective|drugs that are mainly renally excreted|ophthalmologicals|oxazines|amines|bradycardia causing agents|p glycoprotein substrates|adrenergic antagonists|cytochrome p 450 cyp2c19 substrates|hypotensive agents|antiarrhythmic agents|antiglaucoma preparations and miotics|cardiovascular agents|qtc prolonging agents|propanols|adrenergic beta antagonists|cytochrome p 450 substrates|beta blocking agents and thiazides|beta blocking agents, non selective, and thiazides|potential qtc prolonging agents|cytochrome p 450 cyp2d6 substrates|eent drugs, miscellaneous|antihypertensive agents|agents causing hyperkalemia|sulfur compounds|amino alcohols|morpholines|alcohols
treprostinil	prostaglandins i|fatty acids|prostacycline vasodilator|cardiovascular agents|blood and blood forming organs|qtc prolonging agents|prostacyclin analogues|autacoids|vasodilation|prostaglandins|vasodilating agents|cytochrome p 450 substrates|platelet aggregation inhibitors excl. heparin|cytochrome p 450 cyp2c9 substrates|potential qtc prolonging agents|biological factors|eicosanoids|antihypertensive agents|inflammation mediators|lipids|fatty acids, unsaturated
trihexyphenidyl	agents producing tachycardia|cholinergic agents|nervous system|central nervous system agents|anticholinergic agents|anti parkinson drugs|anti dyskinesia agents|piperidines|neurotransmitter agents|tertiary amines|muscarinic antagonists
palonosetron	central nervous system agents|serotonin receptor antagonists|drugs that are mainly renally excreted|cytochrome p 450 cyp3a4 substrates|quinuclidines|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|central nervous system depressants|neurotransmitter agents|antidepressive agents|serotonin 3 receptor antagonists|gastrointestinal agents|cytochrome p 450 substrates|serotonin 5 ht3 receptor antagonists|antiemetics and antinauseants|isoquinolines|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|peripheral nervous system agents|alimentary tract and metabolism|cytochrome p 450 cyp1a2 substrates|antiemetics|autonomic agents
dydrogesterone	hormones, hormone substitutes, and hormone antagonists|cytochrome p 450 cyp3a substrates|adrenal cortex hormones|pregnanes|hormones|progestins|progestogens and estrogens, sequential preparations|steroids|genito urinary system and sex hormones|cytochrome p 450 substrates|pregnadienes|sex hormones and modulators of the genital system|pregnadien derivatives|cytochrome p 450 cyp3a4 substrates|fused ring compounds
mexiletine	membrane transport modulators|amines|cytochrome p 450 cyp3a4 substrates|antiarrhythmics, class ib|cytochrome p 450 cyp2b6 substrates|antiarrhythmic agents|ethers|voltage gated sodium channel blockers|cytochrome p 450 cyp1a2 inhibitors (moderate)|cardiovascular agents|propylamines|phenols|cytochrome p 450 enzyme inhibitors|cytochrome p 450 substrates|phenyl ethers|cytochrome p 450 cyp1a2 inhibitors|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|antiarrhythmics, class i|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 cyp1a2 substrates|benzene derivatives|cardiac therapy|sodium channel blockers
dexrazoxane	diketopiperazines|compounds used in a research, industrial, or household setting|topoisomerase inhibitors|topoisomerase ii inhibitors|detoxifying agents for antineoplastic treatment|miscellaneous therapeutic agents|myelosuppressive agents|immunosuppressive agents|protective agents|cardiotonic agents|piperazines|drugs that are mainly renally excreted|enzyme inhibitors|cardiovascular agents|cytoprotective agent
amlodipine	membrane transport modulators|cytochrome p 450 cyp2c8 inhibitors|cytochrome p 450 cyp2b6 inhibitors (strength unknown)|ace inhibitors and calcium channel blockers|calcium regulating hormones and agents|antihypertensive agents indicated for hypertension|cytochrome p 450 cyp3a5 inhibitors (weak)|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp2d6 inhibitors (weak)|cytochrome p 450 cyp2c8 inhibitors (moderate)|cytochrome p 450 cyp3a5 inhibitors|cytochrome p 450 cyp2b6 substrates|antianginal agents|hypotensive agents|antiarrhythmic agents|calcium channel blockers|selective calcium channel blockers with mainly vascular effects|cardiovascular agents|qtc prolonging agents|pyridines|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 cyp2b6 inhibitors|calcium channel blockers (dihydropyridine)|cytochrome p 450 enzyme inhibitors|vasodilating agents|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|calcium channel blockers and diuretics|angiotensin ii receptor blockers (arbs) and calcium channel blockers|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|antihypertensive agents|agents causing hyperkalemia|angiotensin ii antagonists and calcium channel blockers|dihydropyridines|dihydropyridine derivatives
tacrine	aminoacridines|psychoanaleptics|central nervous system agents|p glycoprotein substrates|cholinesterase inhibitors|neurotransmitter agents|acridines|nervous system|cholinergic agents|agents causing muscle toxicity|cytochrome p 450 substrates|enzyme inhibitors|parasympathomimetics|heterocyclic compounds, fused ring|peripheral nervous system agents|nootropic agents|cytochrome p 450 cyp1a2 substrates|anti dementia drugs|autonomic agents
triamterene	membrane transport modulators|drugs causing inadvertant photosensitivity|epithelial sodium channel blockers|nephrotoxic agents|photosensitizing agents|hypotensive agents|decreased renal k+ excretion|pteridines|cardiovascular agents|increased diuresis|diuretics|natriuretic agents|cytochrome p 450 substrates|heterocyclic compounds, fused ring|potassium sparing diuretics|agents causing hyperkalemia|cytochrome p 450 cyp1a2 substrates|sodium channel blockers
procyclidine	agents producing tachycardia|cholinergic agents|nervous system|central nervous system agents|anticholinergic agents|anti parkinson drugs|anti dyskinesia agents|neurotransmitter agents|pyrrolidines|tertiary amines|muscarinic antagonists
carbimazole	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|agents causing muscle toxicity|imidazoles|antithyroid agents|sulfur containing imidazole derivatives|thyroid products|systemic hormonal preparations, excl. sex hormones and insulins
digoxin	carbohydrates|digoxin, antagonists & inhibitors|cardenolides|drugs that are mainly renally excreted|digoxin and derivatives|cardiac glycosides|bradycardia causing agents|fused ring compounds|p glycoprotein inhibitors|p glycoprotein substrates|digitalis glycosides|protective agents|p glycoprotein inducers|antiarrhythmic agents|oatp1b1/slco1b1 inhibitors|cardiovascular agents|qtc prolonging agents|oatp1b1/slco1b1 substrates|glycosides|bsep/abcb11 substrates with a narrow therapeutic index|potential qtc prolonging agents|compounds used in a research, industrial, or household setting|agents causing hyperkalemia|digoxin, immunology|cardiotonic agents|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|bsep/abcb11 substrates|drugs that are mainly renally excreted with a narrow therapeutic index|cardiac therapy|cardanolides
sulpiride	central nervous system agents|tranquilizing agents|benzoates|psycholeptics|cholinesterase inhibitors|antidepressive agents, second generation|antipsychotic agents|central nervous system depressants|neurotransmitter agents|antidepressive agents|qtc prolonging agents|amides|nervous system|moderate risk qtc prolonging agents|dopamine d2 receptor antagonists|neurotoxic agents|psychotropic drugs|dopamine agents|benzamides and benzamide derivatives|acids, carbocyclic|benzene derivatives|dopamine antagonists
profenamine	agents producing tachycardia|cholinergic agents|histamine agents|cholinesterase inhibitors|adrenergic antagonists|nervous system|heterocyclic compounds, fused ring|adrenergic agents|anticholinergic agents|anti parkinson drugs|sulfur compounds|neurotransmitter agents|nmda receptor antagonists|tertiary amines|muscarinic antagonists
nimodipine	membrane transport modulators|calcium regulating hormones and agents|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|p glycoprotein inhibitors|hypotensive agents|antiarrhythmic agents|calcium channel blockers|selective calcium channel blockers with mainly vascular effects|cardiovascular agents|qtc prolonging agents|pyridines|calcium channel blockers (dihydropyridine)|vasodilating agents|moderate risk qtc prolonging agents|cytochrome p 450 substrates|cytochrome p 450 cyp3a substrates|antihypertensive agents|agents causing hyperkalemia|dihydropyridines|nicotinic acids|dihydropyridine derivatives
beclomethasone dipropionate	hormones, hormone substitutes, and hormone antagonists|anti asthmatic agents|adrenal cortex hormones|oatp1b3 inhibitors|bcrp/abcg2 inhibitors|agents to treat airway disease|steroids, chlorinated|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|p glycoprotein substrates|corticosteroids, potent (group iii)|p glycoprotein inducers|corticosteroids|cytochrome p 450 cyp3a5 inducers (strength unknown)|oatp1b1/slco1b1 inhibitors|antidiarrheals, intestinal antiinflammatory/antiinfective agents|intestinal antiinflammatory agents|hyperglycemia associated agents|anti inflammatory agents|pregnanes|cytochrome p 450 substrates|pregnadienetriols|cytochrome p 450 cyp3a inducers|corticosteroid hormone receptor agonists|drugs for obstructive airway diseases|adrenals|immunosuppressive agents|respiratory system agents|cytochrome p 450 cyp3a substrates|glucocorticoids|cytochrome p 450 cyp3a4 inducers (strength unknown)|nasal preparations|dermatologicals|cytochrome p 450 enzyme inducers|alimentary tract and metabolism|corticosteroids, dermatological preparations|hormones|steroids|thyroxine binding globulin inhibitors|pregnadienes|cytochrome p 450 cyp3a5 inducers|corticosteroids acting locally
carisoprodol	muscle relaxants|muscle relaxants, centrally acting agents|carbamic acid esters|cytochrome p 450 cyp2c19 substrates|central nervous system agents|carbamates|cytochrome p 450 substrates|centrally mediated muscle relaxation|central nervous system depressants|musculo skeletal system
progesterone	hormones, hormone substitutes, and hormone antagonists|gonadal steroid hormones|adrenal cortex hormones|pregnenediones|bcrp/abcg2 inhibitors|progesterone and derivatives|progesterone, antagonists & inhibitors|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp3a7 inhibitors (strength unknown)|fused ring compounds|hormonal contraceptives for systemic use|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp2a6 inducers|cytochrome p 450 cyp2c19 substrates|p glycoprotein inducers|oct2 inhibitors|oatp1b3 inducers|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|sex hormones and modulators of the genital system|oatp1b1/slco1b1 inhibitors|cytochrome p 450 cyp3a7 substrates|cytochrome p 450 enzyme inhibitors|hyperglycemia associated agents|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|pregnanes|progestins|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp2c9 inhibitors|corpus luteum hormones|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a7 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|oct1 inhibitors|cytochrome p 450 enzyme inducers|pregnenes|hormones|progestin containing intrauterine device|steroids|gonadal hormones|genito urinary system and sex hormones|bsep/abcb11 inhibitors|bcrp/abcg2 inducers
phenylpropanolamine	appetite depressants|propanolamines|agents producing tachycardia|adrenergic agents|amines|adrenergic beta 2 receptor agonists|vasoconstrictor agents|agents that produce hypertension|neurotransmitter agents|cardiovascular agents|anti obesity agents|sympathomimetics|agents that reduce seizure threshold|adrenergic agonists|propanols|nasal decongestants|adrenergic alpha agonists|monoamine oxidase a inhibitors  for interaction with monoamine oxidase a substrates|adrenergic beta agonists|respiratory system agents|peripheral nervous system agents|nasal preparations|amino alcohols|nasal decongestants for systemic use|autonomic agents|alcohols
sorafenib	cytochrome p 450 cyp2c8 inhibitors|antineoplastic and immunomodulating agents|cytochrome p 450 cyp3a7 substrates with a narrow therapeutic index|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|bcrp/abcg2 inhibitors|antineoplastic agents|drugs that are mainly renally excreted|kinase inhibitor|phenylurea compounds|cytochrome p 450 cyp2c8 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a4 substrates|tyrosine kinase inhibitors|p glycoprotein inhibitors|ugt1a1 inhibitors|p glycoprotein substrates|cytochrome p 450 cyp2b6 inhibitors (moderate)|ugt1a9 substrates with a narrow therapeutic index|ugt1a9 inhibitors|oatp1b1/slco1b1 inhibitors|bcrp/abcg2 substrates|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|myelosuppressive agents|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|pyridines|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 cyp2b6 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2c9 inhibitors (strong)|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|protein kinase inhibitors|cytochrome p 450 cyp2c9 inhibitors|potential qtc prolonging agents|immunosuppressive agents|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|ugt1a9 substrates|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|nicotinic acids|benzene derivatives|cytochrome p 450 cyp2c8 inhibitors (strong)|cytochrome p 450 cyp2c8 substrates
griseofulvin	antifungal agents|tubulin inhibiting agent|cytochrome p 450 cyp1a2 inducers (strength unknown)|cytochrome p 450 cyp2c8 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers|antifungals for dermatological use|cytochrome p 450 cyp1a2 inducers|microtubule inhibition|decreased mitosis|benzofurans|cytochrome p 450 cyp2c8 inducers|antifungals for topical use|anti infective agents|cytochrome p 450 cyp3a inducers|antifungals for systemic use|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a4 inducers (strength unknown)|dermatologicals|cytochrome p 450 enzyme inducers
nisoldipine	membrane transport modulators|drugs causing inadvertant photosensitivity|calcium regulating hormones and agents|drugs that are mainly renally excreted|antihypertensive agents indicated for hypertension|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|p glycoprotein inhibitors|photosensitizing agents|hypotensive agents|antiarrhythmic agents|calcium channel blockers|selective calcium channel blockers with mainly vascular effects|cardiovascular agents|cytochrome p 450 cyp3a7 substrates|pyridines|calcium channel blockers (dihydropyridine)|vasodilating agents|cytochrome p 450 substrates|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|antihypertensive agents|decreased blood pressure|agents causing hyperkalemia|dihydropyridines|dihydropyridine derivatives
alprazolam	hypnotics and sedatives|central nervous system agents|tranquilizing agents|catechols|drugs that are mainly renally excreted|psycholeptics|amines|cytochrome p 450 cyp3a4 substrates|benzazepines|central nervous system depressants|neurotransmitter agents|cytochrome p 450 cyp3a7 substrates|benzodiazepines and benzodiazepine derivatives|nervous system|phenols|gaba modulators|triazolobenzodiazepines|cytochrome p 450 substrates|gaba agents|biogenic monoamines|cytochrome p 450 cyp2c9 substrates|heterocyclic compounds, fused ring|ethanolamines|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|psychotropic drugs|biogenic amines|amino alcohols|benzene derivatives|alcohols|anti anxiety agents
dexbrompheniramine	histamine agents|pyridines|substituted alkylamines|central nervous system depressants|antihistamines for systemic use|neurotransmitter agents|histamine antagonists|potential qtc prolonging agents|qtc prolonging agents|histamine h1 antagonists
loxapine	drugs causing inadvertant photosensitivity|central nervous system agents|serotonin receptor antagonists|tranquilizing agents|diazepines, oxazepines, thiazepines and oxepines|psycholeptics|p glycoprotein inhibitors|photosensitizing agents|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|antipsychotic agents|central nervous system depressants|neurotransmitter agents|antidepressive agents|nervous system|antipsychotic agents (first generation [typical])|serotonin 5 ht2 receptor antagonists|dibenzoxazepines|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|serotonin 5 ht2c receptor antagonists|miscellaneous antipsychotics|neurotoxic agents|serotonin 5 ht2a receptor antagonists|psychotropic drugs|dopamine agents|dopamine antagonists
remoxipride	central nervous system agents|tranquilizing agents|bromobenzoates|benzoates|psycholeptics|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|antipsychotic agents|central nervous system depressants|neurotransmitter agents|amides|nervous system|cytochrome p 450 enzyme inhibitors|cytochrome p 450 substrates|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp1a2 inhibitors|dopamine d2 receptor antagonists|cytochrome p 450 cyp2d6 substrates|neurotoxic agents|psychotropic drugs|dopamine agents|benzamides and benzamide derivatives|acids, carbocyclic|benzene derivatives|dopamine antagonists
mupirocin	rna synthetase inhibitors|nasal preparations|dermatologicals|anti bacterial agents|epoxy compounds|antibiotics for topical use|fatty acids|protein synthesis inhibitors|pyrans|ethers, cyclic|lipids|enzyme inhibitors|ethers|anti infective agents|rna synthetase inhibitor antibacterial
rosiglitazone	cytochrome p 450 cyp2c8 inhibitors|thiazoles|drugs used in diabetes|drugs that are mainly renally excreted|peroxisome proliferator receptor gamma agonist|cytochrome p 450 cyp3a4 substrates|hypoglycemia associated agents|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|cytochrome p 450 cyp2c8 inhibitors (moderate)|cytochrome p 450 cyp2a6 inhibitors (strength unknown)|blood glucose lowering agents|oatp1b1/slco1b1 inhibitors|peroxisome proliferator activated receptor activity|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|vasodilating agents|thiazolidinediones|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp1a2 inhibitors|cytochrome p 450 cyp3a substrates|alimentary tract and metabolism|sulfur compounds|bsep/abcb11 substrates|cytochrome p 450 cyp2a6 inhibitors|cytochrome p 450 cyp2c8 substrates
pramipexole	thiazoles|benzothiazoles|central nervous system agents|anti dyskinesia agents|drugs that are mainly renally excreted|restless legs syndrome|nonergot derivative dopamine receptor agonists|anti parkinson agents (dopamine agonist)|oct2 substrates|hypotensive agents|oct1 substrates|neurotransmitter agents|nervous system|anti parkinson drugs|heterocyclic compounds, fused ring|antioxidants|dopamine agents|sulfur compounds|dopamine agonists
acetohexamide	drugs used in diabetes|alimentary tract and metabolism|sulfones|sulfonylureas|sulfur compounds|cytochrome p 450 substrates|blood glucose lowering agents|cytochrome p 450 cyp2c9 substrates
ampicillin	amides|aminopenicillins|penicillins with extended spectrum|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|heterocyclic compounds, fused ring|penicillin g|sulfur compounds|sensory organs|drugs that are mainly renally excreted|ophthalmologicals|beta lactams|penicillins|anti infective agents|beta lactam antibacterials|lactams
promazine	phenothiazines|agents producing tachycardia|amino acids, peptides, and proteins|central nervous system agents|serotonin receptor antagonists|tranquilizing agents|adrenergic alpha 1 receptor antagonists|psycholeptics|cytochrome p 450 cyp3a4 substrates|adrenergic antagonists|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|cytochrome p 450 cyp2c19 substrates|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|anticholinergic agents|amino acids|agents that produce hypertension|antipsychotic agents|central nervous system depressants|neurotransmitter agents|antidepressive agents|qtc prolonging agents|amino acids, branched chain|nervous system|cytochrome p 450 enzyme inhibitors|antipsychotic agents (first generation [typical])|gastrointestinal agents|moderate risk qtc prolonging agents|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp1a2 inhibitors|dopamine d2 receptor antagonists|amino acids, essential|heterocyclic compounds, fused ring|muscarinic antagonists|cytochrome p 450 cyp2d6 substrates|serotonin 5 ht2c receptor antagonists|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|neurotoxic agents|peripheral nervous system agents|serotonin 5 ht2a receptor antagonists|phenothiazines with aliphatic side chain|psychotropic drugs|dopamine agents|cytochrome p 450 cyp1a2 substrates|sulfur compounds|antiemetics|autonomic agents|histamine antagonists|dopamine antagonists|histamine h1 antagonists
spironolactone	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|cytochrome p 450 cyp2c8 inhibitors|antihypertensive agents indicated for hypertension|fused ring compounds|cytochrome p 450 cyp2c8 inhibitors (moderate)|hypotensive agents|p glycoprotein inducers|cardiovascular agents|mineralocorticoid receptor antagonists|mineralocorticoid (aldosterone) receptor antagonists|cytochrome p 450 enzyme inhibitors|diuretics|pregnanes|natriuretic agents|potassium sparing diuretics|antihypertensive agents|agents causing hyperkalemia|pregnenes|steroids|bsep/abcb11 substrates|lactones
methocarbamol	acids, acyclic|phenols|phenylcarbamates|muscle relaxants|muscle relaxants, centrally acting agents|carbamic acid esters|peripheral nervous system agents|central nervous system agents|carbamates|catechols|centrally mediated muscle relaxation|methyl ethers|central nervous system depressants|ethers|benzene derivatives|phenyl ethers|musculo skeletal system
hyoscyamine	mydriatics|agents producing tachycardia|anti asthmatic agents|central nervous system agents|aza compounds|azabicyclo compounds|belladonna alkaloids|adjuvants, anesthesia|anticholinergic agents|belladonna alkaloids, tertiary amines|tropanes|antiarrhythmic agents|neurotransmitter agents|cardiovascular agents|qtc prolonging agents|cholinergic agents|parasympatholytics|alkaloids|belladonna and derivatives, plain|atropine derivatives|potential qtc prolonging agents|drugs for functional gastrointestinal disorders|muscarinic antagonists|respiratory system agents|peripheral nervous system agents|alimentary tract and metabolism|bronchodilator agents|solanaceous alkaloids|autonomic agents
zolpidem	hypnotics and sedatives|gaba agonists|central nervous system depression|central nervous system agents|psycholeptics|cytochrome p 450 cyp3a4 substrates|benzodiazepine hypnotics and sedatives|cytochrome p 450 cyp2c19 substrates|miscellaneous anxiolytics sedatives and hypnotics|central nervous system depressants|neurotransmitter agents|pyridines|sleep aids, pharmaceutical|nervous system|gamma aminobutyric acid ergic agonist|cytochrome p 450 substrates|gaba agents|cytochrome p 450 cyp2c9 substrates|hypnotics (nonbenzodiazepine)|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|gaba a receptor agonists|cytochrome p 450 cyp1a2 substrates
famciclovir	nucleosides and nucleotides|ophthalmologicals|cytochrome p 450 cyp3a4 substrates|antivirals for systemic use|herpesvirus nucleoside analog dna polymerase inhibitor|herpes simplex virus nucleoside analog dna polymerase inhibitor|nucleic acid synthesis inhibitors|nucleosides and nucleotides excl. reverse transcriptase inhibitors|cytochrome p 450 substrates|enzyme inhibitors|anti infective agents|antiviral agents|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|antiinfectives for systemic use|sensory organs|direct acting antivirals|purines|cytochrome p 450 cyp3a4 substrates (strength unknown)
triprolidine	histamine agents|pyridines|anti allergic agents|central nervous system depressants|antihistamines for systemic use|neurotransmitter agents|histamine antagonists|potential qtc prolonging agents|qtc prolonging agents|histamine h1 antagonists
streptozotocin	carbohydrates|antineoplastic and immunomodulating agents|alkylating drugs|antineoplastic agents|cytochrome p 450 cyp2e1 inducers (strength unknown)|cytochrome p 450 cyp1a2 inducers (strength unknown)|cytochrome p 450 cyp1a2 inducers|nitrosoureas|p glycoprotein inducers|alkylating activity|nitroso compounds|myelosuppressive agents|nitrosourea compounds|antineoplastic agents, alkylating|glycosides|immunosuppressive agents|cytochrome p 450 cyp2e1 inducers|antibiotics, antineoplastic|cytochrome p 450 enzyme inducers|narrow therapeutic index drugs
trifluridine	carbohydrates|antineoplastic and immunomodulating agents|pyrimidines|antineoplastic agents|drugs that are mainly renally excreted|ophthalmologicals|nucleosides|oat1/slc22a6 substrates|nucleoside metabolic inhibitor|nucleic acid synthesis inhibitors|glycosides|oat1/slc22a6 inhibitors|nucleoside analog antiviral|anti infective agents|antiviral agents|nucleic acids, nucleotides, and nucleosides|noxae|immunosuppressive agents|pyrimidine analogues|deoxyribonucleosides|pyrimidine nucleosides|antimetabolites|sensory organs|toxic actions|oat3/slc22a8 substrates
prochlorperazine	phenothiazines|drugs causing inadvertant photosensitivity|central nervous system agents|tranquilizing agents|psycholeptics|cytochrome p 450 cyp3a4 substrates|photosensitizing agents|antipsychotic agents|central nervous system depressants|neurotransmitter agents|phenothiazines with piperazine structure|qtc prolonging agents|nervous system|schizophrenia|antipsychotic agents (first generation [typical])|gastrointestinal agents|moderate risk qtc prolonging agents|cytochrome p 450 substrates|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|neurotoxic agents|peripheral nervous system agents|psychotropic drugs|dopamine agents|sulfur compounds|antiemetics|autonomic agents|dopamine antagonists|cytochrome p 450 cyp3a4 substrates (strength unknown)
cyproheptadine	agents producing tachycardia|miscellaneous derivatives|drugs causing inadvertant photosensitivity|ugt1a3 substrates|serotonin receptor antagonists|benzocycloheptenes|histamine agents|photosensitizing agents|serotonin agents|anticholinergic agents|central nervous system depressants|antihistamines for systemic use|neurotransmitter agents|antidepressive agents|qtc prolonging agents|dibenzocycloheptenes|agents that reduce seizure threshold|gastrointestinal agents|anti allergic agents|piperidines|serotonin 5 ht2 receptor antagonists|potential qtc prolonging agents|serotonin 5 ht2c receptor antagonists|muscarinic antagonists|serotonin 5 ht2a receptor antagonists|antipruritics|dermatologicals|histamine antagonists|histamine h1 antagonists
bendroflumethiazide	membrane transport modulators|antihypertensive agents indicated for hypertension|bradycardia causing agents|sulfones|hypotensive agents|low ceiling diuretics and potassium sparing agents|cardiovascular agents|amides|increased diuresis|sulfonamides|hyperglycemia associated agents|diuretics|natriuretic agents|gynecological antiinfectives and antiseptics|thiazides|heterocyclic compounds, fused ring|antihypertensive agents|benzothiadiazines|sodium chloride symporter inhibitors|genito urinary system and sex hormones|sulfur compounds
allopurinol	antioxidants|antimetabolites|heterocyclic compounds, fused ring|bcrp/abcg2 substrates|protective agents|preparations inhibiting uric acid production|drugs that are mainly renally excreted|enzyme inhibitors|purines|free radical scavengers|uricosuric agents|antigout preparations|musculo skeletal system|xanthine oxidase inhibitors|oat3/slc22a8 substrates
ceftazidime	amides|nephrotoxic agents|thiazines|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|cephalosporins|heterocyclic compounds, fused ring|sulfur compounds|cephaloridine|third generation cephalosporins|drugs that are mainly renally excreted|oat1/slc22a6 inhibitors|beta lactams|anti infective agents|lactams
cerivastatin	cytochrome p 450 cyp2c8 inhibitors|hydroxymethylglutaryl coa reductase inhibitors|lipid regulating agents|cytochrome p 450 cyp2b6 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|p glycoprotein substrates|lipid modifying agents|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|oatp1b1/slco1b1 inhibitors|bcrp/abcg2 substrates|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 cyp2b6 inducers|cytochrome p 450 cyp3a7 substrates|cytochrome p 450 cyp2d6 inhibitors|oatp1b1/slco1b1 substrates|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a inducers|noxae|cytochrome p 450 cyp2c9 inhibitors|lipid modifying agents, plain|hypolipidemic agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|bsep/abcb11 substrates|anticholesteremic agents|ugt1a1 substrates|toxic actions|cytochrome p 450 cyp2c8 substrates
trimethoprim	cytochrome p 450 cyp2c8 inhibitors|drugs causing inadvertant photosensitivity|antibiotics for pneumocystis pneumonia|antibacterials for systemic use|sulfonamides and trimethoprim|anti infective agents, urinary|pyrimidines|drugs that are mainly renally excreted|mate 2 inhibitors|mate 1 inhibitors|cytochrome p 450 cyp3a4 substrates|mate 2 substrates|folic acid antagonists|p glycoprotein inhibitors|p glycoprotein substrates|photosensitizing agents|cytochrome p 450 cyp2c8 inhibitors (moderate)|antimycobacterials|p glycoprotein inducers|oct2 inhibitors|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|mate substrates|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|anti infective agents|mate inhibitors|trimethoprim and derivatives|cytochrome p 450 cyp3a substrates|antiinfectives for systemic use|agents causing hyperkalemia|renal agents|cytochrome p 450 cyp1a2 substrates|mate 1 substrates|cytochrome p 450 cyp2c8 substrates
gemcitabine	carbohydrates|antineoplastic and immunomodulating agents|pyrimidines|antineoplastic agents|drugs that are mainly renally excreted|nucleosides|p glycoprotein substrates|toxic actions|myelosuppressive agents|nucleoside metabolic inhibitor|ribonucleosides|nucleic acid synthesis inhibitors|glycosides|enzyme inhibitors|anti infective agents|nucleic acids, nucleotides, and nucleosides|noxae|immunosuppressive agents|pyrimidine analogues|cytidine deaminase substrates|deoxyribonucleosides|pyrimidine nucleosides|radiation sensitizing agents|antimetabolites|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|ribonucleotide reductases, antagonists & inhibitors|immunologic factors
entecavir	nucleoside reverse transcriptase inhibitors|nucleosides and nucleotides|antiinfectives for systemic use|nucleoside and nucleotide reverse transcriptase inhibitors|heterocyclic compounds, fused ring|hepatitis b virus nucleoside analog reverse transcriptase inhibitor|purinones|cytochrome p 450 substrates|direct acting antivirals|purines|anti infective agents|antiviral agents|antivirals for systemic use
betamethasone	hormones, hormone substitutes, and hormone antagonists|corticosteroids for systemic use|adrenal cortex hormones|ophthalmologicals|cytochrome p 450 cyp2c8 inducers (strength unknown)|cytochrome p 450 cyp2b6 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|cytochrome p 450 cyp3a5 inducers (weak)|ophthalmological and otological preparations|p glycoprotein substrates|cytochrome p 450 cyp2a6 inducers|corticosteroids, potent (group iii)|cytochrome p 450 cyp2c19 inducers|corticosteroids|cytochrome p 450 cyp2c9 inducers (strength unknown)|corticosteroids for systemic use, plain|antidiarrheals, intestinal antiinflammatory/antiinfective agents|cytochrome p 450 cyp2b6 inducers|steroids, fluorinated|agents causing muscle toxicity|hyperglycemia associated agents|anti inflammatory agents|intestinal antiinflammatory agents|pregnanes|cytochrome p 450 cyp2c8 inducers|cytochrome p 450 substrates|vasoprotectives|pregnadienetriols|cytochrome p 450 cyp3a inducers|otologicals|corticosteroid hormone receptor agonists|drugs for obstructive airway diseases|adrenals|immunosuppressive agents|respiratory system agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2c19 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers (strength unknown)|glucocorticoids|dermatologicals|cytochrome p 450 enzyme inducers|alimentary tract and metabolism|corticosteroids, dermatological preparations|hormones|nasal preparations|steroids|thyroxine binding globulin inhibitors|pregnadienes|agents for treatment of hemorrhoids and anal fissures for topical use|cytochrome p 450 cyp2c9 inducers|cytochrome p 450 cyp3a5 inducers|systemic hormonal preparations, excl. sex hormones and insulins|corticosteroids acting locally
teniposide	cytochrome p 450 cyp2c19 substrates with a narrow therapeutic index|carbohydrates|antineoplastic and immunomodulating agents|topoisomerase inhibitors|cytochrome p 450 cyp2c9 inhibitors (weak)|antineoplastic agents|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|bcrp/abcg2 substrates|myelosuppressive agents|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|glucosides|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|glycosides|enzyme inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2c9 inhibitors|immunosuppressive agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|neurotoxic agents|topoisomerase ii inhibitors|cardiotoxic antineoplastic agents|narrow therapeutic index drugs|podophyllotoxin derivatives
epirubicin	carbohydrates|antineoplastic and immunomodulating agents|topoisomerase inhibitors|ugt2b7 substrates with a narrow therapeutic index|anthracycline topoisomerase inhibitor|antineoplastic agents|hepatotoxic agents|ugt2b7 substrates|cytotoxic antibiotics and related substances|myelosuppressive agents|anthracyclines and related substances|naphthacenes|glycosides|enzyme inhibitors|immunosuppressive agents|antibiotics, antineoplastic|topoisomerase ii inhibitors|cardiotoxic antineoplastic agents|narrow therapeutic index drugs|anthracyclines
chloramphenicol	antibacterials for systemic use|anti bacterial agents|ophthalmologicals|propylene glycols|amphenicols|cytochrome p 450 cyp3a7 inhibitors (strength unknown)|anti acne preparations for topical use|ophthalmological and otological preparations|nitrobenzenes|cytochrome p 450 cyp3a5 inhibitors|antiinfectives for treatment of acne|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|myelosuppressive agents|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|anti acne preparations|antibiotics for topical use|enzyme inhibitors|oat1/slc22a6 inhibitors|anti infective agents|cytochrome p 450 cyp3a inhibitors|gynecological antiinfectives and antiseptics|cytochrome p 450 cyp2c19 inhibitors (strong)|glycols|immunosuppressive agents|otologicals|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a7 inhibitors|nitro compounds|antiinfectives for systemic use|dermatologicals|protein synthesis inhibitors|genito urinary system and sex hormones|sensory organs|cytochrome p 450 cyp3a5 inhibitors (strength unknown)|benzene derivatives|alcohols
loracarbef	amides|nephrotoxic agents|thiazines|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|cephalosporins|heterocyclic compounds, fused ring|sulfur compounds|second generation cephalosporins|beta lactams|anti infective agents|lactams
lansoprazole	gastric acid lowering agents|bcrp/abcg2 inhibitors|cytochrome p 450 cyp2c18 substrates|acid reducers|anti ulcer agents|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp2d6 inhibitors (weak)|cytochrome p 450 cyp2c19 substrates|oat3/slc22a8 inhibitors|cytochrome p 450 cyp2c9 inducers (strength unknown)|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|drugs for peptic ulcer and gastro oesophageal reflux disease (gord)|pyridines|cytochrome p 450 cyp2d6 inhibitors|drugs for acid related disorders|cytochrome p 450 enzyme inhibitors|benzimidazoles|cytochrome p 450 cyp3a4 inhibitors|gastrointestinal agents|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strong)|heterocyclic compounds, fused ring|inhibition gastric acid secretion|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|alimentary tract and metabolism|proton pump inhibitors|sulfur compounds|cytochrome p 450 cyp2c9 inducers|sulfoxides|cytochrome p 450 cyp2c8 substrates
dipivefrine	mydriatics|adrenergic agents|catechols|ophthalmologicals|amines|adrenergic beta 2 receptor agonists|adrenergic alpha 1 receptor agonists|adrenergic alpha 2 receptor agonists|neurotransmitter agents|antiglaucoma preparations and miotics|phenols|adrenergic agonists|adrenergic beta 1 receptor agonists|biogenic monoamines|adrenergic alpha agonists|cholinesterase substrates|adrenergic beta agonists|catecholamines|ethanolamines|sensory organs|biogenic amines|amino alcohols|adrenergic beta 3 receptor agonists|benzene derivatives|sympathomimetics in glaucoma therapy|alcohols|ophthalmics
droperidol	central nervous system agents|tranquilizing agents|adrenergic alpha 1 receptor antagonists|psycholeptics|adjuvants, anesthesia|butyrophenones|adrenergic antagonists|miscellaneous anxiolytics sedatives and hypnotics|antipsychotic agents|agents that produce hypertension|central nervous system depressants|neurotransmitter agents|qtc prolonging agents|nervous system|benzimidazoles|antipsychotic agents (first generation [typical])|gastrointestinal agents|moderate risk qtc prolonging agents|dopamine d2 receptor antagonists|ketones|heterocyclic compounds, fused ring|butyrophenone derivatives|neurotoxic agents|adrenergic alpha antagonists|peripheral nervous system agents|psychotropic drugs|dopamine agents|antiemetics|autonomic agents|dopamine antagonists
levothyroxine	hormones, hormone substitutes, and hormone antagonists|amino acids, peptides, and proteins|cytochrome p 450 cyp2c8 inhibitors|amino acids, cyclic|oatp1b3 inhibitors|thyroid products|amino acids, aromatic|cytochrome p 450 cyp2c8 inhibitors (moderate)|amino acids|p glycoprotein inducers|oatp1b1/slco1b1 inhibitors|ugt1a1 substrates with a narrow therapeutic index|thyroxine binding globulin substrates|cytochrome p 450 enzyme inhibitors|cytochrome p 450 substrates|hormones|narrow therapeutic index drugs|agents used to treat hypothyroidism|ugt1a1 substrates|systemic hormonal preparations, excl. sex hormones and insulins
loratadine	cytochrome p 450 cyp2c8 inhibitors|loratadine and prodrug|benzocycloheptenes|histamine h1 antagonists, non sedating|cytochrome p 450 cyp3a4 inhibitors (weak)|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp2d6 inhibitors (weak)|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp2c8 inhibitors (moderate)|histamine h1 antagonists|cytochrome p 450 cyp2b6 substrates|cytochrome p 450 cyp2c19 inhibitors (weak)|antihistamines for systemic use|neurotransmitter agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|dibenzocycloheptenes|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|anti allergic agents|cytochrome p 450 substrates|piperidines|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|antipruritics|dermatologicals|cytochrome p 450 cyp1a2 substrates|bsep/abcb11 substrates|histamine antagonists|cytochrome p 450 cyp2c8 substrates
cefalotin	amides|agents that reduce seizure threshold|nephrotoxic agents|thiazines|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|cephacetrile|cephalosporins|heterocyclic compounds, fused ring|oat3/slc22a8 inhibitors|sulfur compounds|first generation cephalosporins|oat1/slc22a6 inhibitors|beta lactams|anti infective agents|lactams
prazosin	antiadrenergic agents, peripherally acting|adrenergic alpha 1 receptor antagonists|antihypertensive agents indicated for hypertension|p glycoprotein inhibitors|p glycoprotein substrates|adrenergic antagonists|oct2 substrates|alpha adrenoreceptor antagonists and diuretics|hypotensive agents|oct1 substrates|cardiovascular agents|bcrp/abcg2 substrates|vasodilating agents|heterocyclic compounds, fused ring|quinazolines|oct1 inhibitors|peripheral alpha 1 blockers|adrenergic alpha antagonists|antihypertensive agents
imipramine	adrenergic uptake inhibitors|cytochrome p 450 cyp2c19 substrates with a narrow therapeutic index|agents producing tachycardia|membrane transport modulators|cytochrome p 450 cyp3a7 substrates with a narrow therapeutic index|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|psychoanaleptics|central nervous system agents|adrenergic agents|serotonin receptor antagonists|drugs that are mainly renally excreted|adrenergic alpha 1 receptor antagonists|cytochrome p 450 cyp3a4 substrates|p glycoprotein substrates|adrenergic antagonists|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|cytochrome p 450 cyp2d6 inhibitors (weak)|cytochrome p 450 cyp2c19 substrates|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|anticholinergic agents|cytochrome p 450 cyp2b6 substrates|cytochrome p 450 cyp2d6 substrates with a narrow therapeutic index|cytochrome p 450 cyp2e1 inhibitors|agents that produce hypertension|cytochrome p 450 cyp2c18 substrates with a narrow therapeutic index|hypotensive agents|oct2 inhibitors|central nervous system depressants|cytochrome p 450 cyp2b6 substrates with a narrow therapeutic index|neurotransmitter agents|cytochrome p 450 cyp1a2 inhibitors (moderate)|antidepressive agents|tertiary amine tricyclic antidepressants|cytochrome p 450 cyp3a7 substrates|dibenzazepines|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|nervous system|agents that reduce seizure threshold|antidepressive agents, tricyclic|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|moderate risk qtc prolonging agents|cytochrome p 450 substrates|non selective monoamine reuptake inhibitors|serotonin 5 ht2 receptor antagonists|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp1a2 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strong)|serotonin modulators|heterocyclic compounds, fused ring|muscarinic antagonists|cytochrome p 450 cyp2d6 substrates|serotonin 5 ht2c receptor antagonists|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|combined inhibitors of serotonin/norepinephrine reuptake|cytochrome p 450 cyp2d6 inhibitors (moderate)|neurotoxic agents|neurotransmitter uptake inhibitors|psychotropic drugs|serotonin 5 ht2a receptor antagonists|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|cytochrome p 450 cyp2c18 substrates|histamine antagonists|tricyclics and other norepinephrine reuptake inhibitors|histamine h1 antagonists
acitretin	antipsoriatics|drugs causing inadvertant photosensitivity|keratolytic agents|cyclohexanes|cyclohexenes|hepatotoxic agents|polyenes|retinoids for treatment of psoriasis|photosensitizing agents|cycloparaffins|alkenes|hydrocarbons, acyclic|carotenoids|antipsoriatics for systemic use|retinoids|pigments, biological|biological factors|dermatologicals|terpenes|misc. skin and mucous membrane agents
verteporfin	photosensitizing activity|eent drugs, miscellaneous|photosensitizing agents|radiation sensitizing agents|dermatologicals|heterocyclic compounds, fused ring|photoenhancer|antineovascularisation agents|photoabsorption|sensory organs|ophthalmologicals|pigments, biological|porphyrins|ocular vascular disorder agents|biological factors
nabumetone	drugs causing inadvertant photosensitivity|anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|other nonsteroidal anti inflammatory agents|musculo skeletal system|cox 2 inhibitors|nephrotoxic agents|selective cyclooxygenase 2 inhibitors (nsaids)|photosensitizing agents|analgesics|agents that produce hypertension|butanones|antiinflammatory and antirheumatic products, non steroids|anti inflammatory agents|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|analgesics, non narcotic|antirheumatic agents|ketones|antiinflammatory and antirheumatic products|agents causing hyperkalemia|cytochrome p 450 cyp1a2 substrates|cyclooxygenase inhibitors
ketorolac	mydriatics|drugs causing inadvertant photosensitivity|anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|ophthalmologicals|other nonsteroidal anti inflammatory agents|ugt2b7 substrates|musculo skeletal system|nephrotoxic agents|photosensitizing agents|mydriatics and cycloplegics|analgesics|agents that produce hypertension|non cox 2 selective nsaids|acetic acid derivatives and related substances|antiinflammatory and antirheumatic products, non steroids|sympathomimetics excl. antiglaucoma preparations|anti inflammatory agents|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|analgesics, non narcotic|antirheumatic agents|heterocyclic compounds, fused ring|antiinflammatory and antirheumatic products|agents causing hyperkalemia|sensory organs|cytochrome p 450 cyp2c8 substrates|cyclooxygenase inhibitors
picrotoxin	gaba antagonists|central nervous system stimulants|compounds used in a research, industrial, or household setting|antidotes|central nervous system agents|cyclohexanes|cycloparaffins|protective agents|stimulants|gaba agents|neurotransmitter agents|convulsants|lactones
enoxacin	cytochrome p 450 enzyme inhibitors|topoisomerase inhibitors|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|heterocyclic compounds, fused ring|cytochrome p 450 cyp1a2 inhibitors (strong)|potential qtc prolonging agents|topoisomerase ii inhibitors|quinolones|fluoroquinolones|enzyme inhibitors|anti infective agents|quinolines|chemically induced disorders|cytochrome p 450 cyp1a2 inhibitors|qtc prolonging agents
quinine	cytochrome p 450 cyp2c8 inhibitors|muscle relaxants|sensory system agents|central nervous system agents|agents that produce neuromuscular block (indirect)|herbs (hypotensive properties)|cytochrome p 450 cyp3a4 inducers|musculo skeletal system|cytochrome p 450 cyp3a4 substrates|hypoglycemia associated agents|antiparasitic products, insecticides and repellents|quinuclidines|p glycoprotein inhibitors|p glycoprotein substrates|muscle relaxants, centrally acting agents|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp2c8 inhibitors (moderate)|analgesics|oct2 inhibitors|oct1 substrates|blood glucose lowering agents|central nervous system depressants|neuromuscular agents|oatp1b1/slco1b1 inhibitors|quinolines|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|antiparasitic agents|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|agents that reduce seizure threshold|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|alkaloids|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|anti infective agents|antimalarials|analgesics, non narcotic|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp1a2 inhibitors|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp2c19 inhibitors|oct1 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2d6 inhibitors (moderate)|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 cyp3a5 substrates|methemoglobinemia associated agents|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 enzyme inducers|peripheral nervous system agents|highest risk qtc prolonging agents|cytochrome p 450 cyp1a2 substrates|cinchona alkaloids|antiprotozoals|methanolquinolines|cytochrome p 450 cyp2c8 substrates
tenoxicam	thiazines|anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|sensory system agents|central nervous system agents|other nonsteroidal anti inflammatory agents|musculo skeletal system|nephrotoxic agents|oat3/slc22a8 inhibitors|analgesics|agents that produce hypertension|non cox 2 selective nsaids|antiinflammatory and antirheumatic products, non steroids|anti inflammatory agents|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|oxicams|analgesics, non narcotic|antirheumatic agents|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|sulfur compounds|cyclooxygenase inhibitors
montelukast	acids, acyclic|hormones, hormone substitutes, and hormone antagonists|hormone antagonists|cytochrome p 450 cyp2c8 inhibitors|anti asthmatic agents|leukotriene modifiers|agents to treat airway disease|cytochrome p 450 cyp2a6 substrates|leukotriene antagonists|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp1a2 inducers|fatty acids|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|fatty acids, volatile|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|heterocyclic compounds, fused ring|drugs for obstructive airway diseases|respiratory system agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 enzyme inducers|lipids|cytochrome p 450 cyp2c8 substrates
fluoxetine	membrane transport modulators|nicotinic antagonists|cytochrome p 450 cyp2d6 inhibitors (strong)|psychoanaleptics|central nervous system agents|serotonin receptor antagonists|cytochrome p 450 cyp3a4 inhibitors (weak)|amines|cytochrome p 450 cyp3a4 substrates|hypoglycemia associated agents|p glycoprotein inhibitors|selective serotonin reuptake inhibitors|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|antidepressive agents, second generation|cytochrome p 450 cyp2c19 substrates|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|anticholinergic agents|cytochrome p 450 cyp2b6 substrates|serotonin modulators|central nervous system depressants|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|neurotransmitter agents|antidepressive agents|qtc prolonging agents|propylamines|cytochrome p 450 cyp2d6 inhibitors|nervous system|agents that reduce seizure threshold|cytochrome p 450 enzyme inhibitors|vasodilating agents|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|serotonin 5 ht2 receptor antagonists|cytochrome p 450 cyp3a inhibitors|chemically induced disorders|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp1a2 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strong)|serotonin 5 ht2c receptor antagonists|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|neurotransmitter uptake inhibitors|psychotropic drugs|highest risk qtc prolonging agents|cytochrome p 450 cyp1a2 substrates|cytochrome p 450 cyp2c9 inhibitors (moderate)
hexylcaine	amines|cyclohexanes|cycloparaffins
chlordiazepoxide	carbohydrates|hypnotics and sedatives|nucleotides|cytosine nucleotides|ribonucleotides|central nervous system agents|pyrimidines|tranquilizing agents|psycholeptics|adjuvants, anesthesia|cytochrome p 450 cyp3a4 substrates|benzazepines|central nervous system depressants|neurotransmitter agents|benzodiazepines and benzodiazepine derivatives|nervous system|gaba modulators|cytochrome p 450 substrates|gaba agents|glycosides|pyrimidine nucleotides|nucleic acids, nucleotides, and nucleosides|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|psychotropic drugs|anti anxiety agents|cytochrome p 450 cyp3a4 substrates (strength unknown)
duloxetine	agents producing tachycardia|membrane transport modulators|psychoanaleptics|central nervous system agents|sensory system agents|thiophenes|drugs that are mainly renally excreted|cytochrome p 450 cyp3a4 inhibitors (weak)|cytochrome p 450 cyp3a4 substrates|hypoglycemia associated agents|p glycoprotein inhibitors|selective serotonin reuptake inhibitors|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|analgesics|serotonin modulators|norepinephrine uptake inhibitors|central nervous system depressants|antidepressive agents|serotonin and noradrenaline reuptake inhibitors|cytochrome p 450 cyp2d6 inhibitors|nervous system|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2d6 inhibitors (moderate)|combined inhibitors of serotonin/norepinephrine reuptake|neurotransmitter uptake inhibitors|peripheral nervous system agents|psychotropic drugs|cytochrome p 450 cyp1a2 substrates|sulfur compounds|cytochrome p 450 cyp3a4 substrates (strength unknown)
chlorpromazine	phenothiazines|agents producing tachycardia|drugs causing inadvertant photosensitivity|central nervous system agents|serotonin receptor antagonists|tranquilizing agents|drugs that are mainly renally excreted|adrenergic alpha 1 receptor antagonists|psycholeptics|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|p glycoprotein substrates|cholinesterase inhibitors|adrenergic antagonists|photosensitizing agents|serotonin 5 ht1 receptor antagonists|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|anticholinergic agents|serotonin 5 ht1a receptor antagonists|cytochrome p 450 cyp2e1 inhibitors|antipsychotic agents|agents that produce hypertension|hypotensive agents|central nervous system depressants|neurotransmitter agents|antidepressive agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|nervous system|agents that reduce seizure threshold|cytochrome p 450 enzyme inhibitors|hyperglycemia associated agents|antipsychotic agents (first generation [typical])|gastrointestinal agents|moderate risk qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|serotonin 5 ht2 receptor antagonists|cytochrome p 450 cyp3a inducers|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|muscarinic antagonists|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|cytochrome p 450 cyp2d6 inhibitors (moderate)|cytochrome p 450 cyp3a4 inducers (strength unknown)|neurotoxic agents|cytochrome p 450 enzyme inducers|peripheral nervous system agents|dopamine agents|phenothiazines with aliphatic side chain|psychotropic drugs|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|cytochrome p 450 cyp1a2 substrates|serotonin 5 ht2a receptor antagonists|sulfur compounds|antiemetics|bsep/abcb11 inhibitors|autonomic agents|histamine antagonists|dopamine antagonists|histamine h1 antagonists|cytochrome p 450 cyp3a4 substrates (strength unknown)
rimantadine	cyclic amines|nucleic acid synthesis inhibitors|antiinfectives for systemic use|cycloparaffins|influenza a m2 protein inhibitor|m2 protein inhibitors|adamantanes|enzyme inhibitors|anti infective agents|antiviral agents
amikacin	nephrotoxic agents|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|narrow therapeutic index drugs|glycosides|aminoglycoside antibacterials|drugs that are mainly renally excreted|drugs that are mainly renally excreted with a narrow therapeutic index|anti infective agents
lenalidomide	angiogenesis inhibitors|antineoplastic and immunomodulating agents|phthalimides|antineoplastic agents|drugs that are mainly renally excreted|angiogenesis modulating agents|p glycoprotein substrates|myelosuppressive agents|isoindoles|phthalic acids|growth inhibitors|piperidines|heterocyclic compounds, fused ring|immunosuppressive agents|growth substances|acids, carbocyclic|piperidones|thalidomide analog|imides|immunologic factors
raloxifene	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|cytochrome p 450 cyp2c8 inhibitors|oatp1b3 substrates|estrogen antagonists|estrogen agonist antagonists|benzylidene compounds|p glycoprotein substrates|estrogen agonist/antagonist|sex hormones and modulators of the genital system|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|bcrp/abcg2 substrates|oatp1b1/slco1b1 substrates|cytochrome p 450 cyp2b6 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|stilbenes|cytochrome p 450 cyp2b6 inhibitors (strong)|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|selective estrogen receptor modulators|cytochrome p 450 cyp3a inhibitors|bone density conservation agents|genito urinary system and sex hormones|benzene derivatives|ugt1a1 substrates|estrogen receptor modulators
celecoxib	drugs causing inadvertant photosensitivity|anti inflammatory agents, non steroidal|antineoplastic and immunomodulating agents|cyclooxygenase 2 (cox 2) inhibitors|sensory system agents|central nervous system agents|musculo skeletal system|cytochrome p 450 cyp3a4 substrates|cox 2 inhibitors|nephrotoxic agents|p glycoprotein substrates|selective cyclooxygenase 2 inhibitors (nsaids)|photosensitizing agents|pyrazoles|analgesics|sulfones|agents that produce hypertension|antiarrhythmic agents|calcium channel blockers|selective calcium channel blockers with mainly vascular effects|bcrp/abcg2 substrates|antiinflammatory and antirheumatic products, non steroids|cytochrome p 450 cyp2d6 inhibitors|amides|cytochrome p 450 enzyme inhibitors|sulfonamides|anti inflammatory agents|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|analgesics, non narcotic|gynecological antiinfectives and antiseptics|antirheumatic agents|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2d6 inhibitors (moderate)|methemoglobinemia associated agents|antiinflammatory and antirheumatic products|peripheral nervous system agents|agents causing hyperkalemia|genito urinary system and sex hormones|sulfur compounds|bsep/abcb11 inhibitors|dihydropyridine derivatives|cytochrome p 450 cyp2c8 substrates|cyclooxygenase inhibitors
brimonidine	quinoxalines|adrenergic agonists|dermatologicals|heterocyclic compounds, fused ring|adrenergic agents|hypotensive agents|sensory organs|ophthalmologicals|central nervous system depressants|adrenergic alpha 2 receptor agonists|adrenergic alpha agonists|antiglaucoma preparations and miotics|sympathomimetics in glaucoma therapy|cardiovascular agents|misc. skin and mucous membrane agents
dicloxacillin	amides|cytochrome p 450 cyp3a4 inducers (strength unknown)|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|beta lactamase resistant penicillins|cytochrome p 450 enzyme inducers|heterocyclic compounds, fused ring|sulfur compounds|penicillins|beta lactams|anti infective agents|beta lactam antibacterials|cytochrome p 450 cyp3a inducers|lactams|cytochrome p 450 cyp3a4 inducers
pefloxacin	cytochrome p 450 enzyme inhibitors|topoisomerase inhibitors|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|heterocyclic compounds, fused ring|potential qtc prolonging agents|topoisomerase ii inhibitors|quinolones|fluoroquinolones|enzyme inhibitors|anti infective agents|quinolines|chemically induced disorders|cytochrome p 450 cyp1a2 inhibitors|qtc prolonging agents
altretamine	antineoplastic and immunomodulating agents|alkylating drugs|myelosuppressive agents|triazines|antineoplastic agents|antineoplastic agents, alkylating|alkylating activity|narrow therapeutic index drugs|immunosuppressive agents|noxae|toxic actions
sotalol	beta blocking agents, non selective|adrenergic agents|amines|bradycardia causing agents|adrenergic antagonists|cytochrome p 450 cyp2d6 substrates with a narrow therapeutic index|hypotensive agents|antiarrhythmic agents|neurotransmitter agents|cardiovascular agents|qtc prolonging agents|adrenergic beta antagonists|cytochrome p 450 substrates|beta blocking agents and thiazides|beta blocking agents, non selective, and thiazides|cardiac rhythm alteration|cytochrome p 450 cyp2d6 substrates|ethanolamines|peripheral nervous system agents|agents causing hyperkalemia|highest risk qtc prolonging agents|narrow therapeutic index drugs|amino alcohols|autonomic agents|sympatholytics|alcohols
buspirone	spiro compounds|central nervous system agents|pyrimidines|tranquilizing agents|piperazines|drugs that are mainly renally excreted|psycholeptics|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|miscellaneous anxiolytics sedatives and hypnotics|agents that produce hypertension|central nervous system depressants|neurotransmitter agents|antidepressive agents|cytochrome p 450 cyp3a7 substrates|nervous system|dopamine d2 receptor antagonists|cytochrome p 450 cyp2d6 substrates|azaspirodecanedione derivatives|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|dopamine antagonists
miglitol	carbohydrates|imines|imino sugars|drugs used in diabetes|alimentary tract and metabolism|alkaloids|imino pyranoses|enzyme inhibitors|blood glucose lowering agents|piperidines|glycoside hydrolase inhibitors|hypoglycemia associated agents
fosinopril	acids, acyclic|amino acids, peptides, and proteins|drugs causing inadvertant photosensitivity|imines|amino acids, cyclic|acids|organophosphorus compounds|drugs that are mainly renally excreted|phosphorus acids|antihypertensive agents indicated for hypertension|photosensitizing agents|hypotensive agents|amino acids|cardiovascular agents|agents causing angioedema|enzyme inhibitors|imino acids|acids, noncarboxylic|ace inhibitors and diuretics|agents acting on the renin angiotensin system|protease inhibitors|angiotensin converting enzyme inhibitors|antihypertensive agents|agents causing hyperkalemia|phosphinic acids|phosphorus compounds
cefotaxime	amides|agents that reduce seizure threshold|nephrotoxic agents|thiazines|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|cephacetrile|cephalosporins|heterocyclic compounds, fused ring|oat3/slc22a8 inhibitors|sulfur compounds|third generation cephalosporins|oat1/slc22a6 inhibitors|beta lactams|anti infective agents|lactams
entacapone	nervous system|phenols|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2d6 inhibitors (weak)|ugt1a9 substrates|central nervous system agents|dopamine agents|comt inhibitors|anti parkinson drugs|anti dyskinesia agents|enzyme inhibitors|central nervous system depressants|benzene derivatives|cytochrome p 450 cyp2d6 inhibitors
zidovudine	carbohydrates|nucleoside and nucleotide reverse transcriptase inhibitors|pyrimidines|dideoxynucleosides|cytochrome p 450 cyp2a6 substrates|ugt2b7 substrates|nucleosides|cytochrome p 450 cyp3a4 substrates|antivirals for systemic use|ugt1a1 inducers|oat1/slc22a6 substrates|p glycoprotein substrates|oat3/slc22a8 inhibitors|oat3/slc22a8 substrates|bcrp/abcg2 substrates|anti retroviral agents|myelosuppressive agents|nucleoside reverse transcriptase inhibitors|reverse transcriptase inhibitors|nucleic acid synthesis inhibitors|agents causing muscle toxicity|cytochrome p 450 substrates|glycosides|human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|anti infective agents|antiviral agents|nucleic acids, nucleotides, and nucleosides|noxae|immunosuppressive agents|deoxyribonucleosides|pyrimidine nucleosides|cytochrome p 450 cyp3a substrates|antiinfectives for systemic use|antimetabolites|anti hiv agents|direct acting antivirals|ugt1a1 substrates|toxic actions|cytochrome p 450 cyp2c8 substrates
darifenacin	cytochrome p 450 cyp2d6 substrates|urologicals|agents producing tachycardia|cholinergic agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2d6 inhibitors (moderate)|cytochrome p 450 enzyme inhibitors|urological agents|heterocyclic compounds, fused ring|anticholinergic agents|drugs for urinary frequency and incontinence|genito urinary system and sex hormones|cytochrome p 450 substrates|muscarinic antagonists|neurotransmitter agents|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp2d6 inhibitors
phenindione	anticoagulants|vitamin k antagonists|hematologic agents|narrow therapeutic index drugs|blood and blood forming organs|indenes|indans
flutamide	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|antineoplastic and immunomodulating agents|antineoplastic agents|drugs that are mainly renally excreted|androgen receptor antagonists|amines|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp2c19 substrates|antiandrogens|antineoplastic agents, hormonal|amides|androgen receptor inhibitor|anilides|antiandrogens, non steroidal|cytochrome p 450 substrates|aniline compounds|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|methemoglobinemia associated agents|endocrine therapy|hormone antagonists and related agents|cytochrome p 450 cyp1a2 substrates
tolmetin	anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|antiinflammatory preparations, non steroids for topical use|central nervous system agents|sensory system agents|musculo skeletal system|nephrotoxic agents|analgesics|agents that produce hypertension|non cox 2 selective nsaids|acetic acid derivatives and related substances|antiinflammatory and antirheumatic products, non steroids|topical products for joint and muscular pain|anti inflammatory agents|enzyme inhibitors|oat1/slc22a6 inhibitors|analgesics, non narcotic|antirheumatic agents|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|cyclooxygenase inhibitors
cimetidine	amidines|cytochrome p 450 cyp2c8 inhibitors|gastric acid lowering agents|cytochrome p 450 cyp3a5 inhibitors (moderate)|drugs that are mainly renally excreted|mate 2 inhibitors|cytochrome p 450 cyp3a4 inhibitors (weak)|acid reducers|mate 1 inhibitors|anti ulcer agents|mate 2 substrates|histamine agents|oat1/slc22a6 substrates|p glycoprotein substrates|cytochrome p 450 cyp2d6 inhibitors (weak)|oat3/slc22a8 inhibitors|cytochrome p 450 cyp3a5 inhibitors|oct2 substrates|cytochrome p 450 cyp2e1 inhibitors|p glycoprotein inducers|oct2 inhibitors|oct1 substrates|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|neurotransmitter agents|drugs for peptic ulcer and gastro oesophageal reflux disease (gord)|cytochrome p 450 cyp2d6 inhibitors|drugs for acid related disorders|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|imidazoles|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|gastrointestinal agents|cytochrome p 450 cyp1a2 inhibitors (weak)|mate substrates|enzyme inhibitors|oat1/slc22a6 inhibitors|cytochrome p 450 cyp3a inhibitors|chemically induced disorders|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp1a2 inhibitors|mate inhibitors|cytochrome p 450 cyp3a7 inhibitors (moderate)|guanidines|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a7 inhibitors|oct1 inhibitors|cytochrome p 450 cyp2d6 inhibitors (moderate)|adjuvants|cytochrome p 450 cyp2c8 inhibitors (weak)|alimentary tract and metabolism|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|mate 1 substrates|histamine h2 antagonists|bsep/abcb11 inhibitors|histamine antagonists|oat3/slc22a8 substrates
haloperidol	drugs causing inadvertant photosensitivity|central nervous system agents|tranquilizing agents|anti dyskinesia agents|drugs that are mainly renally excreted|psycholeptics|cytochrome p 450 cyp3a4 substrates|butyrophenones|p glycoprotein inhibitors|p glycoprotein substrates|photosensitizing agents|cytochrome p 450 cyp2c19 substrates|antipsychotic agents|central nervous system depressants|neurotransmitter agents|nmda receptor antagonists|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|nervous system|agents that reduce seizure threshold|cytochrome p 450 enzyme inhibitors|hyperglycemia associated agents|cytochrome p 450 cyp3a4 inhibitors|antipsychotic agents (first generation [typical])|cytochrome p 450 cyp3a4 inhibitors (moderate)|gastrointestinal agents|moderate risk qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inhibitors|dopamine d2 receptor antagonists|ketones|butyrophenone derivatives|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|neurotoxic agents|peripheral nervous system agents|psychotropic drugs|ugt1a9 substrates|dopamine agents|cytochrome p 450 cyp1a2 substrates|antiemetics|autonomic agents|dopamine antagonists
ritonavir	acids, acyclic|hiv protease inhibitors|antivirals for treatment of hcv infections|cytochrome p 450 cyp2c8 inhibitors|thiazoles|cytochrome p 450 cyp2b6 inhibitors (strength unknown)|oatp1b3 inhibitors|bcrp/abcg2 inhibitors|cytochrome p 450 cyp3a4 inhibitors (strong)|cytochrome p 450 cyp1a2 inducers (strength unknown)|cytochrome p 450 cyp2c8 inducers (strength unknown)|experimental unapproved treatments for covid 19|cytochrome p 450 cyp3a4 substrates|antivirals for systemic use|p glycoprotein inhibitors|ugt1a1 inducers|p glycoprotein substrates|cytochrome p 450 cyp1a2 inducers|cytochrome p 450 cyp2c9 inducers (weak)|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|cytochrome p 450 cyp2d6 inhibitors (weak)|udp glucuronosyltransferases inducers|cytochrome p 450 cyp2c8 inhibitors (moderate)|cytochrome p 450 cyp3a5 inhibitors|cytochrome p 450 cyp2c19 inducers|p glycoprotein inducers|oatp1b1/slco1b1 inhibitors|cytochrome p 450 cyp2b6 inducers (weak)|bcrp/abcg2 substrates|anti retroviral agents|cytochrome p 450 cyp2b6 inducers|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 cyp2b6 inhibitors|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|hyperglycemia associated agents|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 cyp2c8 inducers|cytochrome p 450 substrates|enzyme inhibitors|anti infective agents|antiviral agents|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a inhibitors|chemically induced disorders|cytochrome p 450 cyp1a2 inhibitors|potential qtc prolonging agents|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a7 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2d6 inhibitors (moderate)|cytochrome p 450 cyp3a5 inhibitors (strong)|antiinfectives for systemic use|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp3a7 inhibitors (strong)|cytochrome p 450 enzyme inducers|protease inhibitors|sulfur compounds|anti hiv agents|bsep/abcb11 substrates|direct acting antivirals|bsep/abcb11 inhibitors|cytochrome p 450 cyp2c8 inhibitors (strong)|cytochrome p 450 cyp2c9 inducers|breast cancer resistance protein inhibitors
tridihexethyl	drugs for functional gastrointestinal disorders|agents producing tachycardia|onium compounds|alimentary tract and metabolism|anticholinergic agents|nitrogen compounds|ammonium compounds|synthetic anticholinergics, quaternary ammonium compounds|amines|muscarinic antagonists
nitazoxanide	sulfur compounds|antiprotozoals|anti infective agents|antiparasitic agents|antiparasitic products, insecticides and repellents
triflupromazine	phenothiazines|agents producing tachycardia|central nervous system agents|serotonin receptor antagonists|tranquilizing agents|psycholeptics|p glycoprotein inhibitors|cholinesterase inhibitors|serotonin agents|anticholinergic agents|antipsychotic agents|central nervous system depressants|neurotransmitter agents|antidepressive agents|nervous system|gastrointestinal agents|serotonin 5 ht2 receptor antagonists|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|muscarinic antagonists|neurotoxic agents|peripheral nervous system agents|phenothiazines with aliphatic side chain|psychotropic drugs|dopamine agents|sulfur compounds|antiemetics|autonomic agents|dopamine antagonists
vancomycin	carbohydrates|amino acids, peptides, and proteins|antibacterials for systemic use|anti bacterial agents|intestinal antiinfectives|agents that produce neuromuscular block (indirect)|drugs that are mainly renally excreted|glycoconjugates|ophthalmologicals|nephrotoxic agents|peptides|antidiarrheals, intestinal antiinflammatory/antiinfective agents|glycopeptide antibacterials|anti infective agents|antiinfectives for systemic use|alimentary tract and metabolism|narrow therapeutic index drugs|sensory organs|drugs that are mainly renally excreted with a narrow therapeutic index|glycopeptides
aminocaproic acid	acids, acyclic|amino acids, peptides, and proteins|decreased fibrinolysis|aminocaproates|coagulants|fatty acids, volatile|hematologic agents|fatty acids|hemostatics|amino acids|antifibrinolytic agents|lipids|caproates|blood and blood forming organs|fibrin modulating agents
dextromethorphan	nicotinic antagonists|central nervous system agents|opioids|ugt2b7 substrates|morphinans|cytochrome p 450 cyp3a4 substrates|narcotics|sigma 1 receptor agonists|cytochrome p 450 cyp2c19 substrates|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|anticholinergic agents|cytochrome p 450 cyp2b6 substrates|serotonin modulators|central nervous system depressants|neurotransmitter agents|antidepressive agents|nmda receptor antagonists|opiate alkaloids|cytochrome p 450 cyp3a7 substrates|nervous system|excitatory amino acid antagonists|uncompetitive nmda receptor antagonists|uncompetitive n methyl d aspartate receptor antagonist|alkaloids|cytochrome p 450 substrates|opium alkaloids and derivatives|cytochrome p 450 cyp2c9 substrates|sigma 1 agonist|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|respiratory system agents|cytochrome p 450 cyp3a substrates|antitussive agents|combined inhibitors of serotonin/norepinephrine reuptake|cough and cold preparations|cytochrome p 450 cyp3a5 substrates|phenanthrenes|excitatory amino acid agents
cisplatin	antineoplastic and immunomodulating agents|cytochrome p 450 cyp2b6 inhibitors (strength unknown)|antineoplastic agents|drugs that are mainly renally excreted|nephrotoxic agents|cholinesterase inhibitors|cross linking reagents|oct2 substrates|oct2 inhibitors|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|bcrp/abcg2 substrates|myelosuppressive agents|cytochrome p 450 cyp2b6 inhibitors|laboratory chemicals|cytochrome p 450 enzyme inhibitors|nitrogen compounds|indicators and reagents|chlorine compounds|cytochrome p 450 cyp2c9 inhibitors|immunosuppressive agents|compounds used in a research, industrial, or household setting|radiation sensitizing agents|platinum compounds|cardiotoxic antineoplastic agents|narrow therapeutic index drugs|drugs that are mainly renally excreted with a narrow therapeutic index|oct2 substrates with a narrow therapeutic index
albendazole	acids, acyclic|antinematodal agents|antiplatyhelmintic agents|cytochrome p 450 cyp3a4 substrates|antiparasitic products, insecticides and repellents|p glycoprotein substrates|cytochrome p 450 cyp1a2 inducers|cytochrome p 450 cyp2c19 substrates|carbamates|benzimidazole derivatives|cytochrome p 450 cyp1a2 inducers (strong)|anthelmintics|antiparasitic agents|benzimidazoles|antimitotic agents|cytochrome p 450 substrates|antihelminthic|anti infective agents|tubulin modulators|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|mitosis modulators|cytochrome p 450 enzyme inducers|cytochrome p 450 cyp1a2 substrates|anticestodal agents|cytochrome p 450 cyp3a4 substrates (strength unknown)
carteolol	propanolamines|beta blocking agents, non selective|adrenergic agents|ophthalmologicals|phenoxypropanolamines|amines|bradycardia causing agents|adrenergic antagonists|hypotensive agents|antiarrhythmic agents|neurotransmitter agents|antiglaucoma preparations and miotics|quinolines|cardiovascular agents|qtc prolonging agents|propanols|adrenergic beta antagonists|cytochrome p 450 substrates|quinolones|potential qtc prolonging agents|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|antihypertensive agents|peripheral nervous system agents|agents causing hyperkalemia|sensory organs|amino alcohols|autonomic agents|sympatholytics|alcohols
alitretinoin	antineoplastic and immunomodulating agents|cyclohexanes|cyclohexenes|antineoplastic agents|agents for dermatitis, excluding corticosteroids|polyenes|p glycoprotein substrates|cycloparaffins|alkenes|vitamin a|hydrocarbons, acyclic|vitamins (fat soluble)|carotenoids|retinoids|pigments, biological|vitamins|biological factors|tretinoin|dermatologicals|terpenes|misc. skin and mucous membrane agents
metolazone	membrane transport modulators|drugs that are mainly renally excreted|antihypertensive agents indicated for hypertension|thiazide like diuretic|sulfones|hypotensive agents|low ceiling diuretics and potassium sparing agents|cardiovascular agents|quinazolinones|amides|increased diuresis|sulfonamides|hyperglycemia associated agents|diuretics|low ceiling diuretics, excl. thiazides|natriuretic agents|gynecological antiinfectives and antiseptics|heterocyclic compounds, fused ring|quinazolines|antihypertensive agents|sodium chloride symporter inhibitors|genito urinary system and sex hormones|sulfur compounds|non potassium sparing diuretics
tolnaftate	antifungal agents|acids, acyclic|dermatologicals|carbamates|naphthalenes|sulfur compounds|antifungals for topical use|anti infective agents|thiocarbamates|antifungals for dermatological use
cinchocaine	anesthetics, local|sensory system agents|central nervous system agents|ophthalmologicals|cell mediated immunity|antipruritics, incl. antihistamines, anesthetics, etc.|antipruritics and local anesthetics|cholinesterase inhibitors|local anesthetics (amide)|central nervous system depressants|quinolines|amides|nervous system|anesthetics for topical use|vasoprotectives|anesthetics|otologicals|heterocyclic compounds, fused ring|standardized chemical allergen|increased histamine release|peripheral nervous system agents|dermatologicals|sensory organs|agents for treatment of hemorrhoids and anal fissures for topical use|analgesics and anesthetics
erlotinib	cytochrome p 450 cyp2c8 inhibitors|antineoplastic and immunomodulating agents|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|bcrp/abcg2 inhibitors|antineoplastic agents|kinase inhibitor|cytochrome p 450 cyp3a4 substrates|tyrosine kinase inhibitors|p glycoprotein inhibitors|ugt1a1 inhibitors|p glycoprotein substrates|cytochrome p 450 cyp2d6 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a inhibitors|protein kinase inhibitors|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|quinazolines|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|highest risk qtc prolonging agents|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|cytochrome p 450 cyp2c8 inhibitors (strong)|cytochrome p 450 cyp2c8 substrates with a narrow therapeutic index|cytochrome p 450 cyp2c8 substrates
cyclophosphamide	cytochrome p 450 cyp2c19 substrates with a narrow therapeutic index|antineoplastic and immunomodulating agents|alkylating drugs|acids|organophosphorus compounds|antineoplastic agents|phosphoramide mustards|phosphoric acids|phosphorus acids|cytochrome p 450 cyp2c8 inducers (strength unknown)|cytochrome p 450 cyp2a6 substrates|cytochrome p 450 cyp2b6 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp2c8 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a4 substrates|nitrogen mustard analogues|electrolytes|cytochrome p 450 cyp2c19 substrates|ions|anions|cytochrome p 450 cyp2b6 substrates|alkylating activity|cytochrome p 450 cyp2c18 substrates with a narrow therapeutic index|cytochrome p 450 cyp2a6 substrates with a narrow therapeutic index|cytochrome p 450 cyp2b6 substrates with a narrow therapeutic index|myelosuppressive agents|cytochrome p 450 cyp2b6 inducers|mustard compounds|phosphoramides|nitrogen mustard compounds|myeloablative agonists|cytochrome p 450 cyp2c8 inducers|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|antineoplastic agents, alkylating|cytochrome p 450 substrates|mutagens|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|noxae|antirheumatic agents|acids, noncarboxylic|immunosuppressive agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|methemoglobinemia associated agents|hydrocarbons, halogenated|cytochrome p 450 enzyme inducers|neurotoxic agents|cardiotoxic antineoplastic agents|narrow therapeutic index drugs|cytochrome p 450 cyp2c9 substrates with a narrow therapeutic index|cytochrome p 450 cyp2c18 substrates|phosphorus compounds|toxic actions|cytochrome p 450 cyp2c8 substrates|immunologic factors
mephenytoin	central nervous system agents|anti epileptic agent|decreased central nervous system disorganized electrical activity|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp2b6 substrates|anticonvulsants|central nervous system depressants|hydantoins|thyroxine binding globulin substrates|nervous system|cytochrome p 450 enzyme inhibitors|imidazoles|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp1a2 substrates|imidazolidines|cytochrome p 450 cyp2c8 substrates
rofecoxib	cytochrome p 450 cyp2c8 inhibitors|anti inflammatory agents, non steroidal|sensory system agents|central nervous system agents|cytochrome p 450 cyp3a4 inducers|musculo skeletal system|cytochrome p 450 cyp3a4 substrates|cox 2 inhibitors|nephrotoxic agents|selective cyclooxygenase 2 inhibitors (nsaids)|analgesics|agents that produce hypertension|antiinflammatory and antirheumatic products, non steroids|cytochrome p 450 enzyme inhibitors|anti inflammatory agents|cytochrome p 450 cyp1a2 inhibitors (strong)|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|analgesics, non narcotic|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp1a2 inhibitors|antirheumatic agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|antiinflammatory and antirheumatic products|peripheral nervous system agents|agents causing hyperkalemia|cytochrome p 450 cyp2c8 inhibitors (weak)|cytochrome p 450 enzyme inducers|cytochrome p 450 cyp1a2 substrates|sulfur compounds|cyclooxygenase inhibitors
cefdinir	oat1/slc22a6 substrates|thiazines|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|cephalosporins|heterocyclic compounds, fused ring|sulfur compounds|aza compounds|azabicyclo compounds|drugs that are mainly renally excreted|third generation cephalosporins|beta lactams|anti infective agents|lactams|oat3/slc22a8 substrates
ciprofloxacin	drugs causing inadvertant photosensitivity|topoisomerase inhibitors|antibacterials for systemic use|anti bacterial agents|cytochrome p 450 cyp3a5 inhibitors (moderate)|drugs that are mainly renally excreted|mate 2 inhibitors|ophthalmologicals|mate 1 inhibitors|ophthalmological and otological preparations|p glycoprotein substrates|photosensitizing agents|cytochrome p 450 cyp3a5 inhibitors|quinolone antimicrobial|fluoroquinolones|quinolines|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a4 inhibitors (moderate)|cytochrome p 450 cyp1a2 inhibitors (strong)|moderate risk qtc prolonging agents|mate substrates|quinolones|enzyme inhibitors|anti infective agents|cytochrome p 450 cyp3a inhibitors|chemically induced disorders|cytochrome p 450 cyp1a2 inhibitors|otologicals|heterocyclic compounds, fused ring|mate inhibitors|cytochrome p 450 cyp3a7 inhibitors (moderate)|cytochrome p 450 cyp3a7 inhibitors|antiinfectives for systemic use|topoisomerase ii inhibitors|sensory organs|mate 1 substrates
toremifene	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|antineoplastic and immunomodulating agents|antineoplastic agents|benzylidene compounds|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|p glycoprotein substrates|estrogen agonist/antagonist|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|antineoplastic agents, hormonal|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|stilbenes|cytochrome p 450 substrates|selective estrogen receptor modulators|cytochrome p 450 cyp3a inhibitors|bone density conservation agents|anti estrogens|cytochrome p 450 cyp3a substrates|endocrine therapy|highest risk qtc prolonging agents|hormone antagonists and related agents|benzene derivatives|estrogen receptor modulators
nortriptyline	adrenergic uptake inhibitors|cytochrome p 450 cyp2c19 substrates with a narrow therapeutic index|agents producing tachycardia|membrane transport modulators|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|psychoanaleptics|central nervous system agents|adrenergic agents|serotonin receptor antagonists|benzocycloheptenes|adrenergic alpha 1 receptor antagonists|cytochrome p 450 cyp3a4 substrates|p glycoprotein substrates|adrenergic antagonists|serotonin 5 ht1 receptor antagonists|cytochrome p 450 cyp2c19 substrates|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|anticholinergic agents|serotonin 5 ht1a receptor antagonists|cytochrome p 450 cyp2d6 substrates with a narrow therapeutic index|cytochrome p 450 cyp2e1 inhibitors|agents that produce hypertension|serotonin modulators|central nervous system depressants|neurotransmitter agents|antidepressive agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|dibenzocycloheptenes|nervous system|agents that reduce seizure threshold|antidepressive agents, tricyclic|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|non selective monoamine reuptake inhibitors|serotonin 5 ht2 receptor antagonists|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|potential qtc prolonging agents|dopamine d2 receptor antagonists|serotonin 5 ht2c receptor antagonists|muscarinic antagonists|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|combined inhibitors of serotonin/norepinephrine reuptake|cytochrome p 450 cyp3a5 substrates|neurotoxic agents|neurotransmitter uptake inhibitors|psychotropic drugs|serotonin 5 ht2a receptor antagonists|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|histamine antagonists|dopamine antagonists|tricyclics and other norepinephrine reuptake inhibitors|histamine h1 antagonists
vincristine	antineoplastic and immunomodulating agents|cytochrome p 450 cyp3a7 substrates with a narrow therapeutic index|oatp1b3 inhibitors|antineoplastic agents|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|p glycoprotein substrates|indoles|p glycoprotein inducers|indole alkaloids|vinca alkaloids|oatp1b1/slco1b1 inhibitors|bcrp/abcg2 substrates|cytochrome p 450 cyp3a7 substrates|antineoplastic agents, phytogenic|agents causing muscle toxicity|antimitotic agents|alkaloids|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|bsep/abcb11 substrates with a narrow therapeutic index|tubulin modulators|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|heterocyclic compounds, fused ring|immunosuppressive agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|mitosis modulators|neurotoxic agents|cardiotoxic antineoplastic agents|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|bsep/abcb11 substrates|secologanin tryptamine alkaloids
benazepril	agents acting on the renin angiotensin system|ace inhibitors and diuretics|drugs causing inadvertant photosensitivity|agents causing angioedema|angiotensin converting enzyme inhibitors|antihypertensive agents|agents causing hyperkalemia|decreased blood pressure|heterocyclic compounds, fused ring|photosensitizing agents|protease inhibitors|hypotensive agents|enzyme inhibitors|cardiovascular agents|antihypertensive agents indicated for hypertension
amoxapine	adrenergic uptake inhibitors|agents producing tachycardia|membrane transport modulators|psychoanaleptics|central nervous system agents|adrenergic agents|serotonin receptor antagonists|adrenergic alpha 1 receptor antagonists|p glycoprotein inhibitors|adrenergic antagonists|serotonin 5 ht1 receptor antagonists|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|anticholinergic agents|serotonin 5 ht1a receptor antagonists|cytochrome p 450 cyp2d6 substrates with a narrow therapeutic index|antipsychotic agents|agents that produce hypertension|serotonin modulators|central nervous system depressants|neurotransmitter agents|antidepressive agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|nervous system|agents that reduce seizure threshold|antidepressive agents, tricyclic|cytochrome p 450 enzyme inhibitors|antidepressive agents, tetracyclic|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|non selective monoamine reuptake inhibitors|serotonin 5 ht2 receptor antagonists|dibenzoxazepines|potential qtc prolonging agents|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|muscarinic antagonists|cytochrome p 450 cyp2d6 substrates|serotonin 5 ht2c receptor antagonists|neurotoxic agents|adrenergic alpha antagonists|combined inhibitors of serotonin/norepinephrine reuptake|neurotransmitter uptake inhibitors|serotonin 5 ht2a receptor antagonists|psychotropic drugs|dopamine agents|narrow therapeutic index drugs|histamine antagonists|dopamine antagonists|histamine h1 antagonists
fluorouracil	drugs causing inadvertant photosensitivity|antineoplastic and immunomodulating agents|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|pyrimidines|thyroxine binding globulin inducers|antineoplastic agents|cytochrome p 450 cyp2a6 substrates|photosensitizing agents|toxic actions|cytochrome p 450 cyp2a6 substrates with a narrow therapeutic index|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|bcrp/abcg2 substrates|myelosuppressive agents|pyrimidinones|qtc prolonging agents|nucleoside metabolic inhibitor|cytochrome p 450 enzyme inhibitors|nucleic acid synthesis inhibitors|moderate risk qtc prolonging agents|cytochrome p 450 substrates|noxae|cytochrome p 450 cyp2c9 inhibitors|immunosuppressive agents|pyrimidine analogues|fluoropyrimidines|antimetabolites|cardiotoxic antineoplastic agents|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs|fluorouracil and prodrugs|cytochrome p 450 cyp2c8 substrates with a narrow therapeutic index|misc. skin and mucous membrane agents|cytochrome p 450 cyp2c8 substrates|immunologic factors
desoximetasone	hormones, hormone substitutes, and hormone antagonists|steroids, fluorinated|dermatologicals|anti inflammatory agents|adrenal cortex hormones|corticosteroids, dermatological preparations|hormones|pregnadienediols|corticosteroids, potent (group iii)|pregnanes|corticosteroids|steroids|pregnadienes|pregnadienetriols|immunosuppressive agents|fused ring compounds|corticosteroid hormone receptor agonists
zafirlukast	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|cytochrome p 450 cyp2c8 inhibitors|anti asthmatic agents|leukotriene modifiers|agents to treat airway disease|leukotriene antagonists|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp2e1 inhibitors (weak)|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|sulfones|cytochrome p 450 cyp2e1 inhibitors|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp1a2 inhibitors (strong)|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strong)|cytochrome p 450 cyp1a2 inhibitors|drugs for obstructive airway diseases|respiratory system agents|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|sulfur compounds|benzene derivatives|cytochrome p 450 cyp2c8 inhibitors (strong)|cytochrome p 450 cyp2c8 substrates|cytochrome p 450 cyp3a4 substrates (strength unknown)
propylthiouracil	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|thyroid hormone synthesis inhibitor|agents causing muscle toxicity|antimetabolites|antithyroid agents|myelosuppressive agents|pyrimidines|thyroid hormone synthesis inhibitors|toxic actions|thiouracils|thiouracil|thyroid products|immunosuppressive agents|noxae|pyrimidinones|systemic hormonal preparations, excl. sex hormones and insulins
acetohydroxamic acid	urologicals|hydroxylamines|urease inhibitors|hydroxy acids|genito urinary system and sex hormones|enzyme inhibitors|urease inhibitor|amines
methoxsalen	antipsoriatics|photoabsorption|drugs that are mainly renally excreted|psoralens for systemic use|photoactivated radical generator|antipsoriatics for topical use|furocoumarins|cross linking reagents|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|photosensitizing agents|cytochrome p 450 cyp2a6 inhibitors (strength unknown)|coloring agents|photosensitizing activity|benzopyrans|laboratory chemicals|antipsoriatics for systemic use|cytochrome p 450 enzyme inhibitors|indicators and reagents|cytochrome p 450 cyp1a2 inhibitors|heterocyclic compounds, fused ring|photosensitizing agents used for phototherapy|psoralens for topical use|compounds used in a research, industrial, or household setting|radiation sensitizing agents|dermatologicals|pyrans|cytochrome p 450 cyp2a6 inhibitors
piroxicam	cytochrome p 450 cyp2c8 inhibitors|anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|drugs causing inadvertant photosensitivity|thiazines|antiinflammatory preparations, non steroids for topical use|central nervous system agents|sensory system agents|drugs that are mainly renally excreted|ophthalmologicals|other nonsteroidal anti inflammatory agents|musculo skeletal system|nephrotoxic agents|photosensitizing agents|oat3/slc22a8 inhibitors|analgesics|agents that produce hypertension|non cox 2 selective nsaids|antiinflammatory and antirheumatic products, non steroids|topical products for joint and muscular pain|cytochrome p 450 enzyme inhibitors|anti inflammatory agents|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|oat1/slc22a6 inhibitors|oxicams|analgesics, non narcotic|antirheumatic agents|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|sulfur compounds|sensory organs|cytochrome p 450 cyp2c8 substrates|cyclooxygenase inhibitors
lamotrigine	agents producing tachycardia|membrane transport modulators|drugs causing inadvertant photosensitivity|ugt1a3 substrates|central nervous system agents|tranquilizing agents|calcium regulating hormones and agents|drugs that are mainly renally excreted|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|anti epileptic agent|p glycoprotein inhibitors|decreased central nervous system disorganized electrical activity|p glycoprotein substrates|ugt1a1 inducers|photosensitizing agents|anticholinergic agents|oct2 inhibitors|oct1 substrates|antiarrhythmic agents|anticonvulsants|central nervous system depressants|calcium channel blockers|miscellaneous anticonvulsants|ugt1a4 substrates|qtc prolonging agents|nervous system|cytochrome p 450 substrates|mood stabilizer|potential qtc prolonging agents|muscarinic antagonists|cytochrome p 450 cyp3a substrates|agents causing hyperkalemia|psychotropic drugs|triazines|ugt1a1 substrates|sodium channel blockers
hydroxyzine	piperazines|diphenylmethane derivatives|psycholeptics|cytochrome p 450 cyp3a4 substrates|histamine agents|p glycoprotein substrates|miscellaneous anxiolytics sedatives and hypnotics|central nervous system depressants|neurotransmitter agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|nervous system|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|histamine receptor antagonists|potential qtc prolonging agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|antipruritics|dermatologicals|histamine antagonists|histamine h1 antagonists|anti anxiety agents
bosentan	cytochrome p 450 cyp2c9 inducers (moderate)|pyrimidines|hepatotoxic agents|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|sulfones|cardiovascular agents|oatp1b1/slco1b1 substrates|amides|sulfonamides|vasodilating agents|endothelin receptor antagonists|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inducers|gynecological antiinfectives and antiseptics|antihypertensives for pulmonary arterial hypertension|cytochrome p 450 cyp3a4 inducers (moderate)|cytochrome p 450 cyp3a substrates|antihypertensive agents|cytochrome p 450 enzyme inducers|genito urinary system and sex hormones|sulfur compounds|bsep/abcb11 inhibitors|cytochrome p 450 cyp2c9 inducers
tigecycline	tetracyclines|naphthacenes|glycylcyclines|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|protein synthesis inhibitors|agents that produce neuromuscular block (indirect)|enzyme inhibitors|anti infective agents
doxapram	respiratory system agents|central nervous system stimulants|central nervous system agents|agents that produce hypertension|pyrrolidinones|pyrrolidines|increased medullary respiratory drive
benzthiazide	amides|sulfonamides|hyperglycemia associated agents|diuretics|heterocyclic compounds, fused ring|sulfones|stimulants|sodium chloride symporter inhibitors|genito urinary system and sex hormones|sulfur compounds|gynecological antiinfectives and antiseptics|thiazides
methotrexate	drugs causing inadvertant photosensitivity|oatp1b3 substrates|antineoplastic and immunomodulating agents|abortifacient agents, nonsteroidal|antineoplastic agents|drugs that are mainly renally excreted|hepatotoxic agents|cytochrome p 450 cyp3a4 substrates|abortifacient agents|folic acid antagonists|nephrotoxic agents|p glycoprotein substrates|pterins|photosensitizing agents|oat3/slc22a8 inhibitors|pteridines|oat3/slc22a8 substrates with a narrow therapeutic index|bcrp/abcg2 substrates|myelosuppressive agents|oatp1b1/slco1b1 substrates|nucleic acid synthesis inhibitors|agents causing muscle toxicity|cytochrome p 450 substrates|enzyme inhibitors|oat1/slc22a6 inhibitors|pigments, biological|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|noxae|antirheumatic agents|biological factors|heterocyclic compounds, fused ring|immunosuppressive agents|cytochrome p 450 cyp3a substrates|folic acid analogues|antimetabolites|dermatologicals|reproductive control agents|cardiotoxic antineoplastic agents|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|toxic actions|oat3/slc22a8 substrates|immunologic factors
carbamazepine	membrane transport modulators|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|ugt2b7 substrates with a narrow therapeutic index|sensory system agents|central nervous system agents|cytochrome p 450 cyp2c9 inducers|drugs that are mainly renally excreted|cytochrome p 450 cyp2c8 inducers (strength unknown)|cytochrome p 450 cyp2b6 inducers (strong)|ugt2b7 substrates|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|ugt1a1 inducers|decreased central nervous system disorganized electrical activity|p glycoprotein substrates|cytochrome p 450 cyp1a2 inducers|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|serotonergic drugs shown to increase risk of serotonin syndrome|analgesics|cytochrome p 450 cyp2b6 substrates|cytochrome p 450 cyp3a inducers (strong)|cytochrome p 450 cyp2c19 inducers|cytochrome p 450 cyp2c9 inducers (strength unknown)|cytochrome p 450 cyp3a5 inducers (strength unknown)|cytochrome p 450 cyp1a2 inducers (strong)|cytochrome p 450 cyp3a5 inducers (strong)|anticonvulsants|central nervous system depressants|cytochrome p 450 cyp2b6 substrates with a narrow therapeutic index|p glycoprotein inducers|cardiovascular agents|miscellaneous anticonvulsants|myelosuppressive agents|cytochrome p 450 cyp2b6 inducers|cytochrome p 450 cyp3a7 substrates|cytochrome p 450 cyp3a4 inducers (strong)|dibenzazepines|thyroxine binding globulin substrates|cytochrome p 450 enzyme inhibitors|antimanic agents|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 cyp2c8 inducers|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|mood stabilizer|analgesics, non narcotic|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp1a2 inhibitors|ugt1a6 inducer|heterocyclic compounds, fused ring|immunosuppressive agents|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|peripheral nervous system agents|carboxamide derivatives|cytochrome p 450 enzyme inducers|psychotropic drugs|cytochrome p 450 cyp1a2 substrates|cytochrome p 450 cyp2c19 inducers (moderate)|narrow therapeutic index drugs|enzyme inducing antiepileptic drugs|drugs that are mainly renally excreted with a narrow therapeutic index|cytochrome p 450 cyp2c8 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a5 inducers|sodium channel blockers|cytochrome p 450 cyp2c8 substrates|inducers of drug clearance
cephalexin	thiazines|antibacterials for systemic use|anti bacterial agents|aza compounds|azabicyclo compounds|drugs that are mainly renally excreted|cytochrome p 450 cyp3a4 substrates|nephrotoxic agents|oat1/slc22a6 substrates|oat3/slc22a8 inhibitors|beta lactams|amides|cephalosporins|mate substrates|cytochrome p 450 substrates|oat1/slc22a6 inhibitors|anti infective agents|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|antiinfectives for systemic use|sulfur compounds|first generation cephalosporins|mate 1 substrates|lactams|oat3/slc22a8 substrates|cytochrome p 450 cyp3a4 substrates (strength unknown)
cinnarizine	membrane transport modulators|piperazines|calcium regulating hormones and agents|cytochrome p 450 cyp2a6 substrates|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|histamine agents|cytochrome p 450 cyp2b6 substrates|antiarrhythmic agents|neurotransmitter agents|calcium channel blockers|cardiovascular agents|qtc prolonging agents|nervous system|antivertigo preparations|vasodilating agents|moderate risk qtc prolonging agents|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|agents causing hyperkalemia|cytochrome p 450 cyp1a2 substrates|histamine antagonists|histamine h1 antagonists
vinblastine	antineoplastic and immunomodulating agents|antineoplastic agents|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp2d6 inhibitors (weak)|indoles|p glycoprotein inducers|indole alkaloids|vinca alkaloids|oatp1b1/slco1b1 inhibitors|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|myelosuppressive agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|antineoplastic agents, phytogenic|antimitotic agents|cytochrome p 450 cyp3a4 inhibitors|alkaloids|cytochrome p 450 substrates|bsep/abcb11 substrates with a narrow therapeutic index|tubulin modulators|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|heterocyclic compounds, fused ring|immunosuppressive agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|mitosis modulators|cytochrome p 450 enzyme inducers|cardiotoxic antineoplastic agents|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|bsep/abcb11 substrates|bsep/abcb11 inhibitors|secologanin tryptamine alkaloids
propranolol	propanolamines|beta blocking agents, non selective|adrenergic agents|drugs that are mainly renally excreted|phenoxypropanolamines|antihypertensive agents indicated for hypertension|amines|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|p glycoprotein inhibitors|p glycoprotein substrates|adrenergic antagonists|cytochrome p 450 cyp2d6 inhibitors (weak)|cytochrome p 450 cyp2c19 substrates|hypotensive agents|oct2 inhibitors|antiarrhythmic agents|neurotransmitter agents|cardiovascular agents|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|vasodilating agents|propanols|moderate risk qtc prolonging agents|adrenergic beta antagonists|cytochrome p 450 substrates|beta blocking agents and thiazides|beta blocking agents, non selective, and thiazides|monoamine oxidase a inhibitors  for interaction with monoamine oxidase a substrates|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|antihypertensive agents|agents causing hyperkalemia|cytochrome p 450 cyp1a2 substrates|amino alcohols|naphthalenes|alcohols
atropine	mydriatics|agents producing tachycardia|anti asthmatic agents|central nervous system agents|aza compounds|azabicyclo compounds|ophthalmologicals|belladonna alkaloids|adjuvants, anesthesia|mydriatics and cycloplegics|anticholinergic agents|agents that produce hypertension|belladonna alkaloids, tertiary amines|tropanes|antiarrhythmic agents|neurotransmitter agents|cardiovascular agents|qtc prolonging agents|cholinergic agents|parasympatholytics|alkaloids|moderate risk qtc prolonging agents|belladonna and derivatives, plain|atropine derivatives|drugs for functional gastrointestinal disorders|muscarinic antagonists|respiratory system agents|antimuscarinics antispasmodics|peripheral nervous system agents|alimentary tract and metabolism|bronchodilator agents|solanaceous alkaloids|sensory organs|bsep/abcb11 substrates|autonomic agents
fenoprofen	anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|sensory system agents|central nervous system agents|musculo skeletal system|nephrotoxic agents|analgesics|agents that produce hypertension|non cox 2 selective nsaids|antiinflammatory and antirheumatic products, non steroids|phenylpropionates|anti inflammatory agents|enzyme inhibitors|analgesics, non narcotic|antirheumatic agents|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|propionates|acids, carbocyclic|cyclooxygenase inhibitors
clonidine	agents producing tachycardia|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|central alpha 2 adrenergic agonist|antimigraine preparations|adrenergic agents|central nervous system agents|sensory system agents|ophthalmologicals|imidazolines|antihypertensive agents indicated for hypertension|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|anesthetics, general|analgesics|cytochrome p 450 cyp2d6 substrates with a narrow therapeutic index|hypotensive agents|agents that produce hypertension|imidazoline receptor agonists|adrenergic alpha 1 receptor agonists|adrenergic alpha 2 receptor agonists|central nervous system depressants|antiglaucoma preparations and miotics|neurotransmitter agents|cardiovascular agents|nervous system|imidazoles|adrenergic agonists|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|adrenergic alpha agonists|anesthetics|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|antihypertensive agents|peripheral nervous system agents|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs|sensory organs|autonomic agents|sympatholytics|sympathomimetics in glaucoma therapy|antiadrenergic agents, centrally acting|central alpha agonists
sulfamethizole	thiazoles|antibacterials for systemic use|sulfonamides and trimethoprim|ophthalmologicals|sulfanilamides|amines|short acting sulfonamides|sulfathiazoles|sulfones|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|blood and blood forming organs|blood substitutes and perfusion solutions|amides|cytochrome p 450 enzyme inhibitors|sulfonamides|anti infective agents|gynecological antiinfectives and antiseptics|cytochrome p 450 cyp2c9 inhibitors|aniline compounds|irrigating solutions|antiinfectives for systemic use|dermatologicals|genito urinary system and sex hormones|sensory organs|sulfur compounds
valaciclovir	amino acids, peptides, and proteins|nucleosides and nucleotides|drugs that are mainly renally excreted|antivirals for systemic use|nephrotoxic agents|purinones|amino acids|herpesvirus nucleoside analog dna polymerase inhibitor|herpes simplex virus nucleoside analog dna polymerase inhibitor|amino acids, branched chain|nucleic acid synthesis inhibitors|nucleosides and nucleotides excl. reverse transcriptase inhibitors|anti infective agents|antiviral agents|heterocyclic compounds, fused ring|antiinfectives for systemic use|prodrugs|direct acting antivirals|purines|acyclovir and prodrug|herpes zoster virus nucleoside analog dna polymerase inhibitor|oat3/slc22a8 substrates
valdecoxib	anti inflammatory agents, non steroidal|sensory system agents|central nervous system agents|cytochrome p 450 cyp2c9 inhibitors (weak)|musculo skeletal system|cytochrome p 450 cyp3a4 substrates|cox 2 inhibitors|nephrotoxic agents|selective cyclooxygenase 2 inhibitors (nsaids)|analgesics|sulfones|agents that produce hypertension|antiinflammatory and antirheumatic products, non steroids|amides|cytochrome p 450 enzyme inhibitors|anti inflammatory agents|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|analgesics, non narcotic|cytochrome p 450 cyp2c9 inhibitors|antirheumatic agents|cytochrome p 450 cyp3a substrates|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|ugt1a9 substrates|sulfur compounds|cyclooxygenase inhibitors
voriconazole	antifungal agents|hormones, hormone substitutes, and hormone antagonists|hormone antagonists|drugs causing inadvertant photosensitivity|cytochrome p 450 cyp2b6 inhibitors (strength unknown)|cytochrome p 450 cyp3a5 inhibitors (moderate)|cytochrome p 450 cyp2c9 inhibitors (weak)|cytochrome p 450 cyp3a4 inhibitors (strong)|triazoles|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp3a7 inhibitors (strength unknown)|photosensitizing agents|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp3a5 inhibitors|cytochrome p 450 cyp2c19 inhibitors (weak)|antimycotics for systemic use|qtc prolonging agents|steroid synthesis inhibitors|cytochrome p 450 cyp2b6 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a4 inhibitors (moderate)|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|14 alpha demethylase inhibitors|anti infective agents|cytochrome p 450 cyp3a inhibitors|chemically induced disorders|cytochrome p 450 cyp2c9 inhibitors|potential qtc prolonging agents|azole antifungals|triazole derivatives|cytochrome p 450 cyp3a7 inhibitors (moderate)|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a7 inhibitors|cytochrome p 450 cyp3a substrates|antiinfectives for systemic use|cytochrome p 450 cyp3a5 inhibitors (strength unknown)
enalapril	amino acids, peptides, and proteins|drugs causing inadvertant photosensitivity|ace inhibitors and calcium channel blockers|antihypertensive agents indicated for hypertension|p glycoprotein inhibitors|dipeptides|photosensitizing agents|oat3/slc22a8 inhibitors|peptides|hypotensive agents|cardiovascular agents|oatp1b1/slco1b1 substrates|agents causing angioedema|agents causing muscle toxicity|oligopeptides|cytochrome p 450 substrates|enzyme inhibitors|oat1/slc22a6 inhibitors|ace inhibitors and diuretics|agents acting on the renin angiotensin system|cytochrome p 450 cyp3a substrates|angiotensin converting enzyme inhibitors|antihypertensive agents|decreased blood pressure|agents causing hyperkalemia|protease inhibitors
nizatidine	histamine agents|gastric acid lowering agents|cholinesterase inhibitors|p glycoprotein substrates|agents causing muscle toxicity|thiazoles|alimentary tract and metabolism|gastrointestinal agents|sulfur compounds|histamine h2 antagonists|histamine antagonists|neurotransmitter agents|acid reducers|anti ulcer agents|drugs for peptic ulcer and gastro oesophageal reflux disease (gord)|drugs for acid related disorders
diclofenac	ugt1a3 substrates|drugs causing inadvertant photosensitivity|anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|cyclooxygenase 2 (cox 2) inhibitors|antiinflammatory preparations, non steroids for topical use|central nervous system agents|sensory system agents|antimigraine agents, miscellaneous|ophthalmologicals|other nonsteroidal anti inflammatory agents|ugt2b7 substrates|musculo skeletal system|amines|cytochrome p 450 cyp3a4 substrates|nephrotoxic agents|photosensitizing agents|cytochrome p 450 cyp2c19 substrates|oat3/slc22a8 inhibitors|analgesics|cytochrome p 450 cyp2b6 substrates|cytochrome p 450 cyp2e1 inhibitors|p glycoprotein inducers|agents that produce hypertension|non cox 2 selective nsaids|acetic acid derivatives and related substances|oatp1b1/slco1b1 inhibitors|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|antiinflammatory and antirheumatic products, non steroids|topical products for joint and muscular pain|cytochrome p 450 enzyme inhibitors|agents causing angioedema|decreased prostaglandin production|anti inflammatory agents|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|ethylamines|oat1/slc22a6 inhibitors|analgesics, non narcotic|cytochrome p 450 cyp3a inhibitors|antirheumatic agents|cytochrome p 450 cyp3a substrates|peripheral nervous system agents|antiinflammatory and antirheumatic products|dermatologicals|agents causing hyperkalemia|ugt1a9 substrates|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|acids, carbocyclic|cytochrome p 450 cyp1a2 substrates|phenylacetates|bsep/abcb11 substrates|sensory organs|cytochrome p 450 cyp2c18 substrates|ugt1a1 substrates|cytochrome p 450 cyp2c8 substrates|cyclooxygenase inhibitors
cinalukast	sulfur compounds
fluticasone propionate	cytochrome p 450 cyp2c8 inhibitors|anti asthmatic agents|androstenes|adrenal cortex hormones|androstanes|agents to treat airway disease|cytochrome p 450 cyp3a4 substrates|p glycoprotein substrates|cytochrome p 450 cyp3a5 inhibitors|corticosteroids, potent (group iii)|corticosteroids|central nervous system depressants|oatp1b1/slco1b1 inhibitors|androstadienes|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 cyp3a7 substrates|cytochrome p 450 enzyme inhibitors|anti inflammatory agents|cytochrome p 450 cyp3a4 inhibitors|anti allergic agents|cytochrome p 450 substrates|cytochrome p 450 cyp3a inhibitors|immunosuppressive agents|adrenals|respiratory system agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|peripheral nervous system agents|dermatologicals|steroids|corticosteroids, dermatological preparations|bronchodilator agents|cytochrome p 450 cyp3a5 inhibitors (strength unknown)|thyroxine binding globulin inhibitors|autonomic agents|cytochrome p 450 cyp2c8 inhibitors (strong)
lisuride	serotonin 5 ht1 receptor agonists|antimigraine preparations|central nervous system agents|serotonin receptor antagonists|anti dyskinesia agents|cytochrome p 450 cyp3a4 substrates|ergolines|ergot derivative dopamine receptor agonists|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|analgesics|agents that produce hypertension|central nervous system depressants|neurotransmitter agents|antidepressive agents|nervous system|alkaloids|anti parkinson drugs|cytochrome p 450 substrates|serotonin 5 ht2 receptor antagonists|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|ergot alkaloids and derivatives|cytochrome p 450 cyp3a substrates|prolactine inhibitors|dopamine agents|genito urinary system and sex hormones|dopamine agonists|dopamine antagonists|serotonin receptor agonists
doxazosin	adrenergic agents|antiadrenergic agents, peripherally acting|adrenergic alpha 1 receptor antagonists|antihypertensive agents indicated for hypertension|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|adrenergic antagonists|cytochrome p 450 cyp2c19 substrates|hypotensive agents|neurotransmitter agents|cardiovascular agents|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|quinazolines|oct1 inhibitors|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|antihypertensive agents|peripheral alpha 1 blockers|cytochrome p 450 cyp3a4 substrates (strength unknown)
fluocinolone acetonide	hormones, hormone substitutes, and hormone antagonists|adrenal cortex hormones|drugs that are mainly renally excreted|ophthalmologicals|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|corticosteroids|steroids, fluorinated|anti inflammatory agents|pregnanes|cytochrome p 450 substrates|vasoprotectives|cytochrome p 450 cyp3a inducers|otologicals|corticosteroid hormone receptor agonists|immunosuppressive agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|dermatologicals|cytochrome p 450 enzyme inducers|steroids|corticosteroids, dermatological preparations|hormones|pregnadienes|agents for treatment of hemorrhoids and anal fissures for topical use
ethosuximide	succinimides|central nervous system agents|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|anti epileptic agent|succinimide derivatives|decreased central nervous system disorganized electrical activity|anticonvulsants|antiarrhythmic agents|central nervous system depressants|calcium channel blockers|pyrrolidines|qtc prolonging agents|nervous system|cytochrome p 450 substrates|pyrrolidinones|potential qtc prolonging agents|cytochrome p 450 cyp3a substrates|agents causing hyperkalemia|cytochrome p 450 cyp2e1 substrates|imides
amiloride	membrane transport modulators|increased diuresis|pyrazines|agents causing hyperkalemia|diuretics|potassium sparing diuretics|acid sensing ion channel blockers|epithelial sodium channel blockers|hypotensive agents|natriuretic agents|oct2 inhibitors|decreased renal k+ excretion|cardiovascular agents|sodium channel blockers
oxytetracycline	tetracyclines|naphthacenes|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|dermatologicals|antibiotics for topical use|oat3/slc22a8 inhibitors|genito urinary system and sex hormones|sensory organs|agents that produce neuromuscular block (indirect)|oat1/slc22a6 inhibitors|ophthalmologicals|anti infective agents|gynecological antiinfectives and antiseptics|oat3/slc22a8 substrates
labetalol	agents producing tachycardia|adrenergic agents|alpha and beta blocking agents and thiazides|drugs that are mainly renally excreted|adrenergic alpha 1 receptor antagonists|ugt2b7 substrates|antihypertensive agents indicated for hypertension|amines|bradycardia causing agents|adrenergic antagonists|cytochrome p 450 cyp2c19 substrates|hypotensive agents|neurotransmitter agents|cardiovascular agents|cytochrome p 450 cyp2d6 inhibitors|amides|sympathomimetics|cytochrome p 450 enzyme inhibitors|vasodilating agents|adrenergic beta antagonists|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|beta blocking agents and thiazides|cytochrome p 450 cyp2d6 substrates|ethanolamines|peripheral alpha 1 blockers|adrenergic alpha antagonists|antihypertensive agents|peripheral nervous system agents|agents causing hyperkalemia|ugt1a9 substrates|salicylamides|alpha and beta blocking agents|amino alcohols|autonomic agents|ugt1a1 substrates|alcohols
monobenzone	melanin synthesis inhibitors|phenols|depigmenting activity|dermatologicals|depigmenting agents|benzene derivatives|alpha galactosidase, antagonists & inhibitors
linezolid	acids, acyclic|antibacterials for systemic use|anti bacterial agents|oxazoles|acetamides|oxazolidinones|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|fatty acids|serotonin modulators|agents that produce hypertension|central nervous system depressants|antidepressive agents|myelosuppressive agents|oxazolidinone antibacterial|amides|agents that reduce seizure threshold|fatty acids, volatile|enzyme inhibitors|anti infective agents|monoamine oxidase a inhibitors  for interaction with monoamine oxidase a substrates|monoamine oxidase inhibitors|immunosuppressive agents|acetates|antiinfectives for systemic use|protein synthesis inhibitors|lipids
ivermectin	insecticides|anti bacterial agents|antinematodal agents|oatp1b3 inhibitors|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|antiparasitic products, insecticides and repellents|p glycoprotein inhibitors|p glycoprotein substrates|agrochemicals|avermectines|p glycoprotein inducers|pesticides|anthelmintics|oatp1b1/slco1b1 inhibitors|bcrp/abcg2 substrates|antiparasitic agents|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|cytochrome p 450 substrates|pediculicides|scabicides and pediculicides|anti infective agents|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a inducers|compounds used in a research, industrial, or household setting|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|dermatologicals|cytochrome p 450 enzyme inducers|polyketides|lactones|toxic actions
cisapride	cytochrome p 450 cyp2d6 inhibitors (strong)|cytochrome p 450 cyp2a6 substrates|benzoates|anti ulcer agents|aminobenzoates|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp2c19 inhibitors (moderate)|cytochrome p 450 cyp2c19 substrates|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|cytochrome p 450 cyp2b6 substrates|central nervous system depressants|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|neurotransmitter agents|antidepressive agents|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|amides|cytochrome p 450 enzyme inhibitors|para aminobenzoates|gastrointestinal agents|cytochrome p 450 substrates|piperidines|chlorobenzoates|cytochrome p 450 cyp2c9 inhibitors|drugs for functional gastrointestinal disorders|cytochrome p 450 cyp2c19 inhibitors|propulsives|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|alimentary tract and metabolism|benzamides and benzamide derivatives|highest risk qtc prolonging agents|acids, carbocyclic|benzene derivatives|serotonin receptor agonists|cytochrome p 450 cyp2c8 substrates|cytochrome p 450 cyp3a4 substrates (strength unknown)
sulindac	drugs causing inadvertant photosensitivity|anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|sensory system agents|central nervous system agents|other nonsteroidal anti inflammatory agents|musculo skeletal system|nephrotoxic agents|photosensitizing agents|analgesics|agents that produce hypertension|non cox 2 selective nsaids|acetic acid derivatives and related substances|indenes|antiinflammatory and antirheumatic products, non steroids|anti inflammatory agents|enzyme inhibitors|oat1/slc22a6 inhibitors|analgesics, non narcotic|antirheumatic agents|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|cyclooxygenase inhibitors
nafcilline	antibacterials for systemic use|anti bacterial agents|cytochrome p 450 cyp1a2 inducers (strength unknown)|beta lactam antibacterials|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp1a2 inducers|beta lactams|amides|beta lactamase resistant penicillins|oat1/slc22a6 inhibitors|anti infective agents|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a4 inducers (moderate)|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a4 inducers (strength unknown)|antiinfectives for systemic use|cytochrome p 450 enzyme inducers|sulfur compounds|penicillins|lactams
nafcillin	antibacterials for systemic use|anti bacterial agents|cytochrome p 450 cyp1a2 inducers (strength unknown)|beta lactam antibacterials|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp1a2 inducers|beta lactams|amides|beta lactamase resistant penicillins|oat1/slc22a6 inhibitors|anti infective agents|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a4 inducers (moderate)|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a4 inducers (strength unknown)|antiinfectives for systemic use|cytochrome p 450 enzyme inducers|sulfur compounds|penicillins|lactams
chloroquine	drugs causing inadvertant photosensitivity|sensory system agents|antinematodal agents|central nervous system agents|agents that produce neuromuscular block (indirect)|drugs that are mainly renally excreted|aminoquinolines|experimental unapproved treatments for covid 19|cytochrome p 450 cyp3a4 substrates|antiparasitic products, insecticides and repellents|p glycoprotein inhibitors|p glycoprotein substrates|photosensitizing agents|analgesics|amebicides|quinolines|antiparasitic agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|agents that reduce seizure threshold|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|anti inflammatory agents|moderate risk qtc prolonging agents|cytochrome p 450 substrates|anti infective agents|antimalarials|analgesics, non narcotic|antirheumatic agents|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2d6 inhibitors (moderate)|cytochrome p 450 cyp3a5 substrates|methemoglobinemia associated agents|peripheral nervous system agents|antiprotozoals|alpha galactosidase, antagonists & inhibitors|cytochrome p 450 cyp2c8 substrates|filaricides
ethionamide	hypolipidemic agents|drugs causing inadvertant photosensitivity|pyridines|photosensitizing agents|antiinfectives for systemic use|anti bacterial agents|drugs for treatment of tuberculosis|antimycobacterials|antituberculosis agents|isonicotinic acids|lipid regulating agents|anti infective agents|thiocarbamide derivatives|noxae|toxic actions|fatty acid synthesis inhibitors
metaraminol	propanolamines|agents producing tachycardia|adrenergic agents|amines|vasoconstrictor agents|agents that produce hypertension|adrenergic alpha 1 receptor agonists|neurotransmitter agents|cardiovascular agents|cardiac stimulants excl. cardiac glycosides|sympathomimetics|adrenergic agonists|propanols|adrenergic alpha agonists|peripheral nervous system agents|adrenergic and dopaminergic agents|amino alcohols|autonomic agents|cardiac therapy|alcohols
bisoprolol	propanolamines|beta blocking agents, selective, and thiazides|adrenergic agents|drugs that are mainly renally excreted|beta blockers (beta1 selective)|phenoxypropanolamines|antihypertensive agents indicated for hypertension|amines|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|p glycoprotein inhibitors|beta blocking agents, selective|p glycoprotein substrates|adrenergic antagonists|hypotensive agents|antiarrhythmic agents|neurotransmitter agents|cardiovascular agents|adrenergic beta 1 receptor antagonists|propanols|adrenergic beta antagonists|cytochrome p 450 substrates|beta blocking agents and thiazides|beta blocking agents and calcium channel blockers|cytochrome p 450 cyp3a substrates|antihypertensive agents|peripheral nervous system agents|agents causing hyperkalemia|amino alcohols|autonomic agents|sympatholytics|alcohols
amodiaquine	aminoquinolines|antiparasitic products, insecticides and repellents|p glycoprotein inhibitors|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|quinolines|qtc prolonging agents|antiparasitic agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|antimalarials|anti infective agents|potential qtc prolonging agents|cytochrome p 450 cyp2c9 inhibitors|heterocyclic compounds, fused ring|antiprotozoals|cytochrome p 450 cyp2c8 substrates
rifabutin	anti bacterial agents|lactams|antituberculosis agents|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|antimycobacterials|cytochrome p 450 cyp2c19 inducers|cytochrome p 450 cyp2c9 inducers (strength unknown)|p glycoprotein inducers|cytochrome p 450 cyp2b6 inducers (weak)|cytochrome p 450 cyp3a4 inducers (weak)|cytochrome p 450 cyp2b6 inducers|amides|cytochrome p 450 cyp2c8 inducers|cytochrome p 450 substrates|rifamycin antimycobacterial|anti infective agents|cytochrome p 450 cyp3a inducers|lactams, macrocyclic|cytochrome p 450 cyp2c8 inducers (weak)|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|antiinfectives for systemic use|cytochrome p 450 enzyme inducers|drugs for treatment of tuberculosis|cytochrome p 450 cyp2c19 inducers (moderate)|rifamycins|cytochrome p 450 cyp2c9 inducers|antibiotics, antitubercular
demeclocycline	drugs causing inadvertant photosensitivity|naphthacenes|photosensitizing agents|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|dermatologicals|antibiotics for topical use|tetracyclines|agents that produce neuromuscular block (indirect)|anti infective agents
imatinib	drugs causing inadvertant photosensitivity|antineoplastic and immunomodulating agents|pyrimidines|bcrp/abcg2 inhibitors|antineoplastic agents|piperazines|kinase inhibitor|benzoates|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp3a7 inhibitors (strength unknown)|tyrosine kinase inhibitors|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp2d6 inhibitors (weak)|photosensitizing agents|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp3a5 inhibitors|oct2 inhibitors|oct1 substrates|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|bcrp/abcg2 substrates|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|myelosuppressive agents|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|amides|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inhibitors|protein kinase inhibitors|cytochrome p 450 cyp2c9 inhibitors|immunosuppressive agents|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a7 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|benzamides and benzamide derivatives|cardiotoxic antineoplastic agents|highest risk qtc prolonging agents|acids, carbocyclic|cytochrome p 450 cyp1a2 substrates|cytochrome p 450 cyp3a5 inhibitors (strength unknown)|bsep/abcb11 substrates|cytochrome p 450 cyp2c9 inhibitors (moderate)|benzene derivatives|cytochrome p 450 cyp2c8 substrates
triamcinolone	hormones, hormone substitutes, and hormone antagonists|corticosteroids for systemic use|adrenal cortex hormones|ophthalmologicals|agents to treat airway disease|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|corticosteroids|cytochrome p 450 cyp3a5 inducers (strength unknown)|corticosteroids for systemic use, plain|cytochrome p 450 cyp3a7 substrates|steroids, fluorinated|corticosteroids for local oral treatment|agents causing muscle toxicity|hyperglycemia associated agents|anti inflammatory agents|corticosteroids, moderately potent (group ii)|pregnanes|cytochrome p 450 substrates|cytochrome p 450 cyp3a7 inducers (strength unknown)|protein lysine 6 oxidase, antagonists & inhibitors|enzyme inhibitors|vasoprotectives|cytochrome p 450 cyp3a inducers|corticosteroid hormone receptor agonists|drugs for obstructive airway diseases|adrenals|immunosuppressive agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|glucocorticoids|dermatologicals|cytochrome p 450 enzyme inducers|alimentary tract and metabolism|corticosteroids, dermatological preparations|hormones|nasal preparations|steroids|sensory organs|thyroxine binding globulin inhibitors|pregnadienes|cytochrome p 450 cyp3a7 inducers|cytochrome p 450 cyp3a5 inducers|systemic hormonal preparations, excl. sex hormones and insulins|immunologic factors
oxandrolone	androstan derivatives|anabolic agents|hormones, hormone substitutes, and hormone antagonists|cytochrome p 450 enzyme inhibitors|steroids|alimentary tract and metabolism|hormones|androstanes|thyroxine binding globulin inhibitors|anabolic steroids|anabolic agents for systemic use|androstanols|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|androgens|cytochrome p 450 cyp2c9 inhibitors|fused ring compounds
nicardipine	agents producing tachycardia|membrane transport modulators|cytochrome p 450 cyp2c8 inhibitors|calcium regulating hormones and agents|adrenergic alpha 1 receptor antagonists|cytochrome p 450 cyp2b6 inducers (strength unknown)|antihypertensive agents indicated for hypertension|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|p glycoprotein inhibitors|p glycoprotein substrates|adrenergic antagonists|cytochrome p 450 cyp2c8 inhibitors (moderate)|cytochrome p 450 cyp3a5 inhibitors|anticholinergic agents|hypotensive agents|antiarrhythmic agents|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|calcium channel blockers|oatp1b1/slco1b1 inhibitors|cardiovascular agents|selective calcium channel blockers with mainly vascular effects|cytochrome p 450 cyp2b6 inducers|qtc prolonging agents|pyridines|cytochrome p 450 cyp2d6 inhibitors|calcium channel blockers (dihydropyridine)|cytochrome p 450 cyp2c9 inhibitors (strong)|cytochrome p 450 enzyme inhibitors|vasodilating agents|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 inhibitors (moderate)|cytochrome p 450 substrates|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2c9 inhibitors|potential qtc prolonging agents|muscarinic antagonists|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|antihypertensive agents|cytochrome p 450 cyp2d6 inhibitors (moderate)|agents causing hyperkalemia|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 enzyme inducers|dihydropyridines|cytochrome p 450 cyp3a5 inhibitors (strength unknown)|bsep/abcb11 substrates|dihydropyridine derivatives|cytochrome p 450 cyp2c8 substrates
fluphenazine	phenothiazines|drugs causing inadvertant photosensitivity|central nervous system agents|tranquilizing agents|delayed action preparations|psycholeptics|p glycoprotein inhibitors|cytochrome p 450 cyp2d6 inhibitors (weak)|photosensitizing agents|antipsychotic agents|central nervous system depressants|neurotransmitter agents|phenothiazines with piperazine structure|cytochrome p 450 cyp2d6 inhibitors|nervous system|agents that reduce seizure threshold|cytochrome p 450 enzyme inhibitors|antipsychotic agents (first generation [typical])|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|neurotoxic agents|psychotropic drugs|dopamine agents|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|prodrugs|sulfur compounds|dopamine antagonists
testosterone	hormones, hormone substitutes, and hormone antagonists|androgens and estrogens|androstenes|gonadal steroid hormones|oatp1b3 substrates|androstanes|drugs that are mainly renally excreted|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|p glycoprotein inhibitors|cytochrome p 450 cyp2c19 substrates|testosterone congeners|cytochrome p 450 cyp2b6 substrates|sex hormones and modulators of the genital system|bcrp/abcg2 substrates|oat3/slc22a8 inducers|cytochrome p 450 cyp3a7 substrates|testosterone and derivatives|3 oxoandrosten (4) derivatives|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inducers|androstenols|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|steroids|hormones|gonadal hormones|genito urinary system and sex hormones|thyroxine binding globulin inhibitors|androgens|cytochrome p 450 cyp2c8 substrates
efavirenz	cytochrome p 450 cyp2c8 inhibitors|human immunodeficiency virus 1 non nucleoside analog reverse transcriptase inhibitor|cytochrome p 450 cyp3a4 inhibitors (strong)|cytochrome p 450 cyp3a5 inducers (moderate)|cytochrome p 450 cyp2b6 inducers (strength unknown)|oxazines|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|antivirals for systemic use|cytochrome p 450 cyp2c19 inhibitors (moderate)|ugt1a1 inducers|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|cytochrome p 450 cyp2c8 inhibitors (moderate)|cytochrome p 450 cyp2b6 substrates|cytochrome p 450 cyp2c19 inducers|non nucleoside reverse transcriptase inhibitors|central nervous system depressants|anti retroviral agents|cytochrome p 450 cyp2b6 inducers|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|reverse transcriptase inhibitors|cytochrome p 450 enzyme inhibitors|nucleic acid synthesis inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a7 inducers (moderate)|moderate risk qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|enzyme inhibitors|anti infective agents|antiviral agents|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a inhibitors|chemically induced disorders|cytochrome p 450 cyp1a2 inhibitors|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp3a4 inducers (moderate)|heterocyclic compounds, fused ring|cytochrome p 450 cyp2c19 inhibitors|oct1 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2c19 inducers (strength unknown)|antiinfectives for systemic use|cytochrome p 450 enzyme inducers|cytochrome p 450 cyp1a2 substrates|bsep/abcb11 substrates|cytochrome p 450 cyp2c9 inhibitors (moderate)|direct acting antivirals|cytochrome p 450 cyp3a7 inducers|nonnucleoside reverse transcriptase inhibitors|cytochrome p 450 cyp3a5 inducers|inducers of drug clearance
bacitracin	amino acids, peptides, and proteins|antibacterials for systemic use|anti bacterial agents|bacitracins|decreased cell wall synthesis & repair|benzoates|hydroxybenzoates|nephrotoxic agents|peptides|anti infective agents, local|phenols|throat preparations|peptides, cyclic|antibiotics for topical use|anti infective agents|hydroxy acids|antiinfectives for systemic use|dermatologicals|acids, carbocyclic|benzene derivatives
niacin	micronutrients|lipid regulating agents|food|food and beverages|peripheral vasodilators|cytochrome p 450 cyp2e1 inhibitors|lipid modifying agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cardiovascular agents|hypolipidemic agents indicated for hyperlipidemia|pyridines|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|hyperglycemia associated agents|cytochrome p 450 cyp3a4 inhibitors|miscellaneous antilipemic agents|vasodilating agents|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 cyp3a inhibitors|diet, food, and nutrition|noxae|lipid modifying agents, plain|vitamin b complex|vitamins|physiological phenomena|growth substances|hypolipidemic agents|nicotinic acid and derivatives|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|thyroxine binding globulin inhibitors|nicotinic acids|toxic actions
guanabenz	amidines|agents producing tachycardia|guanidines|antihypertensive agents|adrenergic agonists|central alpha 2 adrenergic agonist|adrenergic agents|cytochrome p 450 cyp1a2 substrates|agents that produce hypertension|cytochrome p 450 substrates|adrenergic alpha 2 receptor agonists|adrenergic alpha agonists|neurotransmitter agents|cardiovascular agents
alendronic acid	musculo skeletal system|organophosphonates|agents causing muscle toxicity|organophosphorus compounds|drugs for treatment of bone diseases|drugs affecting bone structure and mineralization|bisphosphonates|bone density conservation agents
clofarabine	carbohydrates|nucleotides|antineoplastic and immunomodulating agents|ribonucleotides|antineoplastic agents|drugs that are mainly renally excreted|nucleosides|adenine nucleotides|hypotensive agents|oat3/slc22a8 substrates with a narrow therapeutic index|oct2 substrates with a narrow therapeutic index|myelosuppressive agents|bcrp/abcg2 substrates|nucleoside metabolic inhibitor|purine nucleotides|nucleic acid synthesis inhibitors|glycosides|nucleic acids, nucleotides, and nucleosides|noxae|heterocyclic compounds, fused ring|immunosuppressive agents|antimetabolites|purine analogues|narrow therapeutic index drugs|purines|toxic actions|arabinonucleosides|oat3/slc22a8 substrates
sulfacetamide	anti bacterial agents|anti infective agents, urinary|ophthalmologicals|sulfanilamides|amines|anti acne preparations for topical use|sulfonamide antibacterial|sulfones|anti infective agents, local|antiinfectives for treatment of acne|amides|sulfonamides|anti acne preparations|anti infective agents|gynecological antiinfectives and antiseptics|aniline compounds|dermatologicals|renal agents|genito urinary system and sex hormones|sensory organs|sulfur compounds
prednisone	hormones, hormone substitutes, and hormone antagonists|corticosteroids for systemic use|adrenal cortex hormones|antineoplastic agents|drugs that are mainly renally excreted|cytochrome p 450 cyp2c8 inducers (strength unknown)|cytochrome p 450 cyp2b6 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp2a6 inducers|cytochrome p 450 cyp2c19 inducers|corticosteroids|cytochrome p 450 cyp2c9 inducers (strength unknown)|cytochrome p 450 cyp3a5 inducers (strength unknown)|p glycoprotein inducers|antineoplastic agents, hormonal|corticosteroids for systemic use, plain|antidiarrheals, intestinal antiinflammatory/antiinfective agents|cytochrome p 450 cyp2b6 inducers|intestinal antiinflammatory agents|hyperglycemia associated agents|anti inflammatory agents|pregnanes|cytochrome p 450 cyp2c8 inducers|cytochrome p 450 substrates|prednisolone and prodrugs|pregnadienediols|cytochrome p 450 cyp3a inducers|corticosteroid hormone receptor agonists|immunosuppressive agents|adrenals|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2c19 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers (strength unknown)|glucocorticoids|cytochrome p 450 enzyme inducers|alimentary tract and metabolism|hormones|steroids|thyroxine binding globulin inhibitors|pregnadienes|cytochrome p 450 cyp2c9 inducers|cytochrome p 450 cyp3a5 inducers|systemic hormonal preparations, excl. sex hormones and insulins|corticosteroids acting locally
clofibrate	acids, acyclic|clofibric acid|thyroxine binding globulin inducers|cytochrome p 450 cyp2e1 inducers (strength unknown)|lipid regulating agents|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|butyrates|fatty acids|cytochrome p 450 cyp2a6 inhibitors (strength unknown)|lipid modifying agents|ethers|isobutyrates|phenols|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|fatty acids, volatile|cytochrome p 450 substrates|phenyl ethers|cytochrome p 450 cyp3a inducers|noxae|lipid modifying agents, plain|cytochrome p 450 cyp2e1 inducers|hypolipidemic agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|lipids|anticholesteremic agents|cytochrome p 450 cyp2a6 inhibitors|benzene derivatives|fibric acids|toxic actions
astemizole	cytochrome p 450 cyp3a7 substrates with a narrow therapeutic index|histamine h1 antagonists, non sedating|cytochrome p 450 cyp3a4 substrates|histamine agents|cytochrome p 450 cyp2d6 substrates with a narrow therapeutic index|antihistamines for systemic use|neurotransmitter agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|benzimidazoles|cytochrome p 450 cyp3a4 inhibitors|anti allergic agents|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|bsep/abcb11 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a inhibitors|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|highest risk qtc prolonging agents|narrow therapeutic index drugs|bsep/abcb11 substrates|histamine antagonists|histamine h1 antagonists|cytochrome p 450 cyp3a4 substrates (strength unknown)
butoconazole	antifungal agents|antifungal agents (vaginal)|genito urinary system and sex hormones|anti infective agents|gynecological antiinfectives and antiseptics|imidazole derivatives|azole antifungals
ado	carbohydrates|agents producing tachycardia|enzymes|oxidoreductases|purinergic p1 receptor agonists|sensory system agents|central nervous system agents|cyclohexanes|miscellaneous therapeutic agents|cyclohexenes|nucleosides|polyenes|purinergic agents|adenosine, antagonists & inhibitors|analgesics|cycloparaffins|alkenes|antiarrhythmic agents|neurotransmitter agents|cardiovascular agents|miscellaneous cardiac drugs|qtc prolonging agents|hydrocarbons, acyclic|ribonucleosides|enzymes and coenzymes|vasodilating agents|moderate risk qtc prolonging agents|purinergic agonists|glycosides|pigments, biological|nucleic acids, nucleotides, and nucleosides|biological factors|heterocyclic compounds, fused ring|purine nucleosides|peripheral nervous system agents|antiarrhythmics, class v|terpenes|purines|cardiac therapy|class iv antiarrythmics
simvastatin	ugt1a3 substrates|cytochrome p 450 cyp2c8 inhibitors|drugs causing inadvertant photosensitivity|hydroxymethylglutaryl coa reductase inhibitors|naphthalenes|lipid regulating agents|cytochrome p 450 cyp2b6 inducers (strength unknown)|ugt2b7 substrates|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|p glycoprotein substrates|photosensitizing agents|cytochrome p 450 cyp2c19 substrates|lipid modifying agents|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|oatp1b1/slco1b1 inhibitors|hypolipidemic agents indicated for hyperlipidemia|cytochrome p 450 cyp2b6 inducers|cytochrome p 450 cyp2b6 inhibitors (weak)|cytochrome p 450 cyp3a7 substrates|oatp1b1/slco1b1 substrates|cytochrome p 450 cyp2b6 inhibitors|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp3a inhibitors|noxae|cytochrome p 450 cyp2c9 inhibitors|lipid modifying agents, plain|cytochrome p 450 cyp2d6 substrates|hypolipidemic agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 enzyme inducers|bsep/abcb11 substrates|anticholesteremic agents|ugt1a1 substrates|cytochrome p 450 cyp2c8 substrates
pemetrexed	amino acids, peptides, and proteins|antineoplastic and immunomodulating agents|antineoplastic agents|drugs that are mainly renally excreted|folic acid antagonists|amino acids, dicarboxylic|purinones|amino acids|oat3/slc22a8 substrates with a narrow therapeutic index|myelosuppressive agents|glutamates|nucleic acid synthesis inhibitors|cytochrome p 450 substrates|enzyme inhibitors|heterocyclic compounds, fused ring|immunosuppressive agents|folic acid analogues|antimetabolites|amino acids, acidic|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs|purines|drugs that are mainly renally excreted with a narrow therapeutic index|oat3/slc22a8 substrates
mebendazole	acids, acyclic|cytochrome p 450 cyp3a substrates|mitosis modulators|benzimidazoles|antimitotic agents|heterocyclic compounds, fused ring|antinematodal agents|carbamates|benzimidazole derivatives|cytochrome p 450 substrates|anthelmintics|antihelminthic|anti infective agents|tubulin modulators|antiparasitic agents|antiparasitic products, insecticides and repellents
dyclonine	anesthetics, local|nervous system|throat preparations|peripheral nervous system agents|sensory system agents|central nervous system agents|central nervous system depressants|anesthetics|ketones
nystatin	antifungal agents|membrane transport modulators|oatp1b3 inhibitors|antifungal agents (vaginal)|intestinal antiinfectives|polyene antifungal|polyenes|antifungals for dermatological use|oatp1b1/slco1b1 inhibitors|antidiarrheals, intestinal antiinflammatory/antiinfective agents|antifungals for topical use|anti infective agents|gynecological antiinfectives and antiseptics|compounds used in a research, industrial, or household setting|dermatologicals|polyketides|alimentary tract and metabolism|genito urinary system and sex hormones|ionophores|lactones
mitotane	p glycoprotein inhibitors|antineoplastic and immunomodulating agents|hydrocarbons, halogenated|cytochrome p 450 enzyme inducers|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a inducers (strong)|cytochrome p 450 cyp3a4 inducers (strong)|hydrocarbons, chlorinated|antineoplastic agents|narrow therapeutic index drugs|thyroxine binding globulin inducers|cytochrome p 450 cyp3a inducers|antineoplastic agents, hormonal
stavudine	carbohydrates|nucleoside and nucleotide reverse transcriptase inhibitors|pyrimidines|dideoxynucleosides|nucleosides|antivirals for systemic use|oat1/slc22a6 substrates|anti retroviral agents|nucleoside reverse transcriptase inhibitors|reverse transcriptase inhibitors|nucleic acid synthesis inhibitors|agents causing muscle toxicity|glycosides|human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor|enzyme inhibitors|anti infective agents|antiviral agents|nucleic acids, nucleotides, and nucleosides|noxae|deoxyribonucleosides|pyrimidine nucleosides|neurotoxic agents|antiinfectives for systemic use|antimetabolites|anti hiv agents|direct acting antivirals|toxic actions
leucovorin	micronutrients|formyltetrahydrofolates|food|food and beverages|pterins|oat3/slc22a8 inhibitors|protective agents|pteridines|folic acid and derivatives|folate analog|antidotes|enzymes and coenzymes|detoxifying agents for antineoplastic treatment|coenzymes|pigments, biological|vitamin b complex|diet, food, and nutrition|biological factors|heterocyclic compounds, fused ring|physiological phenomena|growth substances|compounds used in a research, industrial, or household setting|vitamins|oat3/slc22a8 substrates|tetrahydrofolates
dyphylline	respiratory system agents|anti asthmatic agents|peripheral nervous system agents|vasodilating agents|heterocyclic compounds, fused ring|alkaloids|bronchodilator agents|purinones|drugs that are mainly renally excreted|enzyme inhibitors|purines|xanthine derivatives|autonomic agents|xanthines and adrenergics|cardiovascular agents|phosphodiesterase inhibitors|drugs for obstructive airway diseases
latanoprost	prostaglandins|prostaglandins, synthetic|eicosanoids|antihypertensive agents|prostaglandin analogs reducing intraocular pressure (iop)|prostaglandins f, synthetic|biological factors|oat3/slc22a8 inhibitors|fatty acids|sensory organs|lipids|oat1/slc22a6 inhibitors|ophthalmologicals|antiglaucoma preparations and miotics|fatty acids, unsaturated|autacoids
estrone	hormones, hormone substitutes, and hormone antagonists|gonadal steroid hormones|adrenal cortex hormones|thyroxine binding globulin inducers|bcrp/abcg2 inhibitors|estranes|cytochrome p 450 cyp3a4 substrates|fused ring compounds|ketosteroids|p glycoprotein substrates|cytochrome p 450 cyp2b6 substrates|p glycoprotein inducers|sex hormones and modulators of the genital system|oatp1b1/slco1b1 inhibitors|estrogens|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|17 ketosteroids|natural and semisynthetic estrogens, plain|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|estrenes|cytochrome p 450 cyp2e1 substrates|steroids|hormones|estradiol congeners|cytochrome p 450 cyp1a2 substrates|genito urinary system and sex hormones|gonadal hormones|oat3/slc22a8 substrates
trazodone	membrane transport modulators|psychoanaleptics|central nervous system agents|serotonin receptor antagonists|tranquilizing agents|piperazines|adrenergic alpha 1 receptor antagonists|cytochrome p 450 cyp3a4 substrates|antidepressive agents, triazolopyridine|adrenergic antagonists|selective serotonin reuptake inhibitors|antidepressive agents, second generation|serotonin 5 ht1 receptor antagonists|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|serotonin 5 ht1a receptor antagonists|serotonin modulators|p glycoprotein inducers|agents that produce hypertension|central nervous system depressants|neurotransmitter agents|antidepressive agents|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|pyridines|cytochrome p 450 cyp2d6 inhibitors|nervous system|agents that reduce seizure threshold|cytochrome p 450 enzyme inhibitors|pyridones|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|serotonin 5 ht2 receptor antagonists|potential qtc prolonging agents|cytochrome p 450 cyp2d6 substrates|peripheral alpha 1 blockers|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|cytochrome p 450 cyp3a5 substrates|neurotransmitter uptake inhibitors|serotonin 5 ht2a receptor antagonists|psychotropic drugs|histamine antagonists|histamine h1 antagonists|anti anxiety agents
mecamylamine	secondary and tertiary amines|nicotinic antagonists|ganglion blockers|norbornanes|agents that produce neuromuscular block (indirect)|drugs that are mainly renally excreted|antihypertensive agents indicated for hypertension|antiadrenergic agents, ganglion blocking|autonomic ganglionic blocker|anticholinergic agents|hypotensive agents|neurotransmitter agents|cardiovascular agents|cholinergic agents|decreased autonomic ganglionic activity|monoterpenes|antihypertensive agents|peripheral nervous system agents|terpenes|autonomic agents
acamprosate	hydrocarbons, acyclic|nervous system|alkanesulfonic acids|drugs used in alcohol dependence|central nervous system agents|acids|sulfonic acids|sulfur compounds|drugs used in addictive disorders|alkanes|miscellaneous central nervous system agents|alcohol deterrents|acids, noncarboxylic|sulfur acids
metaxalone	muscle relaxants|muscle relaxants, centrally acting agents|peripheral nervous system agents|serotonergic drugs shown to increase risk of serotonin syndrome|centrally mediated muscle relaxation|drugs that are mainly renally excreted|central nervous system depressants|oxazoles
verapamil	membrane transport modulators|cytochrome p 450 cyp2c8 inhibitors|cytochrome p 450 cyp3a5 inhibitors (moderate)|cytochrome p 450 cyp2c9 inhibitors (weak)|verapamil and analogues|ace inhibitors and calcium channel blockers|drugs that are mainly renally excreted|mate 2 inhibitors|adrenergic alpha 1 receptor antagonists|mate 1 inhibitors|antihypertensive agents indicated for hypertension|amines|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|p glycoprotein inhibitors|p glycoprotein substrates|adrenergic antagonists|cytochrome p 450 cyp2d6 inhibitors (weak)|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp3a5 inhibitors|cytochrome p 450 cyp2b6 substrates|hypotensive agents|oct1 substrates|antiarrhythmic agents|phenylalkylamine derivatives|calcium channel blockers|oatp1b1/slco1b1 inhibitors|cardiovascular agents|selective calcium channel blockers with direct cardiac effects|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|vasodilating agents|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a4 inhibitors (moderate)|calcium channel blockers (nondihydropyridine)|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|miscellaneous calcium channel blocking agents|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2c9 inhibitors|mate inhibitors|oct1 inhibitors|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|antihypertensive agents|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 cyp1a2 substrates|cytochrome p 450 cyp2c18 substrates|cytochrome p 450 cyp2c8 substrates
trimethobenzamide	amides|peripheral nervous system agents|central nervous system agents|benzoates|gastrointestinal agents|acids, carbocyclic|emesis suppression|antiemetics|central nervous system depressants|antihistamines for systemic use|autonomic agents|benzene derivatives|aminoalkyl ethers
flumethasone	hormones, hormone substitutes, and hormone antagonists|adrenal cortex hormones|cytochrome p 450 cyp3a4 substrates|fused ring compounds|corticosteroids|steroids, fluorinated|anti inflammatory agents|corticosteroids, moderately potent (group ii)|pregnanes|cytochrome p 450 substrates|pregnadienetriols|otologicals|immunosuppressive agents|cytochrome p 450 cyp3a substrates|dermatologicals|steroids|corticosteroids, dermatological preparations|hormones|sensory organs|pregnadienes
flumetasone	hormones, hormone substitutes, and hormone antagonists|adrenal cortex hormones|cytochrome p 450 cyp3a4 substrates|fused ring compounds|corticosteroids|steroids, fluorinated|anti inflammatory agents|corticosteroids, moderately potent (group ii)|pregnanes|cytochrome p 450 substrates|pregnadienetriols|otologicals|immunosuppressive agents|cytochrome p 450 cyp3a substrates|dermatologicals|steroids|corticosteroids, dermatological preparations|hormones|sensory organs|pregnadienes
nilutamide	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|cytochrome p 450 cyp2c8 inhibitors|antineoplastic and immunomodulating agents|antineoplastic agents|drugs that are mainly renally excreted|androgen receptor antagonists|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp2c19 inhibitors (weak)|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|antiandrogens|cytochrome p 450 enzyme inhibitors|androgen receptor inhibitor|imidazoles|antiandrogens, non steroidal|cytochrome p 450 substrates|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp2c19 inhibitors|endocrine therapy|hormone antagonists and related agents
sumatriptan	serotonin 1b and serotonin 1d receptor agonist|serotonin 5 ht1 receptor agonists|antimigraine preparations|serotonin 1b receptor agonists|tryptamines|drugs that are mainly renally excreted|amines|p glycoprotein substrates|indoles|selective serotonin 5 ht1 receptor agonists|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|analgesics|sulfones|serotonin modulators|vasoconstrictor agents|agents that produce hypertension|central nervous system depressants|neurotransmitter agents|antidepressive agents|cardiovascular agents|bcrp/abcg2 substrates|serotonin 1d receptor agonists|oatp1b1/slco1b1 substrates|monoamine oxidase a substrates|amides|nervous system|sulfonamides|selective serotonin agonists|biogenic monoamines|triptans|heterocyclic compounds, fused ring|genito urinary system and sex hormones|sulfur compounds|biogenic amines|serotonin receptor agonists
pirenzepine	agents producing tachycardia|cholinergic agents|benzazepines|alimentary tract and metabolism|heterocyclic compounds, fused ring|anticholinergic agents|gastrointestinal agents|benzodiazepinones|muscarinic antagonists|neurotransmitter agents|anti ulcer agents|drugs for peptic ulcer and gastro oesophageal reflux disease (gord)|drugs for acid related disorders
cefixime	amides|thiazines|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|cephacetrile|cephalosporins|heterocyclic compounds, fused ring|sulfur compounds|third generation cephalosporins|beta lactams|anti infective agents|lactams
aprepitant	central nervous system agents|cytochrome p 450 cyp2c9 inhibitors (weak)|aprepitant and prodrugs|oxazines|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp3a7 inhibitors (strength unknown)|neurokinin 1 antagonists|substance p/neurokinin 1 receptor antagonist|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp3a5 inhibitors|neurokinin 1 receptor antagonists|cytochrome p 450 cyp2c9 inducers (strength unknown)|cytochrome p 450 cyp2c19 inhibitors (weak)|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|neurotransmitter agents|cytochrome p 450 cyp3a7 substrates|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 inhibitors (moderate)|gastrointestinal agents|cytochrome p 450 substrates|antiemetics and antinauseants|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a7 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|peripheral nervous system agents|cytochrome p 450 enzyme inducers|alimentary tract and metabolism|cytochrome p 450 cyp3a5 inhibitors (strength unknown)|antiemetics|morpholines|autonomic agents|cytochrome p 450 cyp2c9 inducers
galantamine	amaryllidaceae alkaloids|parasympathomemetic (cholinergic) agents|psychoanaleptics|central nervous system agents|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|p glycoprotein inhibitors|cholinesterase inhibitors|benzazepines|neurotransmitter agents|qtc prolonging agents|nervous system|cholinergic agents|alkaloids|cytochrome p 450 substrates|enzyme inhibitors|potential qtc prolonging agents|parasympathomimetics|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|peripheral nervous system agents|nootropic agents|anti dementia drugs|autonomic agents
tamoxifen	cytochrome p 450 cyp2c19 substrates with a narrow therapeutic index|hormones, hormone substitutes, and hormone antagonists|hormone antagonists|cytochrome p 450 cyp2c8 inhibitors|antineoplastic and immunomodulating agents|cytochrome p 450 cyp3a7 substrates with a narrow therapeutic index|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|ugt2b7 substrates with a narrow therapeutic index|estrogen antagonists|thyroxine binding globulin inducers|antineoplastic agents|cytochrome p 450 cyp2a6 substrates|ugt2b7 substrates|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|p glycoprotein substrates|estrogen receptor modulators|cytochrome p 450 cyp2b6 inhibitors (moderate)|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp2c8 inhibitors (moderate)|cytochrome p 450 cyp2b6 substrates|cytochrome p 450 cyp2d6 substrates with a narrow therapeutic index|p glycoprotein inducers|estrogen agonist/antagonist|cytochrome p 450 cyp2a6 substrates with a narrow therapeutic index|cytochrome p 450 cyp2b6 substrates with a narrow therapeutic index|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|bcrp/abcg2 substrates|antineoplastic agents, hormonal|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 cyp2b6 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|stilbenes|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|selective estrogen receptor modulators|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp2c9 inhibitors|potential qtc prolonging agents|anti estrogens|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp2e1 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 enzyme inducers|endocrine therapy|hormone antagonists and related agents|cardiotoxic antineoplastic agents|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|cytochrome p 450 cyp2c9 substrates with a narrow therapeutic index|bsep/abcb11 inhibitors|benzene derivatives|benzylidene compounds
losartan	ugt1a3 substrates|cytochrome p 450 cyp2c8 inhibitors|drugs causing inadvertant photosensitivity|angiotensin ii receptor blockers (arbs), plain|angiotensin 2 receptor blocker|ugt2b7 substrates|antihypertensive agents indicated for hypertension|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|p glycoprotein substrates|photosensitizing agents|hypotensive agents|antiarrhythmic agents|biphenyl compounds|cardiovascular agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|agents causing angioedema|imidazoles|cytochrome p 450 cyp3a4 inhibitors|angiotensin ii receptor blockers (arbs) and diuretics|angiotensin ii type 2 receptor blockers|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 substrates|oat1/slc22a6 inhibitors|angiotensin ii receptor blockers (arbs) and calcium channel blockers|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inhibitors|potential qtc prolonging agents|cytochrome p 450 cyp2c19 inhibitors|agents acting on the renin angiotensin system|cytochrome p 450 cyp3a substrates|antihypertensive agents|tetrazoles|agents causing hyperkalemia|bsep/abcb11 substrates|benzene derivatives|ugt1a1 substrates|angiotensin receptor antagonists|angiotensin ii type 1 receptor blockers
thioridazine	phenothiazines|drugs causing inadvertant photosensitivity|cytochrome p 450 cyp2d6 inhibitors (strong)|central nervous system agents|serotonin receptor antagonists|tranquilizing agents|adrenergic alpha 1 receptor antagonists|psycholeptics|phenothiazines with piperidine structure|adrenergic antagonists|photosensitizing agents|cytochrome p 450 cyp2c19 substrates|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|cytochrome p 450 cyp2e1 inhibitors|antipsychotic agents|agents that produce hypertension|hypotensive agents|central nervous system depressants|neurotransmitter agents|antidepressive agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|nervous system|cytochrome p 450 enzyme inhibitors|antipsychotic agents (first generation [typical])|cytochrome p 450 substrates|serotonin 5 ht2 receptor antagonists|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|neurotoxic agents|adrenergic alpha antagonists|serotonin 5 ht2a receptor antagonists|psychotropic drugs|dopamine agents|highest risk qtc prolonging agents|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|sulfur compounds|dopamine antagonists
moracizine	phenothiazines|membrane transport modulators|oxazines|antipsychotic agents|antiarrhythmic agents|central nervous system depressants|voltage gated sodium channel blockers|cardiovascular agents|antiarrhythmics, class ic|qtc prolonging agents|potential qtc prolonging agents|heterocyclic compounds, fused ring|neurotoxic agents|antiarrhythmics, class i|sulfur compounds|morpholines|cardiac therapy|sodium channel blockers
amphotericin b	antifungal agents|carbohydrates|anti bacterial agents|intestinal antiinfectives|polyene antifungal|stomatological preparations|polyenes|liposomes|biomimetic materials|nephrotoxic agents|investigative techniques|amebicides|hypotensive agents|lipid based polyene antifungal|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|antimycotics for systemic use|antidiarrheals, intestinal antiinflammatory/antiinfective agents|antiparasitic agents|agents that reduce seizure threshold|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|antiinfectives and antiseptics for local oral treatment|cytochrome p 450 cyp3a4 inhibitors|glycosides|anti infective agents|drug delivery systems|cytochrome p 450 cyp3a inhibitors|gynecological antiinfectives and antiseptics|pharmaceutical preparations|compounds used in a research, industrial, or household setting|antiinfectives for systemic use|polyketides|membranes, artificial|alimentary tract and metabolism|genito urinary system and sex hormones|narrow therapeutic index drugs|antiprotozoals|lactones|drug carriers
warfarin	cytochrome p 450 cyp2c19 substrates with a narrow therapeutic index|cytochrome p 450 cyp2c8 inhibitors|vitamin k antagonists|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|cytochrome p 450 cyp2c9 inducers|drugs that are mainly renally excreted|coumarins|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp2c8 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp2c9 inducers (weak)|cytochrome p 450 cyp2c19 substrates|agrochemicals|cytochrome p 450 cyp2c18 substrates with a narrow therapeutic index|pesticides|cytochrome p 450 cyp3a4 inducers (weak)|blood and blood forming organs|cytochrome p 450 enzyme inhibitors|anticoagulants|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|hematologic agents|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|heterocyclic compounds, fused ring|4 hydroxycoumarins|cytochrome p 450 cyp2c19 inhibitors|compounds used in a research, industrial, or household setting|cytochrome p 450 cyp3a substrates|cytochrome p 450 enzyme inducers|vitamin k inhibitors|pyrans|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs|cytochrome p 450 cyp2c9 substrates with a narrow therapeutic index|drugs that are mainly renally excreted with a narrow therapeutic index|cytochrome p 450 cyp2c18 substrates|toxic actions|cytochrome p 450 cyp2c8 substrates|rodenticides
midazolam	hypnotics and sedatives|central nervous system agents|tranquilizing agents|drugs that are mainly renally excreted|psycholeptics|adjuvants, anesthesia|cytochrome p 450 cyp3a4 substrates|benzodiazepine hypnotics and sedatives|central nervous system depressants|neurotransmitter agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 cyp3a7 substrates|benzodiazepines and benzodiazepine derivatives|nervous system|cytochrome p 450 enzyme inhibitors|gaba modulators|triazolobenzodiazepines|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|gaba agents|anesthetics|cytochrome p 450 cyp3a inhibitors|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|psychotropic drugs|ugt1a4 substrates|anti anxiety agents
fludrocortisone	hormones, hormone substitutes, and hormone antagonists|corticosteroids for systemic use|adrenal cortex hormones|cytochrome p 450 cyp3a4 substrates|fused ring compounds|11 hydroxycorticosteroids|corticosteroids|hydroxycorticosteroids|corticosteroids for systemic use, plain|17 hydroxycorticosteroids|hyperglycemia associated agents|anti inflammatory agents|cytochrome p 450 substrates|immunosuppressive agents|adrenals|cytochrome p 450 cyp3a substrates|steroids|pregnenes|hormones|mineralocorticoids|systemic hormonal preparations, excl. sex hormones and insulins
mycophenolate mofetil	oatp1b3 substrates|anti bacterial agents|antituberculosis agents|mycophenolic acid and prodrugs|drugs that are mainly renally excreted|ugt2b7 substrates|cytochrome p 450 cyp3a4 substrates|ugt1a1 substrates|immunologic factors|p glycoprotein substrates|fatty acids|bcrp/abcg2 substrates|oatp1b1/slco1b1 substrates|agents causing muscle toxicity|cytochrome p 450 substrates|anti infective agents|antimetabolite immunosuppressant|immunosuppressive agents|ugt1a6 substrate|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|antibiotics, antineoplastic|ugt1a9 substrates|lipids|antibiotics, antitubercular|cytochrome p 450 cyp2c8 substrates|imp dehydrogenase, antagonists & inhibitors
moexipril	agents acting on the renin angiotensin system|ace inhibitors and diuretics|drugs causing inadvertant photosensitivity|agents causing angioedema|angiotensin converting enzyme inhibitors|antihypertensive agents|agents causing hyperkalemia|heterocyclic compounds, fused ring|photosensitizing agents|protease inhibitors|hypotensive agents|enzyme inhibitors|isoquinolines|cardiovascular agents|antihypertensive agents indicated for hypertension|potential qtc prolonging agents|qtc prolonging agents
phentolamine	non selective alfa adrenergic blocking agents|adrenergic agents|drugs that are mainly renally excreted|adrenergic alpha 1 receptor antagonists|adrenergic antagonists|peripheral vasodilators|hypotensive agents|agents that produce hypertension|neurotransmitter agents|imidazoline derivatives|cardiovascular agents|sympatholytic (adrenergic blocking) agents|antidotes|imidazoles|vasodilating agents|peripheral alpha 1 blockers|adrenergic alpha antagonists|antihypertensive agents
daunorubicin	carbohydrates|antineoplastic and immunomodulating agents|topoisomerase inhibitors|anthracycline topoisomerase inhibitor|antineoplastic agents|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|p glycoprotein substrates|p glycoprotein inducers|cytochrome p 450 cyp3a5 inducers (strength unknown)|cytotoxic antibiotics and related substances|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|bcrp/abcg2 substrates|anthracyclines and related substances|myelosuppressive agents|cytochrome p 450 enzyme inhibitors|naphthacenes|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|glycosides|bsep/abcb11 substrates with a narrow therapeutic index|enzyme inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a inducers|immunosuppressive agents|cytochrome p 450 cyp3a substrates|antibiotics, antineoplastic|topoisomerase ii inhibitors|cytochrome p 450 enzyme inducers|cardiotoxic antineoplastic agents|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|bsep/abcb11 substrates|anthracyclines|cytochrome p 450 cyp3a5 inducers
furosemide	membrane transport modulators|drugs causing inadvertant photosensitivity|drugs that are mainly renally excreted|benzoates|sulfanilamides|antihypertensive agents indicated for hypertension|amines|aminobenzoates|nephrotoxic agents|photosensitizing agents|increased diuresis at loop of henle|oat3/slc22a8 inhibitors|sulfones|hypotensive agents|sodium potassium chloride symporter inhibitors|cardiovascular agents|high ceiling diuretics and potassium sparing agents|high ceiling diuretics|ototoxic agents|thyroxine binding globulin substrates|amides|sulfonamides|hyperglycemia associated agents|diuretics|natriuretic agents|oat1/slc22a6 inhibitors|aniline compounds|antihypertensive agents|acids, carbocyclic|sulfur compounds|non potassium sparing diuretics|benzene derivatives|ugt1a1 substrates
tizanidine	agents producing tachycardia|muscle relaxants|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|central alpha 2 adrenergic agonist|central nervous system agents|adrenergic agents|sensory system agents|imidazolines|musculo skeletal system|bradycardia causing agents|muscle relaxants, centrally acting agents|analgesics|hypotensive agents|anticonvulsants|adrenergic alpha 2 receptor agonists|central nervous system depressants|neuromuscular agents|neurotransmitter agents|qtc prolonging agents|imidazoles|adrenergic agonists|cytochrome p 450 substrates|adrenergic alpha agonists|potential qtc prolonging agents|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs|autonomic agents
nicergoline	cytochrome p 450 cyp2d6 substrates|ergot alkaloids and derivatives|adrenergic alpha antagonists|adrenergic antagonists|ergolines|vasodilating agents|heterocyclic compounds, fused ring|alkaloids|adrenergic agents|central nervous system agents|nootropic agents|peripheral vasodilators|agents that produce hypertension|cytochrome p 450 substrates|adrenergic alpha 1 receptor antagonists|neurotransmitter agents|cardiovascular agents
eplerenone	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|antihypertensive agents indicated for hypertension|cytochrome p 450 cyp3a4 substrates|fused ring compounds|hypotensive agents|cardiovascular agents|mineralocorticoid receptor antagonists|cytochrome p 450 cyp3a7 substrates|mineralocorticoid (aldosterone) receptor antagonists|diuretics|pregnanes|natriuretic agents|cytochrome p 450 substrates|potassium sparing diuretics|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|antihypertensive agents|agents causing hyperkalemia|pregnenes|steroids|lactones
methazolamide	drugs causing inadvertant photosensitivity|thiazoles|thiadiazoles|ophthalmologicals|photosensitizing agents|hypotensive agents|antiglaucoma preparations and miotics|cardiovascular agents|sulfonamides|diuretics|natriuretic agents|enzyme inhibitors|oat1/slc22a6 inhibitors|gynecological antiinfectives and antiseptics|genito urinary system and sex hormones|sensory organs|sulfur compounds|carbonic anhydrase inhibitors
naltrexone	sensory system agents|central nervous system agents|centrally acting antiobesity products|drugs used in addictive disorders|opioids|morphinans|narcotics|opiate antagonists|serotonergic drugs shown to increase risk of serotonin syndrome|analgesics|opiate alkaloids|antiobesity preparations, excl. diet products|drugs used in alcohol dependence|nervous system|agents causing muscle toxicity|alkaloids|opioid antagonists|heterocyclic compounds, fused ring|natural opium alkaloids|peripheral nervous system agents|alimentary tract and metabolism|phenanthrenes|ugt1a1 substrates|alcohol deterrents
lamivudine	carbohydrates|nucleoside and nucleotide reverse transcriptase inhibitors|pyrimidines|hepatitis b virus nucleoside analog reverse transcriptase inhibitor|drugs that are mainly renally excreted|dideoxynucleosides|nucleosides|antivirals for systemic use|oat1/slc22a6 substrates|p glycoprotein substrates|deoxycytidine|oct2 substrates|oct1 substrates|bcrp/abcg2 substrates|anti retroviral agents|nucleoside reverse transcriptase inhibitors|reverse transcriptase inhibitors|ribonucleosides|nucleic acid synthesis inhibitors|agents causing muscle toxicity|glycosides|human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor|enzyme inhibitors|anti infective agents|antiviral agents|nucleic acids, nucleotides, and nucleosides|deoxyribonucleosides|pyrimidine nucleosides|antiinfectives for systemic use|anti hiv agents|direct acting antivirals
ibandronic acid	musculo skeletal system|organophosphonates|agents causing muscle toxicity|organophosphorus compounds|drugs for treatment of bone diseases|drugs affecting bone structure and mineralization|bisphosphonates|bone density conservation agents|potential qtc prolonging agents|qtc prolonging agents
diethylcarbamazine	acids, acyclic|cholinesterase inhibitors|lipoxygenase inhibitors|antinematodal agents|carbamates|piperazines|filaricides|enzyme inhibitors|anthelmintics|antihelminthic|anti infective agents|piperazine and derivatives|antiparasitic agents|antiparasitic products, insecticides and repellents
oxacillin	amides|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|beta lactamase resistant penicillins|heterocyclic compounds, fused ring|sulfur compounds|drugs that are mainly renally excreted|penicillins|beta lactams|anti infective agents|beta lactam antibacterials|lactams
apomorphine	opiate agonists|emetics|central nervous system agents|serotonin receptor antagonists|benzylisoquinolines|nonergot derivative dopamine receptor agonists|anti parkinson agents (dopamine agonist)|serotonergic drugs shown to increase risk of serotonin syndrome|cytochrome p 450 cyp2b6 substrates|serotonin agents|hypotensive agents|central nervous system depressants|aporphines|neurotransmitter agents|antidepressive agents|comt substrates|qtc prolonging agents|urologicals|nervous system|drugs used in erectile dysfunction|alkaloids|gastrointestinal agents|anti parkinson drugs|cytochrome p 450 substrates|isoquinolines|potential qtc prolonging agents|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|peripheral nervous system agents|dopamine agents|genito urinary system and sex hormones|autonomic agents|dopamine agonists|cytochrome p 450 cyp2c8 substrates
paroxetine	agents producing tachycardia|membrane transport modulators|drugs causing inadvertant photosensitivity|cytochrome p 450 cyp2b6 inhibitors (strength unknown)|cytochrome p 450 cyp2d6 inhibitors (strong)|psychoanaleptics|central nervous system agents|cytochrome p 450 cyp3a4 substrates|hypoglycemia associated agents|p glycoprotein inhibitors|photosensitizing agents|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|antidepressive agents, second generation|cytochrome p 450 cyp2c19 substrates|selective serotonin reuptake inhibitors|serotonergic drugs shown to increase risk of serotonin syndrome|anticholinergic agents|serotonin agents|serotonin modulators|central nervous system depressants|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|neurotransmitter agents|antidepressive agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 cyp2b6 inhibitors|nervous system|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 substrates|piperidines|enzyme inhibitors|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp1a2 inhibitors|muscarinic antagonists|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|neurotransmitter uptake inhibitors|psychotropic drugs|cytochrome p 450 cyp1a2 substrates
norethindrone	norsteroids|adrenal cortex hormones|cytochrome p 450 cyp2a6 substrates|cytochrome p 450 cyp3a4 substrates|fused ring compounds|hormonal contraceptives for systemic use|p glycoprotein inhibitors|cytochrome p 450 cyp2c19 substrates|progestogens and estrogens, sequential preparations|contraceptives, oral, synthetic|cytochrome p 450 cyp2c19 inducers|sex hormones and modulators of the genital system|cytochrome p 450 cyp3a7 substrates|norpregnenes|hyperglycemia associated agents|progestins|contraceptives, oral|cytochrome p 450 substrates|contraceptive agents, female|combination contraceptives (with estrogen and derivatives)|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2c19 inducers (strength unknown)|cytochrome p 450 cyp3a5 substrates|progestin contraceptives|cytochrome p 450 enzyme inducers|reproductive control agents|steroids|cytochrome p 450 cyp1a2 substrates|estren derivatives|genito urinary system and sex hormones|cytochrome p 450 cyp3a4 substrates (strength unknown)
norethisterone	norsteroids|adrenal cortex hormones|cytochrome p 450 cyp2a6 substrates|cytochrome p 450 cyp3a4 substrates|fused ring compounds|hormonal contraceptives for systemic use|p glycoprotein inhibitors|cytochrome p 450 cyp2c19 substrates|progestogens and estrogens, sequential preparations|contraceptives, oral, synthetic|cytochrome p 450 cyp2c19 inducers|sex hormones and modulators of the genital system|cytochrome p 450 cyp3a7 substrates|norpregnenes|hyperglycemia associated agents|progestins|contraceptives, oral|cytochrome p 450 substrates|contraceptive agents, female|combination contraceptives (with estrogen and derivatives)|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2c19 inducers (strength unknown)|cytochrome p 450 cyp3a5 substrates|progestin contraceptives|cytochrome p 450 enzyme inducers|reproductive control agents|steroids|cytochrome p 450 cyp1a2 substrates|estren derivatives|genito urinary system and sex hormones|cytochrome p 450 cyp3a4 substrates (strength unknown)
clodronic acid	musculo skeletal system|organophosphonates|organophosphorus compounds|drugs for treatment of bone diseases|drugs affecting bone structure and mineralization|bisphosphonates|bone density conservation agents
procaine	anesthetics, local|nicotinic antagonists|sensory system agents|central nervous system agents|ophthalmologicals|benzoates|aminobenzoates|cholinesterase inhibitors|serotonergic drugs shown to increase risk of serotonin syndrome|anticholinergic agents|central nervous system depressants|antidepressive agents|nmda receptor antagonists|nervous system|agents that reduce seizure threshold|esters of aminobenzoic acid|para aminobenzoates|vasoprotectives|cholinesterase substrates|anesthetics|monoamine oxidase inhibitors|local anesthetics (ester)|peripheral nervous system agents|acids, carbocyclic|sensory organs|agents for treatment of hemorrhoids and anal fissures for topical use|benzene derivatives
lisinopril	amino acids, peptides, and proteins|drugs causing inadvertant photosensitivity|ace inhibitors and calcium channel blockers|drugs that are mainly renally excreted|antihypertensive agents indicated for hypertension|dipeptides|photosensitizing agents|peptides|protective agents|hypotensive agents|lipid modifying agents|cardiovascular agents|agents causing angioedema|oligopeptides|enzyme inhibitors|ace inhibitors and diuretics|agents acting on the renin angiotensin system|compounds used in a research, industrial, or household setting|angiotensin converting enzyme inhibitors|antihypertensive agents|protease inhibitors|agents causing hyperkalemia|cardiotonic agents
methoxamine	propanolamines|agents producing tachycardia|adrenergic agents|amines|vasoconstrictor agents|agents that produce hypertension|adrenergic alpha 1 receptor agonists|neurotransmitter agents|cardiovascular agents|cardiac stimulants excl. cardiac glycosides|sympathomimetics|adrenergic agonists|propanols|ethylamines|adrenergic alpha agonists|peripheral nervous system agents|adrenergic and dopaminergic agents|amino alcohols|autonomic agents|cardiac therapy|phenethylamines|alcohols
imiquimod	cytochrome p 450 cyp3a substrates|adjuvants, immunologic|dermatologicals|heterocyclic compounds, fused ring|increased cytokine activity|antineoplastic agents|cytochrome p 450 substrates|misc. skin and mucous membrane agents|interferon inducers|aminoquinolines|quinolines|immunosuppressive agents|increased cytokine production|cytochrome p 450 cyp3a4 substrates|immunologic factors
trimipramine	adrenergic uptake inhibitors|cytochrome p 450 cyp2c19 substrates with a narrow therapeutic index|membrane transport modulators|psychoanaleptics|central nervous system agents|adrenergic agents|serotonin receptor antagonists|adrenergic alpha 1 receptor antagonists|p glycoprotein substrates|adrenergic antagonists|serotonin 5 ht1 receptor antagonists|cytochrome p 450 cyp2c19 substrates|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|cytochrome p 450 cyp2b6 substrates|serotonin 5 ht1a receptor antagonists|cytochrome p 450 cyp2d6 substrates with a narrow therapeutic index|serotonin modulators|agents that produce hypertension|tertiary amine tricyclic antidepressants|central nervous system depressants|neurotransmitter agents|antidepressive agents|dibenzazepines|qtc prolonging agents|nervous system|agents that reduce seizure threshold|antidepressive agents, tricyclic|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|non selective monoamine reuptake inhibitors|serotonin 5 ht2 receptor antagonists|potential qtc prolonging agents|heterocyclic compounds, fused ring|serotonin 5 ht2c receptor antagonists|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|combined inhibitors of serotonin/norepinephrine reuptake|neurotoxic agents|neurotransmitter uptake inhibitors|psychotropic drugs|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|cytochrome p 450 cyp2c9 substrates with a narrow therapeutic index|histamine antagonists|tricyclics and other norepinephrine reuptake inhibitors|histamine h1 antagonists
tiabendazole	thiazoles|antinematodal agents|drugs that are mainly renally excreted|antifungals for dermatological use|antiparasitic products, insecticides and repellents|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|benzimidazole derivatives|anthelmintics|antiparasitic agents|cytochrome p 450 enzyme inhibitors|benzimidazoles|antifungals for topical use|cytochrome p 450 substrates|imidazole and triazole derivatives|antihelminthic|anti infective agents|cytochrome p 450 cyp1a2 inhibitors|heterocyclic compounds, fused ring|dermatologicals|cytochrome p 450 cyp1a2 substrates|sulfur compounds
nateglinide	amino acids, peptides, and proteins|amino acids, cyclic|drugs used in diabetes|cyclohexanes|drugs that are mainly renally excreted|cytochrome p 450 cyp3a4 substrates|hypoglycemia associated agents|phenylalanine|amino acids, aromatic|cycloparaffins|potassium channel antagonists|amino acids|blood glucose lowering agents|cytochrome p 450 cyp3a7 substrates|glinide|cytochrome p 450 substrates|oat1/slc22a6 inhibitors|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|alimentary tract and metabolism|ugt1a9 substrates
pralidoxime	cholinesterase reactivators|enzyme reactivators|cholinergic agents|compounds used in a research, industrial, or household setting|hydroxylamines|antidotes|protective agents|drugs that are mainly renally excreted|neurotransmitter agents|oximes|amines
risperidone	central nervous system agents|pyrimidines|serotonin receptor antagonists|tranquilizing agents|adrenergic alpha 1 receptor antagonists|psycholeptics|cytochrome p 450 cyp3a4 substrates|p glycoprotein substrates|adrenergic antagonists|cytochrome p 450 cyp2d6 inhibitors (weak)|serotonin 5 ht1 receptor antagonists|serotonin 5 ht1d receptor antagonists|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|serotonin 5 ht1a receptor antagonists|antipsychotic agents|agents that produce hypertension|central nervous system depressants|neurotransmitter agents|antidepressive agents|pyrimidinones|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|nervous system|agents that reduce seizure threshold|cytochrome p 450 enzyme inhibitors|hyperglycemia associated agents|cytochrome p 450 substrates|serotonin 5 ht2 receptor antagonists|potential qtc prolonging agents|antipsychotic agents (second generation [atypical])|dopamine d2 receptor antagonists|serotonin 5 ht2c receptor antagonists|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|cytochrome p 450 cyp3a5 substrates|neurotoxic agents|serotonin 5 ht2a receptor antagonists|psychotropic drugs|dopamine agents|histamine antagonists|dopamine antagonists|histamine h1 antagonists
naftifine	antifungal agents|allyl compounds|hydrocarbons, acyclic|dermatologicals|alkenes|antifungals for topical use|anti infective agents|amines|antifungals for dermatological use|allylamine antifungal
esomeprazole	drugs causing inadvertant photosensitivity|gastric acid lowering agents|acid reducers|anti ulcer agents|musculo skeletal system|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|p glycoprotein substrates|photosensitizing agents|cytochrome p 450 cyp2c19 substrates|oat3/slc22a8 inhibitors|cytochrome p 450 cyp2c19 inhibitors (weak)|antiinflammatory and antirheumatic products, non steroids|drugs for peptic ulcer and gastro oesophageal reflux disease (gord)|pyridines|drugs for acid related disorders|cytochrome p 450 enzyme inhibitors|benzimidazoles|gastrointestinal agents|cytochrome p 450 substrates|enzyme inhibitors|heterocyclic compounds, fused ring|2 pyridinylmethylsulfinylbenzimidazoles|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|antiinflammatory and antirheumatic products|alimentary tract and metabolism|propionates|proton pump inhibitors|sulfur compounds|sulfoxides
meclizine	central nervous system agents|piperazines|histamine agents|central nervous system depressants|antihistamines for systemic use|neurotransmitter agents|benzhydryl compounds|antivertigo preparations|gastrointestinal agents|anti allergic agents|cytochrome p 450 substrates|piperazine derivatives|cytochrome p 450 cyp2d6 substrates|peripheral nervous system agents|emesis suppression|antiemetics|autonomic agents|benzene derivatives|histamine antagonists|histamine h1 antagonists
pentamidine	antifungal agents|amidines|antibiotics for pneumocystis pneumonia|agents against leishmaniasis and trypanosomiasis|hypoglycemia associated agents|antiparasitic products, insecticides and repellents|nephrotoxic agents|cytochrome p 450 cyp2c19 substrates|blood glucose lowering agents|antiparasitic agents|qtc prolonging agents|trypanocidal agents|hyperglycemia associated agents|moderate risk qtc prolonging agents|cytochrome p 450 substrates|anti infective agents|cytochrome p 450 cyp2d6 substrates|benzamidines|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|agents causing hyperkalemia|antiprotozoals|miscellaneous antiprotozoals
riluzole	thiazoles|benzothiazoles|central nervous system agents|protective agents|anticonvulsants|central nervous system depressants|neurotransmitter agents|bcrp/abcg2 substrates|miscellaneous central nervous system agents|nervous system|excitatory amino acid antagonists|cytochrome p 450 substrates|heterocyclic compounds, fused ring|neuroprotective agents|compounds used in a research, industrial, or household setting|cytochrome p 450 cyp1a2 substrates|sulfur compounds|excitatory amino acid agents
cortisol	hormones, hormone substitutes, and hormone antagonists|corticosteroids for systemic use|adrenal cortex hormones|pregnenediones|ophthalmologicals|stomatological preparations|cytochrome p 450 cyp2c8 inducers (strength unknown)|cytochrome p 450 cyp2b6 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|systemic hormonal preparations, excl. sex hormones and insulins|ophthalmological and otological preparations|11 hydroxycorticosteroids|p glycoprotein substrates|cytochrome p 450 cyp2a6 inducers|cytochrome p 450 cyp2c19 inducers|corticosteroids|cytochrome p 450 cyp2c9 inducers (strength unknown)|p glycoprotein inducers|corticosteroids for systemic use, plain|antidiarrheals, intestinal antiinflammatory/antiinfective agents|cytochrome p 450 cyp2b6 inducers|17 hydroxycorticosteroids|cytochrome p 450 cyp3a7 substrates|hydroxycorticosteroids|hydrocortisone and derivatives|corticosteroids for local oral treatment|corticosteroids, weak (group i)|intestinal antiinflammatory agents|hyperglycemia associated agents|anti inflammatory agents|pregnanes|cytochrome p 450 cyp2c8 inducers|cytochrome p 450 substrates|vasoprotectives|cytochrome p 450 cyp3a inducers|otologicals|corticosteroid hormone receptor agonists|immunosuppressive agents|adrenals|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2c19 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 cyp3a5 substrates|dermatologicals|cytochrome p 450 enzyme inducers|alimentary tract and metabolism|corticosteroids, dermatological preparations|hormones|nasal preparations|pregnenes|steroids|sensory organs|agents for treatment of hemorrhoids and anal fissures for topical use|cytochrome p 450 cyp2c9 inducers|oat3/slc22a8 substrates|corticosteroids acting locally
hydrocortisone	hormones, hormone substitutes, and hormone antagonists|corticosteroids for systemic use|adrenal cortex hormones|pregnenediones|ophthalmologicals|stomatological preparations|cytochrome p 450 cyp2c8 inducers (strength unknown)|cytochrome p 450 cyp2b6 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|systemic hormonal preparations, excl. sex hormones and insulins|ophthalmological and otological preparations|11 hydroxycorticosteroids|p glycoprotein substrates|cytochrome p 450 cyp2a6 inducers|cytochrome p 450 cyp2c19 inducers|corticosteroids|cytochrome p 450 cyp2c9 inducers (strength unknown)|p glycoprotein inducers|corticosteroids for systemic use, plain|antidiarrheals, intestinal antiinflammatory/antiinfective agents|cytochrome p 450 cyp2b6 inducers|17 hydroxycorticosteroids|cytochrome p 450 cyp3a7 substrates|hydroxycorticosteroids|hydrocortisone and derivatives|corticosteroids for local oral treatment|corticosteroids, weak (group i)|intestinal antiinflammatory agents|hyperglycemia associated agents|anti inflammatory agents|pregnanes|cytochrome p 450 cyp2c8 inducers|cytochrome p 450 substrates|vasoprotectives|cytochrome p 450 cyp3a inducers|otologicals|corticosteroid hormone receptor agonists|immunosuppressive agents|adrenals|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2c19 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 cyp3a5 substrates|dermatologicals|cytochrome p 450 enzyme inducers|alimentary tract and metabolism|corticosteroids, dermatological preparations|hormones|nasal preparations|pregnenes|steroids|sensory organs|agents for treatment of hemorrhoids and anal fissures for topical use|cytochrome p 450 cyp2c9 inducers|oat3/slc22a8 substrates|corticosteroids acting locally
mannitol	carbohydrates|osmotic laxatives|food additives|diagnostic agents|drugs that are mainly renally excreted|drugs for constipation|food|sugar alcohols|food and beverages|flavoring agents|i.v. solutions|nephrotoxic agents|p glycoprotein substrates|hypotensive agents|laxatives|expectorants|sweetening agents|cardiovascular agents|diuretics, osmotic|blood and blood forming organs|blood substitutes and perfusion solutions|increased diuresis|osmotic activity|diuretics|natriuretic agents|solutions producing osmotic diuresis|diet, food, and nutrition|pharmaceutical preparations|physiological phenomena|food ingredients|irrigating solutions|compounds used in a research, industrial, or household setting|cough and cold preparations|agents causing hyperkalemia|alimentary tract and metabolism|pharmaceutic aids|kidney function|alcohols
zileuton	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|lipoxygenase inhibitors|sensory system agents|central nervous system agents|agents to treat airway disease|leukotriene antagonists|cytochrome p 450 cyp3a4 substrates|analgesics|decreased leukotriene production|cytochrome p 450 enzyme inhibitors|anti inflammatory agents|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inhibitors|analgesics, non narcotic|cytochrome p 450 cyp3a substrates|peripheral nervous system agents|ugt1a9 substrates|cytochrome p 450 cyp1a2 substrates
modafinil	central nervous system stimulants|cytochrome p 450 cyp2b6 inhibitors (strength unknown)|psychoanaleptics|central nervous system agents|increased sympathetic activity|cytochrome p 450 cyp1a2 inducers (strength unknown)|cytochrome p 450 cyp3a5 inducers (moderate)|cytochrome p 450 cyp2b6 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a5 inhibitors (weak)|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp3a5 inducers (weak)|sympathomimetic like agent|wakefulness promoting agents|cytochrome p 450 cyp1a2 inducers|cytochrome p 450 cyp3a5 inhibitors|cytochrome p 450 cyp2c9 inducers (strength unknown)|centrally acting sympathomimetics|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 inducers (weak)|benzhydryl compounds|cytochrome p 450 cyp2b6 inducers|cytochrome p 450 cyp2b6 inhibitors|nervous system|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|psychostimulants, agents used for adhd and nootropics|cytochrome p 450 substrates|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a inhibitors|chemically induced disorders|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp3a4 inducers (moderate)|stimulants|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|central nervous system stimulation|cytochrome p 450 enzyme inducers|benzene derivatives|cytochrome p 450 cyp2c9 inducers|cytochrome p 450 cyp3a5 inducers
scopolamine	hypnotics and sedatives|agents producing tachycardia|mydriatics|central nervous system agents|aza compounds|azabicyclo compounds|ophthalmologicals|belladonna alkaloids|psycholeptics|adjuvants, anesthesia|p glycoprotein inhibitors|mydriatics and cycloplegics|anticholinergic agents|tropanes|central nervous system depressants|neurotransmitter agents|nervous system|cholinergic agents|alkaloids|gastrointestinal agents|antiemetics and antinauseants|muscarinic antagonists|scopolamine derivatives|antimuscarinics antispasmodics|peripheral nervous system agents|adjuvants|alimentary tract and metabolism|solanaceous alkaloids|sensory organs|antiemetics|autonomic agents
carbinoxamine	histamine agents|cytochrome p 450 cyp3a substrates|drugs causing inadvertant photosensitivity|photosensitizing agents|moderate risk qtc prolonging agents|cytochrome p 450 substrates|central nervous system depressants|antihistamines for systemic use|neurotransmitter agents|histamine antagonists|aminoalkyl ethers|qtc prolonging agents|histamine h1 antagonists
etodolac	ugt1a3 substrates|drugs causing inadvertant photosensitivity|anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|sensory system agents|central nervous system agents|drugs that are mainly renally excreted|other nonsteroidal anti inflammatory agents|ugt2b7 substrates|musculo skeletal system|cox 2 inhibitors|nephrotoxic agents|selective cyclooxygenase 2 inhibitors (nsaids)|indoles|photosensitizing agents|analgesics|agents that produce hypertension|acetic acid derivatives and related substances|antiinflammatory and antirheumatic products, non steroids|anti inflammatory agents|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|oat1/slc22a6 inhibitors|analgesics, non narcotic|antirheumatic agents|heterocyclic compounds, fused ring|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|ugt1a9 substrates|indoleacetic acids|cyclooxygenase inhibitors
prilocaine	amides|anesthetics, local|aniline compounds|nervous system|methemoglobinemia associated agents|anilides|peripheral nervous system agents|sensory system agents|central nervous system agents|local anesthetics (amide)|central nervous system depressants|anesthetics|amines|local anesthesia
tranylcypromine	psychoanaleptics|central nervous system agents|tranquilizing agents|monoamine oxidase inhibitors, non selective|amines|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|cytochrome p 450 cyp2e1 inhibitors|cytochrome p 450 cyp2a6 inhibitors (strong)|agents that produce hypertension|hypotensive agents|serotonin modulators|central nervous system depressants|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|antidepressive agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|propylamines|cytochrome p 450 cyp2d6 inhibitors|nervous system|agents that reduce seizure threshold|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp3a inhibitors|monoamine oxidase a inhibitors  for interaction with monoamine oxidase a substrates|monoamine oxidase inhibitors|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp1a2 inhibitors|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2d6 inhibitors (moderate)|psychotropic drugs|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|cytochrome p 450 cyp2a6 inhibitors|anti anxiety agents
ethotoin	membrane transport modulators|central nervous system agents|cytochrome p 450 cyp3a4 inducers|anti epileptic agent|decreased central nervous system disorganized electrical activity|anticonvulsants|central nervous system depressants|voltage gated sodium channel blockers|hydantoins|cardiovascular agents|thyroxine binding globulin substrates|nervous system|imidazoles|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|imidazolidines|sodium channel blockers
tretinoin	antineoplastic and immunomodulating agents|keratolytic agents|cyclohexanes|cyclohexenes|antineoplastic agents|cytochrome p 450 cyp2a6 substrates|polyenes|cytochrome p 450 cyp3a4 substrates|anti acne preparations for topical use|cytochrome p 450 cyp2b6 substrates|cycloparaffins|alkenes|hypotensive agents|vitamin a|cytochrome p 450 cyp3a7 substrates|hydrocarbons, acyclic|vitamins (fat soluble)|carotenoids|anti acne preparations|retinoids for topical use in acne|cytochrome p 450 substrates|retinoids|cytochrome p 450 cyp2c9 substrates|pigments, biological|cell stimulants and proliferants|biological factors|immunosuppressive agents|tretinoin|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|dermatologicals|cardiotoxic antineoplastic agents|terpenes|cytochrome p 450 cyp2c18 substrates|vitamins|cytochrome p 450 cyp2c8 substrates
hexachlorophene	antiseptics and disinfectants|chlorobenzenes|drugs causing inadvertant photosensitivity|phenols|photosensitizing agents|dermatologicals|hydrocarbons, halogenated|hydrocarbons, chlorinated|phenol and derivatives|anti infective agents, local|benzene derivatives|anti infective agents|chlorophenols
dolasetron	central nervous system agents|serotonin receptor antagonists|cytochrome p 450 cyp3a4 substrates|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|central nervous system depressants|neurotransmitter agents|antidepressive agents|qtc prolonging agents|serotonin 3 receptor antagonists|gastrointestinal agents|moderate risk qtc prolonging agents|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|antiemetics and antinauseants|serotonin 5 ht3 receptor antagonists|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|peripheral nervous system agents|alimentary tract and metabolism|antiemetics|autonomic agents
clopidogrel	antiplatelet agents|purinergic antagonists|cytochrome p 450 cyp2c8 inhibitors|p2y12 platelet inhibitor|purinergic p2y receptor antagonists|thiophenes|purinergic agents|cytochrome p 450 cyp3a4 substrates|thienopyridines|p glycoprotein substrates|decreased platelet aggregation|cytochrome p 450 cyp2b6 inhibitors (moderate)|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp2b6 substrates|oct2 inhibitors|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|neurotransmitter agents|blood and blood forming organs|pyridines|cytochrome p 450 cyp2b6 inhibitors|cytochrome p 450 enzyme inhibitors|purinergic p2 receptor antagonists|hematologic agents|cytochrome p 450 substrates|platelet aggregation inhibitors excl. heparin|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp2c9 inhibitors|heterocyclic compounds, fused ring|oct1 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp1a2 substrates|sulfur compounds|cytochrome p 450 cyp2c8 inhibitors (strong)
tetracycline	drugs causing inadvertant photosensitivity|antibacterials for systemic use|anti bacterial agents|agents that produce neuromuscular block (indirect)|drugs that are mainly renally excreted|ophthalmologicals|stomatological preparations|tetracycline, antagonists & inhibitors|cytochrome p 450 cyp3a4 substrates|ophthalmological and otological preparations|tetracyclines|photosensitizing agents|oat3/slc22a8 inhibitors|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|drugs for peptic ulcer and gastro oesophageal reflux disease (gord)|drugs for acid related disorders|cytochrome p 450 enzyme inhibitors|naphthacenes|antiinfectives and antiseptics for local oral treatment|cytochrome p 450 cyp3a4 inhibitors|antibiotics for topical use|cytochrome p 450 substrates|enzyme inhibitors|oat1/slc22a6 inhibitors|anti infective agents|cytochrome p 450 cyp3a inhibitors|otologicals|cytochrome p 450 cyp3a substrates|antiinfectives for systemic use|dermatologicals|alimentary tract and metabolism|protein synthesis inhibitors|sensory organs|oat3/slc22a8 substrates
meropenem	amides|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|heterocyclic compounds, fused ring|penem antibacterial|sulfur compounds|drugs that are mainly renally excreted|beta lactams|anti infective agents|thienamycins|lactams|carbapenems
kcl	chlorides|acids|drugs that are mainly renally excreted|i.v. solution additives|electrolytes|ions|anions|replacement preparations|blood and blood forming organs|blood substitutes and perfusion solutions|potassium compounds|potassium salt|mineral supplements|caloric agents|chlorine compounds|electrolyte solutions|acids, noncarboxylic|agents causing hyperkalemia|alimentary tract and metabolism|hemodialysis solution|minerals
irinotecan	carbohydrates|antineoplastic and immunomodulating agents|cytochrome p 450 cyp3a7 substrates with a narrow therapeutic index|topoisomerase inhibitors|antineoplastic agents|topoisomerase i inhibitors|cytochrome p 450 cyp3a4 substrates|p glycoprotein substrates|cytochrome p 450 cyp2b6 substrates|cytochrome p 450 cyp2b6 substrates with a narrow therapeutic index|ugt1a9 substrates with a narrow therapeutic index|oatp1b1/slco1b1 inhibitors|ugt1a1 substrates with a narrow therapeutic index|bcrp/abcg2 substrates|myelosuppressive agents|oligosaccharides|cytochrome p 450 cyp3a7 substrates|alkaloids|disaccharides|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|enzyme inhibitors|cholinesterase substrates|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|pharmaceutical preparations|immunosuppressive agents|polysaccharides|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|ugt1a9 substrates|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|ugt1a1 substrates
methimazole	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|cytochrome p 450 cyp3a4 inhibitors (strong)|drugs that are mainly renally excreted|cytochrome p 450 cyp3a4 inhibitors (weak)|thyroid products|cytochrome p 450 cyp2e1 inhibitors (weak)|cytochrome p 450 cyp2d6 inhibitors (weak)|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|cytochrome p 450 cyp2a6 inhibitors (weak)|cytochrome p 450 cyp2e1 inhibitors|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|myelosuppressive agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 cyp2b6 inhibitors|thyroid hormone synthesis inhibitor|cytochrome p 450 enzyme inhibitors|imidazoles|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|thyroid hormone synthesis inhibitors|cytochrome p 450 cyp2b6 inhibitors (strong)|sulfur containing imidazole derivatives|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp1a2 inhibitors|immunosuppressive agents|cytochrome p 450 cyp2c19 inhibitors|antithyroid agents|sulfur compounds|cytochrome p 450 cyp2a6 inhibitors|systemic hormonal preparations, excl. sex hormones and insulins
mometasone	cytochrome p 450 cyp2c8 inhibitors|adrenal cortex hormones|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|corticosteroids, potent (group iii)|corticosteroids|cytochrome p 450 cyp3a5 inducers (strength unknown)|cytochrome p 450 enzyme inhibitors|hyperglycemia associated agents|anti inflammatory agents|pregnanes|anti allergic agents|cytochrome p 450 substrates|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|pregnadienediols|cytochrome p 450 cyp3a inducers|corticosteroid hormone receptor agonists|drugs for obstructive airway diseases|adrenals|immunosuppressive agents|cytochrome p 450 cyp3a substrates|glucocorticoids|cytochrome p 450 cyp3a4 inducers (strength unknown)|nasal preparations|dermatologicals|cytochrome p 450 enzyme inducers|steroids|corticosteroids, dermatological preparations|thyroxine binding globulin inhibitors|pregnadienes|cytochrome p 450 cyp3a5 inducers
clavulanic acid	anti bacterial agents|heterocyclic compounds, fused ring|enzyme inhibitors|beta lactams|beta lactamase inhibitors|anti infective agents|lactams
olopatadine	sensory system agents|central nervous system agents|histamine h1 antagonists, non sedating|ophthalmologicals|histamine h1 inhibitors|mast cell stabilizers|cytochrome p 450 cyp3a4 substrates|antiallergic agents, excl. corticosteroids|histamine agents|p glycoprotein substrates|antihistamine drugs|central nervous system depressants|neurotransmitter agents|decongestants and antiallergics|qtc prolonging agents|anti inflammatory agents|anti allergic agents|cytochrome p 450 substrates|dibenzoxepins|decreased histamine release|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|peripheral nervous system agents|nasal preparations|sensory organs|histamine antagonists|histamine h1 antagonists
prostaglandin e1	urological agents|prostaglandins, synthetic|oat1/slc22a6 substrates|fatty acids|prostaglandin e1 agonist|prostaglandins e|cardiovascular agents|autacoids|prostaglandins|urologicals|drugs used in erectile dysfunction|vasodilating agents|hematologic agents|genitourinary arterial vasodilation|oat1/slc22a6 inhibitors|miscellaneous vasodilatating agents|prostaglandin receptor agonists|biological factors|eicosanoids|inflammation mediators|genito urinary system and sex hormones|fatty acids, monounsaturated|lipids|cardiac therapy|venous vasodilation|fatty acids, unsaturated|oat3/slc22a8 substrates
alprostadil	urological agents|prostaglandins, synthetic|oat1/slc22a6 substrates|fatty acids|prostaglandin e1 agonist|prostaglandins e|cardiovascular agents|autacoids|prostaglandins|urologicals|drugs used in erectile dysfunction|vasodilating agents|hematologic agents|genitourinary arterial vasodilation|oat1/slc22a6 inhibitors|miscellaneous vasodilatating agents|prostaglandin receptor agonists|biological factors|eicosanoids|inflammation mediators|genito urinary system and sex hormones|fatty acids, monounsaturated|lipids|cardiac therapy|venous vasodilation|fatty acids, unsaturated|oat3/slc22a8 substrates
etoposide	carbohydrates|antineoplastic and immunomodulating agents|topoisomerase inhibitors|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|antineoplastic agents|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|ugt1a1 substrates|benzyl compounds|p glycoprotein inhibitors|p glycoprotein substrates|ugt1a1 substrates with a narrow therapeutic index|bcrp/abcg2 substrates|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|myelosuppressive agents|cytochrome p 450 enzyme inhibitors|antineoplastic agents, phytogenic|cytochrome p 450 cyp3a4 inhibitors|glucosides|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|glycosides|enzyme inhibitors|lignans|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|immunosuppressive agents|tetrahydronaphthalenes|cytochrome p 450 cyp2e1 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|topoisomerase ii inhibitors|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 enzyme inducers|cardiotoxic antineoplastic agents|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|podophyllotoxin derivatives|benzene derivatives|podophyllotoxin|naphthalenes
hydroflumethiazide	membrane transport modulators|drugs causing inadvertant photosensitivity|photosensitizing agents|oat3/slc22a8 inhibitors|sulfones|hypotensive agents|cardiovascular agents|amides|increased diuresis|sulfonamides|diuretics|natriuretic agents|oat1/slc22a6 inhibitors|gynecological antiinfectives and antiseptics|thiazides|heterocyclic compounds, fused ring|antihypertensive agents|benzothiadiazines|sodium chloride symporter inhibitors|genito urinary system and sex hormones|sulfur compounds|oat3/slc22a8 substrates
oxcarbazepine	membrane transport modulators|drugs causing inadvertant photosensitivity|central nervous system agents|cytochrome p 450 cyp3a4 inducers|anti epileptic agent|decreased central nervous system disorganized electrical activity|p glycoprotein substrates|photosensitizing agents|cytochrome p 450 cyp3a5 inhibitors|p glycoprotein inducers|cytochrome p 450 cyp3a5 inducers (strength unknown)|anticonvulsants|central nervous system depressants|voltage gated sodium channel blockers|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|miscellaneous anticonvulsants|dibenzazepines|nervous system|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a inducers|heterocyclic compounds, fused ring|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a4 inducers (strength unknown)|carboxamide derivatives|cytochrome p 450 enzyme inducers|cytochrome p 450 cyp3a5 inhibitors (strength unknown)|enzyme inducing antiepileptic drugs|cytochrome p 450 cyp3a5 inducers|sodium channel blockers
roxithromycin	cytochrome p 450 cyp2b6 inhibitors (strength unknown)|antibacterials for systemic use|anti bacterial agents|oatp1b3 inhibitors|erythromycin and similars|cytochrome p 450 cyp3a4 inhibitors (weak)|cytochrome p 450 cyp3a4 substrates|macrolides, lincosamides and streptogramins|oatp1b1/slco1b1 inhibitors|qtc prolonging agents|cytochrome p 450 cyp2b6 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|moderate risk qtc prolonging agents|cytochrome p 450 substrates|anti infective agents|cytochrome p 450 cyp3a inhibitors|macrolides|cytochrome p 450 cyp3a substrates|antiinfectives for systemic use|polyketides|lactones
nalidixic acid	drugs causing inadvertant photosensitivity|topoisomerase inhibitors|antibacterials for systemic use|anti bacterial agents|photosensitizing agents|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|4 quinolones|fluoroquinolones|quinolines|qtc prolonging agents|agents that reduce seizure threshold|cytochrome p 450 enzyme inhibitors|moderate risk qtc prolonging agents|quinolones|enzyme inhibitors|oat1/slc22a6 inhibitors|anti infective agents|cytochrome p 450 cyp1a2 inhibitors|heterocyclic compounds, fused ring|antiinfectives for systemic use|topoisomerase ii inhibitors|naphthyridines
phenelzine	cytochrome p 450 cyp2c8 inhibitors|psychoanaleptics|central nervous system agents|monoamine oxidase inhibitors, non selective|cytochrome p 450 cyp2e1 inducers (strength unknown)|drugs that are mainly renally excreted|cytochrome p 450 cyp3a7 inhibitors (strength unknown)|cytochrome p 450 cyp3a5 inhibitors|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|hypotensive agents|serotonin modulators|agents that produce hypertension|central nervous system depressants|antidepressive agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 cyp2d6 inhibitors|monoamine oxidase a substrates|nervous system|agents that reduce seizure threshold|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|enzyme inhibitors|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp3a inhibitors|monoamine oxidase inhibitors|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp2e1 inducers|cytochrome p 450 cyp3a7 inhibitors|cytochrome p 450 enzyme inducers|psychotropic drugs|hydrazines|cytochrome p 450 cyp3a5 inhibitors (strength unknown)
propantheline	agents producing tachycardia|drugs that are mainly renally excreted|anti ulcer agents|amines|quaternary ammonium compounds|anticholinergic agents|ammonium compounds|neurotransmitter agents|cholinergic agents|onium compounds|gastrointestinal agents|nitrogen compounds|synthetic anticholinergics, quaternary ammonium compounds|drugs for functional gastrointestinal disorders|heterocyclic compounds, fused ring|muscarinic antagonists|alimentary tract and metabolism|xanthenes
estradiol	hormones, hormone substitutes, and hormone antagonists|estrogens, agonists|androgens and estrogens|gonadal steroid hormones|adrenal cortex hormones|thyroxine binding globulin inducers|bcrp/abcg2 inhibitors|drugs that are mainly renally excreted|antiandrogens and estrogens|estranes|estrogen contraceptives|cytochrome p 450 cyp3a4 substrates|fused ring compounds|hormonal contraceptives for systemic use|p glycoprotein substrates|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|cytochrome p 450 cyp2c19 substrates|progestogens and estrogens, sequential preparations|oct2 inhibitors|oat3/slc22a8 substrates|sex hormones and modulators of the genital system|oatp1b1/slco1b1 inhibitors|comt substrates|cytochrome p 450 cyp3a7 substrates|estradiol, agonists|cytochrome p 450 enzyme inhibitors|intravaginal contraceptives|estrogens|contraceptives, oral|cytochrome p 450 substrates|contraceptive agents, female|cytochrome p 450 cyp2c9 substrates|natural and semisynthetic estrogens, plain|cytochrome p 450 cyp1a2 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|estrenes|steroids|hormones|estradiol congeners|cytochrome p 450 cyp1a2 substrates|genito urinary system and sex hormones|gonadal hormones|ugt1a1 substrates|cytochrome p 450 cyp2c8 substrates
mefenamic acid	cytochrome p 450 cyp2c8 inhibitors|anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|drugs causing inadvertant photosensitivity|sensory system agents|central nervous system agents|other nonsteroidal anti inflammatory agents|benzoates|musculo skeletal system|amines|aminobenzoates|nephrotoxic agents|photosensitizing agents|analgesics|agents that produce hypertension|ugt1a9 inhibitors|antiinflammatory and antirheumatic products, non steroids|cytochrome p 450 enzyme inhibitors|anti inflammatory agents|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|analgesics, non narcotic|antirheumatic agents|aniline compounds|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|acids, carbocyclic|ortho aminobenzoates|benzene derivatives|fenamates|cyclooxygenase inhibitors
acyclovir	nucleosides and nucleotides|drugs that are mainly renally excreted|ophthalmologicals|mate 2 substrates|antivirals for systemic use|nephrotoxic agents|oat1/slc22a6 substrates|oat3/slc22a8 inhibitors|purinones|herpesvirus nucleoside analog dna polymerase inhibitor|oct1 substrates|herpes simplex virus nucleoside analog dna polymerase inhibitor|nucleic acid synthesis inhibitors|nucleosides and nucleotides excl. reverse transcriptase inhibitors|mate substrates|cytochrome p 450 substrates|oat1/slc22a6 inhibitors|anti infective agents|antiviral agents|heterocyclic compounds, fused ring|oct1 inhibitors|antiinfectives for systemic use|dermatologicals|cytochrome p 450 cyp1a2 substrates|sensory organs|mate 1 substrates|direct acting antivirals|purines|acyclovir and prodrug|herpes zoster virus nucleoside analog dna polymerase inhibitor|oat3/slc22a8 substrates
naproxen	ugt1a3 substrates|naphthaleneacetic acids|drugs causing inadvertant photosensitivity|anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|antiinflammatory preparations, non steroids for topical use|central nervous system agents|sensory system agents|naphthalenes|other nonsteroidal anti inflammatory agents|ugt2b7 substrates|musculo skeletal system|nephrotoxic agents|p glycoprotein inhibitors|antiinflammatory products for vaginal administration|photosensitizing agents|analgesics|agents that produce hypertension|non cox 2 selective nsaids|antigout preparations|antiinflammatory and antirheumatic products, non steroids|topical products for joint and muscular pain|anti inflammatory agents|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|oat1/slc22a6 inhibitors|analgesics, non narcotic|antirheumatic agents|ugt1a6 substrate|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|propionates|ugt1a9 substrates|cytochrome p 450 cyp1a2 substrates|genito urinary system and sex hormones|bsep/abcb11 substrates|ugt1a1 substrates|cytochrome p 450 cyp2c8 substrates|cyclooxygenase inhibitors
perindopril	ace inhibitors and diuretics|agents acting on the renin angiotensin system|cholinesterase inhibitors|agents causing angioedema|angiotensin converting enzyme inhibitors|antihypertensive agents|agents causing hyperkalemia|heterocyclic compounds, fused ring|indoles|protease inhibitors|hypotensive agents|ace inhibitors and calcium channel blockers|drugs that are mainly renally excreted|enzyme inhibitors|lipid modifying agents|cardiovascular agents|antihypertensive agents indicated for hypertension
tripelennamine	substituted ethylene diamines|aminopyridines|ethylenediamine derivatives|polyamines|amines|antipruritics, incl. antihistamines, anesthetics, etc.|antihistamines for topical use|histamine agents|antihistamines for systemic use|ethylenediamines|neurotransmitter agents|pyridines|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|anti allergic agents|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|diamines|dermatologicals|histamine antagonists|histamine h1 antagonists
haloprogin	antifungal agents|phenols|dermatologicals|antifungals for topical use|ethers|anti infective agents|benzene derivatives|antifungals for dermatological use
primidone	hypnotics and sedatives|nicotinic antagonists|central nervous system agents|pyrimidines|cytochrome p 450 cyp2e1 inducers (strength unknown)|cytochrome p 450 cyp1a2 inducers (strength unknown)|psycholeptics|cytochrome p 450 cyp3a4 inducers|phenobarbital and similars|anti epileptic agent|ugt1a1 inducers|decreased central nervous system disorganized electrical activity|cytochrome p 450 cyp1a2 inducers|cytochrome p 450 cyp2c19 substrates|anticholinergic agents|cytochrome p 450 cyp3a inducers (strong)|cytochrome p 450 cyp2c19 inducers|cytochrome p 450 cyp2c9 inducers (strength unknown)|cytochrome p 450 cyp1a2 inducers (strong)|anticonvulsants|central nervous system depressants|neurotransmitter agents|pyrimidinones|barbiturates|cytochrome p 450 cyp3a4 inducers (strong)|nervous system|gaba modulators|cytochrome p 450 substrates|gaba agents|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp2e1 inducers|cytochrome p 450 cyp2c19 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 enzyme inducers|enzyme inducing antiepileptic drugs|barbiturates and derivatives|cytochrome p 450 cyp2c9 inducers
sulfasalazine	anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|sensory system agents|central nervous system agents|oatp1b3 inhibitors|bcrp/abcg2 inhibitors|nephrotoxic agents|analgesics|sulfones|agents that produce hypertension|non cox 2 selective nsaids|oatp1b1/slco1b1 inhibitors|bcrp/abcg2 substrates|antidiarrheals, intestinal antiinflammatory/antiinfective agents|salicylates|amides|sulfonamides|intestinal antiinflammatory agents|anti inflammatory agents|gastrointestinal agents|anti infective agents|analgesics, non narcotic|gynecological antiinfectives and antiseptics|antirheumatic agents|immunosuppressive agents|aminosalicylate|methemoglobinemia associated agents|peripheral nervous system agents|agents causing hyperkalemia|alimentary tract and metabolism|genito urinary system and sex hormones|sulfur compounds
tolazoline	topical products for joint and muscular pain|peripheral alpha 1 blockers|adrenergic alpha antagonists|adrenergic antagonists|antihypertensive agents|imidazoles|vasodilating agents|adrenergic agents|peripheral vasodilators|hypotensive agents|agents that produce hypertension|imidazoline derivatives|adrenergic alpha 1 receptor antagonists|imidazolines|neurotransmitter agents|cardiovascular agents|musculo skeletal system
gentamicin	carbohydrates|antibacterials for systemic use|anti bacterial agents|agents that produce neuromuscular block (indirect)|aminoglycoside antibacterials|drugs that are mainly renally excreted|ophthalmologicals|nephrotoxic agents|ophthalmological and otological preparations|antibiotics for topical use|glycosides|enzyme inhibitors|oat1/slc22a6 inhibitors|anti infective agents|otologicals|antiinfectives for systemic use|dermatologicals|gentamicins|protein synthesis inhibitors|narrow therapeutic index drugs|sensory organs|drugs that are mainly renally excreted with a narrow therapeutic index|alpha galactosidase, antagonists & inhibitors
fenoldopam	cardiac stimulants excl. cardiac glycosides|dopamine d1 receptor agonists|antihypertensive agents|vasodilating agents|benzazepines|heterocyclic compounds, fused ring|dopamine agents|hypotensive agents|adrenergic and dopaminergic agents|drugs that are mainly renally excreted|neurotransmitter agents|cardiac therapy|dopamine agonists|cardiovascular agents|antihypertensive agents indicated for hypertension
colistin	amino acids, peptides, and proteins|antibacterials for systemic use|anti bacterial agents|intestinal antiinfectives|agents that produce neuromuscular block (indirect)|aminoglycoside antibacterials|drugs that are mainly renally excreted|nephrotoxic agents|peptides|antidiarrheals, intestinal antiinflammatory/antiinfective agents|pore forming cytotoxic proteins|peptides, cyclic|anti infective agents|membrane proteins|antiinfectives for systemic use|antimicrobial cationic peptides|alimentary tract and metabolism|narrow therapeutic index drugs|polymyxins|proteins|lipids|drugs that are mainly renally excreted with a narrow therapeutic index|lipopeptides
dicycloverine	drugs for functional gastrointestinal disorders|agents producing tachycardia|cholinergic agents|antimuscarinics antispasmodics|parasympatholytics|peripheral nervous system agents|alimentary tract and metabolism|anticholinergic agents|cyclohexanes|cycloparaffins|acids, carbocyclic|synthetic anticholinergics, esters with tertiary amino group|drugs that are mainly renally excreted|autonomic agents|neurotransmitter agents|cyclohexanecarboxylic acids|muscarinic antagonists
minaprine	central nervous system stimulants|psychoanaleptics|central nervous system agents|serotonin receptor antagonists|cholinesterase inhibitors|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|agents that produce hypertension|central nervous system depressants|antidepressive agents|nervous system|agents that reduce seizure threshold|cytochrome p 450 substrates|serotonin 5 ht2 receptor antagonists|monoamine oxidase a inhibitors  for interaction with monoamine oxidase a substrates|monoamine oxidase inhibitors|serotonin 5 ht2c receptor antagonists|cytochrome p 450 cyp2d6 substrates|serotonin 5 ht2a receptor antagonists|psychotropic drugs
pentoxifylline	antiplatelet agents|radiation protective agents|drugs that are mainly renally excreted|phosphodiesterase inhibitors|hematologic activity alteration|peripheral vasodilators|protective agents|purinones|free radical scavengers|cardiovascular agents|blood viscosity reducer|phosphodiesterase 5 inhibitors|vasodilating agents|alkaloids|hematologic agents|cytochrome p 450 substrates|enzyme inhibitors|xanthine derivatives|purine derivatives|heterocyclic compounds, fused ring|drugs for obstructive airway diseases|antioxidants|compounds used in a research, industrial, or household setting|cytochrome p 450 cyp1a2 substrates|hemorrheologic agents|purines
proxymetacaine	anesthetics, local|sensory system agents|central nervous system agents|hydroxybenzoate ethers|ophthalmologicals|benzoates|aminobenzoates|local anesthesia|hydroxybenzoates|central nervous system depressants|ethers|phenols|para aminobenzoates|phenyl ethers|anesthetics|hydroxy acids|peripheral nervous system agents|acids, carbocyclic|sensory organs|isomerism|benzene derivatives
indapamide	membrane transport modulators|drugs causing inadvertant photosensitivity|drugs that are mainly renally excreted|antihypertensive agents indicated for hypertension|cytochrome p 450 cyp3a4 substrates|thiazide like diuretic|indoles|photosensitizing agents|sulfones|hypotensive agents|lipid modifying agents|cardiovascular agents|qtc prolonging agents|amides|increased diuresis|sulfonamides|hyperglycemia associated agents|diuretics|low ceiling diuretics, excl. thiazides|natriuretic agents|cytochrome p 450 substrates|potential qtc prolonging agents|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|antihypertensive agents|sodium chloride symporter inhibitors|genito urinary system and sex hormones|sulfur compounds|non potassium sparing diuretics
tropicamide	mydriatics|cholinergic agents|pyridines|peripheral nervous system agents|mydriatics and cycloplegics|anticholinergic agents|sensory organs|ophthalmologicals|autonomic agents|neurotransmitter agents|muscarinic antagonists
biperiden	agents producing tachycardia|nicotinic antagonists|central nervous system agents|anti dyskinesia agents|aza compounds|azabicyclo compounds|anticholinergic agents|neurotransmitter agents|tertiary amines|cytochrome p 450 cyp2d6 inhibitors|nervous system|cholinergic agents|parasympatholytics|cytochrome p 450 enzyme inhibitors|anti parkinson drugs|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|piperidines|muscarinic antagonists|peripheral nervous system agents|autonomic agents
ribavirin	carbohydrates|nucleosides and nucleotides|antivirals for treatment of hcv infections|ribonucleosides|antiinfectives for systemic use|antimetabolites|nucleosides|antivirals for systemic use|glycosides|direct acting antivirals|drugs that are mainly renally excreted|nucleoside analog antiviral|anti infective agents|antiviral agents|nucleic acids, nucleotides, and nucleosides|noxae|toxic actions
phenylbutazone	anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|antiinflammatory preparations, non steroids for topical use|central nervous system agents|sensory system agents|cytochrome p 450 cyp3a4 inducers|musculo skeletal system|nephrotoxic agents|oat3/slc22a8 inhibitors|pyrazoles|analgesics|agents that produce hypertension|non cox 2 selective nsaids|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|antiinflammatory and antirheumatic products, non steroids|topical products for joint and muscular pain|cytochrome p 450 enzyme inhibitors|pyrazolones|anti inflammatory agents|cytochrome p 450 substrates|oat1/slc22a6 inhibitors|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inducers|analgesics, non narcotic|cytochrome p 450 cyp2c9 inhibitors|antirheumatic agents|cytochrome p 450 cyp3a4 inducers (strength unknown)|antiinflammatory and antirheumatic products|peripheral nervous system agents|agents causing hyperkalemia|cytochrome p 450 enzyme inducers|butylpyrazolidines
meloxicam	thiazines|anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|thiazoles|sensory system agents|other nonsteroidal anti inflammatory agents|musculo skeletal system|cytochrome p 450 cyp3a4 substrates|cox 2 inhibitors|nephrotoxic agents|selective cyclooxygenase 2 inhibitors (nsaids)|analgesics|agents that produce hypertension|antiinflammatory and antirheumatic products, non steroids|anti inflammatory agents|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|oxicams|analgesics, non narcotic|antirheumatic agents|cytochrome p 450 cyp3a substrates|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|sulfur compounds|cytochrome p 450 cyp2c8 substrates|cyclooxygenase inhibitors
orciprenaline	agents producing tachycardia|anti asthmatic agents|adrenergic agents|catechols|agents to treat airway disease|tocolytic agents|amines|adrenergic beta 2 receptor agonists|agents that produce hypertension|neurotransmitter agents|sympathomimetics|phenols|adrenergic agonists|adrenergics, inhalants|adrenergic beta agonists|catecholamines|drugs for obstructive airway diseases|non selective beta adrenergic agonists|respiratory system agents|ethanolamines|peripheral nervous system agents|reproductive control agents|bronchodilator agents|adrenergics for systemic use|amino alcohols|autonomic agents|benzene derivatives|selective beta 2 adrenergic agonists|alcohols
propofol	hypnotics and sedatives|central nervous system agents|cytochrome p 450 cyp3a4 inhibitors (weak)|ugt1a1 inhibitors|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|anesthetics, general|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp2b6 substrates|miscellaneous general anesthetics|cytochrome p 450 cyp2e1 inhibitors|hypotensive agents|agents that produce hypertension|p glycoprotein inducers|central nervous system depressants|qtc prolonging agents|nervous system|agents that reduce seizure threshold|phenols|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|anesthetics|cytochrome p 450 cyp3a inhibitors|anesthetics, intravenous|cytochrome p 450 cyp1a2 inhibitors|potential qtc prolonging agents|ugt1a6 substrate|ugt1a9 substrates|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|benzene derivatives|cytochrome p 450 cyp2c18 substrates|ugt1a1 substrates|cytochrome p 450 cyp2c8 substrates
acetazolamide	drugs causing inadvertant photosensitivity|thiazoles|thiadiazoles|antiglaucoma agents|central nervous system agents|ophthalmologicals|photosensitizing agents|anticonvulsants|central nervous system depressants|antiglaucoma preparations and miotics|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cardiovascular agents|cytochrome p 450 enzyme inhibitors|sulfonamides|cytochrome p 450 cyp3a4 inhibitors|diuretics|natriuretic agents|enzyme inhibitors|oat1/slc22a6 inhibitors|cytochrome p 450 cyp3a inhibitors|gynecological antiinfectives and antiseptics|genito urinary system and sex hormones|sensory organs|sulfur compounds|carbonic anhydrase inhibitors
tadalafil	urological agents|drugs used in benign prostatic hypertrophy|drugs that are mainly renally excreted|phosphodiesterase inhibitors|carbolines|cytochrome p 450 cyp3a4 substrates|adrenergic antagonists|indoles|cardiovascular agents|pyridines|phosphodiesterase 5 inhibitors|urologicals|drugs used in erectile dysfunction|vasodilating agents|cytochrome p 450 substrates|enzyme inhibitors|antihypertensives for pulmonary arterial hypertension|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|antihypertensive agents|cytochrome p 450 cyp3a5 substrates|genito urinary system and sex hormones
carprofen	anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|sensory system agents|central nervous system agents|nephrotoxic agents|selective cyclooxygenase 2 inhibitors (nsaids)|indoles|photosensitizing agents|analgesics|agents that produce hypertension|anti inflammatory agents|oat1/slc22a6 inhibitors|analgesics, non narcotic|antirheumatic agents|heterocyclic compounds, fused ring|peripheral nervous system agents|radiation sensitizing agents|dermatologicals|agents causing hyperkalemia
disulfiram	acids, acyclic|central nervous system agents|acids|drugs used in addictive disorders|sulfides|hydrogen sulfide|cytochrome p 450 cyp3a4 substrates|antiparasitic products, insecticides and repellents|electrolytes|ions|anions|carbamates|acetyl aldehyde dehydrogenase inhibitors|cytochrome p 450 cyp2e1 inhibitors|qtc prolonging agents|thiocarbamates|drugs used in alcohol dependence|nervous system|agents that reduce seizure threshold|cytochrome p 450 enzyme inhibitors|aldehyde dehydrogenase inhibitor|cytochrome p 450 substrates|enzyme inhibitors|ectoparasiticides, incl. scabicides, insecticides and repellents|potential qtc prolonging agents|acids, noncarboxylic|gases|disulfides|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|sulfur containing products|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|sulfur compounds|bsep/abcb11 substrates|ectoparasiticides, incl. scabicides|alcohol deterrents
diazepam	hypnotics and sedatives|muscle relaxants|central nervous system agents|tranquilizing agents|drugs that are mainly renally excreted|psycholeptics|adjuvants, anesthesia|benzodiazepine hypnotics and sedatives|cytochrome p 450 cyp3a4 substrates|p glycoprotein substrates|muscle relaxants, centrally acting agents|anesthetics, general|benzazepines|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp2b6 substrates|cytochrome p 450 cyp2e1 inhibitors|anticonvulsants|central nervous system depressants|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 cyp3a7 substrates|benzodiazepines and benzodiazepine derivatives|nervous system|cytochrome p 450 enzyme inhibitors|gaba modulators|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 substrates|gaba agents|cytochrome p 450 cyp2c9 substrates|anesthetics|cytochrome p 450 cyp3a inhibitors|anesthetics, intravenous|heterocyclic compounds, fused ring|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|peripheral nervous system agents|psychotropic drugs|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|autonomic agents|cytochrome p 450 cyp2c18 substrates|benzodiazepinones|cytochrome p 450 cyp2c8 substrates|anti anxiety agents
trifluoperazine	phenothiazines|drugs causing inadvertant photosensitivity|central nervous system agents|tranquilizing agents|adrenergic alpha 1 receptor antagonists|psycholeptics|p glycoprotein inhibitors|p glycoprotein substrates|adrenergic antagonists|photosensitizing agents|antipsychotic agents|agents that produce hypertension|central nervous system depressants|neurotransmitter agents|phenothiazines with piperazine structure|nervous system|antipsychotic agents (first generation [typical])|gastrointestinal agents|cytochrome p 450 substrates|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|neurotoxic agents|adrenergic alpha antagonists|peripheral nervous system agents|psychotropic drugs|dopamine agents|cytochrome p 450 cyp1a2 substrates|sulfur compounds|antiemetics|autonomic agents|dopamine antagonists|ugt1a4 substrates
phensuximide	nervous system|pyrrolidinones|anticonvulsants|central nervous system depressants|pyrrolidines|succinimide derivatives|imides
cefaclor	amides|nephrotoxic agents|thiazines|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|cephalosporins|heterocyclic compounds, fused ring|oat3/slc22a8 inhibitors|sulfur compounds|bsep/abcb11 substrates|drugs that are mainly renally excreted|beta lactams|second generation cephalosporins|anti infective agents|lactams|oat3/slc22a8 substrates
mifepristone	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|cytochrome p 450 cyp2c8 inhibitors|adrenal cortex hormones|progestin antagonist|oatp1b3 inhibitors|contraceptives, postcoital|estranes|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|abortifacient agents|cytochrome p 450 cyp3a7 inhibitors (strength unknown)|fused ring compounds|hormonal contraceptives for systemic use|hypoglycemia associated agents|p glycoprotein inhibitors|contraceptives, oral, synthetic|p glycoprotein inducers|blood glucose lowering agents|sex hormones and modulators of the genital system|oatp1b1/slco1b1 inhibitors|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|progestational hormone receptor antagonists|cytochrome p 450 enzyme inhibitors|menstruation inducing agents|cytochrome p 450 cyp3a4 inhibitors|progesterone receptor modulators|contraceptives, oral|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|contraceptive agents, female|cytochrome p 450 substrates|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp3a7 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|estrenes|cytochrome p 450 enzyme inducers|luteolytic agents|reproductive control agents|highest risk qtc prolonging agents|abortifacient agents, steroidal|steroids|genito urinary system and sex hormones|bsep/abcb11 substrates|cytochrome p 450 cyp2c9 inhibitors (moderate)
brompheniramine	agents producing tachycardia|histamine agents|photosensitizing agents|anticholinergic agents|cytochrome p 450 cyp2b6 substrates|central nervous system depressants|antihistamines for systemic use|neurotransmitter agents|substituted alkylamines|qtc prolonging agents|pyridines|anti allergic agents|cytochrome p 450 substrates|potential qtc prolonging agents|muscarinic antagonists|histamine antagonists|propylamine derivatives|histamine h1 antagonists
loperamide	cytochrome p 450 cyp3a4 inhibitors (strong)|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|p glycoprotein substrates|opioid agonist|cytochrome p 450 cyp2b6 substrates|antiarrhythmic agents|calcium channel blockers|antipropulsives|antidiarrheals, intestinal antiinflammatory/antiinfective agents|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|gastrointestinal agents|moderate risk qtc prolonging agents|cytochrome p 450 substrates|piperidines|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|agents causing hyperkalemia|alimentary tract and metabolism|antidiarrheals|cytochrome p 450 cyp2c8 substrates
clocortolone	hormones, hormone substitutes, and hormone antagonists|steroids, fluorinated|dermatologicals|anti inflammatory agents|adrenal cortex hormones|corticosteroids, dermatological preparations|corticosteroids, moderately potent (group ii)|hormones|pregnadienediols|pregnanes|corticosteroids|steroids|pregnadienes|immunosuppressive agents|fused ring compounds|corticosteroid hormone receptor agonists
tolazamide	drugs used in diabetes|alimentary tract and metabolism|sulfones|sulfonylureas|sulfur compounds|cytochrome p 450 substrates|drugs that are mainly renally excreted|blood glucose lowering agents|cytochrome p 450 cyp2c9 substrates|hypoglycemia associated agents
dobutamine	agents producing tachycardia|adrenergic agents|catechols|selective beta 1 adrenergic agonists|drugs that are mainly renally excreted|amines|adrenergic beta 2 receptor agonists|protective agents|agents that produce hypertension|adrenergic alpha 1 receptor agonists|neurotransmitter agents|cardiovascular agents|comt substrates|cardiac stimulants excl. cardiac glycosides|sympathomimetics|phenols|adrenergic agonists|adrenergic beta 1 receptor agonists|ethylamines|adrenergic alpha agonists|adrenergic beta agonists|catecholamines|compounds used in a research, industrial, or household setting|peripheral nervous system agents|sympathomimetic (adrenergic) agents|cardiotonic agents|adrenergic and dopaminergic agents|autonomic agents|cardiac therapy|benzene derivatives|phenethylamines
donepezil	parasympathomemetic (cholinergic) agents|muscle relaxants|psychoanaleptics|central nervous system agents|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|cholinesterase inhibitors|muscle relaxants, centrally acting agents|central nervous system depressants|indenes|neurotransmitter agents|bcrp/abcg2 substrates|qtc prolonging agents|nervous system|cholinergic agents|cytochrome p 450 substrates|piperidines|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|nootropic agents|anti dementia drugs|indans
nalbuphine	sensory system agents|central nervous system agents|opioids|opiate partial agonists|morphinans|mixed agonist / antagonist opioids|narcotics|serotonergic drugs shown to increase risk of serotonin syndrome|analgesics|central nervous system depressants|opiate alkaloids|nervous system|alkaloids|morphinan derivatives|opioid antagonists|semi synthetic opioids|heterocyclic compounds, fused ring|peripheral nervous system agents|phenanthrenes|opioid agonist/antagonist
clofazimine	cytochrome p 450 cyp2c8 inhibitors|drugs causing inadvertant photosensitivity|anti bacterial agents|bcrp/abcg2 inhibitors|leprostatic agents|p glycoprotein inhibitors|p glycoprotein substrates|photosensitizing agents|cytochrome p 450 cyp3a5 inhibitors|antimycobacterials|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|anti inflammatory agents|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|anti infective agents|cytochrome p 450 cyp3a inhibitors|drugs for treatment of lepra|potential qtc prolonging agents|phenazines|cytochrome p 450 cyp3a substrates|antiinfectives for systemic use|cytochrome p 450 cyp3a5 inhibitors (strength unknown)
fludroxycortide	hormones, hormone substitutes, and hormone antagonists|adrenal cortex hormones|pregnenediones|cytochrome p 450 cyp3a4 substrates|fused ring compounds|corticosteroids, potent (group iii)|corticosteroids|steroids, fluorinated|anti inflammatory agents|pregnanes|cytochrome p 450 substrates|immunosuppressive agents|corticosteroid hormone receptor agonists|cytochrome p 450 cyp3a substrates|dermatologicals|steroids|pregnenes|corticosteroids, dermatological preparations|hormones
flurandrenolide	hormones, hormone substitutes, and hormone antagonists|adrenal cortex hormones|pregnenediones|cytochrome p 450 cyp3a4 substrates|fused ring compounds|corticosteroids, potent (group iii)|corticosteroids|steroids, fluorinated|anti inflammatory agents|pregnanes|cytochrome p 450 substrates|immunosuppressive agents|corticosteroid hormone receptor agonists|cytochrome p 450 cyp3a substrates|dermatologicals|steroids|pregnenes|corticosteroids, dermatological preparations|hormones
perphenazine	phenothiazines|drugs causing inadvertant photosensitivity|central nervous system agents|tranquilizing agents|psycholeptics|cytochrome p 450 cyp3a4 substrates|photosensitizing agents|cytochrome p 450 cyp2c19 substrates|antipsychotic agents|central nervous system depressants|neurotransmitter agents|phenothiazines with piperazine structure|cytochrome p 450 cyp2d6 inhibitors|nervous system|cytochrome p 450 enzyme inhibitors|antipsychotic agents (first generation [typical])|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|neurotoxic agents|psychotropic drugs|dopamine agents|cytochrome p 450 cyp1a2 substrates|sulfur compounds|cytochrome p 450 cyp2c18 substrates|dopamine antagonists|cytochrome p 450 cyp2c8 substrates
dacarbazine	antineoplastic and immunomodulating agents|alkylating drugs|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|antineoplastic agents|drugs that are mainly renally excreted|alkylating activity|myelosuppressive agents|imidazoles|triazenes|antineoplastic agents, alkylating|cytochrome p 450 substrates|noxae|immunosuppressive agents|cytochrome p 450 cyp2e1 substrates with a narrow therapeutic index|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs|toxic actions
pseudoephedrine	propanolamines|agents producing tachycardia|anti asthmatic agents|norepinephrine releasing agent|amines|serotonergic drugs shown to increase risk of serotonin syndrome|vasoconstrictor agents|agents that produce hypertension|adrenergic alpha 1 receptor agonists|adrenergic alpha 2 receptor agonists|cardiovascular agents|sympathomimetics|alpha and beta adrenergic agonists|adrenergic agonists|hyperglycemia associated agents|propanols|nasal decongestants|ethylamines|adrenergic alpha agonists|adrenergic beta agonists|monoamine oxidase a inhibitors  for interaction with monoamine oxidase a substrates|respiratory system agents|amphetamines|peripheral nervous system agents|nasal preparations|bronchodilator agents|sympathomimetic (adrenergic) agents|amino alcohols|nasal decongestants for systemic use|autonomic agents|phenethylamines|alcohols
temozolomide	antineoplastic and immunomodulating agents|alkylating drugs|imidazoles|cytochrome p 450 enzyme inducers|triazenes|myelosuppressive agents|antineoplastic agents|antineoplastic agents, alkylating|alkylating activity|drugs that are mainly renally excreted|narrow therapeutic index drugs|cytochrome p 450 cyp3a inducers|immunosuppressive agents|noxae|toxic actions
5 aminolevulinic acid	amino acids, peptides, and proteins|antineoplastic and immunomodulating agents|antineoplastic agents|photosensitizing agents|keto acids|peptides|amino acids|opioid peptides|levulinic acids|photosensitizing agents used for phototherapy|enkephalins|neuropeptides|nerve tissue proteins|porphyrin precursor|dermatologicals|radiation sensitizing agents|proteins|sensitizers used in photodynamic/radiation therapy|misc. skin and mucous membrane agents
terbinafine	antifungal agents|cytochrome p 450 cyp2c8 inhibitors|naphthalenes|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|antifungals for dermatological use|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|allylamines|antifungals for topical use|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|anti infective agents|cytochrome p 450 cyp3a inducers|antifungals for systemic use|allylamine antifungal|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2d6 inhibitors (moderate)|cytochrome p 450 cyp3a4 inducers (strength unknown)|dermatologicals|cytochrome p 450 cyp2c8 inhibitors (weak)|cytochrome p 450 enzyme inducers|cytochrome p 450 cyp1a2 substrates|cytochrome p 450 cyp2c8 substrates
prednisolone	hormones, hormone substitutes, and hormone antagonists|corticosteroids for systemic use|adrenal cortex hormones|antineoplastic agents|ophthalmologicals|stomatological preparations|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|ophthalmological and otological preparations|p glycoprotein substrates|corticosteroids|antineoplastic agents, hormonal|corticosteroids for systemic use, plain|antidiarrheals, intestinal antiinflammatory/antiinfective agents|corticosteroids for local oral treatment|corticosteroids, weak (group i)|antidotes|intestinal antiinflammatory agents|hyperglycemia associated agents|anti inflammatory agents|pregnanes|cytochrome p 450 substrates|vasoprotectives|pregnadienetriols|cytochrome p 450 cyp3a inducers|otologicals|corticosteroid hormone receptor agonists|immunosuppressive agents|adrenals|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|nasal preparations|dermatologicals|cytochrome p 450 enzyme inducers|alimentary tract and metabolism|corticosteroids, dermatological preparations|hormones|steroids|sensory organs|pregnadienes|agents for treatment of hemorrhoids and anal fissures for topical use|prednisolone and prodrugs|systemic hormonal preparations, excl. sex hormones and insulins|corticosteroids acting locally
diflunisal	drugs causing inadvertant photosensitivity|anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|sensory system agents|central nervous system agents|drugs that are mainly renally excreted|other nonsteroidal anti inflammatory agents|benzoates|hydroxybenzoates|nephrotoxic agents|photosensitizing agents|salicylic acid and derivatives|analgesics|agents that produce hypertension|non cox 2 selective nsaids|ugt1a9 inhibitors|salicylates|nervous system|phenols|anti inflammatory agents|enzyme inhibitors|oat1/slc22a6 inhibitors|analgesics, non narcotic|antirheumatic agents|hydroxy acids|peripheral nervous system agents|agents causing hyperkalemia|acids, carbocyclic|benzene derivatives|cyclooxygenase inhibitors
vardenafil	urological agents|piperazines|phosphodiesterase inhibitors|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|p glycoprotein substrates|cardiovascular agents|qtc prolonging agents|phosphodiesterase 5 inhibitors|urologicals|drugs used in erectile dysfunction|imidazoles|vasodilating agents|cytochrome p 450 substrates|enzyme inhibitors|potential qtc prolonging agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|genito urinary system and sex hormones
ranitidine	gastric acid lowering agents|drugs that are mainly renally excreted|cytochrome p 450 cyp3a4 inhibitors (weak)|acid reducers|anti ulcer agents|p glycoprotein inhibitors|oat1/slc22a6 substrates|cholinesterase inhibitors|p glycoprotein substrates|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|oct2 substrates|oct2 inhibitors|oct1 substrates|drugs for peptic ulcer and gastro oesophageal reflux disease (gord)|furans|drugs for acid related disorders|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|cytochrome p 450 cyp3a4 inhibitors|gastrointestinal agents|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|oat1/slc22a6 inhibitors|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp1a2 inhibitors|oct1 inhibitors|alimentary tract and metabolism|cytochrome p 450 cyp1a2 substrates|histamine h2 antagonists|histamine antagonists|oat3/slc22a8 substrates
tacrolimus	drugs causing inadvertant photosensitivity|antineoplastic and immunomodulating agents|anti bacterial agents|cytochrome p 450 cyp3a4 inhibitors (weak)|agents for dermatitis, excluding corticosteroids|cytochrome p 450 cyp3a4 substrates|calcineurin inhibitor immunosuppressant|nephrotoxic agents|p glycoprotein inhibitors|p glycoprotein substrates|photosensitizing agents|p glycoprotein inducers|oatp1b1/slco1b1 inhibitors|myelosuppressive agents|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|calcineurin inhibitors|cytochrome p 450 cyp3a4 inhibitors|hyperglycemia associated agents|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a inhibitors|potential qtc prolonging agents|immunosuppressive agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|dermatologicals|agents causing hyperkalemia|polyketides|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|lactones|misc. skin and mucous membrane agents|immunologic factors
alprenolol	propanolamines|beta blocking agents, non selective|serotonin receptor antagonists|adrenergic agents|phenoxypropanolamines|amines|bradycardia causing agents|adrenergic antagonists|serotonin 5 ht1 receptor antagonists|serotonin agents|serotonin 5 ht1a receptor antagonists|antiarrhythmic agents|central nervous system depressants|neurotransmitter agents|antidepressive agents|cardiovascular agents|propanols|adrenergic beta antagonists|cytochrome p 450 substrates|cytochrome p 450 cyp2d6 substrates|antihypertensive agents|peripheral nervous system agents|agents causing hyperkalemia|amino alcohols|autonomic agents|sympatholytics|alcohols
ritodrine	propanolamines|agents producing tachycardia|adrenergic agents|tocolytic agents|amines|adrenergic beta 2 receptor agonists|agents that produce hypertension|neurotransmitter agents|sympathomimetics, labour repressants|sympathomimetics|adrenergic agonists|propanols|ethylamines|adrenergic beta agonists|peripheral nervous system agents|reproductive control agents|genito urinary system and sex hormones|amino alcohols|autonomic agents|phenethylamines|alcohols
benzonatate	hydrocarbons, acyclic|respiratory system agents|antitussive agents|cough and cold preparations|central nervous system agents|decreased tracheobronchial stretch receptor activity|non narcotic antitussive|butanes|alkanes|cholinesterase substrates|amines
dorzolamide	drugs that are mainly renally excreted|ophthalmologicals|intraocular pressure, drug effects|sulfones|antiglaucoma preparations and miotics|cardiovascular agents|amides|sulfonamides|diuretics|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|gynecological antiinfectives and antiseptics|cytochrome p 450 cyp3a substrates|antihypertensive agents|cytochrome p 450 cyp2e1 substrates|genito urinary system and sex hormones|sensory organs|sulfur compounds|carbonic anhydrase inhibitors
suprofen	anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|sensory system agents|ugt2b7 substrates|musculo skeletal system|nephrotoxic agents|analgesics|non cox 2 selective nsaids|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|antiinflammatory and antirheumatic products, non steroids|phenylpropionates|cytochrome p 450 enzyme inhibitors|anti inflammatory agents|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|analgesics, non narcotic|cytochrome p 450 cyp2c9 inhibitors|antirheumatic agents|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|propionates|acids, carbocyclic|ugt1a1 substrates|cyclooxygenase inhibitors
terbutaline	agents producing tachycardia|anti asthmatic agents|adrenergic agents|drugs that are mainly renally excreted|agents to treat airway disease|tocolytic agents|amines|adrenergic beta 2 receptor agonists|cholinesterase inhibitors|agents that produce hypertension|neurotransmitter agents|qtc prolonging agents|sympathomimetics|adrenergic agonists|adrenergics, inhalants|adrenergic beta agonists|potential qtc prolonging agents|drugs for obstructive airway diseases|respiratory system agents|ethanolamines|peripheral nervous system agents|reproductive control agents|bronchodilator agents|adrenergics for systemic use|amino alcohols|autonomic agents|selective beta 2 adrenergic agonists|alcohols
guaifenesin	respiratory system agents|phenols|cough and cold preparations|catechols|methyl ethers|ethers|benzene derivatives|expectorants|phenyl ethers
flupentixol	agents producing tachycardia|drugs causing inadvertant photosensitivity|central nervous system agents|serotonin receptor antagonists|tranquilizing agents|piperazines|adrenergic alpha 1 receptor antagonists|psycholeptics|p glycoprotein inhibitors|p glycoprotein substrates|adrenergic antagonists|photosensitizing agents|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|anticholinergic agents|thioxanthenes|antipsychotic agents|agents that produce hypertension|central nervous system depressants|thioxanthene derivatives|neurotransmitter agents|antidepressive agents|qtc prolonging agents|nervous system|antipsychotic agents (first generation [typical])|serotonin 5 ht2 receptor antagonists|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|muscarinic antagonists|neurotoxic agents|adrenergic alpha antagonists|serotonin 5 ht2a receptor antagonists|psychotropic drugs|dopamine agents|highest risk qtc prolonging agents|sulfur compounds|xanthenes|dopamine antagonists
eprosartan	acids, acyclic|agents acting on the renin angiotensin system|agents causing angioedema|agents causing muscle toxicity|antihypertensive agents|agents causing hyperkalemia|angiotensin ii receptor blockers (arbs) and diuretics|angiotensin ii receptor blockers (arbs), plain|hypotensive agents|sulfur compounds|angiotensin 2 receptor blocker|cardiovascular agents|antihypertensive agents indicated for hypertension|angiotensin receptor antagonists|angiotensin ii type 1 receptor blockers
sirolimus	antifungal agents|mtor inhibitors|antineoplastic and immunomodulating agents|cytochrome p 450 cyp3a7 substrates with a narrow therapeutic index|anti bacterial agents|ophthalmologicals|kinase inhibitor|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|mtor inhibitor immunosuppressant|p glycoprotein substrates|p glycoprotein inducers|oatp1b1/slco1b1 inhibitors|myelosuppressive agents|decreased immunologic activity|cytochrome p 450 cyp3a7 substrates|sirolimus and prodrugs|agents causing angioedema|hyperglycemia associated agents|selective immunosuppressants|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|anti infective agents|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|protein kinase inhibitors|immunosuppressive agents|macrolides|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|antibiotics, antineoplastic|polyketides|narrow therapeutic index drugs|sensory organs|p glycoprotein substrates with a narrow therapeutic index|lactones|immunologic factors
chlorhexidine	amidines|household products|decreased cell wall integrity|medicated dressings|ophthalmologicals|stomatological preparations|disinfectants|miscellaneous anti infectives|ophthalmological and otological preparations|biguanides|mouthwashes|miscellaneous local anti infectives|anti infective agents, local|throat preparations|antiinfectives and antiseptics for local oral treatment|biguanides and amidines|dental agents|anti infective agents|otologicals|guanidines|antiseptics and disinfectants|irrigating solutions|compounds used in a research, industrial, or household setting|dermatologicals|alimentary tract and metabolism|sensory organs|medicated dressings with antiinfectives
chlorothiazide	membrane transport modulators|drugs causing inadvertant photosensitivity|photosensitizing agents|sulfones|hypotensive agents|cardiovascular agents|amides|increased diuresis|sulfonamides|hyperglycemia associated agents|diuretics|natriuretic agents|oat1/slc22a6 inhibitors|gynecological antiinfectives and antiseptics|thiazides|heterocyclic compounds, fused ring|antihypertensive agents|benzothiadiazines|sodium chloride symporter inhibitors|genito urinary system and sex hormones|sulfur compounds
quinapril	agents acting on the renin angiotensin system|ace inhibitors and diuretics|protease inhibitors|agents causing angioedema|angiotensin converting enzyme inhibitors|antihypertensive agents|agents causing hyperkalemia|heterocyclic compounds, fused ring|hypotensive agents|tetrahydroisoquinolines|enzyme inhibitors|isoquinolines|cardiovascular agents|antihypertensive agents indicated for hypertension|oat3/slc22a8 substrates
clomifene	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|estrogen antagonists|estrogen agonist antagonists|fertility agents|benzylidene compounds|p glycoprotein substrates|estrogen agonist/antagonist|sex hormones and modulators of the genital system|clomiphene|stilbenes|selective estrogen receptor modulators|ovulation stimulants, synthetic|reproductive control agents|genito urinary system and sex hormones|fertility agents, female|benzene derivatives|estrogen receptor modulators
bumetanide	membrane transport modulators|drugs causing inadvertant photosensitivity|drugs that are mainly renally excreted|benzoates|aminobenzoates|meta aminobenzoates|nephrotoxic agents|photosensitizing agents|increased diuresis at loop of henle|oat3/slc22a8 inhibitors|sulfones|hypotensive agents|sodium potassium chloride symporter inhibitors|cardiovascular agents|high ceiling diuretics and potassium sparing agents|high ceiling diuretics|amides|sulfonamides|agents causing muscle toxicity|hyperglycemia associated agents|diuretics|natriuretic agents|oat1/slc22a6 inhibitors|gynecological antiinfectives and antiseptics|acids, carbocyclic|genito urinary system and sex hormones|sulfur compounds|non potassium sparing diuretics|benzene derivatives|oat3/slc22a8 substrates
granisetron	central nervous system agents|serotonin receptor antagonists|aza compounds|azabicyclo compounds|cytochrome p 450 cyp3a4 substrates|serotonergic drugs shown to increase risk of serotonin syndrome|pyrazoles|serotonin agents|central nervous system depressants|neurotransmitter agents|antidepressive agents|qtc prolonging agents|serotonin 3 receptor antagonists|gastrointestinal agents|moderate risk qtc prolonging agents|cytochrome p 450 substrates|serotonin 5 ht3 receptor antagonists|antiemetics and antinauseants|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|peripheral nervous system agents|alimentary tract and metabolism|antiemetics|autonomic agents|indazoles
dienestrol	hormones, hormone substitutes, and hormone antagonists|phenols|hormones|genito urinary system and sex hormones|estrogens|estrogens, non steroidal|sex hormones and modulators of the genital system|benzene derivatives|synthetic estrogens, plain
sulfapyridine	antibacterials for systemic use|sulfonamides and trimethoprim|sulfanilamides|amines|short acting sulfonamides|sulfones|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|amides|cytochrome p 450 enzyme inhibitors|sulfonamides|anti infective agents|gynecological antiinfectives and antiseptics|cytochrome p 450 cyp2c9 inhibitors|aniline compounds|methemoglobinemia associated agents|antiinfectives for systemic use|dermatologicals|genito urinary system and sex hormones|sulfur compounds
oxybuprocaine	anesthetics, local|para aminobenzoates|peripheral nervous system agents|dermatologicals|sensory system agents|central nervous system agents|anesthetics for topical use|benzoates|acids, carbocyclic|sensory organs|cholinesterase substrates|ophthalmologicals|central nervous system depressants|benzene derivatives|anesthetics|aminobenzoates|antipruritics, incl. antihistamines, anesthetics, etc.
rimexolone	hormones, hormone substitutes, and hormone antagonists|adrenal cortex hormones|ophthalmologicals|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|cytochrome p 450 cyp3a inducers (strong)|corticosteroids|cytochrome p 450 cyp3a5 inducers (strength unknown)|corticosteroids for systemic use, plain|cytochrome p 450 cyp3a4 inducers (strong)|hyperglycemia associated agents|anti inflammatory agents|pregnanes|cytochrome p 450 substrates|cytochrome p 450 cyp3a inducers|corticosteroid hormone receptor agonists|immunosuppressive agents|cytochrome p 450 cyp3a substrates|glucocorticoids|cytochrome p 450 enzyme inducers|steroids|hormones|sensory organs|thyroxine binding globulin inhibitors|cytochrome p 450 cyp3a5 inducers|systemic hormonal preparations, excl. sex hormones and insulins
didanosine	carbohydrates|nucleoside and nucleotide reverse transcriptase inhibitors|drugs that are mainly renally excreted|dideoxynucleosides|nucleosides|antivirals for systemic use|oat1/slc22a6 substrates|anti retroviral agents|nucleoside reverse transcriptase inhibitors|reverse transcriptase inhibitors|ribonucleosides|nucleic acid synthesis inhibitors|glycosides|human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor|enzyme inhibitors|anti infective agents|antiviral agents|nucleic acids, nucleotides, and nucleosides|noxae|heterocyclic compounds, fused ring|purine nucleosides|deoxyribonucleosides|neurotoxic agents|antiinfectives for systemic use|antimetabolites|anti hiv agents|direct acting antivirals|purines|toxic actions
etacrynic acid	acids, acyclic|agents that produce neuromuscular block (indirect)|nephrotoxic agents|increased diuresis at loop of henle|fatty acids|hypotensive agents|sodium potassium chloride symporter inhibitors|phenoxyacetates|cardiovascular agents|high ceiling diuretics|ototoxic agents|hyperglycemia associated agents|diuretics|fatty acids, volatile|natriuretic agents|enzyme inhibitors|oat1/slc22a6 inhibitors|glycolates|acetates|hydroxy acids|lipids|non potassium sparing diuretics|aryloxyacetic acid derivatives
ondansetron	central nervous system agents|serotonin receptor antagonists|cytochrome p 450 cyp3a4 substrates|indoles|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|central nervous system depressants|antidepressive agents|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|serotonin 3 receptor antagonists|cytochrome p 450 enzyme inhibitors|imidazoles|moderate risk qtc prolonging agents|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|antiemetics and antinauseants|serotonin 5 ht3 receptor antagonists|cytochrome p 450 cyp1a2 inhibitors|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|peripheral nervous system agents|cytochrome p 450 cyp2e1 substrates|psychotropic drugs|carbazoles|cytochrome p 450 cyp1a2 substrates|antiemetics|anti anxiety agents
bimatoprost	drugs that are mainly renally excreted|ophthalmologicals|cytochrome p 450 cyp3a4 substrates|prostaglandins, synthetic|fatty acids|antiglaucoma preparations and miotics|cardiovascular agents|prostaglandin analogs reducing intraocular pressure (iop)|autacoids|prostaglandins|amides|cytochrome p 450 substrates|prostaglandins f, synthetic|biological factors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|antihypertensive agents|eicosanoids|inflammation mediators|sensory organs|lipids|fatty acids, unsaturated
tiagabine	membrane transport modulators|central nervous system agents|fatty acid derivatives|gaba uptake inhibitors|cytochrome p 450 cyp3a4 substrates|anti epileptic agent|decreased central nervous system disorganized electrical activity|anticonvulsants|central nervous system depressants|neurotransmitter agents|nervous system|cytochrome p 450 substrates|gaba agents|piperidines|nipecotic acids|cytochrome p 450 cyp3a substrates|neurotransmitter uptake inhibitors|ugt1a1 substrates
quinidine	agents producing tachycardia|cytochrome p 450 cyp3a7 substrates with a narrow therapeutic index|cytochrome p 450 cyp2b6 inhibitors (strength unknown)|adrenergic alpha 1 receptor antagonists|adrenergic antagonists|photosensitizing agents|oat3/slc22a8 inhibitors|antiarrhythmic agents|quinolines|antiparasitic agents|cytochrome p 450 cyp3a7 substrates|alkaloids|antiarrhythmics, class ia|cytochrome p 450 cyp2c8 inducers (weak)|pharmaceutical preparations|heterocyclic compounds, fused ring|compounds used in a research, industrial, or household setting|antiarrhythmics, class i|highest risk qtc prolonging agents|narrow therapeutic index drugs|cinchona alkaloids|agents that produce neuromuscular block (indirect)|drugs that are mainly renally excreted|cytochrome p 450 cyp3a4 substrates|quinuclidines|agents that produce hypertension|cardiovascular agents|agents that reduce seizure threshold|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp1a2 inhibitors (strong)|cytochrome p 450 substrates|enzyme inhibitors|plant extracts|cytochrome p 450 cyp2c9 inhibitors|oct1 inhibitors|adrenergic alpha antagonists|p glycoprotein substrates with a narrow therapeutic index|bsep/abcb11 inhibitors|membrane transport modulators|cytochrome p 450 cyp2c8 inhibitors|polymers|p glycoprotein inhibitors|anticholinergic agents|oct2 inhibitors|voltage gated sodium channel blockers|macromolecular substances|qtc prolonging agents|cytochrome p 450 cyp2c8 inducers|cytochrome p 450 cyp2c9 substrates|chemically induced disorders|cytochrome p 450 cyp1a2 inhibitors|plant preparations|polysaccharides|muscarinic antagonists|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2c8 inhibitors (weak)|cytochrome p 450 cyp2e1 substrates|biopolymers|antiprotozoals|sodium channel blockers|carbohydrates|drugs causing inadvertant photosensitivity|cytochrome p 450 cyp2d6 inhibitors (strong)|adrenergic agents|cytochrome p 450 cyp3a4 inhibitors (weak)|p glycoprotein substrates|neurotransmitter agents|oatp1b1/slco1b1 inhibitors|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 cyp2b6 inhibitors|cholinergic agents|cytochrome p 450 cyp3a4 inhibitors|anti infective agents|antimalarials|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2e1 substrates with a narrow therapeutic index|biological products|cytochrome p 450 enzyme inducers|cytochrome p 450 cyp2c9 inhibitors (moderate)|cytochrome p 450 cyp2c9 substrates with a narrow therapeutic index|drugs that are mainly renally excreted with a narrow therapeutic index|cardiac therapy|complex mixtures
zonisamide	membrane transport modulators|central nervous system agents|calcium regulating hormones and agents|drugs that are mainly renally excreted|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|anti epileptic agent|p glycoprotein inhibitors|decreased central nervous system disorganized electrical activity|cytochrome p 450 cyp2c19 substrates|sulfones|cytochrome p 450 cyp2c19 inhibitors (weak)|antiarrhythmic agents|anticonvulsants|central nervous system depressants|calcium channel blockers|cardiovascular agents|qtc prolonging agents|amides|nervous system|cytochrome p 450 enzyme inhibitors|sulfonamides|diuretics|isoxazoles|monoamine oxidase a inhibitors  for interaction with monoamine oxidase a substrates|gynecological antiinfectives and antiseptics|potential qtc prolonging agents|cytochrome p 450 cyp2c19 inhibitors|compounds used in a research, industrial, or household setting|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|agents causing hyperkalemia|genito urinary system and sex hormones|sulfur compounds|ugt1a1 substrates|carbonic anhydrase inhibitors
tinidazole	alkylating drugs|antibacterials for systemic use|anti bacterial agents|nitroimidazole antimicrobial|drugs that are mainly renally excreted|antitrichomonal agents|cytochrome p 450 cyp3a4 substrates|antiparasitic products, insecticides and repellents|imidazole derivatives|drugs for peptic ulcer and gastro oesophageal reflux disease (gord)|antiparasitic agents|drugs for acid related disorders|imidazoles|cytochrome p 450 substrates|anti infective agents|gynecological antiinfectives and antiseptics|noxae|cytochrome p 450 cyp3a substrates|nitro compounds|antiinfectives for systemic use|nitroimidazole derivatives|alimentary tract and metabolism|genito urinary system and sex hormones|bsep/abcb11 substrates|nitroimidazoles|antiprotozoals|toxic actions
repaglinide	acids, acyclic|cytochrome p 450 cyp3a substrates|stereoisomerism|meglitinides|drugs used in diabetes|alimentary tract and metabolism|potassium channel antagonists|glinide|cytochrome p 450 substrates|bsep/abcb11 substrates|blood glucose lowering agents|hypoglycemia associated agents|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp2c8 substrates|oatp1b1/slco1b1 substrates
phenformin	cytochrome p 450 cyp2d6 substrates|amidines|guanidines|oct1 inhibitors|biguanides|drugs used in diabetes|alimentary tract and metabolism|cytochrome p 450 substrates|oct2 inhibitors|oct1 substrates|blood glucose lowering agents
amantadine	nicotinic antagonists|sensory system agents|central nervous system agents|anti dyskinesia agents|m2 protein inhibitors|adamantanes|drugs that are mainly renally excreted|oct2 substrates|serotonergic drugs shown to increase risk of serotonin syndrome|analgesics|anticholinergic agents|cycloparaffins|oct2 inhibitors|oct1 substrates|neurotransmitter agents|nmda receptor antagonists|qtc prolonging agents|nervous system|anti parkinson drugs|anti infective agents|antiviral agents|analgesics, non narcotic|potential qtc prolonging agents|oct1 inhibitors|peripheral nervous system agents|dopamine agents|influenza a m2 protein inhibitor|adamantane derivatives
metronidazole	cytochrome p 450 cyp2c8 inhibitors|antibacterials for systemic use|anti bacterial agents|nitroimidazole antimicrobial|stomatological preparations|cytochrome p 450 cyp2a6 substrates|antiparasitic products, insecticides and repellents|p glycoprotein inhibitors|miscellaneous local anti infectives|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|imidazole derivatives|drugs for peptic ulcer and gastro oesophageal reflux disease (gord)|antiparasitic agents|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|drugs for acid related disorders|agents that reduce seizure threshold|cytochrome p 450 enzyme inhibitors|imidazoles|antiinfectives and antiseptics for local oral treatment|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|anti infective agents|cytochrome p 450 cyp3a inhibitors|gynecological antiinfectives and antiseptics|cytochrome p 450 cyp2c9 inhibitors|potential qtc prolonging agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|nitro compounds|antiinfectives for systemic use|dermatologicals|nitroimidazole derivatives|alimentary tract and metabolism|genito urinary system and sex hormones|nitroimidazoles|antiprotozoals|miscellaneous antiprotozoals|ugt1a1 substrates
dinoprostone	dinoprostone, antagonists & inhibitors|uterotonic agents|prostaglandins, synthetic|oat1/slc22a6 substrates|oat3/slc22a8 inhibitors|fatty acids|oct2 inhibitors|prostaglandins e|autacoids|oatp1b1/slco1b1 substrates|prostaglandins|oat1/slc22a6 inhibitors|biological factors|oct1 inhibitors|eicosanoids|reproductive control agents|inflammation mediators|genito urinary system and sex hormones|lipids|fatty acids, unsaturated|oat3/slc22a8 substrates
spectinomycin	carbohydrates|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|heterocyclic compounds, fused ring|glycosides|anti infective agents|dioxanes
ketotifen	thiophenes|ophthalmologicals|histamine h1 inhibitors|histamine agents|antihistamine drugs|antihistamines for systemic use|neurotransmitter agents|qtc prolonging agents|decongestants and antiallergics|other antihistamines|anti allergic agents|piperidines|potential qtc prolonging agents|antipruritics|dermatologicals|sulfur compounds|sensory organs|histamine antagonists|histamine h1 antagonists
ceforanide	amides|nephrotoxic agents|thiazines|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|cephalosporins|heterocyclic compounds, fused ring|sulfur compounds|second generation cephalosporins|beta lactams|anti infective agents|lactams
cyclobenzaprine	drugs causing inadvertant photosensitivity|muscle relaxants|central nervous system agents|serotonin receptor antagonists|tranquilizing agents|benzocycloheptenes|musculo skeletal system|cytochrome p 450 cyp3a4 substrates|muscle relaxants, centrally acting agents|photosensitizing agents|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|central nervous system depressants|antidepressive agents|dibenzocycloheptenes|agents that reduce seizure threshold|cytochrome p 450 substrates|centrally mediated muscle relaxation|serotonin 5 ht2 receptor antagonists|serotonin 5 ht2c receptor antagonists|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|neurotoxic agents|serotonin 5 ht2a receptor antagonists|cytochrome p 450 cyp1a2 substrates|ugt1a4 substrates
phenoxybenzamine	oct1 inhibitors|peripheral alpha 1 blockers|adrenergic alpha antagonists|adrenergic antagonists|antihypertensive agents|vasodilating agents|adrenergic agents|peripheral vasodilators|hypotensive agents|agents that produce hypertension|oct2 inhibitors|adrenergic alpha 1 receptor antagonists|ethylamines|neurotransmitter agents|cardiovascular agents|amines
etretinate	antipsoriatics|hydrocarbons, acyclic|carotenoids|antipsoriatics for systemic use|drugs causing inadvertant photosensitivity|retinoids for treatment of psoriasis|dermatologicals|keratolytic agents|cyclohexanes|cycloparaffins|alkenes|cyclohexenes|retinoids|terpenes|pigments, biological|polyenes|biological factors
famotidine	gastric acid lowering agents|thiazoles|acid reducers|mate 1 inhibitors|anti ulcer agents|histamine agents|oat3/slc22a8 inhibitors|oct2 inhibitors|neurotransmitter agents|drugs for peptic ulcer and gastro oesophageal reflux disease (gord)|qtc prolonging agents|drugs for acid related disorders|cytochrome p 450 enzyme inhibitors|gastrointestinal agents|cytochrome p 450 cyp1a2 inhibitors (weak)|cytochrome p 450 cyp1a2 inhibitors|potential qtc prolonging agents|mate inhibitors|alimentary tract and metabolism|sulfur compounds|histamine h2 antagonists|histamine antagonists|oat3/slc22a8 substrates
azacitidine	carbohydrates|antineoplastic and immunomodulating agents|pyrimidines|antineoplastic agents|aza compounds|drugs that are mainly renally excreted|nucleosides|myelosuppressive agents|nucleoside metabolic inhibitor|ribonucleosides|nucleic acid synthesis inhibitors|glycosides|enzyme inhibitors|nucleic acids, nucleotides, and nucleosides|noxae|pyrimidine analogues|immunosuppressive agents|cytidine deaminase substrates|pyrimidine nucleosides|antimetabolites|narrow therapeutic index drugs|toxic actions
misoprostol	drugs causing inadvertant photosensitivity|abortifacient agents, nonsteroidal|uterotonic agents|prostaglandin e1 analog|anti ulcer agents|musculo skeletal system|abortifacient agents|prostaglandins, synthetic|photosensitizing agents|fatty acids|antiinflammatory and antirheumatic products, non steroids|drugs for peptic ulcer and gastro oesophageal reflux disease (gord)|autacoids|drugs for acid related disorders|prostaglandins|gastrointestinal agents|biological factors|eicosanoids|antiinflammatory and antirheumatic products|alimentary tract and metabolism|propionates|reproductive control agents|inflammation mediators|genito urinary system and sex hormones|lipids|prostaglandins e, synthetic|fatty acids, unsaturated
metacycline	tetracyclines|naphthacenes|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|agents that produce neuromuscular block (indirect)|anti infective agents
mesoridazine	phenothiazines|central nervous system agents|serotonin receptor antagonists|tranquilizing agents|psycholeptics|dopamine antagonists|serotonin agents|antipsychotic agents|central nervous system depressants|neurotransmitter agents|antidepressive agents|qtc prolonging agents|nervous system|antipsychotic agents (first generation [typical])|moderate risk qtc prolonging agents|cytochrome p 450 substrates|serotonin 5 ht2 receptor antagonists|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|neurotoxic agents|serotonin 5 ht2a receptor antagonists|psychotropic drugs|dopamine agents|sulfur compounds|phenothiazines with piperidine structure
maprotiline	adrenergic uptake inhibitors|agents producing tachycardia|membrane transport modulators|psychoanaleptics|central nervous system agents|adrenergic agents|drugs that are mainly renally excreted|antidepressive agents, second generation|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|anticholinergic agents|serotonin modulators|central nervous system depressants|neurotransmitter agents|antidepressive agents|qtc prolonging agents|nervous system|agents that reduce seizure threshold|antidepressive agents, tetracyclic|cytochrome p 450 substrates|non selective monoamine reuptake inhibitors|potential qtc prolonging agents|anthracenes|muscarinic antagonists|cytochrome p 450 cyp2d6 substrates|neurotransmitter uptake inhibitors|psychotropic drugs|cytochrome p 450 cyp1a2 substrates|histamine antagonists|tricyclics and other norepinephrine reuptake inhibitors|histamine h1 antagonists
oxymetazoline	agents producing tachycardia|increased sympathetic activity|adrenergic agents|sympathomimetics used as decongestants|ophthalmologicals|vasoconstrictor agents|vasoconstriction|agents that produce hypertension|adrenergic alpha 1 receptor agonists|adrenergic alpha 2 receptor agonists|neurotransmitter agents|cardiovascular agents|decongestants and antiallergics|sympathomimetics|imidazoles|adrenergic agonists|nasal decongestants|adrenergic alpha agonists|respiratory system agents|sympathomimetics, plain|peripheral nervous system agents|nasal preparations|sensory organs|autonomic agents
amfepramone	appetite depressants|anti obesity agents|agents producing tachycardia|sympathomimetics|antiobesity preparations, excl. diet products|amphetamines|alimentary tract and metabolism|increased sympathetic activity|serotonergic drugs shown to increase risk of serotonin syndrome|stimulants|agents that produce hypertension|centrally acting antiobesity products|central nervous system depressants|ethylamines|sympathomimetic amine anorectic|amines|appetite suppression
salmeterol	agents producing tachycardia|cytochrome p 450 cyp2c8 inhibitors|anti asthmatic agents|adrenergic agents|agents to treat airway disease|amines|cytochrome p 450 cyp3a4 substrates|adrenergic beta 2 receptor agonists|agents that produce hypertension|oct2 inhibitors|oct1 substrates|neurotransmitter agents|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|adrenergic agonists|cytochrome p 450 substrates|ethylamines|adrenergics, inhalants|adrenergic beta agonists|potential qtc prolonging agents|drugs for obstructive airway diseases|respiratory system agents|ethanolamines|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|oct1 inhibitors|peripheral nervous system agents|bronchodilator agents|sympathomimetic (adrenergic) agents|amino alcohols|autonomic agents|cytochrome p 450 cyp2c8 inhibitors (strong)|phenethylamines|selective beta 2 adrenergic agonists|alcohols
meclofenamic acid	anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|antiinflammatory preparations, non steroids for topical use|central nervous system agents|sensory system agents|drugs that are mainly renally excreted|benzoates|musculo skeletal system|amines|aminobenzoates|nephrotoxic agents|analgesics|agents that produce hypertension|non cox 2 selective nsaids|antiinflammatory and antirheumatic products, non steroids|thyroxine binding globulin substrates|topical products for joint and muscular pain|anti inflammatory agents|enzyme inhibitors|oat1/slc22a6 inhibitors|analgesics, non narcotic|antirheumatic agents|aniline compounds|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|acids, carbocyclic|ortho aminobenzoates|benzene derivatives|fenamates|cyclooxygenase inhibitors
methantheline	drugs for functional gastrointestinal disorders|agents producing tachycardia|cholinergic agents|gastric acid lowering agents|quaternary ammonium compounds|onium compounds|alimentary tract and metabolism|synthetic anticholinergics, quaternary ammonium compounds|anticholinergic agents|nitrogen compounds|ammonium compounds|histamine h2 antagonists|histamine antagonists|neurotransmitter agents|acid reducers|amines|muscarinic antagonists
zalcitabine	carbohydrates|nucleoside and nucleotide reverse transcriptase inhibitors|pyrimidines|dideoxynucleosides|nucleosides|antivirals for systemic use|oat1/slc22a6 substrates|deoxycytidine|anti retroviral agents|nucleoside reverse transcriptase inhibitors|reverse transcriptase inhibitors|ribonucleosides|nucleic acid synthesis inhibitors|glycosides|enzyme inhibitors|anti infective agents|antiviral agents|nucleic acids, nucleotides, and nucleosides|noxae|deoxyribonucleosides|pyrimidine nucleosides|antiinfectives for systemic use|antimetabolites|anti hiv agents|direct acting antivirals|toxic actions
ddc	carbohydrates|nucleoside and nucleotide reverse transcriptase inhibitors|pyrimidines|dideoxynucleosides|nucleosides|antivirals for systemic use|oat1/slc22a6 substrates|deoxycytidine|anti retroviral agents|nucleoside reverse transcriptase inhibitors|reverse transcriptase inhibitors|ribonucleosides|nucleic acid synthesis inhibitors|glycosides|enzyme inhibitors|anti infective agents|antiviral agents|nucleic acids, nucleotides, and nucleosides|noxae|deoxyribonucleosides|pyrimidine nucleosides|antiinfectives for systemic use|antimetabolites|anti hiv agents|direct acting antivirals|toxic actions
demecarium	cholinergic agents|cholinesterase inhibitors|onium compounds|nitrogen compounds|ammonium compounds|sensory organs|ophthalmologicals|enzyme inhibitors|neurotransmitter agents|antiglaucoma preparations and miotics|amines|parasympathomimetics
aspirin	antiplatelet agents|amino acids, peptides, and proteins|anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|sensory system agents|drugs that are mainly renally excreted|stomatological preparations|musculo skeletal system|hydroxybenzoates|nephrotoxic agents|p glycoprotein substrates|decreased platelet aggregation|oat3/slc22a8 inhibitors|salicylic acid and derivatives|analgesics|amino acids|agents that produce hypertension|cytochrome p 450 cyp2c19 inducers|non cox 2 selective nsaids|p glycoprotein inducers|cardiovascular agents|blood and blood forming organs|salicylates|agents causing angioedema|anticoagulants|decreased prostaglandin production|anti inflammatory agents|hematologic agents|amino acids, basic|cytochrome p 450 substrates|platelet aggregation inhibitors excl. heparin|oat1/slc22a6 inhibitors|cytochrome p 450 cyp2c9 substrates|analgesics, non narcotic|ugt1a6 substrate|cytochrome p 450 cyp2c19 inducers (strength unknown)|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|alimentary tract and metabolism|cytochrome p 450 enzyme inducers|amino acids, diamino|acids, carbocyclic|benzene derivatives|antipyretics|cyclooxygenase inhibitors
fulvestrant	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|antineoplastic and immunomodulating agents|gonadal steroid hormones|estrogen antagonists|antineoplastic agents|estranes|cytochrome p 450 cyp3a4 substrates|fused ring compounds|antineoplastic agents, hormonal|cytochrome p 450 substrates|selective estrogen receptor modulators|estrogen receptor antagonists|anti estrogens|cytochrome p 450 cyp3a substrates|estrenes|steroids|endocrine therapy|hormone antagonists and related agents|hormones|estradiol congeners|gonadal hormones|ugt1a1 substrates
felbamate	acids, acyclic|central nervous system agents|cytochrome p 450 cyp3a4 inducers|propylene glycols|cytochrome p 450 cyp3a4 substrates|anti epileptic agent|decreased central nervous system disorganized electrical activity|carbamates|anticonvulsants|central nervous system depressants|neurotransmitter agents|nmda receptor antagonists|cytochrome p 450 cyp3a4 inducers (weak)|qtc prolonging agents|nervous system|excitatory amino acid antagonists|cytochrome p 450 enzyme inhibitors|phenylcarbamates|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 substrates|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp2c9 inhibitors|potential qtc prolonging agents|glycols|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 enzyme inducers|cytochrome p 450 cyp2c9 inhibitors (moderate)|excitatory amino acid agents|alcohols
fexofenadine	histamine agents|p glycoprotein substrates|oatp1b3 substrates|anti allergic agents|histamine h1 antagonists, non sedating|piperidines|oat3/slc22a8 substrates|benzene derivatives|antihistamines for systemic use|histamine antagonists|neurotransmitter agents|benzhydryl compounds|histamine h1 antagonists|oatp1b1/slco1b1 substrates
isoniazid	hydrazides|cytochrome p 450 cyp2c8 inhibitors|anti bacterial agents|antituberculosis agents|cytochrome p 450 cyp2e1 inducers (strength unknown)|drugs that are mainly renally excreted|lipid regulating agents|hepatotoxic agents|cytochrome p 450 cyp2d6 inhibitors (weak)|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|serotonergic drugs shown to increase risk of serotonin syndrome|antimycobacterials|cytochrome p 450 cyp2e1 inhibitors|cytochrome p 450 cyp2a6 inhibitors (strength unknown)|cytochrome p 450 cyp2c19 inhibitors (weak)|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|pyridines|cytochrome p 450 cyp2d6 inhibitors|agents that reduce seizure threshold|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a4 inhibitors (moderate)|cytochrome p 450 substrates|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|anti infective agents|cytochrome p 450 cyp3a inhibitors|noxae|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strong)|cytochrome p 450 cyp1a2 inhibitors|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp2e1 inducers|hypolipidemic agents|antiinfectives for systemic use|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 enzyme inducers|drugs for treatment of tuberculosis|cytochrome p 450 cyp2e1 inhibitors (moderate)|hydrazines|isonicotinic acids|cytochrome p 450 cyp2a6 inhibitors|toxic actions|fatty acid synthesis inhibitors
rizatriptan	serotonin 1b and serotonin 1d receptor agonist|serotonin 5 ht1 receptor agonists|antimigraine preparations|serotonin 1b receptor agonists|drugs that are mainly renally excreted|amines|indoles|selective serotonin 5 ht1 receptor agonists|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|analgesics|serotonin modulators|agents that produce hypertension|central nervous system depressants|neurotransmitter agents|antidepressive agents|serotonin 1d receptor agonists|monoamine oxidase a substrates|nervous system|selective serotonin agonists|biogenic monoamines|triptans|migraine disorders|heterocyclic compounds, fused ring|biogenic amines|serotonin receptor agonists
dirithromycin	macrolides|cytochrome p 450 enzyme inhibitors|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|cytochrome p 450 cyp3a4 inhibitors|polyketides|macrolides, lincosamides and streptogramins|anti infective agents|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|lactones
norgestimate	norsteroids|adrenal cortex hormones|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|hormonal contraceptives for systemic use|fused ring compounds|p glycoprotein inhibitors|cytochrome p 450 cyp2b6 substrates|progestogens and estrogens, sequential preparations|contraceptives, oral, synthetic|sex hormones and modulators of the genital system|norpregnenes|hyperglycemia associated agents|norpregnanes|progestins|contraceptives, oral|cytochrome p 450 substrates|contraceptive agents, female|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inducers|combination contraceptives (with estrogen and derivatives)|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|progestin contraceptives|cytochrome p 450 enzyme inducers|reproductive control agents|steroids|genito urinary system and sex hormones|ugt1a1 substrates
methylprednisolone	hormones, hormone substitutes, and hormone antagonists|corticosteroids for systemic use|adrenal cortex hormones|central nervous system agents|antineoplastic agents|ophthalmologicals|cytochrome p 450 cyp2c8 inducers (strength unknown)|cytochrome p 450 cyp2b6 inducers (strength unknown)|experimental unapproved treatments for covid 19|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|anti acne preparations for topical use|p glycoprotein substrates|cytochrome p 450 cyp2a6 inducers|protective agents|cytochrome p 450 cyp2c19 inducers|corticosteroids|cytochrome p 450 cyp2c9 inducers (strength unknown)|p glycoprotein inducers|corticosteroids for systemic use, plain|cytochrome p 450 cyp2b6 inducers|corticosteroids, weak (group i)|hyperglycemia associated agents|anti inflammatory agents|anti acne preparations|pregnanes|cytochrome p 450 cyp2c8 inducers|gastrointestinal agents|cytochrome p 450 substrates|pregnadienetriols|cytochrome p 450 cyp3a inducers|corticosteroid hormone receptor agonists|immunosuppressive agents|adrenals|neuroprotective agents|compounds used in a research, industrial, or household setting|cytochrome p 450 cyp2c19 inducers (strength unknown)|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|dermatologicals|cytochrome p 450 enzyme inducers|peripheral nervous system agents|corticosteroids, dermatological preparations|hormones|steroids|sensory organs|antiemetics|pregnadienes|autonomic agents|cytochrome p 450 cyp2c9 inducers|systemic hormonal preparations, excl. sex hormones and insulins
pindolol	propanolamines|beta blocking agents, non selective|serotonin receptor antagonists|adrenergic agents|drugs that are mainly renally excreted|phenoxypropanolamines|antihypertensive agents indicated for hypertension|amines|bradycardia causing agents|adrenergic antagonists|cytochrome p 450 cyp2d6 inhibitors (weak)|serotonin 5 ht1 receptor antagonists|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|serotonin 5 ht1a receptor antagonists|hypotensive agents|central nervous system depressants|neurotransmitter agents|antidepressive agents|cardiovascular agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|vasodilating agents|propanols|adrenergic beta antagonists|cytochrome p 450 substrates|cytochrome p 450 cyp2d6 substrates|antihypertensive agents|agents causing hyperkalemia|amino alcohols|alcohols
mepivacaine	amides|anesthetics, local|nervous system|peripheral nervous system agents|sensory system agents|central nervous system agents|local anesthetics (amide)|drugs that are mainly renally excreted|piperidines|central nervous system depressants|anesthetics|local anesthesia
zaleplon	acids, acyclic|gaba agonists|hypnotics and sedatives|central nervous system depression|central nervous system agents|drugs that are mainly renally excreted|psycholeptics|cytochrome p 450 cyp3a4 substrates|benzodiazepine hypnotics and sedatives|fatty acids|miscellaneous anxiolytics sedatives and hypnotics|anticonvulsants|central nervous system depressants|neurotransmitter agents|cytochrome p 450 cyp3a7 substrates|amides|nervous system|gaba modulators|fatty acids, volatile|cytochrome p 450 substrates|gaba agents|gamma aminobutyric acid a receptor agonist|hypnotics (nonbenzodiazepine)|acetates|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|gaba a receptor agonists|lipids
bromfenac	anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|sensory system agents|central nervous system agents|ophthalmologicals|nephrotoxic agents|selective cyclooxygenase 2 inhibitors (nsaids)|analgesics|hydrocarbons, brominated|anti inflammatory agents|analgesics, non narcotic|antirheumatic agents|ketones|peripheral nervous system agents|hydrocarbons, halogenated|agents causing hyperkalemia|sensory organs|benzene derivatives|cyclooxygenase inhibitors
telmisartan	ugt1a3 substrates|angiotensin ii receptor blockers (arbs), plain|bcrp/abcg2 inhibitors|angiotensin 2 receptor blocker|antihypertensive agents indicated for hypertension|p glycoprotein inhibitors|hypotensive agents|biphenyl compounds|cardiovascular agents|cytochrome p 450 enzyme inhibitors|agents causing angioedema|benzimidazoles|angiotensin ii receptor blockers (arbs) and diuretics|angiotensin ii type 2 receptor blockers|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|angiotensin ii receptor blockers (arbs) and calcium channel blockers|heterocyclic compounds, fused ring|cytochrome p 450 cyp2c19 inhibitors|agents acting on the renin angiotensin system|antihypertensive agents|agents causing hyperkalemia|bsep/abcb11 substrates|benzene derivatives|angiotensin receptor antagonists|angiotensin ii type 1 receptor blockers
desloratadine	p glycoprotein inhibitors|cholinergic agents|histamine agents|loratadine and prodrug|anticholinergic agents|moderate risk qtc prolonging agents|benzocycloheptenes|histamine h1 antagonists, non sedating|piperidines|central nervous system depressants|antihistamines for systemic use|neurotransmitter agents|histamine antagonists|qtc prolonging agents|histamine h1 antagonists|dibenzocycloheptenes
methyldopa	amino acids, peptides, and proteins|amino acids, cyclic|central alpha 2 adrenergic agonist|adrenergic agents|catechols|drugs that are mainly renally excreted|antihypertensive agents indicated for hypertension|amines|bradycardia causing agents|phenylalanine|amino acids, aromatic|aromatic l amino acid decarboxylase inhibitors|hypotensive agents|amino acids|adrenergic alpha 2 receptor agonists|neurotransmitter agents|cardiovascular agents|comt substrates|phenols|agents causing muscle toxicity|adrenergic agonists|enzyme inhibitors|adrenergic alpha agonists|amino acids, essential|catecholamines|antihypertensive agents|peripheral nervous system agents|dihydroxyphenylalanine|autonomic agents|benzene derivatives|sympatholytics|central alpha agonists
alosetron	serotonin receptor antagonists|cytochrome p 450 cyp3a4 substrates|indoles|serotonin agents|cytochrome p 450 cyp2e1 inhibitors|central nervous system depressants|neurotransmitter agents|cytochrome p 450 cyp1a2 inhibitors (moderate)|antidepressive agents|pyridines|serotonin 3 receptor antagonists|cytochrome p 450 enzyme inhibitors|gastrointestinal agents|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|serotonin 5 ht3 receptor antagonists|cytochrome p 450 cyp1a2 inhibitors|drugs for functional gastrointestinal disorders|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|alimentary tract and metabolism|cytochrome p 450 cyp2e1 inhibitors (moderate)|cytochrome p 450 cyp1a2 substrates
dactinomycin	amino acids, peptides, and proteins|antineoplastic and immunomodulating agents|actinomycines|antineoplastic agents|p glycoprotein inhibitors|p glycoprotein substrates|peptides|cytotoxic antibiotics and related substances|myelosuppressive agents|bcrp/abcg2 substrates|nucleic acid synthesis inhibitors|peptides, cyclic|actinomycin|enzyme inhibitors|anti infective agents|heterocyclic compounds, fused ring|immunosuppressive agents|antibiotics, antineoplastic|protein synthesis inhibitors|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index
actinomycin d	amino acids, peptides, and proteins|antineoplastic and immunomodulating agents|actinomycines|antineoplastic agents|p glycoprotein inhibitors|p glycoprotein substrates|peptides|cytotoxic antibiotics and related substances|myelosuppressive agents|bcrp/abcg2 substrates|nucleic acid synthesis inhibitors|peptides, cyclic|actinomycin|enzyme inhibitors|anti infective agents|heterocyclic compounds, fused ring|immunosuppressive agents|antibiotics, antineoplastic|protein synthesis inhibitors|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index
azelastine	cytochrome p 450 cyp2b6 inhibitors (strength unknown)|histamine h1 antagonists, non sedating|ophthalmologicals|cytochrome p 450 cyp2a6 substrates|cytochrome p 450 cyp3a4 substrates|antiallergic agents, excl. corticosteroids|p glycoprotein inhibitors|histamine agents|cytochrome p 450 cyp2c19 substrates|histamine h1 antagonists|cytochrome p 450 cyp2e1 inhibitors|pyridazines|cytochrome p 450 cyp2a6 inhibitors (strength unknown)|central nervous system depressants|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|antihistamines for systemic use|neurotransmitter agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|decongestants and antiallergics|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 cyp2b6 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|anti allergic agents|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp2d6 substrates|respiratory system agents|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|nasal preparations|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|cytochrome p 450 cyp1a2 substrates|sensory organs|cytochrome p 450 cyp2a6 inhibitors|autonomic agents|histamine antagonists|cytochrome p 450 cyp2c8 substrates
ezetimibe	ugt1a3 substrates|cytochrome p 450 cyp2c8 inhibitors|decreased cholesterol absorption|lipid regulating agents|ugt2b7 substrates|p glycoprotein substrates|lipid modifying agents|dietary cholesterol absorption inhibitor|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|bcrp/abcg2 substrates|hypolipidemic agents indicated for hyperlipidemia|oatp1b1/slco1b1 substrates|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp3a inhibitors|lipid modifying agents, plain|hypolipidemic agents|azetines|bsep/abcb11 substrates|anticholesteremic agents|ugt1a1 substrates
dipyridamole	antiplatelet agents|oatp1b3 inhibitors|pyrimidines|phosphodiesterase inhibitors|p glycoprotein inhibitors|p glycoprotein substrates|decreased platelet aggregation|hypotensive agents|oatp1b1/slco1b1 inhibitors|cardiovascular agents|blood and blood forming organs|phosphodiesterase 5 inhibitors|anticoagulants|vasodilating agents|hematologic agents|platelet aggregation inhibitors excl. heparin|enzyme inhibitors|miscellaneous vasodilatating agents|bsep/abcb11 substrates
ethinyl estradiol	hormones, hormone substitutes, and hormone antagonists|norsteroids|cytochrome p 450 cyp2c8 inhibitors|antineoplastic and immunomodulating agents|gonadal steroid hormones|adrenal cortex hormones|bsep/abcb11 inducers|thyroxine binding globulin inducers|estrogen contraceptives|contraceptives, postcoital|norpregnatrienes|ugt2b7 substrates|cytochrome p 450 cyp3a4 substrates|fused ring compounds|hormonal contraceptives for systemic use|ugt1a1 inducers|p glycoprotein substrates|progestogens and estrogens, sequential preparations|sex hormones and modulators of the genital system|hormones and related agents|comt substrates|cytochrome p 450 enzyme inhibitors|hyperglycemia associated agents|norpregnanes|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|estrogens|contraceptives, oral|cytochrome p 450 substrates|contraceptive agents, female|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|estrogenic steroids, alkylated|natural and semisynthetic estrogens, plain|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|steroids|ugt1a9 substrates|endocrine therapy|hormones|estradiol congeners|cytochrome p 450 cyp1a2 substrates|genito urinary system and sex hormones|gonadal hormones|bsep/abcb11 inhibitors|ugt1a1 substrates|ugt1a4 substrates|cytochrome p 450 cyp2c8 substrates
ethinylestradiol	hormones, hormone substitutes, and hormone antagonists|norsteroids|cytochrome p 450 cyp2c8 inhibitors|antineoplastic and immunomodulating agents|gonadal steroid hormones|adrenal cortex hormones|bsep/abcb11 inducers|thyroxine binding globulin inducers|estrogen contraceptives|contraceptives, postcoital|norpregnatrienes|ugt2b7 substrates|cytochrome p 450 cyp3a4 substrates|fused ring compounds|hormonal contraceptives for systemic use|ugt1a1 inducers|p glycoprotein substrates|progestogens and estrogens, sequential preparations|sex hormones and modulators of the genital system|hormones and related agents|comt substrates|cytochrome p 450 enzyme inhibitors|hyperglycemia associated agents|norpregnanes|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|estrogens|contraceptives, oral|cytochrome p 450 substrates|contraceptive agents, female|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|estrogenic steroids, alkylated|natural and semisynthetic estrogens, plain|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|steroids|ugt1a9 substrates|endocrine therapy|hormones|estradiol congeners|cytochrome p 450 cyp1a2 substrates|genito urinary system and sex hormones|gonadal hormones|bsep/abcb11 inhibitors|ugt1a1 substrates|ugt1a4 substrates|cytochrome p 450 cyp2c8 substrates
lomefloxacin	drugs causing inadvertant photosensitivity|topoisomerase inhibitors|antibacterials for systemic use|anti bacterial agents|ophthalmologicals|photosensitizing agents|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|fluoroquinolones|quinolines|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|moderate risk qtc prolonging agents|cytochrome p 450 substrates|quinolones|enzyme inhibitors|anti infective agents|cytochrome p 450 cyp1a2 inhibitors|heterocyclic compounds, fused ring|antiinfectives for systemic use|topoisomerase ii inhibitors|cytochrome p 450 cyp1a2 substrates|sensory organs
cyclopentolate	mydriatics|cholinergic agents|parasympatholytics|peripheral nervous system agents|mydriatics and cycloplegics|anticholinergic agents|acids, carbocyclic|phenylacetates|sensory organs|ophthalmologicals|autonomic agents|cholinesterase substrates|neurotransmitter agents|muscarinic antagonists
eserine	acids, acyclic|miotics|ophthalmologicals|cholinesterase inhibitors|indoles|carbamates|indole alkaloids|neurotransmitter agents|antiglaucoma preparations and miotics|cholinergic agents|phenylcarbamates|antidotes|alkaloids|enzyme inhibitors|parasympathomimetics|heterocyclic compounds, fused ring|peripheral nervous system agents|sensory organs|autonomic agents
physostigmine	acids, acyclic|miotics|ophthalmologicals|cholinesterase inhibitors|indoles|carbamates|indole alkaloids|neurotransmitter agents|antiglaucoma preparations and miotics|cholinergic agents|phenylcarbamates|antidotes|alkaloids|enzyme inhibitors|parasympathomimetics|heterocyclic compounds, fused ring|peripheral nervous system agents|sensory organs|autonomic agents
isotretinoin	drugs causing inadvertant photosensitivity|anti acne preparations for systemic use|cyclohexanes|cyclohexenes|drugs that are mainly renally excreted|polyenes|cytochrome p 450 cyp3a4 substrates|anti acne preparations for topical use|photosensitizing agents|cycloparaffins|alkenes|toxic actions|hydrocarbons, acyclic|carotenoids|agents causing muscle toxicity|anti acne preparations|retinoids for topical use in acne|cytochrome p 450 substrates|retinoids|teratogens|retinoids for treatment of acne|pigments, biological|noxae|biological factors|cytochrome p 450 cyp3a substrates|dermatologicals|terpenes|misc. skin and mucous membrane agents
formoterol	agents producing tachycardia|anti asthmatic agents|adrenergic agents|agents to treat airway disease|cytochrome p 450 cyp2a6 substrates|ugt2b7 substrates|amines|adrenergic beta 2 receptor agonists|cytochrome p 450 cyp2c19 substrates|agents that produce hypertension|oct1 substrates|qtc prolonging agents|adrenergic agonists|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|adrenergics, inhalants|adrenergic beta agonists|potential qtc prolonging agents|drugs for obstructive airway diseases|cytochrome p 450 cyp2d6 substrates|respiratory system agents|ethanolamines|oct1 inhibitors|ugt1a9 substrates|bronchodilator agents|amino alcohols|autonomic agents|selective beta 2 adrenergic agonists|alcohols
dimenhydrinate	ethanolamine derivatives|central nervous system agents|amines|histamine agents|purinones|central nervous system depressants|neurotransmitter agents|benzhydryl compounds|qtc prolonging agents|alkaloids|gastrointestinal agents|moderate risk qtc prolonging agents|ethylamines|pharmaceutical preparations|heterocyclic compounds, fused ring|peripheral nervous system agents|antiemetics|purines|autonomic agents|benzene derivatives|histamine antagonists|histamine h1 antagonists
cytarabine	carbohydrates|antineoplastic and immunomodulating agents|pyrimidines|antineoplastic agents|nucleosides|cytochrome p 450 cyp3a4 substrates|oct1 substrates|myelosuppressive agents|nucleoside metabolic inhibitor|ribonucleosides|nucleic acid synthesis inhibitors|agents causing muscle toxicity|cytochrome p 450 substrates|glycosides|anti infective agents|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|nucleic acids, nucleotides, and nucleosides|noxae|immunosuppressive agents|pyrimidine analogues|cytidine deaminase substrates|pyrimidine nucleosides|cytochrome p 450 cyp3a substrates|antimetabolites|cardiotoxic antineoplastic agents|narrow therapeutic index drugs|toxic actions|arabinonucleosides|immunologic factors
dopamine	agents producing tachycardia|dopamine, metabolism|catechols|selective beta 1 adrenergic agonists|drugs that are mainly renally excreted|amines|oct2 substrates|protective agents|agents that produce hypertension|oct2 inhibitors|oct1 substrates|neurotransmitter agents|cardiovascular agents|comt substrates|cardiac stimulants excl. cardiac glycosides|monoamine oxidase a substrates|sympathomimetics|phenols|biogenic monoamines|catecholamines|compounds used in a research, industrial, or household setting|peripheral nervous system agents|dopamine agents|cardiotonic agents|adrenergic and dopaminergic agents|biogenic amines|autonomic agents|cardiac therapy|benzene derivatives
rivastigmine	acids, acyclic|parasympathomemetic (cholinergic) agents|psychoanaleptics|central nervous system agents|bradycardia causing agents|cholinesterase inhibitors|carbamates|protective agents|neurotransmitter agents|nervous system|cholinergic agents|phenylcarbamates|cytochrome p 450 substrates|enzyme inhibitors|neuroprotective agents|compounds used in a research, industrial, or household setting|cytochrome p 450 cyp3a substrates|anti dementia drugs
exemestane	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|cytochrome p 450 cyp3a substrates|antineoplastic and immunomodulating agents|androstenes|steroids|aromatase inhibitors|endocrine therapy|androstanes|estrogen antagonists|antineoplastic agents|cytochrome p 450 substrates|hormone antagonists and related agents|steroid synthesis inhibitors|enzyme inhibitors|cytochrome p 450 cyp3a4 substrates|fused ring compounds
oxaprozin	acids, acyclic|drugs causing inadvertant photosensitivity|anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|sensory system agents|central nervous system agents|drugs that are mainly renally excreted|other nonsteroidal anti inflammatory agents|musculo skeletal system|oxazoles|nephrotoxic agents|photosensitizing agents|analgesics|fatty acids|agents that produce hypertension|non cox 2 selective nsaids|antiinflammatory and antirheumatic products, non steroids|anti inflammatory agents|fatty acids, volatile|enzyme inhibitors|analgesics, non narcotic|antirheumatic agents|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|propionates|lipids|cyclooxygenase inhibitors
azathioprine	carbohydrates|antineoplastic and immunomodulating agents|purine antimetabolite|drugs that are mainly renally excreted|nucleosides|p glycoprotein substrates|nucleic acid synthesis inhibitors|cytochrome p 450 substrates|glycosides|sulfhydryl compounds|nucleic acids, nucleotides, and nucleosides|noxae|antirheumatic agents|heterocyclic compounds, fused ring|immunosuppressive agents|antimetabolites|cytochrome p 450 cyp1a2 substrates|sulfur compounds|thionucleosides|purines|toxic actions|thiopurine analogs|immunologic factors
neomycin	carbohydrates|antibacterials for systemic use|anti bacterial agents|intestinal antiinfectives|agents that produce neuromuscular block (indirect)|aminoglycoside antibacterials|drugs that are mainly renally excreted|ophthalmologicals|stomatological preparations|nephrotoxic agents|ophthalmological and otological preparations|blood and blood forming organs|antidiarrheals, intestinal antiinflammatory/antiinfective agents|ototoxic agents|blood substitutes and perfusion solutions|throat preparations|antiinfectives and antiseptics for local oral treatment|antibiotics for topical use|glycosides|enzyme inhibitors|anti infective agents|otologicals|irrigating solutions|neurotoxic agents|antiinfectives for systemic use|dermatologicals|alimentary tract and metabolism|protein synthesis inhibitors|narrow therapeutic index drugs|sensory organs|drugs that are mainly renally excreted with a narrow therapeutic index
auranofin	gold compounds|gold preparations|organometallic compounds|organogold compounds|antiinflammatory and antirheumatic products|specific antirheumatic agents|drugs that are mainly renally excreted|musculo skeletal system|antirheumatic agents
gabapentin	acids, acyclic|amino acids, peptides, and proteins|drugs causing inadvertant photosensitivity|sensory system agents|central nervous system agents|cyclohexanes|tranquilizing agents|amines|anti epileptic agent|decreased central nervous system disorganized electrical activity|butyrates|photosensitizing agents|analgesics|cycloparaffins|amino acids|anticonvulsants|central nervous system depressants|neurotransmitter agents|miscellaneous anticonvulsants|nervous system|gabapentin and prodrugs|cyclohexanecarboxylic acids|peripheral nervous system agents|psychotropic drugs|acids, carbocyclic|aminobutyrates
doxorubicin	carbohydrates|drugs causing inadvertant photosensitivity|antineoplastic and immunomodulating agents|cytochrome p 450 cyp2b6 inhibitors (strength unknown)|topoisomerase inhibitors|anthracycline topoisomerase inhibitor|antineoplastic agents|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|p glycoprotein substrates|photosensitizing agents|p glycoprotein inducers|cytotoxic antibiotics and related substances|bcrp/abcg2 substrates|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|anthracyclines and related substances|myelosuppressive agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 cyp2b6 inhibitors|cytochrome p 450 enzyme inhibitors|naphthacenes|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|glycosides|bsep/abcb11 substrates with a narrow therapeutic index|enzyme inhibitors|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|immunosuppressive agents|cytochrome p 450 cyp3a substrates|antibiotics, antineoplastic|topoisomerase ii inhibitors|cardiotoxic antineoplastic agents|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|bsep/abcb11 substrates|anthracyclines
hydrochlorothiazide	membrane transport modulators|drugs causing inadvertant photosensitivity|antihypertensive agents indicated for hypertension|nephrotoxic agents|photosensitizing agents|sulfones|hypotensive agents|low ceiling diuretics and potassium sparing agents|cardiovascular agents|qtc prolonging agents|amides|increased diuresis|sulfonamides|hyperglycemia associated agents|diuretics|natriuretic agents|oat1/slc22a6 inhibitors|gynecological antiinfectives and antiseptics|potential qtc prolonging agents|thiazides|heterocyclic compounds, fused ring|antihypertensive agents|benzothiadiazines|sodium chloride symporter inhibitors|genito urinary system and sex hormones|sulfur compounds|non potassium sparing diuretics|oat3/slc22a8 substrates
ciclacillin	amides|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|heterocyclic compounds, fused ring|sulfur compounds|penicillins|beta lactams|anti infective agents|beta lactam antibacterials|lactams
salbutamol	agents producing tachycardia|anti asthmatic agents|adrenergic agents|drugs that are mainly renally excreted|agents to treat airway disease|tocolytic agents|amines|adrenergic beta 2 receptor agonists|agents that produce hypertension|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|adrenergic agonists|cytochrome p 450 cyp3a4 inhibitors|adrenergics, inhalants|cytochrome p 450 cyp3a inhibitors|adrenergic beta agonists|potential qtc prolonging agents|drugs for obstructive airway diseases|respiratory system agents|ethanolamines|peripheral nervous system agents|reproductive control agents|bronchodilator agents|sympathomimetic (adrenergic) agents|amino alcohols|autonomic agents|phenethylamines|selective beta 2 adrenergic agonists|alcohols
cromoglicic acid	drugs causing inadvertant photosensitivity|anti asthmatic agents|ophthalmologicals|mast cell stabilizers|agents for dermatitis, excluding corticosteroids|antiallergic agents, excl. corticosteroids|photosensitizing agents|antidiarrheals, intestinal antiinflammatory/antiinfective agents|decongestants and antiallergics|benzopyrans|intestinal antiinflammatory agents|anti allergic agents|adrenergics, inhalants|decreased histamine release|heterocyclic compounds, fused ring|drugs for obstructive airway diseases|respiratory system agents|nasal preparations|dermatologicals|alimentary tract and metabolism|pyrans|sensory organs|chromones|cromolyn sodium
ganciclovir	nucleosides and nucleotides|drugs that are mainly renally excreted|ophthalmologicals|mate 2 substrates|antivirals for systemic use|ganciclovir and prodrug|oat3/slc22a8 inhibitors|purinones|oct1 substrates|agents that reduce seizure threshold|nucleic acid synthesis inhibitors|agents causing muscle toxicity|nucleosides and nucleotides excl. reverse transcriptase inhibitors|mate substrates|oat1/slc22a6 inhibitors|nucleoside analog antiviral|anti infective agents|antiviral agents|ganciclovir|heterocyclic compounds, fused ring|oct1 inhibitors|antiinfectives for systemic use|cytomegalovirus nucleoside analog dna polymerase inhibitor|mate 1 substrates|direct acting antivirals|sensory organs|purines
letrozole	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|antineoplastic and immunomodulating agents|estrogen antagonists|antineoplastic agents|triazoles|cytochrome p 450 cyp2a6 substrates|ugt2b7 substrates|cytochrome p 450 cyp3a4 substrates|p glycoprotein substrates|cytochrome p 450 cyp2a6 inhibitors (strong)|steroid synthesis inhibitors|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|aromatase inhibitors|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|endocrine therapy|hormone antagonists and related agents|nitriles|cytochrome p 450 cyp2a6 inhibitors
tioconazole	antifungal agents|cytochrome p 450 cyp2e1 inhibitors (strong)|hormones, hormone substitutes, and hormone antagonists|hormone antagonists|antifungal agents (vaginal)|antifungals for dermatological use|cytochrome p 450 cyp2e1 inhibitors|imidazole derivatives|steroid synthesis inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a4 inhibitors (moderate)|antifungals for topical use|enzyme inhibitors|imidazole and triazole derivatives|14 alpha demethylase inhibitors|anti infective agents|cytochrome p 450 cyp3a inhibitors|gynecological antiinfectives and antiseptics|chemically induced disorders|cytochrome p 450 cyp2c19 inhibitors (strong)|azole antifungals|cytochrome p 450 cyp2c19 inhibitors|dermatologicals|genito urinary system and sex hormones
busulfan	antineoplastic and immunomodulating agents|alkylating drugs|acids|alkanesulfonates|antineoplastic agents|butylene glycols|cytochrome p 450 cyp3a4 substrates|sulfur acids|alkylating activity|mesylates|myelosuppressive agents|hydrocarbons, acyclic|alkanesulfonic acids|myeloablative agonists|antineoplastic agents, alkylating|cytochrome p 450 substrates|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|noxae|glycols|acids, noncarboxylic|immunosuppressive agents|cytochrome p 450 cyp3a substrates|cardiotoxic antineoplastic agents|sulfonic acids|narrow therapeutic index drugs|sulfur compounds|alkanes|toxic actions|alcohols|immunologic factors
ketoprofen	amino acids, peptides, and proteins|cytochrome p 450 cyp2c8 inhibitors|anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|drugs causing inadvertant photosensitivity|antiinflammatory preparations, non steroids for topical use|central nervous system agents|sensory system agents|drugs that are mainly renally excreted|other nonsteroidal anti inflammatory agents|musculo skeletal system|nephrotoxic agents|photosensitizing agents|oat3/slc22a8 inhibitors|analgesics|amino acids|agents that produce hypertension|non cox 2 selective nsaids|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|antiinflammatory and antirheumatic products, non steroids|topical products for joint and muscular pain|phenylpropionates|cytochrome p 450 enzyme inhibitors|anti inflammatory agents|amino acids, basic|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|oat1/slc22a6 inhibitors|analgesics, non narcotic|cytochrome p 450 cyp2c9 inhibitors|antirheumatic agents|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|cytochrome p 450 cyp2c8 inhibitors (weak)|propionates|amino acids, diamino|acids, carbocyclic|ugt1a1 substrates|cyclooxygenase inhibitors
edrophonium	cholinergic agents|compounds used in a research, industrial, or household setting|cholinesterase inhibitors|antidotes|quaternary ammonium compounds|onium compounds|phenylammonium compounds|diagnostic agents|nitrogen compounds|ammonium compounds|protective agents|drugs that are mainly renally excreted|enzyme inhibitors|neurotransmitter agents|amines
metyrapone	diagnostic agents|drugs that are mainly renally excreted|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp2e1 inhibitors|cytochrome p 450 cyp2a6 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|steroid synthesis inhibitors|pyridines|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|enzyme inhibitors|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a inducers|noxae|tests for pituitary function|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|cytochrome p 450 cyp2a6 inhibitors|toxic actions
cinacalcet	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|cytochrome p 450 cyp2d6 inhibitors (strong)|naphthalenes|calcium regulating hormones and agents|cytochrome p 450 cyp3a4 substrates|calcium homeostasis|other miscellaneous therapeutic agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|increased calcium sensing receptor sensitivity|cytochrome p 450 substrates|calcium sensing receptor agonist|anti parathyroid agents|cytochrome p 450 cyp3a substrates|calcimimetic agents|cytochrome p 450 cyp1a2 substrates|systemic hormonal preparations, excl. sex hormones and insulins
balsalazide	inflammatory bowel diseases|anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|sensory system agents|central nervous system agents|benzoates|aminobenzoates|hydroxybenzoates|meta aminobenzoates|nephrotoxic agents|colitis, ulcerative|analgesics|agents that produce hypertension|non cox 2 selective nsaids|antidiarrheals, intestinal antiinflammatory/antiinfective agents|salicylates|phenols|intestinal antiinflammatory agents|anti inflammatory agents|gastrointestinal agents|aminosalicylic acids|analgesics, non narcotic|aminosalicylate|hydroxy acids|peripheral nervous system agents|agents causing hyperkalemia|alimentary tract and metabolism|hydrazines|acids, carbocyclic|prodrugs|benzene derivatives
sulfamethoxazole	drugs causing inadvertant photosensitivity|antibiotics for pneumocystis pneumonia|antibacterials for systemic use|anti bacterial agents|sulfonamides and trimethoprim|drugs that are mainly renally excreted|sulfanilamides|amines|cytochrome p 450 cyp3a4 substrates|hypoglycemia associated agents|intermediate acting sulfonamides|sulfonamide antibacterial|photosensitizing agents|antimycobacterials|sulfones|blood glucose lowering agents|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|sulfonamides|agents causing muscle toxicity|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|anti infective agents|cytochrome p 450 cyp3a inhibitors|gynecological antiinfectives and antiseptics|cytochrome p 450 cyp2c9 inhibitors|potential qtc prolonging agents|aniline compounds|cytochrome p 450 cyp3a substrates|methemoglobinemia associated agents|antiinfectives for systemic use|agents causing hyperkalemia|drugs for treatment of tuberculosis|genito urinary system and sex hormones|sulfur compounds|bsep/abcb11 substrates|bsep/abcb11 inhibitors
glibenclamide	drugs causing inadvertant photosensitivity|drugs used in diabetes|sulfonylureas|cytochrome p 450 cyp3a4 inhibitors (weak)|cytochrome p 450 cyp3a4 substrates|hypoglycemia associated agents|p glycoprotein inhibitors|photosensitizing agents|cytochrome p 450 cyp2c19 substrates|sulfones|blood glucose lowering agents|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|bcrp/abcg2 substrates|cytochrome p 450 cyp3a7 substrates|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|oat1/slc22a6 inhibitors|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|alimentary tract and metabolism|sulfur compounds|bsep/abcb11 substrates|bsep/abcb11 inhibitors
minocycline	drugs causing inadvertant photosensitivity|naphthacenes|photosensitizing agents|agents causing muscle toxicity|antibacterials for systemic use|anti bacterial agents|alimentary tract and metabolism|antiinfectives and antiseptics for local oral treatment|antiinfectives for systemic use|oat3/slc22a8 inhibitors|tetracyclines|agents that produce neuromuscular block (indirect)|oat1/slc22a6 inhibitors|stomatological preparations|anti infective agents
guanfacine	amidines|agents producing tachycardia|central alpha 2 adrenergic agonist|adrenergic agents|drugs that are mainly renally excreted|mate 1 inhibitors|antihypertensive agents indicated for hypertension|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|cytochrome p 450 cyp2c19 substrates|oct2 substrates|hypotensive agents|imidazoline receptor agonists|agents that produce hypertension|oct1 substrates|central nervous system depressants|adrenergic alpha 2 receptor agonists|neurotransmitter agents|cardiovascular agents|adrenergic agonists|cytochrome p 450 substrates|adrenergic alpha agonists|mate inhibitors|guanidines|oct1 inhibitors|cytochrome p 450 cyp3a substrates|antihypertensive agents|antiadrenergic agents, centrally acting|central alpha agonists
bethanechol	acids, acyclic|parasympathomemetic (cholinergic) agents|choline esters|amines|trimethyl ammonium compounds|quaternary ammonium compounds|cholinergic agonists|bethanechol compounds|carbamates|ammonium compounds|neurotransmitter agents|muscarinic agonists|nervous system|cholinergic agents|onium compounds|nitrogen compounds|parasympathomimetics|peripheral nervous system agents|autonomic agents
trichlormethiazide	gynecological antiinfectives and antiseptics|amides|membrane transport modulators|sulfonamides|antihypertensive agents|benzothiadiazines|diuretics|heterocyclic compounds, fused ring|hyperglycemia associated agents|sulfones|natriuretic agents|genito urinary system and sex hormones|low ceiling diuretics and potassium sparing agents|sodium chloride symporter inhibitors|sulfur compounds|cardiovascular agents|thiazides
phylloquinone	reversed anticoagulation activity|quinones|micronutrients|drugs that are mainly renally excreted|food|food and beverages|phytol|increased prothrombin activity|blood and blood forming organs|naphthoquinones|vitamins (fat soluble)|warfarin reversal agent|coagulants|hematologic agents|hemostatics|vitamins|diet, food, and nutrition|physiological phenomena|growth substances|diterpenes|terpenes|vitamin k|naphthalenes|fibrin modulating agents
felodipine	membrane transport modulators|cytochrome p 450 cyp2c8 inhibitors|ace inhibitors and calcium channel blockers|calcium regulating hormones and agents|antihypertensive agents indicated for hypertension|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|p glycoprotein inhibitors|hypotensive agents|antiarrhythmic agents|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|calcium channel blockers|selective calcium channel blockers with mainly vascular effects|cardiovascular agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|pyridines|cytochrome p 450 cyp2d6 inhibitors|calcium channel blockers (dihydropyridine)|cytochrome p 450 enzyme inhibitors|vasodilating agents|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|beta blocking agents and calcium channel blockers|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2c9 inhibitors|potential qtc prolonging agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|antihypertensive agents|agents causing hyperkalemia|dihydropyridines|bsep/abcb11 substrates|cytochrome p 450 cyp2c8 inhibitors (strong)|dihydropyridine derivatives
mycophenolic acid	acids, acyclic|antineoplastic and immunomodulating agents|ugt2b7 substrates with a narrow therapeutic index|anti bacterial agents|antituberculosis agents|mycophenolic acid and prodrugs|ugt1a6 substrates with a narrow therapeutic index|drugs that are mainly renally excreted|caproates|ugt2b7 substrates|ugt1a1 substrates|fatty acids|ugt1a9 substrates with a narrow therapeutic index|ugt1a1 substrates with a narrow therapeutic index|fatty acids, volatile|selective immunosuppressants|enzyme inhibitors|anti infective agents|antimetabolite immunosuppressant|immunosuppressive agents|ugt1a6 substrate|antibiotics, antineoplastic|ugt1a9 substrates|narrow therapeutic index drugs|lipids|antibiotics, antitubercular
amlexanox	pyridines|alimentary tract and metabolism|ophthalmic solutions|anti allergic agents|stomatological preparations|decreased histamine release|amines|drugs for obstructive airway diseases
ketoconazole	antifungal agents|cytochrome p 450 cyp2c8 inhibitors|drugs causing inadvertant photosensitivity|cytochrome p 450 cyp2a6 inhibitors (moderate)|cytochrome p 450 cyp3a4 inhibitors (strong)|piperazines|hepatotoxic agents|cytochrome p 450 cyp3a4 substrates|antifungals for dermatological use|p glycoprotein inhibitors|ugt1a1 inhibitors|p glycoprotein substrates|photosensitizing agents|cytochrome p 450 cyp2b6 inhibitors (moderate)|cytochrome p 450 cyp2c8 inhibitors (moderate)|cytochrome p 450 cyp3a5 inhibitors|cytochrome p 450 cyp1a2 inhibitors (moderate)|oatp1b1/slco1b1 inhibitors|antimycotics for systemic use|imidazole derivatives|qtc prolonging agents|steroid synthesis inhibitors|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 cyp2b6 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|antifungals for topical use|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|enzyme inhibitors|imidazole and triazole derivatives|14 alpha demethylase inhibitors|anti infective agents|cytochrome p 450 cyp3a inhibitors|gynecological antiinfectives and antiseptics|cytochrome p 450 cyp1a2 inhibitors|cytochrome p 450 cyp2c9 inhibitors|azole antifungals|potential qtc prolonging agents|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a7 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2d6 inhibitors (moderate)|cytochrome p 450 cyp3a5 inhibitors (strong)|antiinfectives for systemic use|cytochrome p 450 cyp3a7 inhibitors (strong)|agents causing hyperkalemia|dermatologicals|ugt2b7 inhibitors|bsep/abcb11 substrates|cytochrome p 450 cyp2c9 inhibitors (moderate)|cytochrome p 450 cyp2a6 inhibitors|bsep/abcb11 inhibitors|cytochrome p 450 cyp2c8 inhibitors (strong)
irbesartan	ugt1a3 substrates|cytochrome p 450 cyp2c8 inhibitors|spiro compounds|angiotensin ii receptor blockers (arbs), plain|angiotensin 2 receptor blocker|antihypertensive agents indicated for hypertension|cytochrome p 450 cyp2c8 inhibitors (moderate)|hypotensive agents|biphenyl compounds|cardiovascular agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|angiotensin ii receptor blockers (arbs) and diuretics|angiotensin ii type 2 receptor blockers|cytochrome p 450 substrates|angiotensin ii receptor blockers (arbs) and calcium channel blockers|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inhibitors|agents acting on the renin angiotensin system|antihypertensive agents|tetrazoles|agents causing hyperkalemia|benzene derivatives|angiotensin receptor antagonists|cytochrome p 450 cyp2c8 substrates
topotecan	antineoplastic and immunomodulating agents|topoisomerase inhibitors|mate 1 substrates with a narrow therapeutic index|antineoplastic agents|drugs that are mainly renally excreted|mate 1 inhibitors|cytochrome p 450 cyp3a4 inducers|topoisomerase i inhibitors|mate 2 substrates|mate 2 substrates with a narrow therapeutic index|p glycoprotein substrates|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|bcrp/abcg2 substrates|myelosuppressive agents|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|alkaloids|mate substrates|enzyme inhibitors|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a inducers|immunosuppressive agents|mate inhibitors|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|narrow therapeutic index drugs|mate 1 substrates|p glycoprotein substrates with a narrow therapeutic index
probenecid	drugs that are mainly renally excreted|adjuvants, pharmaceutic|cytochrome p 450 cyp2c8 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers|musculo skeletal system|ugt1a1 inhibitors|preparations increasing uric acid excretion|oat3/slc22a8 inhibitors|sulfones|oct2 inhibitors|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|antigout preparations|amides|cytochrome p 450 enzyme inhibitors|sulfonamides|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 cyp2c8 inducers|oat1/slc22a6 inhibitors|uricosuric agents|cytochrome p 450 cyp3a inducers|gynecological antiinfectives and antiseptics|pharmaceutical preparations|cytochrome p 450 cyp2c9 inhibitors|antirheumatic agents|cytochrome p 450 cyp2c19 inhibitors|oct1 inhibitors|compounds used in a research, industrial, or household setting|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|renal agents|genito urinary system and sex hormones|sulfur compounds|pharmaceutic aids
mercaptopurine	antineoplastic and immunomodulating agents|antineoplastic agents|oat3/slc22a8 inhibitors|oat3/slc22a8 substrates with a narrow therapeutic index|myelosuppressive agents|nucleoside metabolic inhibitor|nucleic acid synthesis inhibitors|enzyme inhibitors|sulfhydryl compounds|xanthine derivatives|noxae|heterocyclic compounds, fused ring|immunosuppressive agents|drugs for obstructive airway diseases|antimetabolites|purine analogues|narrow therapeutic index drugs|sulfur compounds|purines|toxic actions|oat3/slc22a8 substrates|thiopurine analogs|immunologic factors
cerulenin	antifungal agents|amides|hypolipidemic agents|lipid regulating agents|anti infective agents|noxae|toxic actions|fatty acid synthesis inhibitors
procainamide	membrane transport modulators|mate 1 substrates with a narrow therapeutic index|agents that produce neuromuscular block (indirect)|drugs that are mainly renally excreted|benzoates|aminobenzoates|mate 2 substrates|mate 2 substrates with a narrow therapeutic index|cholinesterase inhibitors|cytochrome p 450 cyp2d6 substrates with a narrow therapeutic index|oct2 inhibitors|antiarrhythmic agents|voltage gated sodium channel blockers|cardiovascular agents|qtc prolonging agents|amides|para aminobenzoates|agents causing muscle toxicity|antiarrhythmics, class ia|mate substrates|cytochrome p 450 substrates|cytochrome p 450 cyp2d6 substrates|oct1 inhibitors|antiarrhythmics, class i|benzamides and benzamide derivatives|highest risk qtc prolonging agents|acids, carbocyclic|narrow therapeutic index drugs|mate 1 substrates|drugs that are mainly renally excreted with a narrow therapeutic index|benzene derivatives|cardiac therapy|sodium channel blockers|oct2 substrates with a narrow therapeutic index
tolterodine	propanolamines|agents producing tachycardia|genitourinary smooth muscle relaxants|urological agents|drugs that are mainly renally excreted|amines|cytochrome p 450 cyp3a4 substrates|cresols|cytochrome p 450 cyp2c19 substrates|anticholinergic agents|drugs for urinary frequency and incontinence|neurotransmitter agents|benzhydryl compounds|qtc prolonging agents|urologicals|cholinergic agents|phenols|propanols|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|potential qtc prolonging agents|muscarinic antagonists|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|genito urinary system and sex hormones|amino alcohols|benzene derivatives|alcohols
selegiline	cytochrome p 450 cyp2b6 inhibitors (strength unknown)|central nervous system agents|anti dyskinesia agents|cytochrome p 450 cyp2a6 substrates|amines|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|cytochrome p 450 cyp2d6 inhibitors (weak)|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|cytochrome p 450 cyp2c19 substrates|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|cytochrome p 450 cyp2b6 substrates|protective agents|cytochrome p 450 cyp2e1 inhibitors|hypotensive agents|agents that produce hypertension|serotonin modulators|cytochrome p 450 cyp2a6 inhibitors (strength unknown)|central nervous system depressants|antidepressive agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 cyp2b6 inhibitors|agents that reduce seizure threshold|nervous system|cytochrome p 450 enzyme inhibitors|anti parkinson drugs|cytochrome p 450 substrates|monoamine oxidase b inhibitors|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|ethylamines|monoamine oxidase a inhibitors  for interaction with monoamine oxidase a substrates|monoamine oxidase inhibitors|cytochrome p 450 cyp1a2 inhibitors|cytochrome p 450 cyp2d6 substrates|neuroprotective agents|compounds used in a research, industrial, or household setting|cytochrome p 450 cyp3a substrates|psychotropic drugs|dopamine agents|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|cytochrome p 450 cyp1a2 substrates|cytochrome p 450 cyp2a6 inhibitors|phenethylamines|cytochrome p 450 cyp2c8 substrates
fenofibrate	acids, acyclic|cytochrome p 450 cyp2c8 inhibitors|drugs that are mainly renally excreted|lipid regulating agents|peroxisome proliferator receptor alpha agonist|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|butyrates|cytochrome p 450 cyp2a6 inhibitors (weak)|fatty acids|cytochrome p 450 cyp2c19 inhibitors (weak)|lipid modifying agents|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|ethers|isobutyrates|hypolipidemic agents indicated for hyperlipidemia|phenols|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|fatty acids, volatile|cytochrome p 450 substrates|fribic acid derivatives|phenyl ethers|noxae|cytochrome p 450 cyp2c9 inhibitors|lipid modifying agents, plain|ketones|cytochrome p 450 cyp2c19 inhibitors|hypolipidemic agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2c8 inhibitors (weak)|ugt1a9 substrates|benzophenones|peroxisome proliferator activated receptor alpha agonists|bsep/abcb11 substrates|lipids|cytochrome p 450 cyp2a6 inhibitors|benzene derivatives|fibric acids|toxic actions|cytochrome p 450 cyp3a4 substrates (strength unknown)
thalidomide	drugs causing inadvertant photosensitivity|angiogenesis inhibitors|antineoplastic and immunomodulating agents|anti bacterial agents|phthalimides|antineoplastic agents|leprostatic agents|angiogenesis modulating agents|immunomodulatory agents|photosensitizing agents|cytochrome p 450 cyp2c19 substrates|hypotensive agents|cytochrome p 450 cyp3a5 inducers (strength unknown)|central nervous system depressants|myelosuppressive agents|isoindoles|phthalic acids|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|growth inhibitors|cytochrome p 450 substrates|teratogens|piperidines|cytochrome p 450 cyp2c9 substrates|anti infective agents|cytochrome p 450 cyp3a inducers|noxae|heterocyclic compounds, fused ring|immunosuppressive agents|cytochrome p 450 cyp2c19 inhibitors|growth substances|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 enzyme inducers|cardiotoxic antineoplastic agents|acids, carbocyclic|piperidones|decreased immunologically active molecule activity|cytochrome p 450 cyp3a5 inducers|toxic actions|imides|immunologic factors
melphalan	amino acids, peptides, and proteins|antineoplastic and immunomodulating agents|alkylating drugs|amino acids, cyclic|antineoplastic agents|phenylalanine|amino acids, aromatic|nitrogen mustard analogues|amino acids|alkylating activity|myelosuppressive agents|mustard compounds|nitrogen mustard compounds|myeloablative agonists|antineoplastic agents, alkylating|noxae|amino acids, essential|immunosuppressive agents|hydrocarbons, halogenated|narrow therapeutic index drugs|toxic actions|immunologic factors
memantine	psychoanaleptics|central nervous system agents|anti dyskinesia agents|drugs that are mainly renally excreted|n methyl d aspartate receptor antagonist|cholinesterase inhibitors|cytochrome p 450 cyp2a6 inhibitors (weak)|oct2 substrates|cytochrome p 450 cyp2c19 inhibitors (weak)|neurotransmitter agents|nmda receptor antagonists|miscellaneous central nervous system agents|cytochrome p 450 cyp2b6 inhibitors|nervous system|excitatory amino acid antagonists|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2b6 inhibitors (strong)|anti parkinson drugs|cytochrome p 450 cyp2c19 inhibitors|dopamine agents|anti dementia drugs|cytochrome p 450 cyp2a6 inhibitors
gatifloxacin	topoisomerase inhibitors|antibacterials for systemic use|anti bacterial agents|ophthalmologicals|hypoglycemia associated agents|ophthalmic solutions|pharmaceutical solutions|quinolone antimicrobial|fluoroquinolones|cytochrome p 450 cyp1a2 inhibitors (moderate)|quinolines|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|quinolones|enzyme inhibitors|solutions|anti infective agents|pharmaceutical preparations|potential qtc prolonging agents|cytochrome p 450 cyp1a2 inhibitors|heterocyclic compounds, fused ring|compounds used in a research, industrial, or household setting|antiinfectives for systemic use|topoisomerase ii inhibitors|sensory organs
rifampicin	cytochrome p 450 cyp1a2 inducers (moderate)|cytochrome p 450 cyp2c8 inhibitors|cytochrome p 450 cyp3a7 inducers (strong)|oatp1b3 substrates|cytochrome p 450 cyp2c9 inducers (moderate)|anti bacterial agents|lactams|oatp1b3 inhibitors|antituberculosis agents|rifamycin antibacterial|cytochrome p 450 cyp2e1 inducers (strength unknown)|leprostatic agents|hepatotoxic agents|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp2a6 inducers (moderate)|ugt1a1 inducers|cytochrome p 450 cyp1a2 inducers|ugt1a9 inducers|cytochrome p 450 cyp2a6 inducers|oat3/slc22a8 inhibitors|antimycobacterials|cytochrome p 450 cyp3a inducers (strong)|cytochrome p 450 cyp2b6 inducers (moderate)|cytochrome p 450 cyp2c19 inducers|cytochrome p 450 cyp2c8 inducers (strong)|cytochrome p 450 cyp1a2 inducers (strong)|p glycoprotein inducers|ugt1a9 inhibitors|oatp1b1/slco1b1 inhibitors|cytochrome p 450 cyp2b6 inducers|cytochrome p 450 cyp3a4 inducers (strong)|amides|cytochrome p 450 enzyme inhibitors|nucleic acid synthesis inhibitors|cytochrome p 450 cyp2c8 inducers|cytochrome p 450 cyp2c19 inducers (strong)|cytochrome p 450 substrates|enzyme inhibitors|oat1/slc22a6 inhibitors|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|anti infective agents|cytochrome p 450 cyp3a inducers|lactams, macrocyclic|chemically induced disorders|heterocyclic compounds, fused ring|cytochrome p 450 cyp2e1 inducers|cytochrome p 450 cyp3a substrates|antiinfectives for systemic use|cytochrome p 450 enzyme inducers|drugs for treatment of tuberculosis|cytochrome p 450 cyp2c19 inducers (moderate)|bsep/abcb11 inhibitors|cytochrome p 450 cyp3a7 inducers|cytochrome p 450 cyp2c9 inducers|cytochrome p 450 cyp3a5 inducers|antibiotics, antitubercular|cytochrome p 450 cyp3a7 inducers (weak)|rifamycins|cytochrome p 450 cyp3a5 inducers (strong)
rfp	cytochrome p 450 cyp1a2 inducers (moderate)|cytochrome p 450 cyp2c8 inhibitors|cytochrome p 450 cyp3a7 inducers (strong)|oatp1b3 substrates|cytochrome p 450 cyp2c9 inducers (moderate)|anti bacterial agents|lactams|oatp1b3 inhibitors|antituberculosis agents|rifamycin antibacterial|cytochrome p 450 cyp2e1 inducers (strength unknown)|leprostatic agents|hepatotoxic agents|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp2a6 inducers (moderate)|ugt1a1 inducers|cytochrome p 450 cyp1a2 inducers|ugt1a9 inducers|cytochrome p 450 cyp2a6 inducers|oat3/slc22a8 inhibitors|antimycobacterials|cytochrome p 450 cyp3a inducers (strong)|cytochrome p 450 cyp2b6 inducers (moderate)|cytochrome p 450 cyp2c19 inducers|cytochrome p 450 cyp2c8 inducers (strong)|cytochrome p 450 cyp1a2 inducers (strong)|p glycoprotein inducers|ugt1a9 inhibitors|oatp1b1/slco1b1 inhibitors|cytochrome p 450 cyp2b6 inducers|cytochrome p 450 cyp3a4 inducers (strong)|amides|cytochrome p 450 enzyme inhibitors|nucleic acid synthesis inhibitors|cytochrome p 450 cyp2c8 inducers|cytochrome p 450 cyp2c19 inducers (strong)|cytochrome p 450 substrates|enzyme inhibitors|oat1/slc22a6 inhibitors|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|anti infective agents|cytochrome p 450 cyp3a inducers|lactams, macrocyclic|chemically induced disorders|heterocyclic compounds, fused ring|cytochrome p 450 cyp2e1 inducers|cytochrome p 450 cyp3a substrates|antiinfectives for systemic use|cytochrome p 450 enzyme inducers|drugs for treatment of tuberculosis|cytochrome p 450 cyp2c19 inducers (moderate)|bsep/abcb11 inhibitors|cytochrome p 450 cyp3a7 inducers|cytochrome p 450 cyp2c9 inducers|cytochrome p 450 cyp3a5 inducers|antibiotics, antitubercular|cytochrome p 450 cyp3a7 inducers (weak)|rifamycins|cytochrome p 450 cyp3a5 inducers (strong)
fluocinonide	hormones, hormone substitutes, and hormone antagonists|adrenal cortex hormones|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|corticosteroids, potent (group iii)|corticosteroids|cytochrome p 450 cyp3a5 inducers (strength unknown)|steroids, fluorinated|anti inflammatory agents|pregnanes|anti allergic agents|cytochrome p 450 substrates|cytochrome p 450 cyp3a inducers|corticosteroid hormone receptor agonists|immunosuppressive agents|cytochrome p 450 cyp3a substrates|glucocorticoids|cytochrome p 450 cyp3a4 inducers (strength unknown)|dermatologicals|cytochrome p 450 enzyme inducers|steroids|corticosteroids, dermatological preparations|hormones|thyroxine binding globulin inhibitors|pregnadienes|cytochrome p 450 cyp3a5 inducers
ibuprofen	amino acids, peptides, and proteins|ugt1a3 substrates|anti inflammatory agents, non steroidal|cox 1 inhibitors|antiinflammatory preparations, non steroids for topical use|central nervous system agents|sensory system agents|drugs that are mainly renally excreted|other nonsteroidal anti inflammatory agents|experimental unapproved treatments for covid 19|ugt2b7 substrates|cytochrome p 450 cyp3a4 substrates|cox 2 inhibitors|nephrotoxic agents|p glycoprotein inhibitors|p glycoprotein substrates|antiinflammatory products for vaginal administration|cytochrome p 450 cyp2c19 substrates|oat3/slc22a8 inhibitors|analgesics|amino acids|agents that produce hypertension|non cox 2 selective nsaids|antiinflammatory and antirheumatic products, non steroids|nervous system|phenylpropionates|throat preparations|cytochrome p 450 enzyme inhibitors|agents causing angioedema|topical products for joint and muscular pain|anti inflammatory agents|amino acids, basic|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|oat1/slc22a6 inhibitors|analgesics, non narcotic|pharmaceutical preparations|antirheumatic agents|amino acids, essential|cytochrome p 450 cyp3a substrates|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|propionates|ugt1a9 substrates|amino acids, diamino|acids, carbocyclic|ugt1a1 substrates|cytochrome p 450 cyp2c8 substrates|cyclooxygenase inhibitors
novobiocin	benzopyrans|carbohydrates|nucleic acid synthesis inhibitors|anti bacterial agents|heterocyclic compounds, fused ring|aminocoumarins|oat3/slc22a8 inhibitors|oatp1b3 inhibitors|bcrp/abcg2 inhibitors|pyrans|glycosides|oatp1b1/slco1b1 inhibitors|enzyme inhibitors|oat1/slc22a6 inhibitors|anti infective agents|coumarins
benzylpenicillin	antibacterials for systemic use|anti bacterial agents|beta lactamase sensitive penicillins|penicillin g|ophthalmologicals|beta lactam antibacterials|oat3/slc22a8 inhibitors|natural penicillins|beta lactams|oatp1b1/slco1b1 substrates|amides|oat1/slc22a6 inhibitors|anti infective agents|heterocyclic compounds, fused ring|antiinfectives for systemic use|sulfur compounds|sensory organs|penicillins|lactams|oat3/slc22a8 substrates
nitrendipine	membrane transport modulators|ace inhibitors and calcium channel blockers|calcium regulating hormones and agents|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|p glycoprotein inhibitors|hypotensive agents|antiarrhythmic agents|calcium channel blockers|selective calcium channel blockers with mainly vascular effects|cardiovascular agents|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|pyridines|cytochrome p 450 enzyme inhibitors|vasodilating agents|cytochrome p 450 substrates|cytochrome p 450 cyp3a inhibitors|potential qtc prolonging agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|antihypertensive agents|agents causing hyperkalemia|dihydropyridines|bsep/abcb11 substrates|dihydropyridine derivatives
tocainide	amides|aniline compounds|cytochrome p 450 cyp1a2 inhibitors|cytochrome p 450 enzyme inhibitors|membrane transport modulators|anilides|antiarrhythmics, class i|antiarrhythmics, class ib|sodium channel blockers|cytochrome p 450 cyp1a2 inhibitors (weak)|cytochrome p 450 cyp1a2 substrates|cytochrome p 450 substrates|antiarrhythmic agents|voltage gated sodium channel blockers|cardiac therapy|cardiovascular agents|amines
praziquantel	cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp2c19 substrates|heterocyclic compounds, fused ring|cytochrome p 450 cyp1a2 substrates|cytochrome p 450 cyp3a7 substrates|cytochrome p 450 substrates|antitrematodals|quinoline derivatives and related substances|anthelmintics|antihelminthic|anti infective agents|isoquinolines|antiparasitic agents|antiparasitic products, insecticides and repellents
norfloxacin	topoisomerase inhibitors|antibacterials for systemic use|anti bacterial agents|ophthalmologicals|cytochrome p 450 cyp3a7 inhibitors (strength unknown)|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|quinolone antimicrobial|fluoroquinolones|quinolines|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|cytochrome p 450 cyp3a4 inhibitors|quinolones|enzyme inhibitors|oat1/slc22a6 inhibitors|anti infective agents|cytochrome p 450 cyp3a inhibitors|chemically induced disorders|cytochrome p 450 cyp1a2 inhibitors|potential qtc prolonging agents|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a7 inhibitors|antiinfectives for systemic use|topoisomerase ii inhibitors|sensory organs
amoxicillin	cytochrome p 450 cyp2c8 inhibitors|antibacterials for systemic use|anti bacterial agents|penicillin g|drugs that are mainly renally excreted|beta lactam antibacterials|penicillins with extended spectrum|beta lactams|drugs for peptic ulcer and gastro oesophageal reflux disease (gord)|drugs for acid related disorders|amides|aminopenicillins|cytochrome p 450 enzyme inhibitors|oat1/slc22a6 inhibitors|anti infective agents|heterocyclic compounds, fused ring|antiinfectives for systemic use|cytochrome p 450 cyp2c8 inhibitors (weak)|alimentary tract and metabolism|sulfur compounds|penicillins|lactams
azlocillin	amides|agents that reduce seizure threshold|penicillins with extended spectrum|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|heterocyclic compounds, fused ring|penicillin g|sulfur compounds|penicillins|beta lactams|anti infective agents|beta lactam antibacterials|lactams
oxybutynin	agents producing tachycardia|cytochrome p 450 cyp2c8 inhibitors|urological agents|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp2c8 inhibitors (moderate)|anticholinergic agents|drugs for urinary frequency and incontinence|neurotransmitter agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 cyp2d6 inhibitors|urologicals|parasympatholytics|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|cytochrome p 450 cyp3a inhibitors|muscarinic antagonists|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|hydroxy acids|peripheral nervous system agents|acids, carbocyclic|genito urinary system and sex hormones|autonomic agents
isoprenaline	agents producing tachycardia|anti asthmatic agents|adrenergic agents|catechols|amines|adrenergic beta 2 receptor agonists|protective agents|agents that produce hypertension|neurotransmitter agents|cardiovascular agents|cardiac stimulants excl. cardiac glycosides|sympathomimetics|phenols|adrenergic agonists|cardiac therapy|adrenergics, inhalants|adrenergic beta agonists|catecholamines|drugs for obstructive airway diseases|non selective beta adrenergic agonists|respiratory system agents|ethanolamines|compounds used in a research, industrial, or household setting|peripheral nervous system agents|bronchodilator agents|cardiotonic agents|adrenergics for systemic use|adrenergic and dopaminergic agents|amino alcohols|autonomic agents|benzene derivatives|alcohols
melatonin	hormones, hormone substitutes, and hormone antagonists|hypnotics and sedatives|central nervous system agents|tryptamines|psycholeptics|amines|indoles|melatonin, antagonists & inhibitors|cytochrome p 450 cyp2c19 substrates|oat3/slc22a8 inhibitors|protective agents|central nervous system depressants|nervous system|melatonin, agonists|cytochrome p 450 substrates|melatonin receptor agonists|biogenic monoamines|cytochrome p 450 cyp2c9 substrates|heterocyclic compounds, fused ring|antioxidants|compounds used in a research, industrial, or household setting|hormones|cytochrome p 450 cyp1a2 substrates|biogenic amines
glipizide	cytochrome p 450 cyp3a substrates|drugs used in diabetes|alimentary tract and metabolism|sulfones|sulfonylureas|sulfur compounds|cytochrome p 450 substrates|bsep/abcb11 substrates|drugs that are mainly renally excreted|blood glucose lowering agents|cytochrome p 450 cyp2c9 substrates|ugt1a1 substrates|hypoglycemia associated agents
promethazine	phenothiazines|agents producing tachycardia|drugs causing inadvertant photosensitivity|drugs that are mainly renally excreted|acid reducers|amines|antipruritics, incl. antihistamines, anesthetics, etc.|antihistamines for topical use|histamine agents|p glycoprotein inhibitors|photosensitizing agents|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|anticholinergic agents|cytochrome p 450 cyp2b6 substrates|miscellaneous anxiolytics sedatives and hypnotics|antipsychotic agents|serotonin modulators|central nervous system depressants|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|antihistamines for systemic use|neurotransmitter agents|antidepressive agents|qtc prolonging agents|propylamines|cytochrome p 450 cyp2d6 inhibitors|agents that reduce seizure threshold|cytochrome p 450 enzyme inhibitors|antidotes|phenothiazine derivatives|anti allergic agents|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 inhibitors|dopamine d2 receptor antagonists|potential qtc prolonging agents|heterocyclic compounds, fused ring|muscarinic antagonists|cytochrome p 450 cyp2d6 substrates|neurotoxic agents|antipruritics|dermatologicals|sulfur compounds|histamine h2 antagonists|histamine antagonists|dopamine antagonists|histamine h1 antagonists
fludarabine	carbohydrates|nucleotides|antineoplastic and immunomodulating agents|ribonucleotides|antineoplastic agents|nucleosides|adenine nucleotides|toxic actions|myelosuppressive agents|nucleoside metabolic inhibitor|purine nucleotides|ribonucleosides|nucleic acid synthesis inhibitors|myeloablative agonists|glycosides|enzyme inhibitors|nucleic acids, nucleotides, and nucleosides|noxae|dna (cytosine 5 ) methyltransferases, antagonists & inhibitors|heterocyclic compounds, fused ring|immunosuppressive agents|purine nucleosides|antimetabolites|cardiotoxic antineoplastic agents|purine analogues|narrow therapeutic index drugs|purines|arabinonucleotides|arabinonucleosides|immunologic factors
perhexiline	membrane transport modulators|calcium regulating hormones and agents|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|cytochrome p 450 cyp2b6 substrates|antiarrhythmic agents|calcium channel blockers|cardiovascular agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|vasodilating agents|cytochrome p 450 substrates|piperidines|potential qtc prolonging agents|cytochrome p 450 cyp2d6 substrates|non selective calcium channel blockers|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2d6 inhibitors (moderate)|agents causing hyperkalemia
diphenhydramine	hypnotics and sedatives|agents producing tachycardia|anesthetics, local|drugs causing inadvertant photosensitivity|ethanolamine derivatives|central nervous system agents|amines|antipruritics, incl. antihistamines, anesthetics, etc.|antihistamines for topical use|histamine agents|photosensitizing agents|cytochrome p 450 cyp2c19 substrates|serotonergic drugs shown to increase risk of serotonin syndrome|anticholinergic agents|oct2 inhibitors|central nervous system depressants|antihistamines for systemic use|benzhydryl compounds|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|sleep aids, pharmaceutical|cytochrome p 450 enzyme inhibitors|gastrointestinal agents|anti allergic agents|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|ethylamines|anesthetics|potential qtc prolonging agents|muscarinic antagonists|cytochrome p 450 cyp2d6 substrates|dermatologicals|first generation antihistamines|antiemetics|benzene derivatives|histamine antagonists|aminoalkyl ethers|histamine h1 antagonists
atorvastatin	ugt1a3 substrates|cytochrome p 450 cyp2c8 inhibitors|oatp1b3 substrates|hydroxymethylglutaryl coa reductase inhibitors|lipid regulating agents|cytochrome p 450 cyp2b6 inducers (strength unknown)|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|heptanoic acids|p glycoprotein substrates|fatty acids|lipid modifying agents|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|oatp1b1/slco1b1 inhibitors|hypolipidemic agents indicated for hyperlipidemia|cytochrome p 450 cyp2b6 inducers|cytochrome p 450 cyp3a7 substrates|cytochrome p 450 cyp2d6 inhibitors|oatp1b1/slco1b1 substrates|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp2c9 inhibitors|lipid modifying agents, plain|cytochrome p 450 cyp2c19 inhibitors|hypolipidemic agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 enzyme inducers|bsep/abcb11 substrates|lipids|anticholesteremic agents|ugt1a1 substrates|toxic actions|cytochrome p 450 cyp2c8 substrates
etidronic acid	musculo skeletal system|organophosphonates|organophosphorus compounds|drugs for treatment of bone diseases|drugs affecting bone structure and mineralization|bisphosphonates|bone density conservation agents
tegaserod	cytochrome p 450 cyp2c8 inhibitors|serotonin receptor antagonists|drugs for constipation|cytochrome p 450 cyp2e1 inhibitors (weak)|p glycoprotein substrates|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|cytochrome p 450 cyp2e1 inhibitors|laxatives|central nervous system depressants|antidepressive agents|bcrp/abcg2 substrates|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|gastrointestinal agents|cytochrome p 450 substrates|serotonin 5 ht2 receptor antagonists|cytochrome p 450 cyp1a2 inhibitors|heterocyclic compounds, fused ring|serotonin 5 ht2c receptor antagonists|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp2d6 inhibitors (moderate)|serotonin 5 ht2a receptor antagonists|cytochrome p 450 cyp2c8 inhibitors (weak)|alimentary tract and metabolism
vigabatrin	acids, acyclic|central nervous system agents|fatty acid derivatives|anti epileptic agent|butyrates|fatty acids|cytochrome p 450 cyp2c9 inducers (strength unknown)|anticonvulsants|central nervous system depressants|neurotransmitter agents|miscellaneous anticonvulsants|nervous system|gaba agents|enzyme inhibitors|cytochrome p 450 enzyme inducers|lipids|cytochrome p 450 cyp2c9 inducers|aminobutyrates
diphenoxylate	peripheral nervous system agents|alimentary tract and metabolism|central nervous system agents|analgesics|gastrointestinal agents|sensory system agents|serotonergic drugs shown to increase risk of serotonin syndrome|opioids|piperidines|central nervous system depressants|isonipecotic acids|antipropulsives|antidiarrheals|antidiarrheals, intestinal antiinflammatory/antiinfective agents
orlistat	anti obesity agents|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|alimentary tract and metabolism|intestinal lipase inhibitor|lipase inhibitors|peripherally acting antiobesity products|enzyme inhibitors|lipid regulating agents|cytochrome p 450 cyp3a inducers|lactones|cytochrome p 450 cyp3a4 inducers|miscellaneous gi drugs|antiobesity preparations, excl. diet products
emedastine	histamine agents|qtc prolonging agents|moderate risk qtc prolonging agents|anti allergic agents|sensory organs|ophthalmologicals|histamine h1 inhibitors|neurotransmitter agents|histamine antagonists|decongestants and antiallergics|histamine h1 antagonists|heterocyclic compounds, fused ring
pilocarpine	parasympathomemetic (cholinergic) agents|miotics|ophthalmologicals|cholinergic receptor agonist|cholinergic agonists|cytochrome p 450 cyp2a6 inhibitors (strong)|neurotransmitter agents|antiglaucoma preparations and miotics|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|muscarinic agonists|nervous system|cholinergic agents|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|alkaloids|cytochrome p 450 cyp3a inhibitors|parasympathomimetics|peripheral nervous system agents|sensory organs|cytochrome p 450 cyp2a6 inhibitors|autonomic agents
benzocaine	anesthetics, local|sensory system agents|central nervous system agents|benzoates|aminobenzoates|cell mediated immunity|antipruritics, incl. antihistamines, anesthetics, etc.|antipruritics and local anesthetics|p glycoprotein inhibitors|central nervous system depressants|nervous system|throat preparations|esters of aminobenzoic acid|para aminobenzoates|anesthetics for topical use|vasoprotectives|anesthetics|standardized chemical allergen|local anesthetics (ester)|increased histamine release|methemoglobinemia associated agents|peripheral nervous system agents|dermatologicals|acids, carbocyclic|agents for treatment of hemorrhoids and anal fissures for topical use|benzene derivatives
primaquine	antibiotics for pneumocystis pneumonia|cytochrome p 450 cyp1a2 inducers (strength unknown)|aminoquinolines|cytochrome p 450 cyp3a4 substrates|antiparasitic products, insecticides and repellents|p glycoprotein inhibitors|cytochrome p 450 cyp1a2 inducers|cytochrome p 450 cyp2d6 inhibitors (weak)|quinolines|antiparasitic agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a4 inhibitors (moderate)|moderate risk qtc prolonging agents|cytochrome p 450 substrates|antimalarials|anti infective agents|cytochrome p 450 cyp3a inhibitors|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2d6 inhibitors (moderate)|methemoglobinemia associated agents|cytochrome p 450 enzyme inducers|cytochrome p 450 cyp1a2 substrates|antiprotozoals
iloprost	antiplatelet agents|prostaglandins, synthetic|fibrinolytic agents|fatty acids|hypotensive agents|cardiovascular agents|blood and blood forming organs|prostacyclin analogues|autacoids|prostaglandins|anticoagulants|agents causing muscle toxicity|vasodilating agents|hematologic agents|platelet aggregation inhibitors excl. heparin|biological factors|eicosanoids|inflammation mediators|lipids|fatty acids, unsaturated
pentolinium	cholinergic agents|nicotinic antagonists|antihypertensive agents|peripheral nervous system agents|anticholinergic agents|ganglion blockers|autonomic agents|neurotransmitter agents|pyrrolidines|cardiovascular agents
butenafine	antifungal agents|dermatologicals|antifungals for topical use|benzyl compounds|benzylamines|anti infective agents|benzene derivatives|benzylamine antifungal|amines|antifungals for dermatological use
ouabain	strophanthins|carbohydrates|oatp1b3 substrates|cardenolides|cardiac glycosides|fused ring compounds|oat3/slc22a8 inhibitors|protective agents|oatp1b1/slco1b1 inhibitors|cardiovascular agents|oatp1b1/slco1b1 substrates|strophanthus glycosides|glycosides|enzyme inhibitors|compounds used in a research, industrial, or household setting|steroids|cardiotonic agents|cardiac therapy|cardanolides
dmso	miscellaneous therapeutic agents|drugs that are mainly renally excreted|musculo skeletal system|cryoprotective agents|solvents|protective agents|free radical scavengers|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 cyp2d6 inhibitors|urologicals|topical products for joint and muscular pain|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 cyp3a inhibitors|antioxidants|cytochrome p 450 cyp2c19 inhibitors|compounds used in a research, industrial, or household setting|genito urinary system and sex hormones|sulfur compounds|sulfoxides
fluvastatin	ugt1a3 substrates|cytochrome p 450 cyp2c8 inhibitors|oatp1b3 substrates|hydroxymethylglutaryl coa reductase inhibitors|lipid regulating agents|cytochrome p 450 cyp2b6 inducers (strength unknown)|ugt2b7 substrates|cytochrome p 450 cyp3a4 substrates|heptanoic acids|indoles|cytochrome p 450 cyp2c8 inhibitors (moderate)|fatty acids|lipid modifying agents|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|oatp1b1/slco1b1 inhibitors|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|hypolipidemic agents indicated for hyperlipidemia|cytochrome p 450 cyp2b6 inducers|oatp1b1/slco1b1 substrates|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2c9 inhibitors|lipid modifying agents, plain|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp2c19 inhibitors|hypolipidemic agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 enzyme inducers|lipids|ugt1a1 substrates|cytochrome p 450 cyp2c8 substrates
leflunomide	cytochrome p 450 enzyme inhibitors|antineoplastic and immunomodulating agents|agents causing muscle toxicity|adjuvants|selective immunosuppressants|disease modifying antirheumatic agents|immunosuppressive agents|cytochrome p 450 cyp1a2 substrates|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|isoxazoles|bcrp/abcg2 substrates|cytochrome p 450 cyp2c9 inhibitors|antirheumatic agents|immunologic factors
rosuvastatin	drugs used in diabetes|hydroxymethylglutaryl coa reductase inhibitors|fluorobenzenes|pyrimidines|lipid regulating agents|cytochrome p 450 cyp3a4 substrates|oat3/slc22a8 inhibitors|cytochrome p 450 cyp3a5 inhibitors|sulfones|hydrocarbons, fluorinated|lipid modifying agents|oatp1b1/slco1b1 inhibitors|bcrp/abcg2 substrates|hypolipidemic agents indicated for hyperlipidemia|oatp1b1/slco1b1 substrates|amides|cytochrome p 450 enzyme inhibitors|sulfonamides|agents causing muscle toxicity|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inhibitors|gynecological antiinfectives and antiseptics|noxae|lipid modifying agents, plain|hypolipidemic agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|hydrocarbons, halogenated|alimentary tract and metabolism|genito urinary system and sex hormones|sulfur compounds|bsep/abcb11 substrates|anticholesteremic agents|benzene derivatives|toxic actions|oat3/slc22a8 substrates|cytochrome p 450 cyp3a4 substrates (strength unknown)
flucytosine	antifungal agents|nucleoside analog antifungal|drugs causing inadvertant photosensitivity|pyrimidines|drugs that are mainly renally excreted|antifungals for dermatological use|photosensitizing agents|myelosuppressive agents|antimycotics for systemic use|pyrimidinones|cytosine|antifungals for topical use|anti infective agents|noxae|immunosuppressive agents|antiinfectives for systemic use|antimetabolites|dermatologicals|fluorouracil and prodrugs|toxic actions
pimozide	cytochrome p 450 cyp3a7 substrates with a narrow therapeutic index|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|central nervous system agents|tranquilizing agents|anti dyskinesia agents|psycholeptics|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|cytochrome p 450 cyp2d6 substrates with a narrow therapeutic index|antipsychotic agents|central nervous system depressants|neurotransmitter agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|nervous system|agents that reduce seizure threshold|cytochrome p 450 enzyme inhibitors|benzimidazoles|cytochrome p 450 cyp3a4 inhibitors|antipsychotic agents (first generation [typical])|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|miscellaneous antipsychotics|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|neurotoxic agents|psychotropic drugs|dopamine agents|highest risk qtc prolonging agents|cytochrome p 450 cyp1a2 substrates|diphenylbutylpiperidine derivatives|narrow therapeutic index drugs|dopamine antagonists|cytochrome p 450 cyp3a4 substrates (strength unknown)
capecitabine	carbohydrates|antineoplastic and immunomodulating agents|pyrimidines|antineoplastic agents|drugs that are mainly renally excreted|nucleosides|deoxycytidine|myelosuppressive agents|pyrimidinones|nucleoside metabolic inhibitor|ribonucleosides|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2c9 inhibitors (strong)|nucleic acid synthesis inhibitors|cytochrome p 450 substrates|glycosides|cytochrome p 450 cyp2c9 substrates|nucleic acids, nucleotides, and nucleosides|noxae|cytochrome p 450 cyp2c9 inhibitors|immunosuppressive agents|pyrimidine analogues|cytidine deaminase substrates|deoxyribonucleosides|pyrimidine nucleosides|fluoropyrimidines|antimetabolites|cardiotoxic antineoplastic agents|narrow therapeutic index drugs|cytochrome p 450 cyp2c9 substrates with a narrow therapeutic index|fluorouracil and prodrugs|toxic actions
mepacrine	aminoacridines|antinematodal agents|antiplatyhelmintic agents|cytochrome p 450 cyp3a4 substrates|antiparasitic products, insecticides and repellents|p glycoprotein inhibitors|oct2 inhibitors|acridines|antiparasitic agents|cytochrome p 450 substrates|enzyme inhibitors|anti infective agents|antimalarials|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|anticestodal agents|antiprotozoals
sertraline	membrane transport modulators|drugs causing inadvertant photosensitivity|cytochrome p 450 cyp2b6 inhibitors (strength unknown)|psychoanaleptics|central nervous system agents|amines|cytochrome p 450 cyp3a4 substrates|hypoglycemia associated agents|cytochrome p 450 cyp2c19 inhibitors (moderate)|p glycoprotein inhibitors|cytochrome p 450 cyp2d6 inhibitors (weak)|photosensitizing agents|selective serotonin reuptake inhibitors|cytochrome p 450 cyp2c19 substrates|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|cytochrome p 450 cyp2b6 substrates|serotonin modulators|central nervous system depressants|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|neurotransmitter agents|antidepressive agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|monoamine oxidase a substrates|cytochrome p 450 cyp2b6 inhibitors|agents that reduce seizure threshold|nervous system|cytochrome p 450 enzyme inhibitors|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|neurotransmitter uptake inhibitors|cytochrome p 450 cyp2e1 substrates|psychotropic drugs|naphthalenes
sibutramine	appetite depressants|agents producing tachycardia|central nervous system agents|centrally acting antiobesity products|drugs that are mainly renally excreted|cytochrome p 450 cyp3a4 substrates|selective serotonin reuptake inhibitors|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|cycloparaffins|serotonin modulators|norepinephrine uptake inhibitors|central nervous system depressants|antidepressive agents|serotonin and noradrenaline reuptake inhibitors|antiobesity preparations, excl. diet products|dopamine uptake inhibitors|anti obesity agents|cytochrome p 450 substrates|norepinephrine, serotonin, and dopamine reuptake inhibitor anorectic|appetite suppression|stimulants|cytochrome p 450 cyp3a substrates|combined inhibitors of serotonin/norepinephrine reuptake|psychotropic drugs|alimentary tract and metabolism
levocabastine	antiallergic agents, excl. corticosteroids|histamine agents|qtc prolonging agents|nasal preparations|anti allergic agents|sensory organs|histamine h1 antagonists, non sedating|ophthalmologicals|central nervous system depressants|neurotransmitter agents|histamine antagonists|potential qtc prolonging agents|decongestants and antiallergics|histamine h1 antagonists
miconazole	antifungal agents|cytochrome p 450 cyp2e1 inhibitors (strong)|hormones, hormone substitutes, and hormone antagonists|hormone antagonists|cytochrome p 450 cyp2c8 inhibitors|cytochrome p 450 cyp2b6 inhibitors (strength unknown)|antifungal agents (vaginal)|intestinal antiinfectives|stomatological preparations|antifungals for dermatological use|p glycoprotein inhibitors|cytochrome p 450 cyp2e1 inhibitors|cytochrome p 450 cyp2a6 inhibitors (strong)|imidazole derivatives|steroid synthesis inhibitors|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 cyp2b6 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2c9 inhibitors (strong)|imidazoles|antiinfectives and antiseptics for local oral treatment|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a4 inhibitors (moderate)|antifungals for topical use|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|enzyme inhibitors|imidazole and triazole derivatives|14 alpha demethylase inhibitors|anti infective agents|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp3a inhibitors|gynecological antiinfectives and antiseptics|chemically induced disorders|cytochrome p 450 cyp2c19 inhibitors (strong)|cytochrome p 450 cyp2c9 inhibitors|azole antifungals|otologicals|cytochrome p 450 cyp2c19 inhibitors|dermatologicals|vaginal creams, foams, and jellies|genito urinary system and sex hormones|sensory organs|cytochrome p 450 cyp2c9 inhibitors (moderate)|cytochrome p 450 cyp2a6 inhibitors
cefuroxime	amides|nephrotoxic agents|thiazines|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|cephalosporins|heterocyclic compounds, fused ring|sulfur compounds|sensory organs|ophthalmologicals|second generation cephalosporins|beta lactams|anti infective agents|lactams
papaverine	urological agents|benzylisoquinolines|phosphodiesterase inhibitors|hypotensive agents|opiate alkaloids|cardiovascular agents|qtc prolonging agents|urologicals|papaverine and derivatives|drugs used in erectile dysfunction|vasodilating agents|alkaloids|moderate risk qtc prolonging agents|enzyme inhibitors|isoquinolines|miscellaneous vasodilatating agents|drugs for functional gastrointestinal disorders|heterocyclic compounds, fused ring|alimentary tract and metabolism|genito urinary system and sex hormones
chlorphenamine	cytochrome p 450 cyp3a4 substrates|histamine agents|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|serotonin modulators|oct2 inhibitors|central nervous system depressants|antihistamines for systemic use|neurotransmitter agents|antidepressive agents|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|pyridines|cytochrome p 450 cyp2d6 inhibitors|substituted alkylamines|cytochrome p 450 enzyme inhibitors|moderate risk qtc prolonging agents|anti allergic agents|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|cytochrome p 450 cyp2d6 substrates|oct1 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|combined inhibitors of serotonin/norepinephrine reuptake|antipruritics|dermatologicals|histamine antagonists|propylamine derivatives|histamine h1 antagonists
nifedipine	membrane transport modulators|cytochrome p 450 cyp2c8 inhibitors|adrenal cortex hormones|calcium regulating hormones and agents|drugs that are mainly renally excreted|cytochrome p 450 cyp2a6 substrates|cytochrome p 450 cyp2b6 inducers (strength unknown)|tocolytic agents|antihypertensive agents indicated for hypertension|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|cytochrome p 450 cyp2e1 inhibitors|hypotensive agents|cytochrome p 450 cyp2c9 inducers (strength unknown)|p glycoprotein inducers|antiarrhythmic agents|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|calcium channel blockers|oatp1b1/slco1b1 inhibitors|cardiovascular agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|selective calcium channel blockers with mainly vascular effects|cytochrome p 450 cyp2b6 inducers|cytochrome p 450 cyp3a7 substrates|pyridines|cytochrome p 450 cyp2d6 inhibitors|qtc prolonging agents|calcium channel blockers (dihydropyridine)|cytochrome p 450 enzyme inhibitors|vasodilating agents|cytochrome p 450 cyp3a4 inhibitors|moderate risk qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|calcium channel blockers and diuretics|cytochrome p 450 substrates|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|beta blocking agents and calcium channel blockers|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp1a2 inhibitors|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|antihypertensive agents|cytochrome p 450 cyp3a4 inducers (strength unknown)|agents causing hyperkalemia|cytochrome p 450 enzyme inducers|reproductive control agents|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|cytochrome p 450 cyp1a2 substrates|dihydropyridines|bsep/abcb11 substrates|bsep/abcb11 inhibitors|cytochrome p 450 cyp2c9 inducers|dihydropyridine derivatives
atovaquone	quinones|antibiotics for pneumocystis pneumonia|cytochrome p 450 cyp3a4 substrates|antiparasitic products, insecticides and repellents|p glycoprotein inhibitors|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|antiparasitic agents|naphthoquinones|cytochrome p 450 enzyme inhibitors|cytochrome p 450 substrates|enzyme inhibitors|antimalarials|anti infective agents|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp3a substrates|antiprotozoals|miscellaneous antiprotozoals|naphthalenes
amiodarone	cytochrome p 450 cyp2c19 substrates with a narrow therapeutic index|membrane transport modulators|drugs causing inadvertant photosensitivity|cytochrome p 450 cyp2a6 inhibitors (moderate)|cytochrome p 450 cyp2c8 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|antiarrhythmics, class iii|p glycoprotein inhibitors|cytochrome p 450 cyp2d6 inhibitors (weak)|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|photosensitizing agents|cytochrome p 450 cyp2c19 substrates|hypotensive agents|p glycoprotein inducers|cytochrome p 450 cyp2c19 inhibitors (weak)|oct2 inhibitors|antiarrhythmic agents|calcium channel blockers|cardiovascular agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|benzofurans|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|vasodilating agents|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 substrates|bsep/abcb11 substrates with a narrow therapeutic index|enzyme inhibitors|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp1a2 inhibitors|cytochrome p 450 cyp2c9 inhibitors|heterocyclic compounds, fused ring|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|agents causing hyperkalemia|highest risk qtc prolonging agents|narrow therapeutic index drugs|bsep/abcb11 substrates|cytochrome p 450 cyp2c9 inhibitors (moderate)|cytochrome p 450 cyp2a6 inhibitors|bsep/abcb11 inhibitors|cardiac therapy|potassium channel blockers|sodium channel blockers|alpha galactosidase, antagonists & inhibitors|cytochrome p 450 cyp2c8 substrates|cytochrome p 450 cyp3a4 substrates (strength unknown)
diazoxide	drugs for treatment of hypoglycemia|thiazide derivatives|sulfones|hypotensive agents|cardiovascular agents|amides|sulfonamides|vasodilating agents|hyperglycemia associated agents|diuretics|gynecological antiinfectives and antiseptics|arteriolar smooth muscle, agents acting on|heterocyclic compounds, fused ring|antihypertensive agents|benzothiadiazines|genito urinary system and sex hormones|sulfur compounds|direct vasodilators
gliclazide	cytochrome p 450 cyp2c19 substrates|alimentary tract and metabolism|drugs used in diabetes|sulfones|sulfonylureas|sulfur compounds|cytochrome p 450 substrates|blood glucose lowering agents|cytochrome p 450 cyp2c9 substrates|hypoglycemia associated agents
tolbutamide	cytochrome p 450 cyp2c8 inhibitors|drugs used in diabetes|diagnostic agents|sulfonylureas|drugs that are mainly renally excreted|hypoglycemia associated agents|cytochrome p 450 cyp2c19 substrates|sulfones|blood glucose lowering agents|tests for diabetes|cytochrome p 450 enzyme inhibitors|cytochrome p 450 substrates|oat1/slc22a6 inhibitors|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|alimentary tract and metabolism|sulfur compounds|cytochrome p 450 cyp2c18 substrates|cytochrome p 450 cyp2c8 substrates
econazole	antifungal agents|hormones, hormone substitutes, and hormone antagonists|hormone antagonists|antifungal agents (vaginal)|cytochrome p 450 cyp3a4 inhibitors (strong)|antifungals for dermatological use|p glycoprotein inhibitors|cytochrome p 450 cyp2e1 inhibitors|imidazole derivatives|steroid synthesis inhibitors|cytochrome p 450 enzyme inhibitors|imidazoles|cytochrome p 450 cyp3a4 inhibitors|antifungals for topical use|enzyme inhibitors|imidazole and triazole derivatives|14 alpha demethylase inhibitors|anti infective agents|cytochrome p 450 cyp3a inhibitors|gynecological antiinfectives and antiseptics|chemically induced disorders|azole antifungals|dermatologicals|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|genito urinary system and sex hormones
bicalutamide	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|antineoplastic and immunomodulating agents|antineoplastic agents|cytochrome p 450 cyp3a4 inhibitors (weak)|androgen receptor antagonists|amines|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|sulfones|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|antiandrogens|hormones and related agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 cyp2d6 inhibitors|amides|cytochrome p 450 enzyme inhibitors|androgen receptor inhibitor|antiandrogens, non steroidal|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2c9 inhibitors|aniline compounds|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|endocrine therapy|hormone antagonists and related agents|narrow therapeutic index drugs|sulfur compounds|benzene derivatives
rabeprazole	acids, acyclic|cytochrome p 450 cyp2c8 inhibitors|gastric acid lowering agents|antiinflammatory preparations, non steroids for topical use|bcrp/abcg2 inhibitors|drugs that are mainly renally excreted|cytochrome p 450 cyp1a2 inducers (strength unknown)|acid reducers|anti ulcer agents|musculo skeletal system|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp1a2 inducers|cytochrome p 450 cyp2d6 inhibitors (weak)|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp2c8 inhibitors (moderate)|pyrazoles|fatty acids|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|antiinflammatory and antirheumatic products, non steroids|drugs for peptic ulcer and gastro oesophageal reflux disease (gord)|pyridines|cytochrome p 450 cyp2d6 inhibitors|drugs for acid related disorders|topical products for joint and muscular pain|cytochrome p 450 enzyme inhibitors|pyrazolones|benzimidazoles|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|fatty acids, volatile|gastrointestinal agents|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2c9 inhibitors|heterocyclic compounds, fused ring|2 pyridinylmethylsulfinylbenzimidazoles|acetates|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|hydroxy acids|antiinflammatory and antirheumatic products|cytochrome p 450 enzyme inducers|alimentary tract and metabolism|proton pump inhibitors|sulfur compounds|lipids|butylpyrazolidines|sulfoxides
prednicarbate	hormones, hormone substitutes, and hormone antagonists|adrenal cortex hormones|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|corticosteroids, potent (group iii)|corticosteroids|anti inflammatory agents|pregnanes|cytochrome p 450 substrates|pregnadienetriols|cytochrome p 450 cyp3a inducers|immunosuppressive agents|corticosteroid hormone receptor agonists|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|dermatologicals|cytochrome p 450 enzyme inducers|steroids|corticosteroids, dermatological preparations|hormones|pregnadienes
proguanil	amidines|antiparasitic products, insecticides and repellents|folic acid antagonists|cytochrome p 450 cyp2d6 inhibitors (weak)|biguanides|cytochrome p 450 cyp2c19 substrates|antiparasitic agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|antimalarials|anti infective agents|noxae|guanidines|cytochrome p 450 cyp3a substrates|antimetabolites|antiprotozoals|toxic actions
pioglitazone	cytochrome p 450 cyp2c8 inhibitors|thiazoles|drugs used in diabetes|oatp1b3 inhibitors|peroxisome proliferator receptor gamma agonist|cytochrome p 450 cyp3a4 inducers|hypoglycemia associated agents|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp2c8 inhibitors (moderate)|blood glucose lowering agents|oatp1b1/slco1b1 inhibitors|peroxisome proliferator activated receptor activity|cytochrome p 450 enzyme inhibitors|thiazolidinediones|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|alimentary tract and metabolism|sulfur compounds|cytochrome p 450 cyp2c8 substrates
carvedilol	propanolamines|membrane transport modulators|adrenergic agents|calcium regulating hormones and agents|adrenergic alpha 1 receptor antagonists|ugt2b7 substrates|antihypertensive agents indicated for hypertension|amines|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|p glycoprotein inhibitors|adrenergic antagonists|indoles|protective agents|hypotensive agents|antiarrhythmic agents|neurotransmitter agents|calcium channel blockers|cardiovascular agents|vasodilating agents|adrenergic beta 1 receptor antagonists|propanols|adrenergic beta antagonists|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|adrenergic beta2 antagonists|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|antioxidants|compounds used in a research, industrial, or household setting|adrenergic alpha antagonists|antihypertensive agents|cytochrome p 450 cyp3a substrates|agents causing hyperkalemia|cytochrome p 450 cyp2e1 substrates|carbazoles|cytochrome p 450 cyp1a2 substrates|alpha and beta blocking agents|amino alcohols|ugt1a1 substrates|alcohols
levofloxacin	drugs causing inadvertant photosensitivity|topoisomerase inhibitors|antibacterials for systemic use|anti bacterial agents|anti infective agents, urinary|drugs that are mainly renally excreted|mate 2 inhibitors|ophthalmologicals|mate 1 inhibitors|p glycoprotein inhibitors|oat1/slc22a6 substrates|p glycoprotein substrates|photosensitizing agents|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|quinolone antimicrobial|fluoroquinolones|oct2 inhibitors|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|quinolines|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|moderate risk qtc prolonging agents|mate substrates|quinolones|enzyme inhibitors|anti infective agents|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp1a2 inhibitors|heterocyclic compounds, fused ring|mate inhibitors|oct1 inhibitors|antiinfectives for systemic use|topoisomerase ii inhibitors|alimentary tract and metabolism|renal agents|sensory organs|mate 1 substrates
sulfinpyrazone	antiplatelet agents|cytochrome p 450 cyp2c8 inhibitors|cytochrome p 450 cyp2b6 inducers (strength unknown)|musculo skeletal system|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|preparations increasing uric acid excretion|pyrazoles|antigout preparations|cytochrome p 450 cyp2b6 inducers|cytochrome p 450 enzyme inhibitors|pyrazolones|cytochrome p 450 substrates|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|uricosuric agents|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|renal agents|bsep/abcb11 substrates|cytochrome p 450 cyp2c9 inhibitors (moderate)
cefadroxil	amides|nephrotoxic agents|thiazines|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|cephalosporins|heterocyclic compounds, fused ring|oat3/slc22a8 inhibitors|sulfur compounds|first generation cephalosporins|drugs that are mainly renally excreted|oat1/slc22a6 inhibitors|beta lactams|anti infective agents|lactams
doxepin	hypnotics and sedatives|agents producing tachycardia|psychoanaleptics|central nervous system agents|serotonin receptor antagonists|drugs that are mainly renally excreted|adrenergic alpha 1 receptor antagonists|acid reducers|cytochrome p 450 cyp3a4 substrates|antipruritics, incl. antihistamines, anesthetics, etc.|antipruritics and local anesthetics|histamine agents|p glycoprotein substrates|adrenergic antagonists|serotonin 5 ht1 receptor antagonists|cytochrome p 450 cyp2c19 substrates|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|anticholinergic agents|serotonin 5 ht1a receptor antagonists|serotonin modulators|agents that produce hypertension|tertiary amine tricyclic antidepressants|central nervous system depressants|neurotransmitter agents|antidepressive agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|sleep aids, pharmaceutical|nervous system|agents that reduce seizure threshold|antidepressive agents, tricyclic|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|ethers, cyclic|cytochrome p 450 cyp2c9 substrates|non selective monoamine reuptake inhibitors|serotonin 5 ht2 receptor antagonists|dibenzoxepins|potential qtc prolonging agents|heterocyclic compounds, fused ring|muscarinic antagonists|cytochrome p 450 cyp2d6 substrates|serotonin 5 ht2c receptor antagonists|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|combined inhibitors of serotonin/norepinephrine reuptake|neurotoxic agents|dermatologicals|psychotropic drugs|serotonin 5 ht2a receptor antagonists|cytochrome p 450 cyp1a2 substrates|histamine h2 antagonists|histamine antagonists|dopamine antagonists|tricyclics and other norepinephrine reuptake inhibitors|histamine h1 antagonists
amifostine	organothiophosphates|organophosphates|compounds used in a research, industrial, or household setting|detoxifying agents for antineoplastic treatment|organothiophosphorus compounds|organophosphorus compounds|protective agents|hypotensive agents|radiation protective agents|sulfur compounds|cytoprotective agent|free radical scavenging activity
diclofenamide	amides|sulfonamides|diuretics|sulfones|hypotensive agents|genito urinary system and sex hormones|sensory organs|sulfur compounds|ophthalmologicals|enzyme inhibitors|antiglaucoma preparations and miotics|gynecological antiinfectives and antiseptics|carbonic anhydrase inhibitors|ophthalmics
diphenylpyraline	antihistamines for systemic use|histamine antagonists|aminoalkyl ethers|histamine h1 antagonists
cloxacillin	amides|penicillinase resistant penicillins|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|beta lactamase resistant penicillins|heterocyclic compounds, fused ring|sulfur compounds|oat1/slc22a6 inhibitors|beta lactams|penicillins|anti infective agents|beta lactam antibacterials|lactams
flavoxate	benzopyrans|agents producing tachycardia|flavonoids|parasympatholytics|urologicals|peripheral nervous system agents|urological agents|heterocyclic compounds, fused ring|anticholinergic agents|drugs for urinary frequency and incontinence|flavones|genito urinary system and sex hormones|pyrans|drugs that are mainly renally excreted|chromones|autonomic agents|muscarinic antagonists
nefazodone	membrane transport modulators|psychoanaleptics|central nervous system agents|oatp1b3 inhibitors|serotonin receptor antagonists|cytochrome p 450 cyp3a4 inhibitors (strong)|drugs that are mainly renally excreted|adrenergic alpha 1 receptor antagonists|cytochrome p 450 cyp3a4 substrates|hypoglycemia associated agents|p glycoprotein inhibitors|antidepressive agents, triazolopyridine|adrenergic antagonists|cytochrome p 450 cyp2d6 inhibitors (weak)|antidepressive agents, second generation|selective serotonin reuptake inhibitors|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin 5 ht1 receptor antagonists|analgesics|serotonin 5 ht1a receptor antagonists|serotonin agents|p glycoprotein inducers|agents that produce hypertension|serotonin modulators|central nervous system depressants|neurotransmitter agents|antidepressive agents|serotonin and noradrenaline reuptake inhibitors|cytochrome p 450 cyp2d6 inhibitors|nervous system|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|serotonin 5 ht2 receptor antagonists|cytochrome p 450 cyp3a inhibitors|serotonin 5 ht2c receptor antagonists|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|combined inhibitors of serotonin/norepinephrine reuptake|neurotransmitter uptake inhibitors|serotonin 5 ht2a receptor antagonists|psychotropic drugs|bsep/abcb11 substrates
desipramine	adrenergic uptake inhibitors|agents producing tachycardia|membrane transport modulators|cytochrome p 450 cyp2b6 inhibitors (strength unknown)|psychoanaleptics|central nervous system agents|adrenergic agents|serotonin receptor antagonists|drugs that are mainly renally excreted|cytochrome p 450 cyp2e1 inhibitors (weak)|p glycoprotein inhibitors|cytochrome p 450 cyp2d6 inhibitors (weak)|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|anticholinergic agents|cytochrome p 450 cyp2b6 substrates|cytochrome p 450 cyp2d6 substrates with a narrow therapeutic index|cytochrome p 450 cyp2e1 inhibitors|agents that produce hypertension|serotonin modulators|oct2 inhibitors|central nervous system depressants|neurotransmitter agents|antidepressive agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|dibenzazepines|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 cyp2b6 inhibitors|agents that reduce seizure threshold|nervous system|antidepressive agents, tricyclic|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|enzyme inhibitors|non selective monoamine reuptake inhibitors|serotonin 5 ht2 receptor antagonists|cytochrome p 450 cyp3a inhibitors|potential qtc prolonging agents|heterocyclic compounds, fused ring|muscarinic antagonists|cytochrome p 450 cyp2d6 substrates|oct1 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2d6 inhibitors (moderate)|combined inhibitors of serotonin/norepinephrine reuptake|neurotoxic agents|neurotransmitter uptake inhibitors|psychotropic drugs|serotonin 5 ht2a receptor antagonists|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|narrow therapeutic index drugs|histamine antagonists|tricyclics and other norepinephrine reuptake inhibitors|histamine h1 antagonists
sertaconazole	antifungal agents|dermatologicals|genito urinary system and sex hormones|antifungals for topical use|azole antifungals|sulfur compounds|imidazole and triazole derivatives|anti infective agents|gynecological antiinfectives and antiseptics|imidazole derivatives|antifungals for dermatological use
bupropion	drugs causing inadvertant photosensitivity|miscellaneous antidepressants|cytochrome p 450 cyp2d6 inhibitors (strong)|psychoanaleptics|central nervous system agents|centrally acting antiobesity products|drugs that are mainly renally excreted|increased norepinephrine activity|photosensitizing agents|cytochrome p 450 cyp2b6 substrates|oct2 inhibitors|norepinephrine uptake inhibitors|central nervous system depressants|antidepressive agents|antiobesity preparations, excl. diet products|dopamine uptake inhibitors|cytochrome p 450 cyp2d6 inhibitors|nervous system|agents that reduce seizure threshold|cytochrome p 450 enzyme inhibitors|increased dopamine activity|smoking cessation agents|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|ketones|neurotransmitter uptake inhibitors|cytochrome p 450 cyp2e1 substrates|psychotropic drugs|dopamine agents|aminoketone
bretylium	adrenergic agents|amines|bradycardia causing agents|antiarrhythmics, class iii|adrenergic antagonists|quaternary ammonium compounds|ammonium compounds|hypotensive agents|benzylammonium compounds|antiarrhythmic agents|neurotransmitter agents|cardiovascular agents|bretylium compounds|qtc prolonging agents|onium compounds|nitrogen compounds|potential qtc prolonging agents|antihypertensive agents|cardiac therapy
terazosin	quinazolines|urologicals|p glycoprotein inhibitors|peripheral alpha 1 blockers|adrenergic alpha antagonists|adrenergic antagonists|antihypertensive agents|urological agents|heterocyclic compounds, fused ring|adrenergic agents|hypotensive agents|genito urinary system and sex hormones|drugs used in benign prostatic hypertrophy|adrenergic alpha 1 receptor antagonists|neurotransmitter agents|antihypertensive agents indicated for hypertension
mecillinam	amides|penicillins with extended spectrum|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|heterocyclic compounds, fused ring|anti infective agents, urinary|renal agents|sulfur compounds|penicillins|beta lactams|anti infective agents|beta lactam antibacterials|lactams
ofloxacin	topoisomerase inhibitors|antibacterials for systemic use|anti bacterial agents|anti infective agents, urinary|ophthalmologicals|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|quinolone antimicrobial|fluoroquinolones|quinolines|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|moderate risk qtc prolonging agents|quinolones|enzyme inhibitors|oat1/slc22a6 inhibitors|anti infective agents|chemically induced disorders|cytochrome p 450 cyp1a2 inhibitors|otologicals|heterocyclic compounds, fused ring|antiinfectives for systemic use|topoisomerase ii inhibitors|renal agents|sensory organs|bsep/abcb11 substrates
cilostazol	antiplatelet agents|agents producing tachycardia|anti asthmatic agents|central nervous system agents|drugs that are mainly renally excreted|phosphodiesterase inhibitors|cytochrome p 450 cyp3a4 substrates|phosphodiesterase 3 inhibitors|cytochrome p 450 cyp2c19 substrates|protective agents|quinolines|cardiovascular agents|blood and blood forming organs|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|vasodilating agents|hematologic agents|cytochrome p 450 substrates|platelet aggregation inhibitors excl. heparin|enzyme inhibitors|potential qtc prolonging agents|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|respiratory system agents|neuroprotective agents|compounds used in a research, industrial, or household setting|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|peripheral nervous system agents|tetrazoles|bronchodilator agents|cytochrome p 450 cyp1a2 substrates|autonomic agents|fibrin modulating agents
itraconazole	antifungal agents|hormones, hormone substitutes, and hormone antagonists|hormone antagonists|drugs causing inadvertant photosensitivity|cytochrome p 450 cyp3a4 inhibitors (strong)|piperazines|triazoles|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|photosensitizing agents|cytochrome p 450 cyp3a5 inhibitors|cytochrome p 450 cyp2e1 inhibitors|antimycotics for systemic use|qtc prolonging agents|steroid synthesis inhibitors|cytochrome p 450 cyp2b6 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2b6 inhibitors (strong)|cytochrome p 450 substrates|enzyme inhibitors|14 alpha demethylase inhibitors|anti infective agents|cytochrome p 450 cyp3a inhibitors|chemically induced disorders|potential qtc prolonging agents|triazole derivatives|azole antifungals|cytochrome p 450 cyp3a7 inhibitors|cytochrome p 450 cyp3a7 inhibitors (strong)|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 inhibitors (strong)|antiinfectives for systemic use|agents causing hyperkalemia|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|breast cancer resistance protein inhibitors
procarbazine	antineoplastic and immunomodulating agents|alkylating drugs|antineoplastic agents|benzoates|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|serotonin modulators|alkylating activity|central nervous system depressants|antidepressive agents|myelosuppressive agents|amides|agents causing muscle toxicity|methylhydrazines|monoamine oxidase inhibitors|immunosuppressive agents|benzamides and benzamide derivatives|acids, carbocyclic|narrow therapeutic index drugs|benzene derivatives
guanethidine	amidines|adrenergic agents|antiadrenergic agents, peripherally acting|drugs that are mainly renally excreted|ophthalmologicals|guanidine derivatives|catecholamine depleting sympatholytic|adrenergic antagonists|gastrointestinal acidifying agents|neurotransmitter agents|antiglaucoma preparations and miotics|cardiovascular agents|guanidines|antihypertensive agents|peripheral nervous system agents|guanidine derivatives and diuretics|sensory organs|autonomic agents|sympatholytics
moclobemide	psychoanaleptics|central nervous system agents|benzoates|cytochrome p 450 cyp2c19 substrates|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|serotonin modulators|agents that produce hypertension|central nervous system depressants|antidepressive agents|cytochrome p 450 cyp2d6 inhibitors|amides|agents that reduce seizure threshold|nervous system|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|monoamine oxidase a inhibitors|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|monoamine oxidase a inhibitors  for interaction with monoamine oxidase a substrates|chlorobenzoates|monoamine oxidase inhibitors|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp2c19 inhibitors|psychotropic drugs|benzamides and benzamide derivatives|acids, carbocyclic|benzene derivatives
kanamycin	carbohydrates|antibacterials for systemic use|anti bacterial agents|intestinal antiinfectives|agents that produce neuromuscular block (indirect)|aminoglycoside antibacterials|drugs that are mainly renally excreted|ophthalmologicals|nephrotoxic agents|antidiarrheals, intestinal antiinflammatory/antiinfective agents|glycosides|enzyme inhibitors|anti infective agents|antiinfectives for systemic use|alimentary tract and metabolism|protein synthesis inhibitors|narrow therapeutic index drugs|sensory organs|drugs that are mainly renally excreted with a narrow therapeutic index
orphenadrine	agents producing tachycardia|muscle relaxants|cytochrome p 450 cyp2d6 inhibitors (strong)|central nervous system agents|anti dyskinesia agents|cytochrome p 450 cyp3a4 inhibitors (weak)|musculo skeletal system|amines|cytochrome p 450 cyp3a4 substrates|muscle relaxants, centrally acting agents|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|anticholinergic agents|cytochrome p 450 cyp2e1 inhibitors|central nervous system depressants|neurotransmitter agents|nmda receptor antagonists|benzhydryl compounds|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 cyp2b6 inhibitors|cholinergic agents|nervous system|cytochrome p 450 enzyme inhibitors|parasympatholytics|cytochrome p 450 cyp2b6 inhibitors (strong)|anti parkinson drugs|cytochrome p 450 substrates|centrally mediated muscle relaxation|enzyme inhibitors|ethylamines|cytochrome p 450 cyp3a inhibitors|chemically induced disorders|cytochrome p 450 cyp1a2 inhibitors|potential qtc prolonging agents|muscarinic antagonists|cytochrome p 450 cyp3a substrates|peripheral nervous system agents|ethers, chemically close to antihistamines|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|miscellaneous skeletal muscle relaxants|autonomic agents|benzene derivatives|histamine antagonists|histamine h1 antagonists
escitalopram	membrane transport modulators|drugs causing inadvertant photosensitivity|psychoanaleptics|central nervous system agents|amines|cytochrome p 450 cyp3a4 substrates|hypoglycemia associated agents|p glycoprotein substrates|cytochrome p 450 cyp2d6 inhibitors (weak)|photosensitizing agents|antidepressive agents, second generation|cytochrome p 450 cyp2c19 substrates|selective serotonin reuptake inhibitors|serotonergic drugs shown to increase risk of serotonin syndrome|anticholinergic agents|serotonin agents|serotonin modulators|central nervous system depressants|neurotransmitter agents|antidepressive agents|qtc prolonging agents|propylamines|cytochrome p 450 cyp2d6 inhibitors|benzofurans|nervous system|cytochrome p 450 enzyme inhibitors|cytochrome p 450 substrates|heterocyclic compounds, fused ring|muscarinic antagonists|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|combined inhibitors of serotonin/norepinephrine reuptake|neurotransmitter uptake inhibitors|psychotropic drugs|nitriles|highest risk qtc prolonging agents
cyclizine	central nervous system agents|piperazines|histamine agents|central nervous system depressants|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|antihistamines for systemic use|neurotransmitter agents|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|gastrointestinal agents|piperazine derivatives|potential qtc prolonging agents|cytochrome p 450 cyp2c9 inhibitors|peripheral nervous system agents|antiemetics|autonomic agents|histamine antagonists|histamine h1 antagonists
idarubicin	carbohydrates|antineoplastic and immunomodulating agents|topoisomerase inhibitors|anthracycline topoisomerase inhibitor|antineoplastic agents|cytochrome p 450 cyp2d6 substrates with a narrow therapeutic index|cytotoxic antibiotics and related substances|myelosuppressive agents|anthracyclines and related substances|naphthacenes|cytochrome p 450 substrates|glycosides|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|immunosuppressive agents|cytochrome p 450 cyp2d6 substrates|antibiotics, antineoplastic|topoisomerase ii inhibitors|cardiotoxic antineoplastic agents|narrow therapeutic index drugs|anthracyclines|cytochrome p 450 cyp2c9 substrates with a narrow therapeutic index
chlormezanone	oxazol, thiazine, and triazine derivatives|thiazines|muscle relaxants|muscle relaxants, centrally acting agents|peripheral nervous system agents|psychotropic drugs|central nervous system agents|tranquilizing agents|sulfur compounds|central nervous system depressants|neuromuscular agents|musculo skeletal system|anti anxiety agents
ppt	decreased mitosis|antineoplastic agents, phytogenic|mitosis modulators|antimitotic agents|dermatologicals|keratolytic agents|benzyl compounds|lignans|tubulin modulators|benzene derivatives|antiviral agents|misc. skin and mucous membrane agents|naphthalenes|tetrahydronaphthalenes
podophyllotoxin	decreased mitosis|antineoplastic agents, phytogenic|mitosis modulators|antimitotic agents|dermatologicals|keratolytic agents|benzyl compounds|lignans|tubulin modulators|benzene derivatives|antiviral agents|misc. skin and mucous membrane agents|naphthalenes|tetrahydronaphthalenes
rescinnamine	agents acting on the renin angiotensin system|agents causing angioedema|angiotensin converting enzyme inhibitors|antihypertensive agents|agents causing hyperkalemia|heterocyclic compounds, fused ring|alkaloids|indoles|agents that produce hypertension|indole alkaloids|antiadrenergic agents, centrally acting|secologanin tryptamine alkaloids
ifosfamide	cytochrome p 450 cyp2c19 substrates with a narrow therapeutic index|antineoplastic and immunomodulating agents|alkylating drugs|acids|organophosphorus compounds|antineoplastic agents|phosphoramide mustards|phosphoric acids|drugs that are mainly renally excreted|phosphorus acids|cytochrome p 450 cyp2c8 inducers (strength unknown)|cytochrome p 450 cyp2a6 substrates|oxazines|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp2c8 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a4 substrates|nitrogen mustard analogues|electrolytes|cytochrome p 450 cyp2c19 substrates|ions|anions|cytochrome p 450 cyp2b6 substrates|alkylating activity|cytochrome p 450 cyp2c18 substrates with a narrow therapeutic index|cytochrome p 450 cyp2a6 substrates with a narrow therapeutic index|cytochrome p 450 cyp2b6 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|myelosuppressive agents|mustard compounds|phosphoramides|nitrogen mustard compounds|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c8 inducers|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|antineoplastic agents, alkylating|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|noxae|acids, noncarboxylic|immunosuppressive agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|methemoglobinemia associated agents|hydrocarbons, halogenated|cytochrome p 450 enzyme inducers|cardiotoxic antineoplastic agents|narrow therapeutic index drugs|cytochrome p 450 cyp2c9 substrates with a narrow therapeutic index|cytochrome p 450 cyp2c18 substrates|phosphorus compounds|toxic actions|cytochrome p 450 cyp2c8 substrates
propafenone	membrane transport modulators|propiophenones|cytochrome p 450 cyp2d6 inhibitors (strong)|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|p glycoprotein inhibitors|adrenergic antagonists|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|agents that produce hypertension|antiarrhythmic agents|voltage gated sodium channel blockers|cardiovascular agents|antiarrhythmics, class ic|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|moderate risk qtc prolonging agents|adrenergic beta antagonists|cytochrome p 450 substrates|cytochrome p 450 cyp1a2 inhibitors|ketones|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|antiarrhythmics, class i|agents causing hyperkalemia|cytochrome p 450 cyp1a2 substrates|cardiac therapy|sodium channel blockers
naloxone	sensory system agents|central nervous system agents|cytochrome p 450 cyp3a4 inhibitors (strong)|drugs that are mainly renally excreted|drugs for constipation|morphinans|narcotics|p glycoprotein substrates|opiate antagonists|analgesics|opiate alkaloids|nervous system|cytochrome p 450 enzyme inhibitors|antidotes|peripheral opioid receptor antagonists|cytochrome p 450 cyp3a4 inhibitors|alkaloids|opioid antagonists|cytochrome p 450 cyp3a inhibitors|heterocyclic compounds, fused ring|natural opium alkaloids|peripheral nervous system agents|alimentary tract and metabolism|phenanthrenes|ugt1a1 substrates
domperidone	central nervous system agents|cytochrome p 450 cyp3a4 substrates|p glycoprotein substrates|cytochrome p 450 cyp2b6 substrates|neurotransmitter agents|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|benzimidazoles|gastrointestinal agents|cytochrome p 450 substrates|piperidines|prokinetic agents|dopamine d2 receptor antagonists|drugs for functional gastrointestinal disorders|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|propulsives|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|peripheral nervous system agents|alimentary tract and metabolism|dopamine agents|highest risk qtc prolonging agents|cytochrome p 450 cyp1a2 substrates|antiemetics|autonomic agents|dopamine antagonists|cytochrome p 450 cyp2c8 substrates
fluoxymesterone	anabolic agents|androstenols|hormones, hormone substitutes, and hormone antagonists|steroids, fluorinated|androstenes|3 oxoandrosten (4) derivatives|steroids|hormones|androstenediols|androstanes|genito urinary system and sex hormones|sex hormones and modulators of the genital system|androgens|fused ring compounds
pergolide	agents producing tachycardia|ergolines|ergot derivative dopamine receptor agonists|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|agents that produce hypertension|adrenergic alpha 1 receptor agonists|adrenergic alpha 2 receptor agonists|central nervous system depressants|neurotransmitter agents|antidepressive agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|ergot derived dopamine receptor agonist|nervous system|cytochrome p 450 enzyme inhibitors|adrenergic agonists|cytochrome p 450 cyp3a4 inhibitors|alkaloids|anti parkinson drugs|serotonin 5 ht2 receptor agonists|adrenergic alpha agonists|cytochrome p 450 cyp3a inhibitors|heterocyclic compounds, fused ring|ergot alkaloids and derivatives|dopamine agents|dopamine agonists|serotonin receptor agonists
ciclopirox	antifungal agents|decreased rna replication|hydroxypyridones|pyridines|pyridones|decreased dna replication|dermatologicals|vaginal creams, foams, and jellies|cyclohexanes|cycloparaffins|decreased protein synthesis|genito urinary system and sex hormones|antifungals for topical use|protein synthesis inhibitors|anti infective agents|gynecological antiinfectives and antiseptics|antifungals for dermatological use
clindamycin	antibiotics for pneumocystis pneumonia|antibacterials for systemic use|anti bacterial agents|agents that produce neuromuscular block (indirect)|cytochrome p 450 cyp3a4 substrates|anti acne preparations for topical use|p glycoprotein substrates|decreased sebaceous gland activity|macrolides, lincosamides and streptogramins|antiinfectives for treatment of acne|pyrrolidines|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|anti acne preparations|cytochrome p 450 cyp3a4 inhibitors (moderate)|cytochrome p 450 substrates|glycosides|enzyme inhibitors|anti infective agents|cytochrome p 450 cyp3a inhibitors|gynecological antiinfectives and antiseptics|lincomycins|macrolides|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|neurotoxic agents|antiinfectives for systemic use|dermatologicals|lincosamide antibacterial|protein synthesis inhibitors|genito urinary system and sex hormones|lincosamides
dexfenfluramine	centrally acting antiobesity products|amines|cytochrome p 450 cyp2e1 inhibitors (weak)|cytochrome p 450 cyp2d6 inhibitors (weak)|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|cytochrome p 450 cyp2e1 inhibitors|central nervous system depressants|neurotransmitter agents|antidepressive agents|antiobesity preparations, excl. diet products|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 substrates|ethylamines|cytochrome p 450 cyp2d6 substrates|alimentary tract and metabolism|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|cytochrome p 450 cyp1a2 substrates|phenethylamines
acebutolol	propanolamines|beta blocking agents, selective, and thiazides|adrenergic agents|beta blockers (beta1 selective)|phenoxypropanolamines|antihypertensive agents indicated for hypertension|amines|bradycardia causing agents|beta blocking agents, selective|p glycoprotein substrates|adrenergic antagonists|hypotensive agents|antiarrhythmic agents|neurotransmitter agents|cardiovascular agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|sympathomimetics|cytochrome p 450 enzyme inhibitors|adrenergic beta 1 receptor antagonists|propanols|moderate risk qtc prolonging agents|adrenergic beta antagonists|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|beta blocking agents and thiazides|cytochrome p 450 cyp2d6 substrates|antihypertensive agents|peripheral nervous system agents|agents causing hyperkalemia|amino alcohols|autonomic agents|alcohols
brinzolamide	amides|cytochrome p 450 cyp3a substrates|sulfonamides|diuretics|sulfones|genito urinary system and sex hormones|cytochrome p 450 substrates|sensory organs|ophthalmologicals|enzyme inhibitors|sulfur compounds|antiglaucoma preparations and miotics|gynecological antiinfectives and antiseptics|carbonic anhydrase inhibitors|cytochrome p 450 cyp3a4 substrates|ophthalmics
flecainide	membrane transport modulators|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|mate 1 substrates with a narrow therapeutic index|mate 1 inhibitors|p glycoprotein substrates|cytochrome p 450 cyp2d6 substrates with a narrow therapeutic index|antiarrhythmic agents|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|voltage gated sodium channel blockers|cardiovascular agents|antiarrhythmics, class ic|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|moderate risk qtc prolonging agents|mate substrates|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|piperidines|cytochrome p 450 cyp2c9 inhibitors|mate inhibitors|cytochrome p 450 cyp2d6 substrates|antiarrhythmics, class i|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs|mate 1 substrates|p glycoprotein substrates with a narrow therapeutic index|cardiac therapy|sodium channel blockers
captopril	acids, acyclic|amino acids, peptides, and proteins|drugs causing inadvertant photosensitivity|imines|amino acids, cyclic|antihypertensive agents indicated for hypertension|p glycoprotein inhibitors|oat1/slc22a6 substrates|photosensitizing agents|hypotensive agents|amino acids|cardiovascular agents|agents causing angioedema|agents causing muscle toxicity|enzyme inhibitors|oat1/slc22a6 inhibitors|imino acids|agents acting on the renin angiotensin system|ace inhibitors and diuretics|protease inhibitors|angiotensin converting enzyme inhibitors|antihypertensive agents|agents causing hyperkalemia|oat3/slc22a8 substrates
cp	acids, acyclic|amino acids, peptides, and proteins|drugs causing inadvertant photosensitivity|imines|amino acids, cyclic|antihypertensive agents indicated for hypertension|p glycoprotein inhibitors|oat1/slc22a6 substrates|photosensitizing agents|hypotensive agents|amino acids|cardiovascular agents|agents causing angioedema|agents causing muscle toxicity|enzyme inhibitors|oat1/slc22a6 inhibitors|imino acids|agents acting on the renin angiotensin system|ace inhibitors and diuretics|protease inhibitors|angiotensin converting enzyme inhibitors|antihypertensive agents|agents causing hyperkalemia|oat3/slc22a8 substrates
zopiclone	hypnotics and sedatives|drugs causing inadvertant photosensitivity|central nervous system agents|aza compounds|psycholeptics|cytochrome p 450 cyp3a4 substrates|benzodiazepine hypnotics and sedatives|photosensitizing agents|miscellaneous anxiolytics sedatives and hypnotics|central nervous system depressants|nervous system|zopiclone and prodrugs|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|sleep initiation and maintenance disorders|hypnotics (nonbenzodiazepine)|cytochrome p 450 cyp3a substrates|methemoglobinemia associated agents|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 cyp2c8 substrates
tubocurarine	nicotinic antagonists|muscle relaxants|benzylisoquinolines|ganglion blockers|tetrahydroisoquinolines|musculo skeletal system|amines|cholinesterase inhibitors|quaternary ammonium compounds|anticholinergic agents|ammonium compounds|oct1 substrates|central nervous system depressants|neuromuscular agents|neurotransmitter agents|cholinergic agents|onium compounds|alkaloids|nitrogen compounds|neuromuscular blocking agents (nondepolarizing)|isoquinolines|cholinesterase substrates|heterocyclic compounds, fused ring|neurotoxic agents|peripheral nervous system agents|curare alkaloids|neuromuscular blocking agents|muscle relaxants, peripherally acting agents
bromocriptine	hormones, hormone substitutes, and hormone antagonists|agents producing tachycardia|hormone antagonists|central nervous system agents|anti dyskinesia agents|adrenergic alpha 1 receptor antagonists|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|p glycoprotein substrates|adrenergic antagonists|ergolines|ergot derivative dopamine receptor agonists|anti parkinson agents (dopamine agonist)|serotonin agents|hypotensive agents|serotonin modulators|agents that produce hypertension|adrenergic alpha 1 receptor agonists|adrenergic alpha 2 receptor agonists|blood glucose lowering agents|central nervous system depressants|antidepressive agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|neurotransmitter agents|ergotamines|nervous system|cytochrome p 450 enzyme inhibitors|adrenergic agonists|cytochrome p 450 cyp3a4 inhibitors|alkaloids|anti parkinson drugs|cytochrome p 450 substrates|serotonin 5 ht2 receptor agonists|adrenergic alpha agonists|cytochrome p 450 cyp3a inhibitors|heterocyclic compounds, fused ring|ergot alkaloids and derivatives|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|prolactine inhibitors|dopamine agents|genito urinary system and sex hormones|dopamine agonists|serotonin receptor agonists
rifapentine	anti bacterial agents|lactams|antituberculosis agents|leprostatic agents|cytochrome p 450 cyp2c8 inducers (strength unknown)|cytochrome p 450 cyp2b6 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|antimycobacterials|cytochrome p 450 cyp3a inducers (strong)|cytochrome p 450 cyp2c19 inducers|cytochrome p 450 cyp2c9 inducers (strength unknown)|cytochrome p 450 cyp2b6 inducers|amides|cytochrome p 450 cyp2c8 inducers|cytochrome p 450 cyp2c19 inducers (strong)|cytochrome p 450 substrates|rifamycin antimycobacterial|anti infective agents|cytochrome p 450 cyp3a inducers|lactams, macrocyclic|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|antiinfectives for systemic use|cytochrome p 450 enzyme inducers|drugs for treatment of tuberculosis|rifamycins|cytochrome p 450 cyp2c9 inducers|antibiotics, antitubercular
levetiracetam	acetamides|amides|decreased central nervous system disorganized electrical activity|nervous system|p glycoprotein substrates|central nervous system agents|pyrrolidinones|anticonvulsants|central nervous system depressants|pyrrolidines|miscellaneous anticonvulsants
nadolol	propanolamines|drugs causing inadvertant photosensitivity|beta blocking agents, non selective|adrenergic agents|drugs that are mainly renally excreted|phenoxypropanolamines|antihypertensive agents indicated for hypertension|amines|bradycardia causing agents|mate 2 substrates|p glycoprotein substrates|adrenergic antagonists|photosensitizing agents|hypotensive agents|antiarrhythmic agents|neurotransmitter agents|cardiovascular agents|propanols|adrenergic beta antagonists|cytochrome p 450 substrates|mate substrates|beta blocking agents and thiazides|beta blocking agents, non selective, and thiazides|cytochrome p 450 cyp2d6 substrates|antihypertensive agents|peripheral nervous system agents|agents causing hyperkalemia|mate 1 substrates|amino alcohols|autonomic agents|sympatholytics|alcohols
mitoxantrone	quinones|antineoplastic and immunomodulating agents|topoisomerase inhibitors|sensory system agents|central nervous system agents|antineoplastic agents|cytochrome p 450 cyp2e1 inducers (strength unknown)|p glycoprotein inhibitors|p glycoprotein substrates|analgesics|p glycoprotein inducers|cytotoxic antibiotics and related substances|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|bcrp/abcg2 substrates|anthracyclines and related substances|myelosuppressive agents|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp3a inhibitors|anthracenes|immunosuppressive agents|cytochrome p 450 cyp2e1 substrates with a narrow therapeutic index|cytochrome p 450 cyp2e1 inducers|peripheral nervous system agents|topoisomerase ii inhibitors|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 enzyme inducers|cardiotoxic antineoplastic agents|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|anthraquinones
flumazenil	compounds used in a research, industrial, or household setting|antidotes|gaba modulators|benzazepines|heterocyclic compounds, fused ring|protective agents|gaba agents|drugs that are mainly renally excreted|benzodiazepinones|neurotransmitter agents|benzodiazepine antagonist|miscellaneous central nervous system agents
sparfloxacin	topoisomerase inhibitors|antibacterials for systemic use|anti bacterial agents|antituberculosis agents|p glycoprotein substrates|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|fluoroquinolones|quinolines|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|quinolones|enzyme inhibitors|anti infective agents|cytochrome p 450 cyp1a2 inhibitors|heterocyclic compounds, fused ring|antiinfectives for systemic use|topoisomerase ii inhibitors|highest risk qtc prolonging agents
levobunolol	propanolamines|adrenergic agents|ophthalmologicals|phenoxypropanolamines|amines|bradycardia causing agents|adrenergic antagonists|hypotensive agents|neurotransmitter agents|antiglaucoma preparations and miotics|propanols|adrenergic beta antagonists|cytochrome p 450 substrates|bunolol|tetrahydronaphthalenes|cytochrome p 450 cyp2d6 substrates|beta adrenergic agents|peripheral nervous system agents|agents causing hyperkalemia|sensory organs|amino alcohols|autonomic agents|sympatholytics|naphthalenes|alcohols
clarithromycin	antibacterials for systemic use|anti bacterial agents|oatp1b3 inhibitors|erythromycin and similars|cytochrome p 450 cyp3a4 inhibitors (strong)|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp3a5 inhibitors|macrolides, lincosamides and streptogramins|oatp1b1/slco1b1 inhibitors|drugs for peptic ulcer and gastro oesophageal reflux disease (gord)|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|drugs for acid related disorders|macrolide antimicrobial|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|moderate risk qtc prolonging agents|cytochrome p 450 substrates|enzyme inhibitors|anti infective agents|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a inducers|chemically induced disorders|macrolides|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 inhibitors (strong)|cytochrome p 450 cyp3a5 substrates|antiinfectives for systemic use|polyketides|cytochrome p 450 enzyme inducers|alimentary tract and metabolism|protein synthesis inhibitors|bsep/abcb11 substrates|other macrolides|lactones
fomepizole	cytochrome p 450 cyp2e1 inducers|compounds used in a research, industrial, or household setting|cytochrome p 450 enzyme inhibitors|antidotes|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 enzyme inducers|pyrazoles|protective agents|cytochrome p 450 cyp2e1 inhibitors|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|cytochrome p 450 substrates|cytochrome p 450 cyp2e1 inducers (strength unknown)|cytochrome p 450 cyp2a6 inhibitors (strength unknown)|drugs that are mainly renally excreted|cytochrome p 450 cyp2a6 inhibitors|enzyme inhibitors
finasteride	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|androstenes|urological agents|androstanes|drugs used in benign prostatic hypertrophy|cytochrome p 450 cyp3a4 substrates|fused ring compounds|5 alpha reductase inhibitors|adrenergic antagonists|agents that produce hypertension|cytochrome p 450 cyp3a7 substrates|steroid synthesis inhibitors|urologicals|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|cytochrome p 450 cyp3a5 substrates|dermatologicals|steroids|azasteroids|genito urinary system and sex hormones|misc. skin and mucous membrane agents
anastrozole	hormones, hormone substitutes, and hormone antagonists|ugt1a3 substrates|hormone antagonists|cytochrome p 450 cyp2c8 inhibitors|antineoplastic and immunomodulating agents|estrogen antagonists|antineoplastic agents|triazoles|ugt2b7 substrates|cytochrome p 450 cyp3a4 substrates|p glycoprotein substrates|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|antineoplastic agents, hormonal|steroid synthesis inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|aromatase inhibitors|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp1a2 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|endocrine therapy|hormone antagonists and related agents|cardiotoxic antineoplastic agents|nitriles|ugt1a4 substrates|cytochrome p 450 cyp2c8 substrates
halofantrine	cytochrome p 450 cyp3a4 substrates|agents that reduce seizure threshold|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 enzyme inhibitors|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 cyp2d6 inhibitors (strong)|highest risk qtc prolonging agents|cytochrome p 450 substrates|antimalarials|anti infective agents|antiprotozoals|antiparasitic agents|cytochrome p 450 cyp2c8 substrates|antiparasitic products, insecticides and repellents
dantrolene	muscle relaxants|central nervous system agents|dantrolene and derivatives|agents that produce neuromuscular block (indirect)|hepatotoxic agents|musculo skeletal system|muscle relaxants, centrally acting agents|decreased striated muscle contraction|central nervous system depressants|neuromuscular agents|hydantoins|direct acting skeletal muscle relaxants|thyroxine binding globulin substrates|imidazoles|cytochrome p 450 substrates|decreased striated muscle tone|cytochrome p 450 cyp3a substrates|peripheral nervous system agents|agents causing hyperkalemia|imidazolidines
rifaximin	anti bacterial agents|intestinal antiinfectives|cytochrome p 450 cyp2c8 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp3a inducers (strong)|cytochrome p 450 cyp2c19 inducers|antidiarrheals, intestinal antiinflammatory/antiinfective agents|cytochrome p 450 cyp3a4 inducers (strong)|amides|antibiotics for topical use|cytochrome p 450 cyp2c8 inducers|gastrointestinal agents|cytochrome p 450 cyp2c19 inducers (strong)|cytochrome p 450 substrates|anti infective agents|cytochrome p 450 cyp3a inducers|lactams, macrocyclic|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|dermatologicals|cytochrome p 450 enzyme inducers|alimentary tract and metabolism|rifamycins|lactams|rifamycin antibacterial
budesonide	hormones, hormone substitutes, and hormone antagonists|corticosteroids for systemic use|anti asthmatic agents|adrenal cortex hormones|pregnenediones|drugs that are mainly renally excreted|agents to treat airway disease|cytochrome p 450 cyp2c8 inducers (strength unknown)|cytochrome p 450 cyp3a5 inducers (moderate)|cytochrome p 450 cyp2b6 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|p glycoprotein substrates|cytochrome p 450 cyp2a6 inducers|corticosteroids, potent (group iii)|cytochrome p 450 cyp2c19 inducers|corticosteroids|cytochrome p 450 cyp2c9 inducers (strength unknown)|antidiarrheals, intestinal antiinflammatory/antiinfective agents|cytochrome p 450 cyp2b6 inducers|intestinal antiinflammatory agents|anti inflammatory agents|pregnanes|cytochrome p 450 cyp2c8 inducers|cytochrome p 450 substrates|cytochrome p 450 cyp3a inducers|corticosteroid hormone receptor agonists|drugs for obstructive airway diseases|adrenals|immunosuppressive agents|respiratory system agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2c19 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers (strength unknown)|nasal preparations|dermatologicals|cytochrome p 450 enzyme inducers|alimentary tract and metabolism|corticosteroids, dermatological preparations|bronchodilator agents|hormones|peripheral nervous system agents|pregnenes|steroids|bsep/abcb11 substrates|autonomic agents|cytochrome p 450 cyp2c9 inducers|cytochrome p 450 cyp3a5 inducers|oat3/slc22a8 substrates|corticosteroids acting locally
aminophylline	purinergic antagonists|anti asthmatic agents|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|polyamines|xanthines and adrenergics|phosphodiesterase inhibitors|purinergic agents|amines|cytochrome p 450 cyp3a4 substrates|purinergic p1 receptor antagonists|respiratory smooth muscle relaxants|protective agents|purinones|ethylenediamines|neurotransmitter agents|cardiovascular agents|agents that reduce seizure threshold|alkaloids|cytochrome p 450 substrates|enzyme inhibitors|xanthine derivatives|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|pharmaceutical preparations|diamines|drugs for obstructive airway diseases|cytochrome p 450 cyp2e1 substrates with a narrow therapeutic index|heterocyclic compounds, fused ring|respiratory system agents|compounds used in a research, industrial, or household setting|cytochrome p 450 cyp3a substrates|peripheral nervous system agents|cytochrome p 450 cyp2e1 substrates|bronchodilator agents|cardiotonic agents|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs|purines|autonomic agents
quetiapine	agents producing tachycardia|central nervous system agents|serotonin receptor antagonists|tranquilizing agents|drugs that are mainly renally excreted|thiepins|adrenergic alpha 1 receptor antagonists|diazepines, oxazepines, thiazepines and oxepines|psycholeptics|cytochrome p 450 cyp3a4 substrates|thiazepines|p glycoprotein substrates|adrenergic antagonists|serotonin 5 ht1 receptor antagonists|cytochrome p 450 cyp2c19 substrates|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|anticholinergic agents|serotonin 5 ht1a receptor antagonists|hypotensive agents|antipsychotic agents|agents that produce hypertension|central nervous system depressants|antidepressive agents|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|azepines|nervous system|hyperglycemia associated agents|dibenzothiazepines|moderate risk qtc prolonging agents|cytochrome p 450 substrates|serotonin 5 ht2 receptor antagonists|antipsychotic agents (second generation [atypical])|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|muscarinic antagonists|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|cytochrome p 450 cyp3a5 substrates|serotonin 5 ht2a receptor antagonists|psychotropic drugs|histamine antagonists|dopamine antagonists|histamine h1 antagonists
paclitaxel	oatp1b3 substrates|antineoplastic and immunomodulating agents|cytochrome p 450 cyp3a7 substrates with a narrow therapeutic index|taxane derivatives|antineoplastic agents|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|p glycoprotein substrates|cycloparaffins|hypotensive agents|microtubule inhibition|myelosuppressive agents|cytochrome p 450 cyp3a7 substrates|taxoids|antineoplastic agents, phytogenic|agents causing muscle toxicity|antimitotic agents|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|bsep/abcb11 substrates with a narrow therapeutic index|microtubule inhibitors|tubulin modulators|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|immunosuppressive agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|mitosis modulators|neurotoxic agents|cytochrome p 450 enzyme inducers|cardiotoxic antineoplastic agents|narrow therapeutic index drugs|diterpenes|p glycoprotein substrates with a narrow therapeutic index|bsep/abcb11 substrates|terpenes|bsep/abcb11 inhibitors|cytochrome p 450 cyp2c8 substrates with a narrow therapeutic index|cyclodecanes|cytochrome p 450 cyp2c8 substrates
pemoline	central nervous system stimulants|nervous system|psychoanaleptics|central nervous system agents|psychostimulants, agents used for adhd and nootropics|centrally acting sympathomimetics|oxazoles
diphenidol	agents producing tachycardia|peripheral nervous system agents|central nervous system agents|anticholinergic agents|gastrointestinal agents|emesis suppression|antiemetics|autonomic agents|muscarinic antagonists
saquinavir	hiv protease inhibitors|cytochrome p 450 cyp2c8 inhibitors|bcrp/abcg2 inhibitors|cytochrome p 450 cyp3a4 inhibitors (strong)|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp3a7 inhibitors (strength unknown)|antivirals for systemic use|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp2d6 inhibitors (weak)|cytochrome p 450 cyp2c8 inhibitors (moderate)|cytochrome p 450 cyp3a5 inhibitors|p glycoprotein inducers|oatp1b1/slco1b1 inhibitors|quinolines|anti retroviral agents|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|hyperglycemia associated agents|cytochrome p 450 cyp3a4 inhibitors|moderate risk qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|anti infective agents|antiviral agents|cytochrome p 450 cyp3a inhibitors|isoquinolines|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a7 inhibitors (weak)|cytochrome p 450 cyp3a7 inhibitors|cytochrome p 450 cyp3a7 inhibitors (strong)|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 inhibitors (strong)|cytochrome p 450 cyp3a5 substrates|antiinfectives for systemic use|oct1 inhibitors|protease inhibitors|anti hiv agents|bsep/abcb11 substrates|cytochrome p 450 cyp3a5 inhibitors (strength unknown)|direct acting antivirals
metoclopramide	central nervous system agents|drugs that are mainly renally excreted|benzoates|aminobenzoates|cytochrome p 450 cyp3a4 substrates|hydroxybenzoates|p glycoprotein substrates|cholinesterase inhibitors|serotonergic drugs shown to increase risk of serotonin syndrome|central nervous system depressants|neurotransmitter agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|amides|cytochrome p 450 enzyme inhibitors|para aminobenzoates|agents causing muscle toxicity|gastrointestinal agents|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|prokinetic agents|chlorobenzoates|potential qtc prolonging agents|dopamine d2 receptor antagonists|drugs for functional gastrointestinal disorders|cytochrome p 450 cyp2d6 substrates|propulsives|cytochrome p 450 cyp3a substrates|methemoglobinemia associated agents|peripheral nervous system agents|alimentary tract and metabolism|dopamine agents|benzamides and benzamide derivatives|acids, carbocyclic|cytochrome p 450 cyp1a2 substrates|antiemetics|autonomic agents|dopamine antagonists
dexamethasone	stomatological preparations|cytochrome p 450 cyp2b6 inducers (strength unknown)|cytochrome p 450 cyp3a inducers (strong)|corticosteroids|cytochrome p 450 cyp3a7 substrates|gastrointestinal agents|cytochrome p 450 cyp3a7 inducers (strength unknown)|vasoprotectives|pregnadienetriols|cytochrome p 450 cyp3a4 inducers (moderate)|corticosteroid hormone receptor agonists|immunosuppressive agents|otologicals|steroids|cytochrome p 450 cyp3a7 inducers|oat3/slc22a8 substrates|adrenal cortex hormones|bsep/abcb11 inducers|cytochrome p 450 cyp2e1 inducers (strength unknown)|ophthalmologicals|cytochrome p 450 cyp3a5 inducers (moderate)|cytochrome p 450 cyp3a4 substrates|fused ring compounds|p glycoprotein inducers|cytochrome p 450 cyp3a4 inducers (strong)|steroids, fluorinated|corticosteroids for local oral treatment|cytochrome p 450 enzyme inhibitors|corticosteroids, moderately potent (group ii)|cytochrome p 450 substrates|cytochrome p 450 cyp2c19 inducers (strength unknown)|hormones|sensory organs|antiemetics|pregnadienes|cytochrome p 450 cyp3a5 inducers|inducers of drug clearance|hormones, hormone substitutes, and hormone antagonists|corticosteroids for systemic use|central nervous system agents|bcrp/abcg2 inhibitors|cytochrome p 450 cyp3a4 inducers|p glycoprotein inhibitors|ophthalmological and otological preparations|cytochrome p 450 cyp2a6 inducers|cytochrome p 450 cyp2c19 inducers|cytochrome p 450 cyp2b6 inducers|anti inflammatory agents|cytochrome p 450 cyp2c8 inducers|adrenals|cytochrome p 450 cyp2e1 inducers|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|peripheral nervous system agents|corticosteroids, dermatological preparations|autonomic agents|systemic hormonal preparations, excl. sex hormones and insulins|antineoplastic agents|cytochrome p 450 cyp3a4 inhibitors (weak)|cytochrome p 450 cyp2c8 inducers (strength unknown)|experimental unapproved treatments for covid 19|anti acne preparations for topical use|p glycoprotein substrates|antineoplastic agents, hormonal|corticosteroids for systemic use, plain|agents causing muscle toxicity|hyperglycemia associated agents|cytochrome p 450 cyp3a4 inhibitors|anti acne preparations|pregnanes|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a inhibitors|nasal preparations|dermatologicals|cytochrome p 450 enzyme inducers|alimentary tract and metabolism|agents for treatment of hemorrhoids and anal fissures for topical use
levodopa	amino acids, peptides, and proteins|amino acids, cyclic|central nervous system agents|anti dyskinesia agents|catechols|levodopa, antagonists & inhibitors|amines|phenylalanine|amino acids, aromatic|dopa and dopa derivatives|anti parkinson agents (dopamine agonist)|serotonergic drugs shown to increase risk of serotonin syndrome|hypotensive agents|amino acids|central nervous system depressants|neurotransmitter agents|nervous system|phenols|anti parkinson drugs|biogenic monoamines|amino acids, essential|catecholamines|dihydroxyphenylalanine|dopamine agents|biogenic amines|benzene derivatives
aripiprazole	agents producing tachycardia|serotonin 5 ht1 receptor agonists|central nervous system agents|serotonin receptor antagonists|tranquilizing agents|piperazines|adrenergic alpha 1 receptor antagonists|psycholeptics|cytochrome p 450 cyp3a4 substrates|adrenergic antagonists|serotonin 5 ht1 receptor antagonists|serotonin 5 ht1d receptor antagonists|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|anticholinergic agents|antipsychotic agents|agents that produce hypertension|qtc shortening agents|central nervous system depressants|neurotransmitter agents|antidepressive agents|quinolines|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|nervous system|hyperglycemia associated agents|cytochrome p 450 substrates|quinolones|histamine antagonists|serotonin 5 ht2 receptor antagonists|potential qtc prolonging agents|antipsychotic agents (second generation [atypical])|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|muscarinic antagonists|cytochrome p 450 cyp2d6 substrates|serotonin 5 ht2c receptor antagonists|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|cytochrome p 450 cyp3a5 substrates|neurotoxic agents|serotonin 5 ht2a receptor antagonists|psychotropic drugs|dopamine agents|aripiprazole and prodrugs|dopamine agonists|dopamine antagonists|serotonin receptor agonists|histamine h1 antagonists
chlorprothixene	agents producing tachycardia|central nervous system agents|serotonin receptor antagonists|tranquilizing agents|psycholeptics|p glycoprotein inhibitors|serotonin agents|thioxanthenes|anticholinergic agents|antipsychotic agents|central nervous system depressants|thioxanthene derivatives|neurotransmitter agents|antidepressive agents|qtc prolonging agents|nervous system|antipsychotic agents (first generation [typical])|serotonin 5 ht2 receptor antagonists|potential qtc prolonging agents|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|muscarinic antagonists|neurotoxic agents|serotonin 5 ht2a receptor antagonists|psychotropic drugs|dopamine agents|sulfur compounds|xanthenes|histamine antagonists|dopamine antagonists|histamine h1 antagonists
gemfibrozil	acids, acyclic|ugt1a3 substrates|cytochrome p 450 cyp2c8 inhibitors|drugs causing inadvertant photosensitivity|oatp1b3 inhibitors|drugs that are mainly renally excreted|cytochrome p 450 cyp2c8 inducers (strength unknown)|lipid regulating agents|ugt2b7 substrates|peroxisome proliferator receptor alpha agonist|cytochrome p 450 cyp3a4 substrates|ugt1a1 inhibitors|butyrates|photosensitizing agents|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|oat3/slc22a8 inhibitors|fatty acids|ugt1a3 inhibitors|lipid modifying agents|ethers|isobutyrates|oatp1b1/slco1b1 inhibitors|hypolipidemic agents indicated for hyperlipidemia|valerates|phenols|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2c9 inhibitors (strong)|agents causing muscle toxicity|fatty acids, volatile|cytochrome p 450 cyp2c8 inducers|cytochrome p 450 substrates|enzyme inhibitors|fribic acid derivatives|phenyl ethers|chemically induced disorders|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strong)|cytochrome p 450 cyp1a2 inhibitors|lipid modifying agents, plain|noxae|pentanoic acids|cytochrome p 450 cyp2c19 inhibitors|hypolipidemic agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 enzyme inducers|ugt1a9 substrates|peroxisome proliferator activated receptor alpha agonists|lipids|benzene derivatives|cytochrome p 450 cyp2c8 inhibitors (strong)|ugt1a1 substrates|fibric acids|toxic actions
clomipramine	cytochrome p 450 cyp2c19 substrates with a narrow therapeutic index|membrane transport modulators|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|psychoanaleptics|central nervous system agents|serotonin receptor antagonists|drugs that are mainly renally excreted|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|cytochrome p 450 cyp2c19 substrates|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|cytochrome p 450 cyp2b6 substrates|cytochrome p 450 cyp2d6 substrates with a narrow therapeutic index|hypotensive agents|agents that produce hypertension|serotonin modulators|tertiary amine tricyclic antidepressants|central nervous system depressants|neurotransmitter agents|antidepressive agents|dibenzazepines|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|nervous system|agents that reduce seizure threshold|antidepressive agents, tricyclic|cytochrome p 450 enzyme inhibitors|moderate risk qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|non selective monoamine reuptake inhibitors|serotonin 5 ht2 receptor antagonists|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp2c19 inhibitors (strong)|heterocyclic compounds, fused ring|serotonin 5 ht2c receptor antagonists|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|neurotoxic agents|combined inhibitors of serotonin/norepinephrine reuptake|neurotransmitter uptake inhibitors|serotonin 5 ht2a receptor antagonists|psychotropic drugs|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs|tricyclics and other norepinephrine reuptake inhibitors
chloroxine	antifungal agents|anti bacterial agents|anti infective agents|quinolines|heterocyclic compounds, fused ring|hydroxyquinolines
bepridil	membrane transport modulators|calcium regulating hormones and agents|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|p glycoprotein inhibitors|hypotensive agents|antiarrhythmic agents|phenylalkylamine derivatives|calcium channel blockers|pyrrolidines|cardiovascular agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|vasodilating agents|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|cytochrome p 450 cyp2d6 substrates|non selective calcium channel blockers|cytochrome p 450 cyp3a substrates|antihypertensive agents|agents causing hyperkalemia|highest risk qtc prolonging agents
alimemazine	phenothiazines|histamine agents|antipsychotic agents|central nervous system depressants|antihistamines for systemic use|neurotransmitter agents|qtc prolonging agents|phenothiazine derivatives|cytochrome p 450 cyp3a inducers|potential qtc prolonging agents|heterocyclic compounds, fused ring|neurotoxic agents|antipruritics|cytochrome p 450 enzyme inducers|dermatologicals|sulfur compounds|histamine antagonists|histamine h1 antagonists
isocarboxazid	drugs causing inadvertant photosensitivity|psychoanaleptics|central nervous system agents|monoamine oxidase inhibitors, non selective|photosensitizing agents|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|hypotensive agents|serotonin modulators|agents that produce hypertension|central nervous system depressants|antidepressive agents|nervous system|agents that reduce seizure threshold|enzyme inhibitors|isoxazoles|monoamine oxidase a inhibitors  for interaction with monoamine oxidase a substrates|monoamine oxidase inhibitors|psychotropic drugs
docetaxel	oatp1b3 substrates|antineoplastic and immunomodulating agents|cytochrome p 450 cyp3a7 substrates with a narrow therapeutic index|taxane derivatives|antineoplastic agents|hepatotoxic agents|cytochrome p 450 cyp3a4 substrates|p glycoprotein substrates|cycloparaffins|microtubule inhibition|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|bcrp/abcg2 substrates|myelosuppressive agents|cytochrome p 450 cyp3a7 substrates|taxoids|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|antimitotic agents|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|microtubule inhibitors|tubulin modulators|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a inhibitors|immunosuppressive agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|mitosis modulators|cardiotoxic antineoplastic agents|narrow therapeutic index drugs|diterpenes|p glycoprotein substrates with a narrow therapeutic index|terpenes|cyclodecanes
iodixanol	x ray contrast activity|compounds used in a research, industrial, or household setting|iodobenzoates|diagnostic uses of chemicals|acids, carbocyclic|contrast media|drugs that are mainly renally excreted|iodinated contrast agents|x ray contrast media, iodinated|benzene derivatives|benzoates|radiographic contrast agent|roentgenography|watersoluble, nephrotropic, low osmolar x ray contrast media
gliquidone	drugs used in diabetes|alimentary tract and metabolism|sulfones|sulfonylureas|sulfur compounds|cytochrome p 450 substrates|blood glucose lowering agents|cytochrome p 450 cyp2c9 substrates
ergometrine	agents producing tachycardia|uterotonic agents|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|ergolines|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|serotonin modulators|agents that produce hypertension|adrenergic alpha 1 receptor agonists|central nervous system depressants|antidepressive agents|cytochrome p 450 enzyme inhibitors|adrenergic agonists|alkaloids|cytochrome p 450 substrates|adrenergic alpha agonists|cytochrome p 450 cyp3a inhibitors|heterocyclic compounds, fused ring|ergot alkaloids and derivatives|cytochrome p 450 cyp3a substrates|reproductive control agents|genito urinary system and sex hormones
dasatinib	drugs causing inadvertant photosensitivity|thiazoles|antineoplastic and immunomodulating agents|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|pyrimidines|bcrp/abcg2 inhibitors|antineoplastic agents|cytochrome p 450 cyp3a4 inhibitors (weak)|kinase inhibitor|cytochrome p 450 cyp3a4 substrates|tyrosine kinase inhibitors|p glycoprotein inhibitors|p glycoprotein substrates|photosensitizing agents|bcrp/abcg2 substrates|myelosuppressive agents|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a inhibitors|protein kinase inhibitors|potential qtc prolonging agents|immunosuppressive agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|sulfur compounds
lapatinib	cytochrome p 450 cyp2c8 inhibitors|antineoplastic and immunomodulating agents|antineoplastic agents|cytochrome p 450 cyp3a4 inhibitors (weak)|kinase inhibitor|hepatotoxic agents|cytochrome p 450 cyp3a4 substrates|tyrosine kinase inhibitors|p glycoprotein inhibitors|cytochrome p 450 cyp2c19 substrates|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp3a inhibitors|protein kinase inhibitors|potential qtc prolonging agents|heterocyclic compounds, fused ring|quinazolines|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp2c8 substrates
sitagliptin	hormones, hormone substitutes, and hormone antagonists|drugs used in diabetes|incretins|triazoles|drugs that are mainly renally excreted|hypoglycemia associated agents|cytochrome p 450 cyp3a4 substrates|p glycoprotein substrates|dpp iv inhibitors|blood glucose lowering agents|agents causing angioedema|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp3a substrates|protease inhibitors|alimentary tract and metabolism|hormones|cytochrome p 450 cyp2c8 substrates|oat3/slc22a8 substrates
decitabine	carbohydrates|antineoplastic and immunomodulating agents|pyrimidines|antineoplastic agents|aza compounds|nucleosides|myelosuppressive agents|nucleoside metabolic inhibitor|ribonucleosides|nucleic acid synthesis inhibitors|glycosides|enzyme inhibitors|nucleic acids, nucleotides, and nucleosides|noxae|pyrimidine analogues|immunosuppressive agents|cytidine deaminase substrates|pyrimidine nucleosides|antimetabolites|narrow therapeutic index drugs|toxic actions
sunitinib	angiogenesis inhibitors|antineoplastic and immunomodulating agents|cytochrome p 450 cyp3a7 substrates with a narrow therapeutic index|bcrp/abcg2 inhibitors|antineoplastic agents|angiogenesis modulating agents|kinase inhibitor|hepatotoxic agents|cytochrome p 450 cyp3a4 substrates|hypoglycemia associated agents|tyrosine kinase inhibitors|p glycoprotein inhibitors|p glycoprotein substrates|indoles|blood glucose lowering agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|growth inhibitors|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a inhibitors|protein kinase inhibitors|potential qtc prolonging agents|heterocyclic compounds, fused ring|immunosuppressive agents|growth substances|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|narrow therapeutic index drugs
varenicline	quinoxalines|nervous system|cholinergic agents|miscellaneous autonomic drugs|drugs used in nicotine dependence|smoking cessation agents|benzazepines|cholinergic agonists|heterocyclic compounds, fused ring|oct2 substrates|partial cholinergic nicotinic agonist|drugs used in addictive disorders|drugs that are mainly renally excreted|oct2 inhibitors|neurotransmitter agents|partial cholinergic nicotinic agonists|nicotinic agonists
hydralazine	hydrazinophthalazine derivatives|drugs that are mainly renally excreted|antihypertensive agents indicated for hypertension|hypotensive agents|pyridazines|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cardiovascular agents|cytochrome p 450 enzyme inhibitors|vasodilating agents|cytochrome p 450 cyp3a4 inhibitors|phthalazines|cytochrome p 450 cyp3a inhibitors|arteriolar smooth muscle, agents acting on|hydrazinophthalazine derivatives and diuretics|antihypertensive agents|arteriolar vasodilation|arteriolar vasodilator|direct vasodilators
carbetocin	hormones, hormone substitutes, and hormone antagonists|amino acids, peptides, and proteins|uterotonic agents|delayed action preparations|investigative techniques|peptides|hypotensive agents|posterior pituitary lobe hormones|peptide hormones|drug delivery systems|pharmaceutical preparations|reproductive control agents|hormones|pituitary and hypothalamic hormones and analogues|pituitary hormones, posterior|oxytocin and analogues|pituitary hormones|systemic hormonal preparations, excl. sex hormones and insulins
fenoterol	agents producing tachycardia|anti asthmatic agents|adrenergic agents|catechols|agents to treat airway disease|tocolytic agents|amines|adrenergic beta 2 receptor agonists|anticholinergic agents|agents that produce hypertension|neurotransmitter agents|sympathomimetics, labour repressants|sympathomimetics|phenols|adrenergic agonists|metaproterenol|adrenergics, inhalants|adrenergic beta agonists|drugs for obstructive airway diseases|respiratory system agents|ethanolamines|peripheral nervous system agents|reproductive control agents|bronchodilator agents|genito urinary system and sex hormones|adrenergics for systemic use|amino alcohols|autonomic agents|benzene derivatives|selective beta 2 adrenergic agonists|alcohols
glucosamine	carbohydrates|amino sugars|musculo skeletal system|antiinflammatory and antirheumatic products|hexosamines|antiinflammatory and antirheumatic products, non steroids
practolol	propanolamines|adrenergic agents|phenoxypropanolamines|amines|bradycardia causing agents|beta blocking agents, selective|adrenergic antagonists|antiarrhythmic agents|neurotransmitter agents|cardiovascular agents|acetanilides|amides|anilides|adrenergic beta 1 receptor antagonists|propanols|adrenergic beta antagonists|cytochrome p 450 substrates|cytochrome p 450 cyp2d6 substrates|aniline compounds|antihypertensive agents|agents causing hyperkalemia|amino alcohols|alcohols
sulfadoxine	amides|aniline compounds|sulfonamides|sulfanilamides|long acting sulfonamides|anti infective agents, urinary|renal agents|sulfones|genito urinary system and sex hormones|sulfur compounds|anti infective agents|antimalarials|antiprotozoals|gynecological antiinfectives and antiseptics|amines|antiparasitic agents
rolitetracycline	tetracyclines|naphthacenes|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|agents that produce neuromuscular block (indirect)|anti infective agents
josamycin	macrolides|cytochrome p 450 enzyme inhibitors|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|polyketides|macrolides, lincosamides and streptogramins|anti infective agents|cytochrome p 450 cyp3a inhibitors|lactones
quinethazone	gynecological antiinfectives and antiseptics|amides|membrane transport modulators|sulfonamides|diuretics|heterocyclic compounds, fused ring|low ceiling diuretics, excl. thiazides|sulfones|natriuretic agents|genito urinary system and sex hormones|sodium chloride symporter inhibitors|sulfur compounds|cardiovascular agents
cefazolin	amides|nephrotoxic agents|oat1/slc22a6 substrates|thiazines|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|cephalosporins|heterocyclic compounds, fused ring|oat3/slc22a8 inhibitors|sulfur compounds|first generation cephalosporins|oat1/slc22a6 inhibitors|beta lactams|anti infective agents|lactams|oat3/slc22a8 substrates
cefotetan	amides|nephrotoxic agents|thiazines|tetrazoles|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|cephalosporins|heterocyclic compounds, fused ring|sulfur compounds|drugs that are mainly renally excreted|second generation cephalosporins|beta lactams|anti infective agents|cephamycins|lactams
cefoxitin	amides|nephrotoxic agents|thiazines|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|cephalosporins|heterocyclic compounds, fused ring|sulfur compounds|second generation cephalosporins|beta lactams|anti infective agents|cephamycins|lactams
pancuronium	agents producing tachycardia|nicotinic antagonists|muscle relaxants|androstanes|musculo skeletal system|fused ring compounds|cholinesterase inhibitors|anticholinergic agents|oct1 substrates|central nervous system depressants|neuromuscular agents|neurotransmitter agents|neuromuscular nondepolarizing blockade|cholinergic agents|neuromuscular blocking agents (nondepolarizing)|androstanols|muscarinic antagonists|oct1 inhibitors|peripheral nervous system agents|steroids|neuromuscular blocking agents|muscle relaxants, peripherally acting agents
vecuronium	nicotinic antagonists|muscle relaxants|androstanes|musculo skeletal system|fused ring compounds|p glycoprotein substrates|anticholinergic agents|central nervous system depressants|neuromuscular agents|neurotransmitter agents|neuromuscular nondepolarizing blockade|cholinergic agents|neuromuscular blocking agents (nondepolarizing)|androstanols|peripheral nervous system agents|steroids|neuromuscular blocking agents|muscle relaxants, peripherally acting agents
mestranol	hormones, hormone substitutes, and hormone antagonists|norsteroids|gonadal steroid hormones|adrenal cortex hormones|thyroxine binding globulin inducers|ethinyl estradiol|estrogen contraceptives|norpregnatrienes|cytochrome p 450 cyp3a4 substrates|fused ring compounds|hormonal contraceptives for systemic use|hyperglycemia associated agents|norpregnanes|estrogens|cytochrome p 450 substrates|contraceptive agents, female|cytochrome p 450 cyp2c9 substrates|estrogenic steroids, alkylated|cytochrome p 450 cyp3a substrates|steroids|hormones|estradiol congeners|gonadal hormones|cytochrome p 450 cyp2c8 substrates
penbutolol	propanolamines|beta blocking agents, non selective|serotonin receptor antagonists|adrenergic agents|drugs that are mainly renally excreted|phenoxypropanolamines|amines|bradycardia causing agents|adrenergic antagonists|serotonin 5 ht1 receptor antagonists|serotonin agents|serotonin 5 ht1a receptor antagonists|hypotensive agents|central nervous system depressants|neurotransmitter agents|antidepressive agents|cardiovascular agents|propanols|adrenergic beta antagonists|cytochrome p 450 substrates|cytochrome p 450 cyp2d6 substrates|antihypertensive agents|agents causing hyperkalemia|amino alcohols|alcohols
iohexol	x ray contrast activity|agents that reduce seizure threshold|compounds used in a research, industrial, or household setting|iodobenzoates|diagnostic uses of chemicals|acids, carbocyclic|contrast media|iodinated contrast agents|triiodobenzoic acids|benzene derivatives|benzoates|x ray contrast media, iodinated|radiographic contrast agent|roentgenography|watersoluble, nephrotropic, low osmolar x ray contrast media
ephedrine	propanolamines|agents producing tachycardia|central nervous system stimulants|norepinephrine releasing agent|central nervous system agents|adrenergic agents|centrally acting antiobesity products|ophthalmologicals|amines|increased norepinephrine activity|epinephrine and similars|mydriatics and cycloplegics|herbs and natural products|vasoconstrictor agents|agents that produce hypertension|central nervous system depressants|neurotransmitter agents|antidepressive agents|cardiovascular agents|antiobesity preparations, excl. diet products|cardiac stimulants excl. cardiac glycosides|sympathomimetics|sympathomimetics excl. antiglaucoma preparations|alpha and beta adrenergic agonists|adrenergic agonists|propanols|ethylamines|adrenergic alpha agonists|cholinesterase substrates|adrenergic beta agonists|drugs for obstructive airway diseases|sympathomimetics, plain|peripheral nervous system agents|nasal preparations|alimentary tract and metabolism|sympathomimetic (adrenergic) agents|adrenergics for systemic use|adrenergic and dopaminergic agents|sensory organs|amino alcohols|autonomic agents|cardiac therapy|phenethylamines|alcohols
mephentermine	agents producing tachycardia|adrenergic agents|amines|serotonergic drugs shown to increase risk of serotonin syndrome|vasoconstrictor agents|agents that produce hypertension|adrenergic alpha 1 receptor agonists|neurotransmitter agents|cardiovascular agents|cardiac stimulants excl. cardiac glycosides|sympathomimetics|adrenergic agonists|ethylamines|adrenergic alpha agonists|amphetamines|peripheral nervous system agents|adrenergic and dopaminergic agents|autonomic agents|cardiac therapy|phenethylamines
procaterol	agents producing tachycardia|anti asthmatic agents|adrenergic agents|amines|adrenergic beta 2 receptor agonists|agents that produce hypertension|neurotransmitter agents|quinolines|hydroxyquinolines|sympathomimetics|adrenergic agonists|adrenergics, inhalants|adrenergic beta agonists|heterocyclic compounds, fused ring|drugs for obstructive airway diseases|respiratory system agents|ethanolamines|peripheral nervous system agents|bronchodilator agents|adrenergics for systemic use|amino alcohols|autonomic agents|selective beta 2 adrenergic agonists|alcohols
cortisone acetate	hormones, hormone substitutes, and hormone antagonists|corticosteroids for systemic use|adrenal cortex hormones|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|corticosteroids|cytochrome p 450 cyp3a5 inducers (strength unknown)|hydroxycorticosteroids|17 hydroxycorticosteroids|hyperglycemia associated agents|anti inflammatory agents|pregnanes|cytochrome p 450 substrates|cytochrome p 450 cyp3a inducers|immunosuppressive agents|adrenals|cytochrome p 450 cyp3a substrates|glucocorticoids|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|pregnenes|hormones|steroids|cytochrome p 450 cyp3a5 inducers
mibefradil	membrane transport modulators|calcium regulating hormones and agents|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|cytochrome p 450 cyp3a7 inhibitors (strength unknown)|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|cytochrome p 450 cyp3a5 inhibitors|antiarrhythmic agents|calcium channel blockers|selective calcium channel blockers with mainly vascular effects|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cardiovascular agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|benzimidazoles|vasodilating agents|cytochrome p 450 cyp3a4 inhibitors|moderate risk qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp3a inhibitors|chemically induced disorders|cytochrome p 450 cyp1a2 inhibitors|heterocyclic compounds, fused ring|tetrahydronaphthalenes|cytochrome p 450 cyp3a7 inhibitors|cytochrome p 450 cyp3a substrates|antihypertensive agents|agents causing hyperkalemia|cytochrome p 450 cyp3a5 inhibitors (strength unknown)|naphthalenes
yohimbine	mydriatics|urological agents|serotonin receptor antagonists|adrenergic agents|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|adrenergic antagonists|indoles|serotonin 5 ht1 receptor antagonists|serotonin 5 ht1d receptor antagonists|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|adrenergic alpha 2 receptor antagonists|agents that produce hypertension|indole alkaloids|central nervous system depressants|neurotransmitter agents|other miscellaneous therapeutic agents|antidepressive agents|urologicals|drugs used in erectile dysfunction|alkaloids|cytochrome p 450 substrates|serotonin 5 ht2 receptor antagonists|heterocyclic compounds, fused ring|serotonin 5 ht2c receptor antagonists|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|peripheral nervous system agents|serotonin 5 ht2a receptor antagonists|genito urinary system and sex hormones|autonomic agents|dopamine antagonists|secologanin tryptamine alkaloids
bezafibrate	acids, acyclic|cytochrome p 450 cyp2c8 inhibitors|lipid regulating agents|benzoates|cytochrome p 450 cyp3a4 substrates|butyrates|fatty acids|lipid modifying agents|ethers|isobutyrates|oatp1b1/slco1b1 inhibitors|hypolipidemic agents indicated for hyperlipidemia|amides|phenols|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|fatty acids, volatile|cytochrome p 450 substrates|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|fribic acid derivatives|phenyl ethers|chlorobenzoates|lipid modifying agents, plain|noxae|hypolipidemic agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2c8 inhibitors (weak)|benzamides and benzamide derivatives|acids, carbocyclic|lipids|benzene derivatives|fibric acids|toxic actions
colchicine	cytochrome p 450 cyp2c8 inhibitors|cytochrome p 450 cyp2b6 inhibitors (strength unknown)|cytochrome p 450 cyp2e1 inducers (strength unknown)|drugs that are mainly renally excreted|experimental unapproved treatments for covid 19|cytochrome p 450 cyp3a4 inducers|musculo skeletal system|cytochrome p 450 cyp3a4 substrates|p glycoprotein substrates|p glycoprotein inducers|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|antigout preparations|cytochrome p 450 cyp2b6 inhibitors|cytochrome p 450 enzyme inhibitors|agents causing muscle toxicity|antimitotic agents|cytochrome p 450 cyp3a4 inhibitors|alkaloids|preparations with no effect on uric acid metabolism|cytochrome p 450 substrates|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|tubulin modulators|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a inducers|immunosuppressive agents|cytochrome p 450 cyp2e1 inducers|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|mitosis modulators|cytochrome p 450 enzyme inducers
digitoxin	carbohydrates|cardenolides|cardiac glycosides|cytochrome p 450 cyp3a4 substrates|fused ring compounds|p glycoprotein substrates|digitalis glycosides|protective agents|antiarrhythmic agents|cardiovascular agents|qtc prolonging agents|cytochrome p 450 substrates|glycosides|enzyme inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|potential qtc prolonging agents|compounds used in a research, industrial, or household setting|cytochrome p 450 cyp3a substrates|steroids|cardiotonic agents|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|cardiac therapy|cardanolides
neostigmine	parasympathomemetic (cholinergic) agents|ophthalmologicals|amines|cholinesterase inhibitors|quaternary ammonium compounds|ammonium compounds|neurotransmitter agents|antiglaucoma preparations and miotics|nervous system|cholinergic agents|onium compounds|phenylammonium compounds|nitrogen compounds|enzyme inhibitors|parasympathomimetics|peripheral nervous system agents|sensory organs|autonomic agents
levomepromazine	phenothiazines|agents producing tachycardia|drugs causing inadvertant photosensitivity|cytochrome p 450 cyp2d6 inhibitors (strong)|sensory system agents|central nervous system agents|serotonin receptor antagonists|tranquilizing agents|adrenergic alpha 1 receptor antagonists|psycholeptics|adrenergic antagonists|photosensitizing agents|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|analgesics|anticholinergic agents|cytochrome p 450 cyp2e1 inhibitors|antipsychotic agents|agents that produce hypertension|central nervous system depressants|neurotransmitter agents|antidepressive agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|nervous system|cytochrome p 450 enzyme inhibitors|hyperglycemia associated agents|antipsychotic agents (first generation [typical])|cytochrome p 450 substrates|serotonin 5 ht2 receptor antagonists|analgesics, non narcotic|potential qtc prolonging agents|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|muscarinic antagonists|cytochrome p 450 cyp2d6 substrates|serotonin 5 ht2c receptor antagonists|neurotoxic agents|adrenergic alpha antagonists|peripheral nervous system agents|serotonin 5 ht2a receptor antagonists|phenothiazines with aliphatic side chain|psychotropic drugs|dopamine agents|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|sulfur compounds|histamine antagonists|dopamine antagonists|histamine h1 antagonists
danazol	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|estrogen antagonists|cytochrome p 450 cyp3a4 inhibitors (strong)|fused ring compounds|sex hormones and modulators of the genital system|cytochrome p 450 enzyme inhibitors|hyperglycemia associated agents|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a4 inhibitors (moderate)|pregnanes|cytochrome p 450 cyp3a inhibitors|steroids|genito urinary system and sex hormones|thyroxine binding globulin inhibitors|pregnadienes|androgens|antigonadotropins and similar agents
clenbuterol	agents producing tachycardia|anti asthmatic agents|adrenergic agents|agents to treat airway disease|amines|adrenergic beta 2 receptor agonists|agents that produce hypertension|neurotransmitter agents|sympathomimetics|adrenergic agonists|adrenergics, inhalants|adrenergic beta agonists|drugs for obstructive airway diseases|respiratory system agents|ethanolamines|peripheral nervous system agents|bronchodilator agents|adrenergics for systemic use|amino alcohols|autonomic agents|selective beta 2 adrenergic agonists|alcohols
bambuterol	agents producing tachycardia|anti asthmatic agents|delayed action preparations|agents to treat airway disease|amines|adrenergic beta 2 receptor agonists|cholinesterase inhibitors|agents that produce hypertension|adrenergic agonists|cholinesterase substrates|adrenergic beta agonists|drugs for obstructive airway diseases|respiratory system agents|ethanolamines|peripheral nervous system agents|bronchodilator agents|prodrugs|adrenergics for systemic use|amino alcohols|autonomic agents|selective beta 2 adrenergic agonists|alcohols
pranlukast	respiratory system agents|benzopyrans|hormones, hormone substitutes, and hormone antagonists|hormone antagonists|cytochrome p 450 cyp3a substrates|anti asthmatic agents|cytochrome p 450 enzyme inhibitors|leukotriene antagonists|heterocyclic compounds, fused ring|drugs for obstructive airway diseases|pyrans|cytochrome p 450 substrates|agents to treat airway disease|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp3a4 substrates (strength unknown)
theobromine	anti asthmatic agents|purinones|cardiovascular agents|vasodilating agents|diuretics|alkaloids|low ceiling diuretics, excl. thiazides|cytochrome p 450 substrates|xanthine derivatives|heterocyclic compounds, fused ring|drugs for obstructive airway diseases|respiratory system agents|peripheral nervous system agents|cytochrome p 450 cyp2e1 substrates|bronchodilator agents|cytochrome p 450 cyp1a2 substrates|purines|autonomic agents
cefepime	amides|nephrotoxic agents|thiazines|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|cephalosporins|fourth generation cephalosporins|heterocyclic compounds, fused ring|sulfur compounds|beta lactams|anti infective agents|lactams
cefpodoxime	amides|nephrotoxic agents|thiazines|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|cephacetrile|cephalosporins|heterocyclic compounds, fused ring|prodrugs|sulfur compounds|third generation cephalosporins|beta lactams|anti infective agents|lactams
acenocoumarol	cytochrome p 450 cyp2c19 substrates with a narrow therapeutic index|vitamin k antagonists|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|coumarins|cytochrome p 450 cyp3a4 substrates|p glycoprotein substrates|cytochrome p 450 cyp2c19 substrates|blood and blood forming organs|benzopyrans|anticoagulants|hematologic agents|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|heterocyclic compounds, fused ring|4 hydroxycoumarins|cytochrome p 450 cyp3a substrates|pyrans|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|cytochrome p 450 cyp2c9 substrates with a narrow therapeutic index
testosterone propionate	hormones, hormone substitutes, and hormone antagonists|androstenes|gonadal steroid hormones|androstanes|drugs that are mainly renally excreted|cytochrome p 450 cyp3a4 substrates|fused ring compounds|ugt1a1 inducers|p glycoprotein substrates|testosterone congeners|comt inhibitors|testosterone and derivatives|cytochrome p 450 substrates|androstenols|cytochrome p 450 cyp3a substrates|steroids|hormones|gonadal hormones|thyroxine binding globulin inhibitors|androgens
paromomycin	carbohydrates|nephrotoxic agents|anti bacterial agents|alimentary tract and metabolism|amebicides|intestinal antiinfectives|glycosides|agents that produce neuromuscular block (indirect)|aminoglycoside antibacterials|drugs that are mainly renally excreted|anti infective agents|antiprotozoals|antidiarrheals, intestinal antiinflammatory/antiinfective agents|antiparasitic agents
alizapride	drugs for functional gastrointestinal disorders|propulsives|peripheral nervous system agents|alimentary tract and metabolism|central nervous system agents|gastrointestinal agents|antiemetics|autonomic agents|dopamine antagonists|dopamine d2 receptor antagonists
oxybenzone	compounds used in a research, industrial, or household setting|dermatologicals|household products|ketones|radiation protective agents|protective agents|sunscreen agents|drugs that are mainly renally excreted|benzene derivatives|cosmetics
phenazone	anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|sensory system agents|central nervous system agents|cytochrome p 450 cyp2a6 substrates|cytochrome p 450 cyp3a4 substrates|nephrotoxic agents|cytochrome p 450 cyp2c19 substrates|pyrazoles|analgesics|cytochrome p 450 cyp2b6 substrates|agents that produce hypertension|non cox 2 selective nsaids|cytochrome p 450 cyp2d6 inhibitors|nervous system|cytochrome p 450 enzyme inhibitors|pyrazolones|anti inflammatory agents|cytochrome p 450 substrates|oat1/slc22a6 inhibitors|cytochrome p 450 cyp2c9 substrates|analgesics, non narcotic|otologicals|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|methemoglobinemia associated agents|peripheral nervous system agents|agents causing hyperkalemia|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 cyp1a2 substrates|sensory organs|cytochrome p 450 cyp2c18 substrates|analgesics and anesthetics|cytochrome p 450 cyp2c8 substrates
alfacalcidol	cholestenes|vitamins (fat soluble)|musculo skeletal system|steroids|alimentary tract and metabolism|drugs for treatment of bone diseases|sterols|drugs affecting bone structure and mineralization|cholestanes|lipids|vitamin d and analogues|secosteroids|bone density conservation agents|vitamins|fused ring compounds|membrane lipids
phenazopyridine	urologicals|antipruritics and local anesthetics|nephrotoxic agents|pyridines|aminopyridines|methemoglobinemia associated agents|genito urinary system and sex hormones|drugs that are mainly renally excreted|amines
amt	indoles|stimulants|biogenic amines|biogenic monoamines|amines|heterocyclic compounds, fused ring
ethylestrenol	anabolic agents|hormones, hormone substitutes, and hormone antagonists|norsteroids|norpregnanes|alimentary tract and metabolism|hormones|norpregnenes|steroids|estren derivatives|anabolic steroids|anabolic agents for systemic use|fused ring compounds
androstenedione	hormones, hormone substitutes, and hormone antagonists|ketosteroids|cytochrome p 450 cyp3a substrates|androstenes|gonadal steroid hormones|adrenal cortex hormones|steroids|hormones|testosterone congeners|androstanes|gonadal hormones|cytochrome p 450 substrates|17 ketosteroids|cytochrome p 450 cyp3a4 substrates|fused ring compounds
metrizamide	carbohydrates|compounds used in a research, industrial, or household setting|iodobenzoates|diagnostic uses of chemicals|acids, carbocyclic|glycosides|contrast media|triiodobenzoic acids|benzene derivatives|benzoates|x ray contrast media, iodinated|watersoluble, nephrotropic, low osmolar x ray contrast media
oxprenolol	propanolamines|beta blocking agents, non selective|central nervous system agents|adrenergic agents|tranquilizing agents|phenoxypropanolamines|amines|bradycardia causing agents|adrenergic antagonists|hypotensive agents|oct2 inhibitors|antiarrhythmic agents|central nervous system depressants|neurotransmitter agents|cardiovascular agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|vasodilating agents|propanols|moderate risk qtc prolonging agents|adrenergic beta antagonists|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|beta blocking agents and thiazides|beta blocking agents, non selective, and thiazides|cytochrome p 450 cyp2d6 substrates|antihypertensive agents|peripheral nervous system agents|agents causing hyperkalemia|amino alcohols|autonomic agents|sympatholytics|alcohols|anti anxiety agents
sulfamerazine	amides|aniline compounds|sulfonamide antibacterial|sulfonamides|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|dermatologicals|long acting sulfonamides|sulfonamides and trimethoprim|sulfones|genito urinary system and sex hormones|sulfur compounds|anti infective agents|sulfanilamides|gynecological antiinfectives and antiseptics|amines
sulfadimidine	amides|aniline compounds|sulfonamides|antiinfectives for systemic use|antibacterials for systemic use|short acting sulfonamides|sulfonamides and trimethoprim|sulfones|genito urinary system and sex hormones|sulfur compounds|anti infective agents|sulfanilamides|gynecological antiinfectives and antiseptics|amines
everolimus	mtor inhibitors|antineoplastic and immunomodulating agents|anti bacterial agents|oatp1b3 inhibitors|antineoplastic agents|kinase inhibitor|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|mtor inhibitor immunosuppressant|p glycoprotein substrates|oatp1b1/slco1b1 inhibitors|myelosuppressive agents|decreased immunologic activity|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|hyperglycemia associated agents|cytochrome p 450 cyp3a4 inhibitors|selective immunosuppressants|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a inhibitors|protein kinase inhibitors|immunosuppressive agents|macrolides|cytochrome p 450 cyp3a substrates|polyketides|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|lactones|immunologic factors
solifenacin	agents producing tachycardia|urological agents|tetrahydroisoquinolines|drugs used in benign prostatic hypertrophy|cytochrome p 450 cyp3a4 substrates|quinuclidines|anticholinergic agents|drugs for urinary frequency and incontinence|agents that produce hypertension|neurotransmitter agents|qtc prolonging agents|urologicals|cholinergic agents|cytochrome p 450 substrates|isoquinolines|potential qtc prolonging agents|heterocyclic compounds, fused ring|muscarinic antagonists|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|genito urinary system and sex hormones
fer	transition elements|iron preparations|micronutrients|food|metals, heavy|food and beverages|supplements|iron compounds|blood and blood forming organs|elements|diet, food, and nutrition|organometallic compounds|physiological phenomena|growth substances|trace elements|antianemic preparations|alimentary tract and metabolism|metals|minerals|antianemia drugs
nitrazepam	hypnotics and sedatives|muscle relaxants|central nervous system agents|tranquilizing agents|psycholeptics|cytochrome p 450 cyp3a4 substrates|benzodiazepine hypnotics and sedatives|muscle relaxants, centrally acting agents|benzazepines|cytochrome p 450 cyp2e1 inhibitors|anticonvulsants|central nervous system depressants|neurotransmitter agents|benzodiazepines and benzodiazepine derivatives|nervous system|cytochrome p 450 enzyme inhibitors|gaba modulators|cytochrome p 450 substrates|gaba agents|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|psychotropic drugs|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|benzodiazepinones|anti anxiety agents
cilastatin	protease inhibitors|oat3/slc22a8 inhibitors|cycloparaffins|renal dehydropeptidase inhibitor|dipeptidase inhibitors|enzyme inhibitors|cyclopropanes|oat1/slc22a6 inhibitors
imipenem	amides|agents that reduce seizure threshold|neurotoxic agents|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|heterocyclic compounds, fused ring|penem antibacterial|sulfur compounds|beta lactams|anti infective agents|beta lactam antibacterials|thienamycins|lactams|carbapenems
probucol	antioxidants|hypolipidemic agents|phenols|compounds used in a research, industrial, or household setting|protective agents|moderate risk qtc prolonging agents|toxic actions|lipid modifying agents|anticholesteremic agents|lipid regulating agents|benzene derivatives|noxae|lipid modifying agents, plain|qtc prolonging agents
tiaprofenic acid	acids, acyclic|anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|sensory system agents|central nervous system agents|other nonsteroidal anti inflammatory agents|musculo skeletal system|nephrotoxic agents|photosensitizing agents|analgesics|fatty acids|agents that produce hypertension|non cox 2 selective nsaids|antiinflammatory and antirheumatic products, non steroids|anti inflammatory agents|fatty acids, volatile|analgesics, non narcotic|prostaglandin antagonists|antirheumatic agents|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|propionates|lipids
lopinavir	hiv protease inhibitors|cytochrome p 450 cyp2b6 inhibitors (strength unknown)|oatp1b3 inhibitors|cytochrome p 450 cyp2c9 inhibitors (weak)|cytochrome p 450 cyp3a4 inhibitors (strong)|experimental unapproved treatments for covid 19|cytochrome p 450 cyp3a4 substrates|antivirals for systemic use|nephrotoxic agents|p glycoprotein inhibitors|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|p glycoprotein inducers|cytochrome p 450 cyp2c9 inducers (strength unknown)|cytochrome p 450 cyp2c19 inhibitors (weak)|oatp1b1/slco1b1 inhibitors|anti retroviral agents|pyrimidinones|qtc prolonging agents|cytochrome p 450 cyp2b6 inhibitors (weak)|cytochrome p 450 cyp2b6 inhibitors|cytochrome p 450 enzyme inhibitors|hyperglycemia associated agents|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|enzyme inhibitors|organic anion transporting polypeptide 1b1 inhibitors|anti infective agents|antiviral agents|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp1a2 inhibitors|potential qtc prolonging agents|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|protease inhibitors|antiinfectives for systemic use|cytochrome p 450 enzyme inducers|cytochrome p 450 cyp1a2 substrates|anti hiv agents|direct acting antivirals|bsep/abcb11 inhibitors|cytochrome p 450 cyp2c9 inducers
bacampicilline	amides|penicillins with extended spectrum|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|heterocyclic compounds, fused ring|penicillin g|sulfur compounds|penicillins|beta lactams|anti infective agents|beta lactam antibacterials|lactams
pivampicillin	amides|penicillins with extended spectrum|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|heterocyclic compounds, fused ring|penicillin g|sulfur compounds|penicillins|beta lactams|anti infective agents|beta lactam antibacterials|lactams
pivmecillinam	amides|penicillins with extended spectrum|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|heterocyclic compounds, fused ring|anti infective agents, urinary|renal agents|sulfur compounds|penicillins|beta lactams|anti infective agents|beta lactam antibacterials|lactams
tazobactam	antibacterials for systemic use|aza compounds|azabicyclo compounds|beta lactam antibacterials|oat1/slc22a6 substrates|oat3/slc22a8 inhibitors|sulfones|beta lactams|amides|enzyme inhibitors|oat1/slc22a6 inhibitors|anti infective agents|beta lactamase inhibitors|heterocyclic compounds, fused ring|antiinfectives for systemic use|sulfur compounds|lactams|oat3/slc22a8 substrates
ticarcillin	amides|penicillins with extended spectrum|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|heterocyclic compounds, fused ring|sulfur compounds|penicillins|beta lactams|anti infective agents|beta lactam antibacterials|lactams
hydroxychloroquine	drugs causing inadvertant photosensitivity|aminoquinolines|cytochrome p 450 cyp3a4 substrates|antiparasitic products, insecticides and repellents|p glycoprotein inhibitors|photosensitizing agents|quinolines|antiparasitic agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|enzyme inhibitors|antimalarials|anti infective agents|potential qtc prolonging agents|antirheumatic agents|heterocyclic compounds, fused ring|immunosuppressive agents|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|antiprotozoals|cytochrome p 450 cyp2c8 substrates
acepromazine	phenothiazines|central nervous system agents|serotonin receptor antagonists|tranquilizing agents|adrenergic alpha 1 receptor antagonists|psycholeptics|adrenergic antagonists|serotonin 5 ht1 receptor antagonists|serotonin agents|serotonin 5 ht1a receptor antagonists|antipsychotic agents|agents that produce hypertension|central nervous system depressants|neurotransmitter agents|nervous system|serotonin 5 ht2 receptor antagonists|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|neurotoxic agents|adrenergic alpha antagonists|serotonin 5 ht2a receptor antagonists|phenothiazines with aliphatic side chain|psychotropic drugs|dopamine agents|sulfur compounds|dopamine antagonists
alverine	drugs for functional gastrointestinal disorders|parasympatholytics|peripheral nervous system agents|serotonin 5 ht1 receptor antagonists|alimentary tract and metabolism|serotonin agents|serotonin receptor antagonists|serotonin 5 ht1a receptor antagonists|central nervous system depressants|autonomic agents|antidepressive agents|amines
molindone	central nervous system agents|serotonin receptor antagonists|tranquilizing agents|psycholeptics|indoles|serotonin 5 ht1 receptor antagonists|serotonin agents|serotonin 5 ht1a receptor antagonists|antipsychotic agents|indole derivatives|central nervous system depressants|antidepressive agents|nervous system|antipsychotic agents (first generation [typical])|serotonin 5 ht2 receptor antagonists|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|neurotoxic agents|serotonin 5 ht2a receptor antagonists|psychotropic drugs|dopamine antagonists
pheniramine	antihistamines for topical use|histamine agents|pyridines|antipruritics|dermatologicals|anti allergic agents|antihistamines for systemic use|histamine antagonists|potential qtc prolonging agents|qtc prolonging agents|histamine h1 antagonists|antipruritics, incl. antihistamines, anesthetics, etc.
thioproperazine	phenothiazines|serotonin receptor antagonists|adrenergic alpha 1 receptor antagonists|psycholeptics|adrenergic antagonists|serotonin 5 ht1 receptor antagonists|serotonin agents|serotonin 5 ht1a receptor antagonists|antipsychotic agents|agents that produce hypertension|central nervous system depressants|phenothiazines with piperazine structure|antidepressive agents|nervous system|antipsychotic agents (first generation [typical])|serotonin 5 ht2 receptor antagonists|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|neurotoxic agents|adrenergic alpha antagonists|serotonin 5 ht2a receptor antagonists|sulfur compounds|dopamine antagonists
thiothixene	drugs causing inadvertant photosensitivity|central nervous system agents|serotonin receptor antagonists|tranquilizing agents|psycholeptics|photosensitizing agents|serotonin agents|thioxanthenes|antipsychotic agents|central nervous system depressants|thioxanthene derivatives|neurotransmitter agents|antidepressive agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|nervous system|cytochrome p 450 enzyme inhibitors|antipsychotic agents (first generation [typical])|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|serotonin 5 ht2 receptor antagonists|potential qtc prolonging agents|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|neurotoxic agents|serotonin 5 ht2a receptor antagonists|psychotropic drugs|dopamine agents|cytochrome p 450 cyp1a2 substrates|sulfur compounds|xanthenes|dopamine antagonists
zuclopenthixol	central nervous system agents|serotonin receptor antagonists|tranquilizing agents|adrenergic alpha 1 receptor antagonists|psycholeptics|cytochrome p 450 cyp3a4 substrates|adrenergic antagonists|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|thioxanthenes|antipsychotic agents|agents that produce hypertension|central nervous system depressants|thioxanthene derivatives|neurotransmitter agents|antidepressive agents|qtc prolonging agents|nervous system|antipsychotic agents (first generation [typical])|cytochrome p 450 substrates|serotonin 5 ht2 receptor antagonists|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|neurotoxic agents|serotonin 5 ht2a receptor antagonists|psychotropic drugs|dopamine agents|highest risk qtc prolonging agents|sulfur compounds|xanthenes|histamine antagonists|dopamine antagonists|histamine h1 antagonists|cytochrome p 450 cyp3a4 substrates (strength unknown)
pargyline	agents that reduce seizure threshold|mao inhibitors and diuretics|antihypertensive agents|serotonergic drugs shown to increase risk of serotonin syndrome|monoamine oxidase inhibitors|agents that produce hypertension|benzyl compounds|benzylamines|central nervous system depressants|benzene derivatives|enzyme inhibitors|antidepressive agents|cardiovascular agents|monoamine oxidase a inhibitors  for interaction with monoamine oxidase a substrates|amines
lincomycin	carbohydrates|neurotoxic agents|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|pyrrolidines|protein synthesis inhibitors|glycosides|agents that produce neuromuscular block (indirect)|enzyme inhibitors|macrolides, lincosamides and streptogramins|anti infective agents|lincosamides
etoricoxib	anti inflammatory agents, non steroidal|sensory system agents|central nervous system agents|musculo skeletal system|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp2e1 inhibitors (weak)|cox 2 inhibitors|nephrotoxic agents|selective cyclooxygenase 2 inhibitors (nsaids)|cytochrome p 450 cyp2d6 inhibitors (weak)|analgesics|sulfones|cytochrome p 450 cyp2e1 inhibitors|agents that produce hypertension|cytochrome p 450 cyp2c19 inhibitors (weak)|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|antiinflammatory and antirheumatic products, non steroids|pyridines|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|anti inflammatory agents|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|analgesics, non narcotic|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2c9 inhibitors|antirheumatic agents|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|cytochrome p 450 cyp1a2 substrates|sulfur compounds|cyclooxygenase inhibitors
genistein	hormones, hormone substitutes, and hormone antagonists|cytochrome p 450 cyp2c8 inhibitors|bcrp/abcg2 inhibitors|antineoplastic agents|estrogens, non steroidal|isoflavones|cytochrome p 450 cyp3a4 inducers|tyrosine kinase inhibitors|flavonoids|p glycoprotein inhibitors|anticarcinogenic agents|cytochrome p 450 cyp2c8 inhibitors (moderate)|protective agents|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|oatp1b1/slco1b1 inhibitors|cytochrome p 450 cyp3a4 inducers (weak)|benzopyrans|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp1a2 inhibitors (weak)|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp3a inducers|protein kinase inhibitors|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp1a2 inhibitors|heterocyclic compounds, fused ring|compounds used in a research, industrial, or household setting|cytochrome p 450 enzyme inducers|hormones|pyrans|cytochrome p 450 cyp1a2 substrates|chromones|phytoestrogens
rutin	benzopyrans|flavonoids|cytochrome p 450 cyp2c8 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|heterocyclic compounds, fused ring|pyrans|capillary stabilizing agents|flavonols|chromones|vasoprotectives|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 inhibitors (strength unknown)
aica ribonucleotide	carbohydrates|nucleotides|imidazoles|glycosides|blood glucose lowering agents|nucleic acids, nucleotides, and nucleosides
pyrazolanthrone	
hyperforin	benzene derivatives|phenols|oatp1b1/slco1b1 inhibitors
rolipram	psychotropic drugs|pyrrolidines|central nervous system agents|phosphodiesterase 4 inhibitors|enzyme inhibitors|central nervous system depressants|pyrrolidinones|antidepressive agents|phosphodiesterase inhibitors
staurosporine	p glycoprotein inhibitors|indoles|alkaloids|carbazoles|indole alkaloids|enzyme inhibitors|heterocyclic compounds, fused ring
alrestatin	parasympatholytics|peripheral nervous system agents|enzyme inhibitors|autonomic agents|heterocyclic compounds, fused ring
olomoucine	cytokinins|enzyme inhibitors|cyclin dependent kinases, antagonists & inhibitors|purines|heterocyclic compounds, fused ring
propidium	laboratory chemicals|compounds used in a research, industrial, or household setting|intercalating agents|indicators and reagents|coloring agents|phenanthridines|heterocyclic compounds, fused ring
equilin	hormones, hormone substitutes, and hormone antagonists|ketosteroids|cytochrome p 450 cyp3a substrates|estrenes|gonadal steroid hormones|adrenal cortex hormones|steroids|hormones|estradiol congeners|gonadal hormones|cytochrome p 450 substrates|estranes|17 ketosteroids|cytochrome p 450 cyp3a4 substrates|fused ring compounds
7 nitroindazole	neuroprotective agents|compounds used in a research, industrial, or household setting|peripheral nervous system agents|heterocyclic compounds, fused ring|nitric oxide synthase, antagonists & inhibitors|central nervous system agents|analgesics|protective agents|psychotropic drugs|pyrazoles|sensory system agents|tranquilizing agents|enzyme inhibitors|anticonvulsants|central nervous system depressants|anti anxiety agents
taxifolin	benzopyrans|flavonoids|anti inflammatory agents, non steroidal|peripheral nervous system agents|anti inflammatory agents|heterocyclic compounds, fused ring|central nervous system agents|analgesics|sensory system agents|pyrans|agents that produce hypertension|flavonols|chromones|non cox 2 selective nsaids|analgesics, non narcotic|antirheumatic agents
ilomastat	amino acids, peptides, and proteins|hydroxylamines|hydroxy acids|protease inhibitors|oligopeptides|peptides|enzyme inhibitors|matrix metalloproteinase inhibitors|amines|heterocyclic compounds, fused ring
flufenamic acid	aniline compounds|musculo skeletal system|antiinflammatory and antirheumatic products|anti inflammatory agents|acids, carbocyclic|ortho aminobenzoates|oat1/slc22a6 inhibitors|benzene derivatives|benzoates|antiinflammatory and antirheumatic products, non steroids|amines|aminobenzoates|fenamates
calcipotriol	antipsoriatics|cholestenes|vitamins (fat soluble)|antipsoriatics for topical use|dermatologicals|steroids|sterols|lipids|cholestanes|vitamin d and analogues|vitamins|secosteroids|misc. skin and mucous membrane agents|fused ring compounds|membrane lipids
prostaglandin b2	prostaglandins|eicosanoids|biological factors|fatty acids|inflammation mediators|lipids|fatty acids, unsaturated|autacoids
carbenoxolone	triterpenes|glycyrrhetinic acid|alimentary tract and metabolism|gastrointestinal agents|pentacyclic triterpenes|terpenes|anti ulcer agents|drugs for peptic ulcer and gastro oesophageal reflux disease (gord)|drugs for acid related disorders
myricetin	benzopyrans|pyrans|chromones|heterocyclic compounds, fused ring
myc	benzopyrans|pyrans|chromones|heterocyclic compounds, fused ring
geldanamycin	amides|protease inhibitors|quinones|antibiotics, antineoplastic|antineoplastic agents|enzyme inhibitors|cysteine proteinase inhibitors|anti infective agents|hsp90 heat shock proteins|lactams|tyrosine kinase inhibitors
farnesol	sesquiterpenes|terpenes|fatty alcohols|lipids|alcohols
fexaramine	
shh	amides|aniline compounds|hydroxy acids|histone deacetylase inhibitors|antineoplastic and immunomodulating agents|anilides|hydroxylamines|hyperglycemia associated agents|potential qtc prolonging agents|myelosuppressive agents|antineoplastic agents|narrow therapeutic index drugs|enzyme inhibitors|hydroxamic acids|immunosuppressive agents|amines|qtc prolonging agents
vorinostat	amides|aniline compounds|hydroxy acids|histone deacetylase inhibitors|antineoplastic and immunomodulating agents|anilides|hydroxylamines|hyperglycemia associated agents|potential qtc prolonging agents|myelosuppressive agents|antineoplastic agents|narrow therapeutic index drugs|enzyme inhibitors|hydroxamic acids|immunosuppressive agents|amines|qtc prolonging agents
forskolin	respiratory system agents|p glycoprotein inhibitors|compounds used in a research, industrial, or household setting|anti asthmatic agents|peripheral nervous system agents|vasodilating agents|adjuvants, immunologic|bronchodilator agents|protective agents|cardiotonic agents|diterpenes|terpenes|autonomic agents|cardiovascular agents|immunologic factors
colforsin	respiratory system agents|p glycoprotein inhibitors|compounds used in a research, industrial, or household setting|anti asthmatic agents|peripheral nervous system agents|vasodilating agents|adjuvants, immunologic|bronchodilator agents|protective agents|cardiotonic agents|diterpenes|terpenes|autonomic agents|cardiovascular agents|immunologic factors
ly 294002	benzopyrans|pyrans|enzyme inhibitors|phosphatidylinositol 3 kinases, antagonists & inhibitors|oxazines|heterocyclic compounds, fused ring
cholic acid	oatp1b3 substrates|bsep/abcb11 inducers|fused ring compounds|oat3/slc22a8 inhibitors|p glycoprotein inducers|bile acid preparations|cholanes|bile and liver therapy|oatp1b1/slco1b1 inhibitors|oatp1b1/slco1b1 substrates|cholic acids|bile acids and salts|bile acids and derivatives|bile therapy|steroids|alimentary tract and metabolism|bsep/abcb11 substrates|bsep/abcb11 inhibitors|oatp1b1/slco1b1 inducers|oat3/slc22a8 substrates
glycocholic acid	detergents|amino acids, peptides, and proteins|compounds used in a research, industrial, or household setting|n substituted glycines|household products|peptides|steroids|gastrointestinal agents|surface active agents|amino acids|cholanes|fused ring compounds|cholic acids|cholagogues and choleretics|peptoids|bile acids and salts
nicotinamide	micronutrients|food|food and beverages|cytochrome p 450 cyp2e1 inhibitors|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|pyridines|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|cytochrome p 450 cyp3a inhibitors|diet, food, and nutrition|vitamin b complex|physiological phenomena|growth substances|cytochrome p 450 cyp2e1 substrates|alimentary tract and metabolism|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|nicotinic acids|vitamins
resveratrol	antiplatelet agents|angiogenesis inhibitors|sensory system agents|central nervous system agents|antimutagenic agents|flavonoids|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|anticarcinogenic agents|analgesics|flavones|protective agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|benzopyrans|phenols|cytochrome p 450 enzyme inhibitors|antineoplastic agents, phytogenic|vasodilating agents|anti inflammatory agents|cytochrome p 450 cyp3a4 inhibitors|hematologic agents|stilbenes|cytochrome p 450 substrates|enzyme inhibitors|analgesics, non narcotic|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp1a2 inhibitors|antirheumatic agents|heterocyclic compounds, fused ring|antioxidants|compounds used in a research, industrial, or household setting|peripheral nervous system agents|pyrans|cytochrome p 450 cyp1a2 substrates|chromones|benzene derivatives|polyphenols|benzylidene compounds
acetamide	acetates|acids, acyclic|amides|fatty acids, volatile|fatty acids|lipids
pregnenolone	hormones, hormone substitutes, and hormone antagonists|cytochrome p 450 cyp3a substrates|gonadal steroid hormones|adrenal cortex hormones|pregnanes|hormones|pregnenes|progesterone congeners|gonadal hormones|steroids|cytochrome p 450 substrates|hydroxycorticosteroids|cytochrome p 450 cyp3a4 substrates|fused ring compounds
thiazolidinecarboxylic acid	
ttnpb	hydrocarbons, acyclic|carotenoids|cyclohexanes|cycloparaffins|alkenes|acids, carbocyclic|cyclohexenes|terpenes|benzene derivatives|pigments, biological|polyenes|biological factors
zardaverine	respiratory system agents|anti asthmatic agents|peripheral nervous system agents|bronchodilator agents|enzyme inhibitors|autonomic agents|phosphodiesterase inhibitors
piretanide	gynecological antiinfectives and antiseptics|amides|membrane transport modulators|sulfonamides|diuretics|sulfones|natriuretic agents|genito urinary system and sex hormones|sulfur compounds|sodium potassium chloride symporter inhibitors|cardiovascular agents|high ceiling diuretics
doramapimod	protein kinase inhibitors
zebularine	carbohydrates|pyrimidine nucleosides|ribonucleosides|nucleic acids, nucleotides, and nucleosides|pyrimidines|glycosides|nucleosides
beta alanine	amino acids, peptides, and proteins|alanine|amino acids
acetylcholine	cholinergic receptor agonist|cholinergic agents|vasodilating agents|cholinergic agonists|miotics|sensory organs|biogenic amines|oct1 substrates|ophthalmologicals|neurotransmitter agents|antiglaucoma preparations and miotics|cardiovascular agents|amines|parasympathomimetics
sphingosine	p glycoprotein substrates|amino alcohols|amines|glycols|alcohols
isoliquiritigenin	benzopyrans|flavonoids|propiophenones|heterocyclic compounds, fused ring|aldehyde reductase, antagonists & inhibitors|pyrans|chromones|enzyme inhibitors|plants|ketones
pc	carbohydrates|nucleotides|cytosine nucleotides|ribonucleotides|pyrimidines|pyrimidine nucleotides|glycosides|nucleic acids, nucleotides, and nucleosides
ubenimex	amino acids, peptides, and proteins|protease inhibitors|aminopeptidases, antagonists & inhibitors|antibiotics, antineoplastic|adjuvants, immunologic|anti bacterial agents|amino acids, branched chain|amino acids|anti hiv agents|enzyme inhibitors|anti infective agents|amino acids, essential|immunologic factors
sparfosic acid	acids, acyclic|amino acids, peptides, and proteins|organophosphorus compounds|antineoplastic agents|excitatory amino acids|organophosphonates|amino acids, dicarboxylic|fatty acids|amino acids|fatty acids, volatile|enzyme inhibitors|anti infective agents|noxae|acetates|antimetabolites|amino acids, acidic|lipids|toxic actions
naringenin	benzopyrans|flavonoids|hormone antagonists|hormones, hormone substitutes, and hormone antagonists|heterocyclic compounds, fused ring|estrogen antagonists|gastrointestinal agents|bcrp/abcg2 inhibitors|pyrans|chromones|anti ulcer agents
alvocidib	benzopyrans|heterocyclic compounds, fused ring|growth inhibitors|pyrans|antineoplastic agents|chromones|cyclin dependent kinases, antagonists & inhibitors|enzyme inhibitors|protein kinase inhibitors|bcrp/abcg2 substrates|ugt1a1 substrates
mevalonic acid	hydroxy acids
spermidine	biogenic amines|oct1 substrates|polyamines|biogenic polyamines|amines|diamines
oxyphenbutazone	anti inflammatory agents, non steroidal|antiinflammatory preparations, non steroids for topical use|central nervous system agents|sensory system agents|ophthalmologicals|other nonsteroidal anti inflammatory agents|musculo skeletal system|nephrotoxic agents|pyrazoles|analgesics|agents that produce hypertension|non cox 2 selective nsaids|antiinflammatory and antirheumatic products, non steroids|topical products for joint and muscular pain|pyrazolones|anti inflammatory agents|oat1/slc22a6 inhibitors|analgesics, non narcotic|antirheumatic agents|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|sensory organs|butylpyrazolidines
tiratricol	amino acids, aromatic|hormones, hormone substitutes, and hormone antagonists|amino acids, peptides, and proteins|amino acids, cyclic|dermatologicals|hormones|thyronines|amino acids|agents used to treat hypothyroidism|thyroid products|systemic hormonal preparations, excl. sex hormones and insulins
ribostamycin	carbohydrates|nephrotoxic agents|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|narrow therapeutic index drugs|glycosides|agents that produce neuromuscular block (indirect)|aminoglycoside antibacterials|drugs that are mainly renally excreted|drugs that are mainly renally excreted with a narrow therapeutic index|anti infective agents
deoxycholic acid	dermatologicals|bsep/abcb11 inducers|cytolytic agent|steroids|decreased cell membrane integrity|gastrointestinal agents|cholanes|fused ring compounds|other miscellaneous therapeutic agents|cholic acids|cholagogues and choleretics|bile acids and salts
digoxigenin	carbohydrates|digitalis glycosides|steroids|cardenolides|glycosides|digoxin and derivatives|fused ring compounds|cardiac glycosides|cardanolides
vanoxerine	membrane transport modulators|cytochrome p 450 cyp3a substrates|neurotransmitter uptake inhibitors|dopamine agents|cytochrome p 450 substrates|neurotransmitter agents|cytochrome p 450 cyp3a4 substrates|dopamine uptake inhibitors
doconexent	dietary fats, unsaturated|fatty acids, omega 3|fish oils|food|oils|food and beverages|dietary fats|fatty acids|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|cytochrome p 450 enzyme inhibitors|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|fats|diet, food, and nutrition|cytochrome p 450 cyp2c9 inhibitors|physiological phenomena|lipids|fatty acids, unsaturated
radicicol	antifungal agents|polyketides|enzyme inhibitors|antiprotozoals|anti infective agents|lactones|antiparasitic agents|tyrosine kinase inhibitors
dnqx	excitatory amino acid antagonists|neurotransmitter agents|excitatory amino acid agents|heterocyclic compounds, fused ring
propanoic acid	acids, acyclic|fatty acids, volatile|fatty acids|sensory organs|lipids|ophthalmologicals|anti infective agents
phenacetin	sensory system agents|central nervous system agents|cytochrome p 450 cyp2a6 substrates|amines|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp2c19 substrates|analgesics|acetanilides|amides|nervous system|anilides|cytochrome p 450 substrates|oat1/slc22a6 inhibitors|cytochrome p 450 cyp2c9 substrates|analgesics, non narcotic|cytochrome p 450 cyp2d6 substrates|aniline compounds|cytochrome p 450 cyp3a substrates|peripheral nervous system agents|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 cyp1a2 substrates
gw 3965	ligands|acids, carbocyclic|benzene derivatives|amines|benzyl compounds
benzoic acid	antifungal agents|food additives|various alimentary tract and metabolism products|diagnostic agents|food|benzoates|food and beverages|oat3/slc22a8 inhibitors|tests for gastric secretion|urea cycle disorder agents|anti infective agents|diet, food, and nutrition|physiological phenomena|food preservatives|food ingredients|ammonium ion binding activity|compounds used in a research, industrial, or household setting|nitrogen binding agent|alimentary tract and metabolism|acids, carbocyclic|benzene derivatives
epigallocatechin	benzopyrans|flavonoids|heterocyclic compounds, fused ring|pyrans|chromones|chromans
cilomilast	cyclohexanes|cycloparaffins|phosphodiesterase 4 inhibitors|acids, carbocyclic|enzyme inhibitors|phosphodiesterase inhibitors
batimastat	amino acids, aromatic|amino acids, peptides, and proteins|protease inhibitors|amino acids, cyclic|amino acids|antineoplastic agents|sulfur compounds|enzyme inhibitors|metalloendopeptidases, antagonists & inhibitors|amino acids, essential
clorgiline	propylamines|psychotropic drugs|serotonergic drugs shown to increase risk of serotonin syndrome|central nervous system agents|agents that produce hypertension|monoamine oxidase a inhibitors|enzyme inhibitors|central nervous system depressants|antidepressive agents|monoamine oxidase inhibitors|amines
mdl 29951	acids, acyclic|fatty acids, volatile|fatty acids|lipids|heterocyclic compounds, fused ring
digitoxigenin	carbohydrates|digitalis glycosides|steroids|cardenolides|glycosides|fused ring compounds|cardiac glycosides|cardanolides
benzofuran	heterocyclic compounds, fused ring
dequalinium	antiseptics and disinfectants|quinoline derivatives|throat preparations|dermatologicals|heterocyclic compounds, fused ring|genito urinary system and sex hormones|anti infective agents, local|quinolinium compounds|anti infective agents|quinolines|gynecological antiinfectives and antiseptics|miscellaneous anti infectives
quercetin	antioxidants|benzopyrans|flavonoids|compounds used in a research, industrial, or household setting|cytochrome p 450 cyp2c8 inhibitors|cytochrome p 450 enzyme inhibitors|p glycoprotein inhibitors|heterocyclic compounds, fused ring|comt inhibitors|bcrp/abcg2 inhibitors|protective agents|pyrans|flavonols|chromones|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|oatp1b1/slco1b1 inhibitors|comt substrates
trichostatin a	antifungal agents|hydroxylamines|hydroxy acids|histone deacetylase inhibitors|protein synthesis inhibitors|antineoplastic agents|enzyme inhibitors|anti infective agents|amines
monastrol	mitosis modulators|antimitotic agents|antineoplastic agents|sulfur compounds|enzyme inhibitors
taurocholic acid	oatp1b3 substrates|household products|bsep/abcb11 inducers|acids|bcrp/abcg2 inhibitors|surface active agents|fused ring compounds|p glycoprotein inhibitors|oat1/slc22a6 substrates|p glycoprotein substrates|oat3/slc22a8 inhibitors|cholanes|oatp1b1/slco1b1 inhibitors|oatp1b1/slco1b1 substrates|hydrocarbons, acyclic|alkanesulfonic acids|gastrointestinal agents|oat1/slc22a6 inhibitors|cholic acids|cholagogues and choleretics|bile acids and salts|acids, noncarboxylic|detergents|compounds used in a research, industrial, or household setting|steroids|sulfonic acids|sulfur compounds|bsep/abcb11 substrates|alkanes|oatp1b1/slco1b1 inducers|oat3/slc22a8 substrates|sulfur acids
niflumic acid	anti inflammatory agents, non steroidal|antiinflammatory preparations, non steroids for topical use|central nervous system agents|sensory system agents|benzoates|musculo skeletal system|amines|aminobenzoates|nephrotoxic agents|selective cyclooxygenase 2 inhibitors (nsaids)|analgesics|agents that produce hypertension|ugt1a9 inhibitors|antiinflammatory and antirheumatic products, non steroids|pyridines|topical products for joint and muscular pain|anti inflammatory agents|enzyme inhibitors|niflumic acid and prodrugs|analgesics, non narcotic|antirheumatic agents|aniline compounds|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|acids, carbocyclic|ortho aminobenzoates|nicotinic acids|benzene derivatives|fenamates|cyclooxygenase inhibitors
latamoxef	antibacterials for systemic use|anti bacterial agents|acids|sulfides|hydrogen sulfide|nephrotoxic agents|electrolytes|ions|anions|beta lactams|amides|cephalosporins|anti infective agents|acids, noncarboxylic|gases|heterocyclic compounds, fused ring|antiinfectives for systemic use|sulfur compounds|third generation cephalosporins|lactams
trioxsalen	antipsoriatics|benzopyrans|psoralens for topical use|antipsoriatics for systemic use|antipsoriatics for topical use|furocoumarins|photosensitizing agents|dermatologicals|heterocyclic compounds, fused ring|radiation sensitizing agents|pyrans|photosensitizing agents used for phototherapy|psoralens for systemic use|coumarins
thiotepa	antineoplastic and immunomodulating agents|alkylating drugs|acids|azirines|organophosphorus compounds|antineoplastic agents|phosphoric acids|phosphorus acids|cytochrome p 450 cyp3a4 substrates|triethylenephosphoramide|aziridines|ethylene imines|cholinesterase inhibitors|cytochrome p 450 cyp2b6 inhibitors (moderate)|electrolytes|ions|anions|alkylating activity|myelosuppressive agents|phosphoramides|cytochrome p 450 cyp2b6 inhibitors|cytochrome p 450 enzyme inhibitors|myeloablative agonists|antineoplastic agents, alkylating|cytochrome p 450 substrates|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|noxae|acids, noncarboxylic|immunosuppressive agents|cytochrome p 450 cyp3a substrates|narrow therapeutic index drugs|phosphorus compounds|toxic actions|immunologic factors
estriol	hormones, hormone substitutes, and hormone antagonists|estrenes|p glycoprotein substrates|gonadal steroid hormones|steroids|hormones|thyroxine binding globulin inducers|estradiol congeners|estrogens|genito urinary system and sex hormones|gonadal hormones|p glycoprotein inducers|estranes|sex hormones and modulators of the genital system|natural and semisynthetic estrogens, plain|fused ring compounds
1 benzylimidazole	adrenergic alpha antagonists|adrenergic antagonists|adrenergic agents|agents that produce hypertension|neurotransmitter agents
aniracetam	nervous system|psychotropic drugs|psychoanaleptics|central nervous system agents|psychostimulants, agents used for adhd and nootropics|pyrrolidines|nootropic agents|central nervous system depressants|antidepressive agents
5 iodotubercidin	carbohydrates|purine nucleosides|ribonucleosides|heterocyclic compounds, fused ring|nucleosides|glycosides|enzyme inhibitors|purines|nucleic acids, nucleotides, and nucleosides|adenosine kinase, antagonists & inhibitors
apramycin	carbohydrates|nephrotoxic agents|anti bacterial agents|glycosides|agents that produce neuromuscular block (indirect)|aminoglycoside antibacterials|drugs that are mainly renally excreted|anti infective agents
corticosterone	hormones, hormone substitutes, and hormone antagonists|cytochrome p 450 cyp3a substrates|11 hydroxycorticosteroids|anti inflammatory agents|adrenal cortex hormones|hormones|pregnanes|pregnenediones|pregnenes|steroids|cytochrome p 450 substrates|hydroxycorticosteroids|cytochrome p 450 cyp3a4 substrates|fused ring compounds
coumarin	benzopyrans|anticoagulants|vitamin k antagonists|heterocyclic compounds, fused ring|pyrans|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|edema, drug therapy
camptothecin	p glycoprotein substrates|antineoplastic agents, phytogenic|topoisomerase inhibitors|alkaloids|antineoplastic agents|enzyme inhibitors|bcrp/abcg2 substrates|topoisomerase i inhibitors
butyrolactone	4 butyrolactone, analogs & derivatives|solvents|compounds used in a research, industrial, or household setting|4 butyrolactone|lactones|furans
hesperidin	benzopyrans|flavonoids|heterocyclic compounds, fused ring|pyrans|chromones|flavanones
hydroxyfasudil	amides|sulfonamides|sulfones|sulfur compounds|piperazines|isoquinolines|heterocyclic compounds, fused ring
adipiodone	x ray contrast activity|compounds used in a research, industrial, or household setting|iodobenzoates|diagnostic uses of chemicals|acids, carbocyclic|contrast media|iodinated contrast agents|watersoluble, hepatotropic x ray contrast media|triiodobenzoic acids|benzene derivatives|benzoates|x ray contrast media, iodinated|radiographic contrast agent|roentgenography
nimesulide	antiplatelet agents|anti inflammatory agents, non steroidal|antiinflammatory preparations, non steroids for topical use|central nervous system agents|sensory system agents|musculo skeletal system|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|nephrotoxic agents|selective cyclooxygenase 2 inhibitors (nsaids)|analgesics|sulfones|agents that produce hypertension|antiarrhythmic agents|calcium channel blockers|antiinflammatory and antirheumatic products, non steroids|amides|topical products for joint and muscular pain|anti inflammatory agents|cytochrome p 450 substrates|enzyme inhibitors|analgesics, non narcotic|antirheumatic agents|cytochrome p 450 cyp3a substrates|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|sulfur compounds|cyclooxygenase inhibitors
lawsone	antifungal agents|oxidoreductases|compounds used in a research, industrial, or household setting|quinones|dermatologicals|household products|radiation protective agents|naphthalenes|protective agents|sunscreen agents|enzyme inhibitors|coloring agents|anti infective agents|cosmetics
purvalanol a	heterocyclic compounds, fused ring|cdc2 protein kinase, antagonists & inhibitors
suramin	trypanocidal agents|arylsulfonates|antinematodal agents|acids|naphthalenes|sulfonic acids|antineoplastic agents|sulfur acids|sulfur compounds|naphthalenesulfonates|anti infective agents|antiprotozoals|arylsulfonic acids|agents against leishmaniasis and trypanosomiasis|antiparasitic agents|acids, noncarboxylic|antiparasitic products, insecticides and repellents
bifonazole	antifungal agents|cytochrome p 450 enzyme inhibitors|dermatologicals|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2e1 inhibitors|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|antifungals for topical use|azole antifungals|cytochrome p 450 cyp3a4 inhibitors (weak)|imidazole and triazole derivatives|anti infective agents|cytochrome p 450 cyp3a inhibitors|antifungals for dermatological use
thenoyltrifluoroacetone	compounds used in a research, industrial, or household setting|sulfur compounds|chelating agents|thiophenes|sequestering agents|butanones|ketones
bithionol	phenols|anti acne preparations for topical use|dermatologicals|anti acne preparations|anti infective agents, local|antiplatyhelmintic agents|antitrematodals|anthelmintics|preparations containing sulfur|anti infective agents|benzene derivatives|antiparasitic agents|antiparasitic products, insecticides and repellents
clioquinol	medicated dressings|hydroxyquinoline derivatives|cell mediated immunity|antiparasitic products, insecticides and repellents|quinolines|hydroxyquinolines|quinoline derivatives|miscellaneous antifungals|anti infective agents|gynecological antiinfectives and antiseptics|otologicals|heterocyclic compounds, fused ring|standardized chemical allergen|antiseptics and disinfectants|increased histamine release|dermatologicals|genito urinary system and sex hormones|sensory organs|antiprotozoals|medicated dressings with antiinfectives
dantron	enemas|quinones|alimentary tract and metabolism|gastrointestinal agents|mutagens|laxatives|drugs for constipation|contact laxatives|noxae|toxic actions|anthracenes
metamizole	anti inflammatory agents, non steroidal|sensory system agents|central nervous system agents|cytochrome p 450 cyp2b6 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers|nephrotoxic agents|pyrazoles|analgesics|agents that produce hypertension|non cox 2 selective nsaids|cytochrome p 450 cyp2b6 inducers|nervous system|pyrazolones|anti inflammatory agents|cytochrome p 450 cyp3a inducers|analgesics, non narcotic|aminopyrine|cytochrome p 450 cyp3a4 inducers (strength unknown)|peripheral nervous system agents|agents causing hyperkalemia|cytochrome p 450 enzyme inducers|antipyretics
iproniazid	psychoanaleptics|central nervous system agents|monoamine oxidase inhibitors, non selective|serotonergic drugs shown to increase risk of serotonin syndrome|agents that produce hypertension|central nervous system depressants|antidepressive agents|pyridines|cytochrome p 450 cyp2d6 inhibitors|nervous system|agents that reduce seizure threshold|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|enzyme inhibitors|monoamine oxidase a inhibitors  for interaction with monoamine oxidase a substrates|monoamine oxidase inhibitors|cytochrome p 450 cyp2c9 inhibitors|psychotropic drugs|hydrazines|isonicotinic acids|cytochrome p 450 cyp2c9 inhibitors (moderate)
methapyrilene	substituted ethylene diamines|hypnotics and sedatives|histamine agents|pyridines|aminopyridines|diamines|central nervous system agents|anti allergic agents|central nervous system depressants|polyamines|antihistamines for systemic use|ethylenediamines|histamine antagonists|neurotransmitter agents|amines|histamine h1 antagonists
nialamide	nervous system|agents that reduce seizure threshold|pyridines|psychotropic drugs|psychoanaleptics|central nervous system agents|serotonergic drugs shown to increase risk of serotonin syndrome|isonicotinic acids|monoamine oxidase inhibitors, non selective|agents that produce hypertension|enzyme inhibitors|central nervous system depressants|antidepressive agents|monoamine oxidase inhibitors
nomifensine	membrane transport modulators|nervous system|neurotransmitter uptake inhibitors|heterocyclic compounds, fused ring|psychoanaleptics|dopamine agents|central nervous system depressants|isoquinolines|neurotransmitter agents|antidepressive agents|dopamine uptake inhibitors
phenolphthalein	laboratory chemicals|phenols|compounds used in a research, industrial, or household setting|alimentary tract and metabolism|indicators and reagents|laxatives|drugs for constipation|contact laxatives|benzene derivatives|phenolphthaleins
prenylamine	membrane transport modulators|adrenergic agents|calcium regulating hormones and agents|amines|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|calmodulin, antagonists & inhibitors|vasodilators used in cardiac diseases|antiarrhythmic agents|neurotransmitter agents|calcium channel blockers|cardiovascular agents|qtc prolonging agents|vasodilating agents|moderate risk qtc prolonging agents|cytochrome p 450 substrates|ethylamines|cytochrome p 450 cyp3a substrates|hydroxy acids|agents causing hyperkalemia|phenethylamines|cardiac therapy
urethane	acids, acyclic|anesthetics, general|central nervous system agents|carbamates|antineoplastic agents|central nervous system depressants|carcinogens|anesthetics|anesthetics, intravenous|noxae|toxic actions
tienilic acid	acids, acyclic|thiophenes|fatty acids|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|phenoxyacetates|cardiovascular agents|antigout preparations|high ceiling diuretics|cytochrome p 450 enzyme inhibitors|diuretics|fatty acids, volatile|natriuretic agents|uricosuric agents|cytochrome p 450 cyp2c9 inhibitors|antirheumatic agents|glycolates|acetates|hydroxy acids|antihypertensive agents|renal agents|sulfur compounds|lipids|aryloxyacetic acid derivatives
zimelidine	membrane transport modulators|psychoanaleptics|hypoglycemia associated agents|p glycoprotein inhibitors|selective serotonin reuptake inhibitors|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|serotonin modulators|central nervous system depressants|neurotransmitter agents|antidepressive agents|pyridines|nervous system|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a4 inhibitors (moderate)|monoamine oxidase a inhibitors  for interaction with monoamine oxidase a substrates|cytochrome p 450 cyp3a inhibitors|neurotransmitter uptake inhibitors
maraviroc	cyclohexanes|viral fusion protein inhibitors|triazoles|hepatotoxic agents|cytochrome p 450 cyp3a4 substrates|antivirals for systemic use|ccr5 receptor antagonists|cycloparaffins|anti retroviral agents|ccr5 co receptor antagonist|cytochrome p 450 substrates|anti infective agents|antiviral agents|cytochrome p 450 cyp3a substrates|antiinfectives for systemic use|anti hiv agents|direct acting antivirals|hiv fusion inhibitors
debrisoquine	cytochrome p 450 cyp2d6 substrates|p glycoprotein substrates|antihypertensive agents|peripheral nervous system agents|heterocyclic compounds, fused ring|adrenergic agents|cytochrome p 450 substrates|antiadrenergic agents, peripherally acting|autonomic agents|guanidine derivatives|isoquinolines|cardiovascular agents|neurotransmitter agents|sympatholytics|catecholamines
flunarizine	membrane transport modulators|central nervous system agents|antimigraine agents, miscellaneous|piperazines|calcium regulating hormones and agents|cytochrome p 450 cyp2a6 substrates|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|histamine agents|anticonvulsants|antiarrhythmic agents|central nervous system depressants|calcium channel blockers|neurotransmitter agents|cardiovascular agents|nervous system|antivertigo preparations|vasodilating agents|cytochrome p 450 substrates|piperazine derivatives|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|agents causing hyperkalemia|cytochrome p 450 cyp1a2 substrates|histamine antagonists|histamine h1 antagonists
fluspirilene	spiro compounds|central nervous system agents|serotonin receptor antagonists|tranquilizing agents|psycholeptics|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|antipsychotic agents|antiarrhythmic agents|central nervous system depressants|neurotransmitter agents|calcium channel blockers|antidepressive agents|qtc prolonging agents|nervous system|imidazoles|moderate risk qtc prolonging agents|cytochrome p 450 substrates|piperidines|serotonin 5 ht2 receptor antagonists|dopamine d2 receptor antagonists|cytochrome p 450 cyp3a substrates|neurotoxic agents|serotonin 5 ht2a receptor antagonists|agents causing hyperkalemia|psychotropic drugs|dopamine agents|diphenylbutylpiperidine derivatives|dopamine antagonists
mepenzolate	drugs for functional gastrointestinal disorders|agents producing tachycardia|hydroxy acids|alimentary tract and metabolism|anticholinergic agents|acids, carbocyclic|phenylacetates|diphenylacetic acids|synthetic anticholinergics, quaternary ammonium compounds|muscarinic antagonists
tetrabenazine	cytochrome p 450 cyp2d6 substrates|membrane transport modulators|nervous system|neurotransmitter uptake inhibitors|adrenergic agents|highest risk qtc prolonging agents|cytochrome p 450 substrates|quinolizines|vesicular monoamine transporter 2 inhibitor|neurotransmitter agents|vesicular monoamine transporter 2 inhibitors|miscellaneous central nervous system agents|qtc prolonging agents|heterocyclic compounds, fused ring
celiprolol	propanolamines|adrenergic agents|beta blockers (beta1 selective)|phenylurea compounds|phenoxypropanolamines|amines|bradycardia causing agents|adrenergic beta 2 receptor agonists|beta blocking agents, selective|adrenergic antagonists|antiarrhythmic agents|neurotransmitter agents|cardiovascular agents|qtc prolonging agents|sympathomimetics|vasodilating agents|adrenergic agonists|adrenergic beta 1 receptor antagonists|propanols|adrenergic beta antagonists|cytochrome p 450 substrates|adrenergic beta agonists|potential qtc prolonging agents|cytochrome p 450 cyp2d6 substrates|antihypertensive agents|peripheral nervous system agents|agents causing hyperkalemia|amino alcohols|adrenergic beta 3 receptor agonists|autonomic agents|benzene derivatives|alcohols
cediranib	antineoplastic and immunomodulating agents|antineoplastic agents|enzyme inhibitors|protein kinase inhibitors|heterocyclic compounds, fused ring|tyrosine kinase inhibitors
febuxostat	drugs causing inadvertant photosensitivity|thiazoles|photosensitizing agents|preparations inhibiting uric acid production|sulfur compounds|antigout preparations|musculo skeletal system|xanthine oxidase inhibitors|antirheumatic agents
huperzine a	cholinergic agents|compounds used in a research, industrial, or household setting|cholinesterase inhibitors|neuroprotective agents|central nervous system agents|protective agents|terpenes|enzyme inhibitors|neurotransmitter agents
homoharringtonine	antineoplastic and immunomodulating agents|antineoplastic agents, phytogenic|benzazepines|heterocyclic compounds, fused ring|alkaloids|protein synthesis inhibitors|antineoplastic agents|narrow therapeutic index drugs|enzyme inhibitors|harringtonines
nilotinib	cytochrome p 450 cyp2c8 inhibitors|drugs causing inadvertant photosensitivity|antineoplastic and immunomodulating agents|bcrp/abcg2 inhibitors|antineoplastic agents|cytochrome p 450 cyp3a4 inhibitors (strong)|kinase inhibitor|cytochrome p 450 cyp2c8 inducers (strength unknown)|cytochrome p 450 cyp2b6 inducers (strength unknown)|cytochrome p 450 cyp3a4 substrates|tyrosine kinase inhibitors|p glycoprotein inhibitors|ugt1a1 inhibitors|p glycoprotein substrates|photosensitizing agents|cytochrome p 450 cyp2c8 inhibitors (moderate)|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|oatp1b1/slco1b1 inhibitors|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|bcrp/abcg2 substrates|myelosuppressive agents|cytochrome p 450 cyp2b6 inducers|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|hyperglycemia associated agents|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c8 inducers|cytochrome p 450 substrates|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|protein kinase inhibitors|cytochrome p 450 cyp2c9 inhibitors|immunosuppressive agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2d6 inhibitors (moderate)|cytochrome p 450 enzyme inducers|highest risk qtc prolonging agents|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index
vatalanib	pyridazines|enzyme inhibitors|protein kinase inhibitors|tyrosine kinase inhibitors
milnacipran	adrenergic uptake inhibitors|agents producing tachycardia|membrane transport modulators|psychoanaleptics|central nervous system agents|adrenergic agents|sensory system agents|drugs that are mainly renally excreted|cyclopropanes|cytochrome p 450 cyp3a4 substrates|hypoglycemia associated agents|selective serotonin reuptake inhibitors|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|analgesics|serotonin modulators|norepinephrine uptake inhibitors|central nervous system depressants|neurotransmitter agents|antidepressive agents|serotonin and noradrenaline reuptake inhibitors|nervous system|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a4 inhibitors (moderate)|cytochrome p 450 substrates|cytochrome p 450 cyp3a inhibitors|analgesics, non narcotic|cytochrome p 450 cyp3a substrates|combined inhibitors of serotonin/norepinephrine reuptake|neurotransmitter uptake inhibitors|peripheral nervous system agents|psychotropic drugs
oxibendazole	anthelmintics|anti infective agents|antiparasitic agents|heterocyclic compounds, fused ring
itopride	drugs for functional gastrointestinal disorders|amides|propulsives|alimentary tract and metabolism|acids, carbocyclic|benzene derivatives|benzoates
tamibarotene	benzene derivatives|naphthalenes|acids, carbocyclic
acadesine	carbohydrates|imidazoles|nucleosides|glycosides|cardiac therapy|nucleic acids, nucleotides, and nucleosides
iloperidone	central nervous system agents|serotonin receptor antagonists|tranquilizing agents|adrenergic alpha 1 receptor antagonists|psycholeptics|cytochrome p 450 cyp3a4 substrates|adrenergic antagonists|serotonin 5 ht1 receptor antagonists|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|serotonin 5 ht1a receptor antagonists|antipsychotic agents|agents that produce hypertension|central nervous system depressants|antidepressive agents|cytochrome p 450 cyp3a7 substrates|qtc prolonging agents|nervous system|hyperglycemia associated agents|schizophrenia|cytochrome p 450 substrates|serotonin 5 ht2 receptor antagonists|antipsychotic agents (second generation [atypical])|dopamine d2 receptor antagonists|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|cytochrome p 450 cyp3a5 substrates|neurotoxic agents|serotonin 5 ht2a receptor antagonists|cytochrome p 450 cyp2e1 substrates|psychotropic drugs|highest risk qtc prolonging agents|histamine antagonists|dopamine antagonists|histamine h1 antagonists
lofexidine	agents producing tachycardia|sensory system agents|central nervous system agents|adrenergic agents|drugs used in addictive disorders|drugs that are mainly renally excreted|imidazolines|mate 1 inhibitors|drugs used in opioid dependence|cytochrome p 450 cyp2c19 substrates|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|hypotensive agents|agents that produce hypertension|central nervous system depressants|adrenergic alpha 2 receptor agonists|neurotransmitter agents|antidepressive agents|cardiovascular agents|qtc prolonging agents|nervous system|imidazoles|adrenergic agonists|moderate risk qtc prolonging agents|serotonin 5 ht2 receptor agonists|cytochrome p 450 substrates|adrenergic alpha agonists|mate inhibitors|cytochrome p 450 cyp2d6 substrates|antihypertensive agents|peripheral nervous system agents|cytochrome p 450 cyp1a2 substrates|serotonin receptor agonists
pirfenidone	antineoplastic and immunomodulating agents|sensory system agents|central nervous system agents|antineoplastic agents|cytochrome p 450 cyp2c19 substrates|analgesics|pyridines|cytochrome p 450 enzyme inhibitors|pyridones|anti inflammatory agents|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|analgesics, non narcotic|cytochrome p 450 cyp1a2 inhibitors|antirheumatic agents|immunosuppressive agents|cytochrome p 450 cyp2d6 substrates|peripheral nervous system agents|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 cyp1a2 substrates|antifibrotic agents
tipifarnib	p glycoprotein inhibitors|antineoplastic agents|quinolines|heterocyclic compounds, fused ring
belinostat	cytochrome p 450 cyp2c8 inhibitors|antineoplastic and immunomodulating agents|antineoplastic agents|cytochrome p 450 cyp2a6 substrates|amines|cytochrome p 450 cyp3a4 substrates|p glycoprotein substrates|cytochrome p 450 cyp1a2 inducers|sulfones|cytochrome p 450 cyp2a6 substrates with a narrow therapeutic index|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|ugt1a4 inhibitors|ugt1a1 substrates with a narrow therapeutic index|myelosuppressive agents|amides|hydroxylamines|cytochrome p 450 enzyme inhibitors|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp2c9 inhibitors|immunosuppressive agents|cytochrome p 450 cyp3a substrates|histone deacetylase inhibitors|hydroxy acids|cytochrome p 450 cyp2c8 inhibitors (weak)|cytochrome p 450 enzyme inducers|narrow therapeutic index drugs|sulfur compounds|p glycoprotein substrates with a narrow therapeutic index|ugt1a1 substrates|ugt1a4 substrates|cytochrome p 450 cyp1a2 inducers (weak)
ataluren	oat3/slc22a8 inhibitors|ugt1a9 substrates|oatp1b3 inhibitors|oat1/slc22a6 inhibitors|musculo skeletal system|oxazoles
amonafide	laboratory chemicals|compounds used in a research, industrial, or household setting|heterocyclic compounds, fused ring|intercalating agents|antineoplastic agents|indicators and reagents|enzyme inhibitors|piperidines|piperidones|anti infective agents|imides|isoquinolines|naphthalenes
fenretinide	hydrocarbons, acyclic|carotenoids|compounds used in a research, industrial, or household setting|anticarcinogenic agents|cyclohexanes|cycloparaffins|alkenes|antineoplastic agents|cyclohexenes|protective agents|retinoids|terpenes|pigments, biological|polyenes|biological factors
tanespimycin	amides|hsp90 heat shock proteins, antagonists & inhibitors|quinones|protein serine threonine kinases, antagonists & inhibitors|lactams
lobeline	respiratory system agents|cholinergic agents|peripheral nervous system agents|ganglionic stimulants|cholinergic agonists|alkaloids|piperidines|autonomic agents|neurotransmitter agents|nicotinic agonists
alisertib	protein kinase inhibitors
ibudilast	antiplatelet agents|phosphodiesterase 5 inhibitors|respiratory system agents|anti asthmatic agents|peripheral nervous system agents|vasodilating agents|hematologic agents|bronchodilator agents|enzyme inhibitors|autonomic agents|cardiovascular agents|phosphodiesterase inhibitors|leukotriene antagonists|drugs for obstructive airway diseases
canertinib	acids, acyclic|compounds used in a research, industrial, or household setting|peripheral nervous system agents|sensory system agents|central nervous system agents|protective agents|oxazines|antineoplastic agents|cardiotonic agents|central nervous system depressants|anesthetics|cardiovascular agents|tyrosine kinase inhibitors
px 12	electrolytes|ions|anions|acids|gases|sulfur compounds|sulfides|hydrogen sulfide|acids, noncarboxylic
tandutinib	potential qtc prolonging agents|qtc prolonging agents|heterocyclic compounds, fused ring|tyrosine kinase inhibitors
vx 702	benzene derivatives
ifnw1	immunosuppressive agents|myelosuppressive agents
pelitinib	heterocyclic compounds, fused ring|antineoplastic agents|erbb receptors, antagonists & inhibitors|enzyme inhibitors|protein kinase inhibitors|quinolines|amines
motesanib	pyridines|enzyme inhibitors|nicotinic acids|protein kinase inhibitors|heterocyclic compounds, fused ring|tyrosine kinase inhibitors
elesclomol	amides|sulfur compounds
abiraterone	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|cytochrome p 450 cyp2c8 inhibitors|antineoplastic and immunomodulating agents|androstenes|androstanes|antineoplastic agents|cytochrome p 450 cyp3a4 substrates|fused ring compounds|cytochrome p 450 cyp2c19 inhibitors (moderate)|cytochrome p 450 cyp2c8 inhibitors (moderate)|steroid synthesis inhibitors|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a4 inhibitors (moderate)|cytochrome p 450 cyp1a2 inhibitors (strong)|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp3a inhibitors|chemically induced disorders|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp1a2 inhibitors|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2d6 inhibitors (moderate)|cytochrome p 450 cyp2c8 inhibitors (weak)|steroids|endocrine therapy|hormone antagonists and related agents|cytochrome p450 17a1 inhibitors|cytochrome p 450 cyp2c9 inhibitors (moderate)
osi 930	heterocyclic compounds, fused ring|sulfur compounds
dovitinib	oatp1b3 inhibitors|bcrp/abcg2 inhibitors|cytochrome p 450 cyp1a2 inducers (strength unknown)|cytochrome p 450 cyp3a4 inhibitors (weak)|tyrosine kinase inhibitors|p glycoprotein inhibitors|cytochrome p 450 cyp1a2 inducers|ugt1a3 inhibitors|cytochrome p 450 cyp2c19 inhibitors (weak)|oatp1b1/slco1b1 inhibitors|quinolines|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a inhibitors|heterocyclic compounds, fused ring|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 enzyme inducers|ugt2b7 inhibitors|bcrp/abcg2 inducers
plinabulin	piperazines|deuterium
azd 8330	protein kinase inhibitors|pyridines
linsitinib	
sns 314	protein kinase inhibitors|benzene derivatives|sulfur compounds
sertindole	central nervous system agents|serotonin receptor antagonists|tranquilizing agents|psycholeptics|cytochrome p 450 cyp3a4 substrates|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|antipsychotic agents|indole derivatives|central nervous system depressants|antidepressive agents|qtc prolonging agents|nervous system|cytochrome p 450 substrates|serotonin 5 ht2 receptor antagonists|antipsychotic agents (second generation [atypical])|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|serotonin 5 ht2c receptor antagonists|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|neurotoxic agents|serotonin 5 ht2a receptor antagonists|psychotropic drugs|dopamine antagonists
spiramycin	carbohydrates|antibacterials for systemic use|anti bacterial agents|leucomycins|macrolides, lincosamides and streptogramins|coccidiostats|antiparasitic agents|cytochrome p 450 enzyme inhibitors|cytochrome p 450 substrates|glycosides|anti infective agents|cytochrome p 450 cyp3a inhibitors|macrolides|cytochrome p 450 cyp3a substrates|antiinfectives for systemic use|polyketides|antiprotozoals|lactones
sulfathiazole	sulfathiazoles|amides|aniline compounds|sulfonamides|thiazoles|antiinfectives for systemic use|antibacterials for systemic use|dermatologicals|short acting sulfonamides|sulfonamides and trimethoprim|sulfones|genito urinary system and sex hormones|sulfur compounds|anti infective agents|sulfanilamides|gynecological antiinfectives and antiseptics|amines
mianserin	psychoanaleptics|central nervous system agents|adrenergic agents|serotonin receptor antagonists|cytochrome p 450 cyp3a4 substrates|histamine agents|antidepressive agents, second generation|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|cytochrome p 450 cyp2b6 substrates|serotonin modulators|agents that produce hypertension|central nervous system depressants|neurotransmitter agents|antidepressive agents|dibenzazepines|nervous system|antidepressive agents, tetracyclic|cytochrome p 450 substrates|serotonin 5 ht2 receptor antagonists|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|serotonin 5 ht2c receptor antagonists|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|combined inhibitors of serotonin/norepinephrine reuptake|serotonin 5 ht2a receptor antagonists|psychotropic drugs|cytochrome p 450 cyp1a2 substrates|histamine antagonists|dopamine antagonists|histamine h1 antagonists
teicoplanin	carbohydrates|amino acids, peptides, and proteins|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|lipoglycopeptides|peptides|narrow therapeutic index drugs|lipids|glycopeptide antibacterials|glycoconjugates|anti infective agents|lipopeptides|glycopeptides
sulfadimethoxine	cytochrome p 450 cyp2c9 inhibitors|amides|aniline compounds|cytochrome p 450 enzyme inhibitors|sulfonamides|antiinfectives for systemic use|antibacterials for systemic use|sulfonamides and trimethoprim|long acting sulfonamides|sulfones|genito urinary system and sex hormones|sulfur compounds|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|anti infective agents|sulfanilamides|gynecological antiinfectives and antiseptics|amines
acetylcysteine	amino acids, peptides, and proteins|antidote for acetaminophen overdose|ophthalmologicals|protective agents|amino acids|free radical scavengers|expectorants|oatp1b1/slco1b1 inhibitors|antidotes|sulfhydryl compounds|increased glutathione concentration|anti infective agents|cysteine|respiratory system agents|antioxidants|compounds used in a research, industrial, or household setting|amino acids, neutral|cough and cold preparations|amino acids, sulfur|sulfur compounds|sensory organs|reduction activity|decreased respiratory secretion viscosity
buphenine	propanolamines|agents producing tachycardia|adrenergic agents|tocolytic agents|amines|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|peripheral vasodilators|agents that produce hypertension|antiarrhythmic agents|neurotransmitter agents|calcium channel blockers|cardiovascular agents|sympathomimetics, labour repressants|sympathomimetics|vasodilating agents|adrenergic agonists|propanols|cytochrome p 450 substrates|ethylamines|2 amino 1 phenylethanol derivatives|adrenergic beta agonists|miscellaneous vasodilatating agents|cytochrome p 450 cyp3a substrates|peripheral nervous system agents|agents causing hyperkalemia|reproductive control agents|genito urinary system and sex hormones|amino alcohols|autonomic agents|phenethylamines|alcohols
pizotifen	agents producing tachycardia|sensory system agents|antimigraine preparations|central nervous system agents|serotonin receptor antagonists|antimigraine agents, miscellaneous|thiophenes|adrenergic alpha 1 receptor antagonists|adrenergic antagonists|serotonin 5 ht1 receptor antagonists|serotonin 5 ht1d receptor antagonists|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|analgesics|anticholinergic agents|serotonin 5 ht1a receptor antagonists|agents that produce hypertension|central nervous system depressants|neurotransmitter agents|antidepressive agents|nervous system|serotonin 5 ht2 receptor antagonists|analgesics, non narcotic|serotonin 5 ht2c receptor antagonists|muscarinic antagonists|adrenergic alpha antagonists|peripheral nervous system agents|serotonin 5 ht2a receptor antagonists|psychotropic drugs|sulfur compounds|histamine antagonists|histamine h1 antagonists
rimonabant	anti obesity agents|agents producing tachycardia|cannabinoid receptor antagonists|cytochrome p 450 cyp3a substrates|hormones, hormone substitutes, and hormone antagonists|alimentary tract and metabolism|hormones|cannabinoids and similars|pyrazoles|receptor, cannabinoid, cb1, antagonists & inhibitors|cytochrome p 450 substrates|piperidines|neurotransmitter agents|cytochrome p 450 cyp3a4 substrates|antiobesity preparations, excl. diet products
noscapine	respiratory system agents|opiate alkaloids|antitussive agents|cough and cold preparations|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|heterocyclic compounds, fused ring|central nervous system agents|alkaloids|opium alkaloids and derivatives|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|isoquinolines|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 cyp2c9 inhibitors
darinaparsin	amino acids, peptides, and proteins|oligopeptides|peptides|organometallic compounds
ispinesib	amides|heterocyclic compounds, fused ring|acids, carbocyclic|benzene derivatives|benzoates
zosuquidar	p glycoprotein inhibitors|drug resistance, multiple|benzocycloheptenes|heterocyclic compounds, fused ring
asenapine	central nervous system agents|serotonin receptor antagonists|tranquilizing agents|adrenergic alpha 1 receptor antagonists|diazepines, oxazepines, thiazepines and oxepines|acid reducers|psycholeptics|cytochrome p 450 cyp3a4 substrates|adrenergic antagonists|cytochrome p 450 cyp2d6 inhibitors (weak)|serotonin 5 ht1 receptor antagonists|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|serotonin 5 ht1a receptor antagonists|antipsychotic agents|agents that produce hypertension|central nervous system depressants|antidepressive agents|ugt1a4 substrates|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|nervous system|cytochrome p 450 enzyme inhibitors|hyperglycemia associated agents|cytochrome p 450 substrates|serotonin 5 ht2 receptor antagonists|antipsychotic agents (second generation [atypical])|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|serotonin 5 ht2c receptor antagonists|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|neurotoxic agents|serotonin 5 ht2a receptor antagonists|psychotropic drugs|highest risk qtc prolonging agents|cytochrome p 450 cyp1a2 substrates|histamine h2 antagonists|histamine antagonists|dopamine antagonists|serotonin receptor agonists|histamine h1 antagonists
rivaroxaban	thiophenes|drugs that are mainly renally excreted|oxazines|antithrombins|cytochrome p 450 cyp3a4 substrates|factor xa inhibitors|p glycoprotein substrates|bcrp/abcg2 substrates|blood and blood forming organs|anticoagulants|hematologic agents|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|protease inhibitors|serine protease inhibitors|sulfur compounds|morpholines
deforolimus	macrolides|cytochrome p 450 enzyme inhibitors|antineoplastic and immunomodulating agents|protein kinase inhibitors|polyketides|anti bacterial agents|cytochrome p 450 cyp3a4 inhibitors|antineoplastic agents|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|lactones
lonidamine	trypanocidal agents|antineoplastic and immunomodulating agents|radiation sensitizing agents|adrenal cortex hormones|heterocyclic compounds, fused ring|pyrazoles|reproductive control agents|contraceptive agents, male|antineoplastic agents|antispermatogenic agents|anti infective agents|antiprotozoals|noxae|toxic actions|antiparasitic agents|hormonal contraceptives for systemic use
levocetirizine	histamine agents|cytochrome p 450 cyp3a substrates|qtc prolonging agents|cytochrome p 450 substrates|histamine h1 antagonists, non sedating|drugs that are mainly renally excreted|piperazine derivatives|central nervous system depressants|piperazines|antihistamines for systemic use|neurotransmitter agents|histamine antagonists|potential qtc prolonging agents|cytochrome p 450 cyp3a4 substrates|histamine h1 antagonists
temsirolimus	mtor inhibitors|antineoplastic and immunomodulating agents|cytochrome p 450 cyp3a7 substrates with a narrow therapeutic index|anti bacterial agents|antineoplastic agents|kinase inhibitor|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp2d6 inhibitors (weak)|cytochrome p 450 cyp3a5 inhibitors|myelosuppressive agents|cytochrome p 450 cyp3a7 substrates|cytochrome p 450 cyp2d6 inhibitors|sirolimus and prodrugs|cytochrome p 450 enzyme inhibitors|agents causing angioedema|hyperglycemia associated agents|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a inhibitors|protein kinase inhibitors|immunosuppressive agents|macrolides|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|polyketides|narrow therapeutic index drugs|cytochrome p 450 cyp3a5 inhibitors (strength unknown)|p glycoprotein substrates with a narrow therapeutic index|lactones
amisulpride	central nervous system agents|serotonin receptor antagonists|tranquilizing agents|benzoates|psycholeptics|antidepressive agents, second generation|serotonin agents|antipsychotic agents|central nervous system depressants|neurotransmitter agents|antidepressive agents|qtc prolonging agents|amides|nervous system|serotonin 5 ht2 receptor antagonists|potential qtc prolonging agents|antipsychotic agents (second generation [atypical])|dopamine d2 receptor antagonists|neurotoxic agents|serotonin 5 ht2a receptor antagonists|psychotropic drugs|dopamine agents|benzamides and benzamide derivatives|acids, carbocyclic|benzene derivatives|dopamine antagonists
xaliproden	nervous system|serotonin agents|central nervous system depressants|neurotransmitter agents|antidepressive agents
ambrisentan	ugt1a3 substrates|oatp1b3 substrates|ugt2b7 substrates|cytochrome p 450 cyp3a4 substrates|p glycoprotein substrates|cytochrome p 450 cyp2c19 substrates|cardiovascular agents|hypertension, pulmonary|oatp1b1/slco1b1 substrates|vasodilating agents|endothelin receptor antagonists|cytochrome p 450 substrates|antihypertensives for pulmonary arterial hypertension|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|antihypertensive agents|ugt1a9 substrates|acids, carbocyclic
doxercalciferol	micronutrients|food|secosteroids|fused ring compounds|food and beverages|cholestenes|calcium homeostasis|vitamin d and analogues|vitamins (fat soluble)|diet, food, and nutrition|bone density conservation agents|physiological phenomena|anti parathyroid agents|growth substances|steroids|lipids|cholestanes|vitamins|systemic hormonal preparations, excl. sex hormones and insulins|sterols|membrane lipids
oxymetholone	hormones, hormone substitutes, and hormone antagonists|androstanes|cytochrome p 450 cyp3a7 inhibitors (strength unknown)|fused ring compounds|cytochrome p 450 cyp3a5 inhibitors|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 cyp2d6 inhibitors|anabolic agents|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|anabolic steroids|androstanols|cytochrome p 450 cyp3a inhibitors|androstan derivatives|cytochrome p 450 cyp3a7 inhibitors|steroids|alimentary tract and metabolism|hormones|cytochrome p 450 cyp3a5 inhibitors (strength unknown)|thyroxine binding globulin inhibitors|anabolic agents for systemic use|androgens
semaxanib	growth substances|angiogenesis inhibitors|heterocyclic compounds, fused ring|growth inhibitors|antineoplastic agents|enzyme inhibitors|angiogenesis modulating agents|protein kinase inhibitors
tyloxapol	detergents|compounds used in a research, industrial, or household setting|cough and cold preparations|household products|ethylene glycols|polymers|expectorants|macromolecular substances|surface active agents|glycols|alcohols
remacemide	acetates|acids, acyclic|amides|compounds used in a research, industrial, or household setting|cytochrome p 450 enzyme inhibitors|neuroprotective agents|cytochrome p 450 cyp3a4 inhibitors|fatty acids, volatile|central nervous system agents|fatty acids|protective agents|lipids|anticonvulsants|central nervous system depressants|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 inhibitors (strength unknown)
lestaurtinib	cytochrome p 450 enzyme inhibitors|indoles|cytochrome p 450 cyp3a4 inhibitors|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|tyrosine kinase inhibitors
clomethiazole	hypnotics and sedatives|thiazoles|central nervous system agents|cytochrome p 450 cyp2a6 substrates|psycholeptics|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp2b6 substrates|protective agents|anticonvulsants|central nervous system depressants|neurotransmitter agents|nervous system|gaba modulators|cytochrome p 450 substrates|gaba agents|neuroprotective agents|compounds used in a research, industrial, or household setting|cytochrome p 450 cyp3a substrates|sulfur compounds
propentofylline	nervous system|neuroprotective agents|compounds used in a research, industrial, or household setting|heterocyclic compounds, fused ring|psychoanaleptics|central nervous system agents|alkaloids|protective agents|psychostimulants, agents used for adhd and nootropics|cytochrome p 450 cyp1a2 substrates|cytochrome p 450 substrates|purinones|purines|xanthine derivatives|anti ulcer agents
enzastaurin	heterocyclic compounds, fused ring
gaboxadol	appetite depressants|gaba agonists|peripheral nervous system agents|sensory system agents|central nervous system agents|analgesics|gaba agents|anticonvulsants|central nervous system depressants|neurotransmitter agents|anesthetics
pazopanib	cytochrome p 450 cyp2c8 inhibitors|angiogenesis inhibitors|antineoplastic and immunomodulating agents|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|antineoplastic agents|cytochrome p 450 cyp3a4 inhibitors (weak)|kinase inhibitor|hepatotoxic agents|cytochrome p 450 cyp3a4 substrates|tyrosine kinase inhibitors|ugt1a1 inhibitors|p glycoprotein substrates|cytochrome p 450 cyp2d6 inhibitors (weak)|sulfones|oatp1b1/slco1b1 inhibitors|bcrp/abcg2 substrates|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|amides|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|moderate risk qtc prolonging agents|cytochrome p 450 substrates|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|protein kinase inhibitors|immunosuppressive agents|cytochrome p 450 cyp2d6 substrates|receptors, vascular endothelial growth factor, antagonists & inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2c8 inhibitors (weak)|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|sulfur compounds|cytochrome p 450 cyp2c8 substrates with a narrow therapeutic index|cytochrome p 450 cyp2c8 substrates
midostaurin	cytochrome p 450 cyp2e1 inhibitors (strong)|cytochrome p 450 cyp2c8 inhibitors|antineoplastic and immunomodulating agents|cytochrome p 450 cyp2d6 inhibitors (strong)|antineoplastic agents|cytochrome p 450 cyp3a4 inhibitors (strong)|cytochrome p 450 cyp1a2 inducers (strength unknown)|kinase inhibitor|cytochrome p 450 cyp2c8 inducers (strength unknown)|cytochrome p 450 cyp2b6 inducers (strength unknown)|receptor tyrosine kinase inhibitors|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|tyrosine kinase inhibitors|cytochrome p 450 cyp1a2 inducers|indoles|cytochrome p 450 cyp3a inducers (strong)|cytochrome p 450 cyp2e1 inhibitors|cytochrome p 450 cyp2c19 inducers|cytochrome p 450 cyp2c9 inducers (strength unknown)|cytochrome p 450 cyp3a5 inducers (strength unknown)|cytochrome p 450 cyp2c19 inhibitors (weak)|indole alkaloids|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|cytochrome p 450 cyp2b6 inducers|cytochrome p 450 cyp3a4 inducers (strong)|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|alkaloids|cytochrome p 450 cyp1a2 inhibitors (strong)|cytochrome p 450 cyp2c8 inducers|cytochrome p 450 substrates|cytochrome p 450 cyp3a7 inducers (strength unknown)|enzyme inhibitors|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp1a2 inhibitors|cytochrome p 450 cyp2c9 inhibitors|protein kinase inhibitors|heterocyclic compounds, fused ring|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2c19 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|carbazoles|narrow therapeutic index drugs|protein kinase c, antagonists & inhibitors|cytochrome p 450 cyp3a7 inducers|cytochrome p 450 cyp2c9 inducers|cytochrome p 450 cyp3a5 inducers
panobinostat	antineoplastic and immunomodulating agents|antineoplastic agents|amines|cytochrome p 450 cyp3a4 substrates|p glycoprotein substrates|indoles|hydroxamic acids|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|hydroxylamines|cytochrome p 450 enzyme inhibitors|moderate risk qtc prolonging agents|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|heterocyclic compounds, fused ring|immunosuppressive agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2d6 inhibitors (moderate)|histone deacetylase inhibitors|hydroxy acids|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index
bosutinib	cytochrome p 450 cyp2c8 inhibitors|antineoplastic and immunomodulating agents|antineoplastic agents|kinase inhibitor|amines|cytochrome p 450 cyp3a4 substrates|tyrosine kinase inhibitors|p glycoprotein inhibitors|p glycoprotein substrates|myelosuppressive agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a inhibitors|protein kinase inhibitors|heterocyclic compounds, fused ring|immunosuppressive agents|cytochrome p 450 cyp3a substrates|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index
flupirtine	nervous system|pyridines|peripheral nervous system agents|sensory system agents|central nervous system agents|analgesics|drugs that are mainly renally excreted|amines
axitinib	cytochrome p 450 cyp2c19 substrates with a narrow therapeutic index|antineoplastic and immunomodulating agents|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|antineoplastic agents|kinase inhibitor|benzoates|receptor tyrosine kinase inhibitors|cytochrome p 450 cyp3a4 substrates|tyrosine kinase inhibitors|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp2c19 substrates|pyrazoles|oatp1b1/slco1b1 inhibitors|ugt1a1 substrates with a narrow therapeutic index|oatp1b1/slco1b1 substrates|amides|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|protein kinase inhibitors|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|benzamides and benzamide derivatives|acids, carbocyclic|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|benzene derivatives|indazoles|ugt1a1 substrates
zibotentan	
vicriviroc	cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a4 substrates
safinamide	amino acids, peptides, and proteins|cytochrome p 450 cyp2b6 inhibitors (strength unknown)|bcrp/abcg2 inhibitors|amines|cytochrome p 450 cyp3a4 substrates|benzyl compounds|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|cytochrome p 450 cyp3a5 inhibitors|serotonergic drugs shown to increase risk of serotonin syndrome|cytochrome p 450 cyp2e1 inhibitors|amino acids|agents that produce hypertension|central nervous system depressants|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|antidepressive agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 cyp2b6 inhibitors|agents that reduce seizure threshold|nervous system|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|anti parkinson drugs|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|monoamine oxidase b inhibitors|cytochrome p 450 cyp3a inhibitors|monoamine oxidase a inhibitors  for interaction with monoamine oxidase a substrates|monoamine oxidase inhibitors|cytochrome p 450 cyp1a2 inhibitors|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|dopamine agents|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|cytochrome p 450 cyp3a5 inhibitors (strength unknown)|benzene derivatives|breast cancer resistance protein inhibitors
mepyramine	substituted ethylene diamines|hypnotics and sedatives|aminopyridines|central nervous system agents|amines|antipruritics, incl. antihistamines, anesthetics, etc.|antihistamines for topical use|histamine agents|central nervous system depressants|antihistamines for systemic use|neurotransmitter agents|qtc prolonging agents|pyridines|cytochrome p 450 cyp2d6 inhibitors|sleep aids, pharmaceutical|cytochrome p 450 enzyme inhibitors|anti allergic agents|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|potential qtc prolonging agents|dermatologicals|histamine antagonists|histamine h1 antagonists
mevastatin	antifungal agents|hypolipidemic agents|agents causing muscle toxicity|hydroxymethylglutaryl coa reductase inhibitors|enzyme inhibitors|anticholesteremic agents|lipid regulating agents|anti infective agents|noxae|toxic actions|naphthalenes
xylometazoline	agents producing tachycardia|sympathomimetics used as decongestants|ophthalmologicals|antihistamine drugs|vasoconstrictor agents|agents that produce hypertension|adrenergic alpha 1 receptor agonists|adrenergic alpha 2 receptor agonists|antiarrhythmic agents|calcium channel blockers|cardiovascular agents|decongestants and antiallergics|vasodilating agents|adrenergic agonists|nasal decongestants|adrenergic alpha agonists|respiratory system agents|sympathomimetics, plain|nasal preparations|sensory organs
artemether	reactive oxygen species|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|antiparasitic products, insecticides and repellents|electrolytes|cytochrome p 450 cyp2c19 substrates|ions|anions|cytochrome p 450 cyp2b6 substrates|oxides|cytochrome p 450 cyp2c19 inducers|peroxides|cytochrome p 450 cyp2b6 inducers (weak)|cytochrome p 450 cyp3a4 inducers (weak)|cytochrome p 450 cyp2b6 inducers|antiparasitic agents|qtc prolonging agents|artemisinins|artemisinin and derivatives, plain|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|antimalarials|anti infective agents|cytochrome p 450 cyp3a inducers|oxygen compounds|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 enzyme inducers|sesquiterpenes|highest risk qtc prolonging agents|terpenes|antiprotozoals|free radicals
betahistine	nervous system|histamine agents|pyridines|antivertigo preparations|vasodilating agents|miscellaneous therapeutic agents|histamine antagonists|neurotransmitter agents|histamine agonists|miscellaneous central nervous system agents
iobenguane	amidines|diagnostic uses of chemicals|tumour detection|diagnostic radiopharmaceuticals|iodine (131i) compounds|laboratory chemicals|hydrocarbons, iodinated|indicators and reagents|enzyme inhibitors|iodobenzenes|guanidines|compounds used in a research, industrial, or household setting|hydrocarbons, halogenated|radiopharmaceutical activity|radiopharmaceuticals|narrow therapeutic index drugs|therapeutic radiopharmaceuticals|benzene derivatives|radioactive diagnostic agent
isometheptene	drugs for functional gastrointestinal disorders|agents producing tachycardia|methemoglobinemia associated agents|adrenergic agonists|alimentary tract and metabolism|agents that produce hypertension|adrenergic alpha 1 receptor agonists|adrenergic alpha agonists|amines
naphazoline	agents producing tachycardia|adrenergic agents|sympathomimetics used as decongestants|ophthalmologicals|vasoconstrictor agents|agents that produce hypertension|adrenergic alpha 1 receptor agonists|adrenergic alpha 2 receptor agonists|neurotransmitter agents|cardiovascular agents|decongestants and antiallergics|imidazoles|adrenergic agonists|nasal decongestants|adrenergic alpha agonists|respiratory system agents|sympathomimetics, plain|nasal preparations|sensory organs
stanozolol	androstan derivatives|anabolic agents|hormones, hormone substitutes, and hormone antagonists|steroids|alimentary tract and metabolism|hormones|androstanes|thyroxine binding globulin inhibitors|anabolic steroids|anabolic agents for systemic use|androstanols|androgens|fused ring compounds
sulfaphenazole	cytochrome p 450 cyp2c8 inhibitors|cytochrome p 450 cyp2b6 inhibitors (strength unknown)|antibacterials for systemic use|sulfonamides and trimethoprim|ophthalmologicals|sulfanilamides|amines|intermediate acting sulfonamides|pyrazoles|sulfones|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|cytochrome p 450 cyp2d6 inhibitors|amides|cytochrome p 450 cyp2b6 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2c9 inhibitors (strong)|sulfonamides|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|anti infective agents|gynecological antiinfectives and antiseptics|cytochrome p 450 cyp2c9 inhibitors|aniline compounds|cytochrome p 450 cyp2d6 inhibitors (moderate)|antiinfectives for systemic use|long acting sulfonamides|genito urinary system and sex hormones|sensory organs|sulfur compounds
aceclofenac	anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|antiinflammatory preparations, non steroids for topical use|central nervous system agents|sensory system agents|drugs that are mainly renally excreted|musculo skeletal system|nephrotoxic agents|selective cyclooxygenase 2 inhibitors (nsaids)|analgesics|agents that produce hypertension|acetic acid derivatives and related substances|antiinflammatory and antirheumatic products, non steroids|topical products for joint and muscular pain|anti inflammatory agents|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|analgesics, non narcotic|antirheumatic agents|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|acids, carbocyclic|phenylacetates
gavestinel	ugt1a3 substrates|excitatory amino acid antagonists|ugt1a9 substrates|glycine agents|neurotransmitter agents|ugt1a1 substrates|excitatory amino acid agents|heterocyclic compounds, fused ring
ambroxol	respiratory system agents|aniline compounds|cytochrome p 450 cyp3a substrates|cough and cold preparations|drugs for obstructive airway diseases|cyclohexanes|cycloparaffins|adrenergics for systemic use|cytochrome p 450 substrates|expectorants|selective beta 2 adrenergic agonists|amines|cytochrome p 450 cyp3a4 substrates|cyclohexylamines
pinacidil	amidines|guanidines|membrane transport modulators|cytochrome p 450 cyp3a substrates|antihypertensive agents|vasodilating agents|cytochrome p 450 substrates|guanidine derivatives|cardiovascular agents|arteriolar smooth muscle, agents acting on|cytochrome p 450 cyp3a4 substrates
tetrahydrozoline	agents producing tachycardia|sympathomimetics used as decongestants|ophthalmologicals|vasoconstrictor agents|ophthalmic solutions|pharmaceutical solutions|agents that produce hypertension|adrenergic alpha 1 receptor agonists|cardiovascular agents|decongestants and antiallergics|sympathomimetics|adrenergic agonists|nasal decongestants|solutions|adrenergic alpha agonists|pharmaceutical preparations|respiratory system agents|sympathomimetics, plain|compounds used in a research, industrial, or household setting|peripheral nervous system agents|nasal preparations|sensory organs|autonomic agents
capsaicin	anesthetics, local|sensory system agents|catechols|capsaicin, antagonists & inhibitors|cytochrome p 450 cyp1a2 inducers (strength unknown)|musculo skeletal system|polyunsaturated alkamides|basic lotions and liniments|cholinesterase inhibitors|cytochrome p 450 cyp1a2 inducers|fatty acids|alkenes|alkynes|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|hydrocarbons, acyclic|amides|nervous system|phenols|cytochrome p 450 enzyme inhibitors|topical products for joint and muscular pain|cytochrome p 450 cyp3a4 inhibitors|alkaloids|cytochrome p 450 substrates|anesthetics|cytochrome p 450 cyp3a inhibitors|monoamine oxidase a inhibitors  for interaction with monoamine oxidase a substrates|peripheral nervous system agents|antipruritics|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 enzyme inducers|dermatologicals|solanaceous alkaloids|cytochrome p 450 cyp1a2 substrates|fatty acids, monounsaturated|lipids|capsaicin and similar agents|benzene derivatives|fatty acids, unsaturated
chenodeoxycholic acid	bile therapy|cytochrome p 450 cyp3a substrates|steroids|alimentary tract and metabolism|gastrointestinal agents|ugt2b7 inhibitors|cytochrome p 450 substrates|bile acid preparations|cholanes|fused ring compounds|cholic acids|bile and liver therapy|cytochrome p 450 cyp3a4 substrates|bile acids and salts|bile acids and derivatives
deoxycorticosterone acetate	hormones, hormone substitutes, and hormone antagonists|cytochrome p 450 cyp3a substrates|desoxycorticosterone|adrenal cortex hormones|pregnanes|hormones|pregnenediones|pregnenes|steroids|cytochrome p 450 substrates|mineralocorticoids|hydroxycorticosteroids|cytochrome p 450 cyp3a4 substrates|fused ring compounds
halcinonide	cytochrome p 450 cyp3a substrates|dermatologicals|anti inflammatory agents|adrenal cortex hormones|corticosteroids, dermatological preparations|pregnanes|pregnenediones|pregnenes|steroids|corticosteroids|corticosteroids, very potent (group iv)|cytochrome p 450 substrates|immunosuppressive agents|cytochrome p 450 cyp3a4 substrates|fused ring compounds|corticosteroid hormone receptor agonists
levopropoxyphene	respiratory system agents|acids, acyclic|agents that reduce seizure threshold|antitussive agents|fatty acids, volatile|propionates|central nervous system agents|fatty acids|lipids
mafenide	amides|folic acid antagonists|sulfonamide antibacterial|methemoglobinemia associated agents|sulfonamides|dermatologicals|anti bacterial agents|sulfones|genito urinary system and sex hormones|anti infective agents, local|sulfur compounds|drugs that are mainly renally excreted|enzyme inhibitors|anti infective agents|gynecological antiinfectives and antiseptics
methenamine	amides|hydroxy acids|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|keto acids|anti infective agents, urinary|benzoates|cycloparaffins|acids, carbocyclic|renal agents|urinary acidifying agents|polyamines|anti infective agents|benzene derivatives|amines
niclosamide	antinematodal agents|antiplatyhelmintic agents|amines|antiparasitic products, insecticides and repellents|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|agrochemicals|pesticides|anthelmintics|salicylic acid derivatives|antiparasitic agents|amides|salicylanilides|cytochrome p 450 enzyme inhibitors|anilides|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|anti infective agents|cytochrome p 450 cyp1a2 inhibitors|aniline compounds|compounds used in a research, industrial, or household setting|molluscacides|salicylamides|anticestodal agents|toxic actions
nonoxynol 9	compounds used in a research, industrial, or household setting|spermatocidal agents|adrenal cortex hormones|polyethylene glycols|reproductive control agents|ethylene glycols|contraceptive agents, male|hormonal contraceptives for systemic use|polymers|antispermatogenic agents|contraceptive agents, female|noxae|macromolecular substances|toxic actions|surface active agents|glycols|alcohols
plerixafor	increased hematopoietic stem cell mobilization|antineoplastic and immunomodulating agents|adjuvants, immunologic|hematopoietic stem cell mobilizer|anti hiv agents|drugs that are mainly renally excreted|anti infective agents|hematinics
pyrvinium	heterocyclic compounds, fused ring|antinematodal agents|anthelmintics|quinolinium compounds|anti infective agents|quinolines|antiparasitic agents|antiparasitic products, insecticides and repellents
raltegravir	hiv integrase inhibitors|human immunodeficiency virus integrase strand transfer inhibitor|agents causing muscle toxicity|antiinfectives for systemic use|antivirals for systemic use|anti hiv agents|direct acting antivirals|enzyme inhibitors|integrase inhibitors|pyrrolidinones|anti infective agents|antiviral agents|pyrrolidines|ugt1a1 substrates|anti retroviral agents
phenylbutyrate	ammonium ion binding activity|nitrogen binding agent|cytochrome p 450 cyp2d6 inhibitors (moderate)|cytochrome p 450 enzyme inhibitors|various alimentary tract and metabolism products|alimentary tract and metabolism|antineoplastic agents|acids, carbocyclic|urea cycle disorder agents|cytochrome p 450 cyp2d6 inhibitors
sulconazole	antifungal agents|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp2d6 inhibitors (moderate)|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|dermatologicals|antifungals for topical use|azole antifungals|imidazole and triazole derivatives|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|anti infective agents|cytochrome p 450 cyp1a2 inhibitors|antifungals for dermatological use|cytochrome p 450 cyp2d6 inhibitors
viomycin	amino acids, peptides, and proteins|neurotoxic agents|peptides, cyclic|anti bacterial agents|peptides|antituberculosis agents|protein synthesis inhibitors|agents that produce neuromuscular block (indirect)|enzyme inhibitors|anti infective agents|antibiotics, antitubercular
bisphenol a	antioxidants|benzopyrans|hormones, hormone substitutes, and hormone antagonists|compounds used in a research, industrial, or household setting|heterocyclic compounds, fused ring|hormones|protective agents|pyrans|estrogens|estrogens, non steroidal|air pollutants, occupational|free radical scavengers|benzene derivatives|air pollutants|toxic actions|environmental pollutants
plx 4720	amides|sulfones|sulfur compounds|heterocyclic compounds, fused ring
pd 0325901	amides|aniline compounds|acids, carbocyclic|benzene derivatives|benzoates|amines
hymecromone	benzopyrans|laboratory chemicals|bile therapy|compounds used in a research, industrial, or household setting|heterocyclic compounds, fused ring|alimentary tract and metabolism|pyrans|indicators and reagents|coumarins|bile and liver therapy|umbelliferones
veliparib	antineoplastic agents|poly(adp ribose) polymerase inhibitors|enzyme inhibitors|heterocyclic compounds, fused ring
reversine	protein kinase inhibitors|heterocyclic compounds, fused ring|oxazines
brefeldin a	macrolides|p glycoprotein inhibitors|cytochrome p 450 enzyme inhibitors|polyketides|anti bacterial agents|cytochrome p 450 cyp3a4 inhibitors|protein synthesis inhibitors|enzyme inhibitors|anti infective agents|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|lactones
apigenin	benzopyrans|flavonoids|heterocyclic compounds, fused ring|flavones|pyrans|chromones
anisomycin	nucleic acid synthesis inhibitors|anti bacterial agents|protein synthesis inhibitors|enzyme inhibitors|antiprotozoals|anti infective agents|pyrrolidines|antiparasitic agents
azapropazone	anti inflammatory agents, non steroidal|sensory system agents|central nervous system agents|musculo skeletal system|nephrotoxic agents|analgesics|agents that produce hypertension|antigout preparations|antiinflammatory and antirheumatic products, non steroids|anti inflammatory agents|uricosuric agents|analgesics, non narcotic|antirheumatic agents|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|renal agents|triazines
andarine	acetates|acids, acyclic|amides|aniline compounds|phenols|fatty acids, volatile|fatty acids|lipids|benzene derivatives|amines
felbinac	nephrotoxic agents|topical products for joint and muscular pain|anti inflammatory agents, non steroidal|peripheral nervous system agents|agents causing hyperkalemia|anti inflammatory agents|antiinflammatory preparations, non steroids for topical use|analgesics|central nervous system agents|sensory system agents|acids, carbocyclic|agents that produce hypertension|non cox 2 selective nsaids|analgesics, non narcotic|musculo skeletal system|antirheumatic agents
cct 018159	heterocyclic compounds, fused ring
tranilast	antiplatelet agents|membrane transport modulators|sensory system agents|central nervous system agents|calcium regulating hormones and agents|benzoates|aminobenzoates|bradycardia causing agents|cytochrome p 450 cyp3a4 substrates|histamine agents|analgesics|antiarrhythmic agents|neurotransmitter agents|calcium channel blockers|cardiovascular agents|anti inflammatory agents|hematologic agents|anti allergic agents|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|analgesics, non narcotic|antirheumatic agents|cytochrome p 450 cyp3a substrates|peripheral nervous system agents|agents causing hyperkalemia|acids, carbocyclic|benzene derivatives
emodin	anthraquinones|quinones|biological products|gastrointestinal agents|laxatives|enzyme inhibitors|cascara|protein kinase inhibitors|plant extracts|pharmaceutical preparations|complex mixtures|plant preparations|anthracenes
epibatidine	cholinergic agents|peripheral nervous system agents|cholinergic agonists|central nervous system agents|analgesics|sensory system agents|neurotransmitter agents|analgesics, non narcotic|nicotinic agonists
tert butylhydroquinone	antioxidants|phenols|compounds used in a research, industrial, or household setting|protective agents|enzyme inhibitors|benzene derivatives|calcium transporting atpases, antagonists & inhibitors
epitestosterone	hormones, hormone substitutes, and hormone antagonists|androstenols|androstenes|gonadal steroid hormones|steroids|hormones|testosterone congeners|androstanes|gonadal hormones|fused ring compounds
phloretin	benzopyrans|flavonoids|phenols|propiophenones|phloroglucinol|heterocyclic compounds, fused ring|pyrans|hydroxypropiophenone|chromones|benzene derivatives|ketones
harmine	hallucinogens|pyridines|indoles|heterocyclic compounds, fused ring|psychotropic drugs|alkaloids|central nervous system agents|indole alkaloids|harmala alkaloids|enzyme inhibitors|central nervous system depressants|antidepressive agents|monoamine oxidase inhibitors|carbolines
hexestrol	hormones, hormone substitutes, and hormone antagonists|hormones|stilbenes|thyroxine binding globulin inducers|antineoplastic agents|estrogens|estrogens, non steroidal|benzene derivatives|antineoplastic agents, hormonal|benzylidene compounds
h 89	amides|sulfones|sulfur compounds|enzyme inhibitors|protein kinase inhibitors|heterocyclic compounds, fused ring
su 11652	heterocyclic compounds, fused ring
wortmannin	antifungal agents|hormones, hormone substitutes, and hormone antagonists|hormone antagonists|androstenes|serotonin receptor antagonists|androstanes|fused ring compounds|serotonin agents|central nervous system depressants|antidepressive agents|androstadienes|insulin antagonists|enzyme inhibitors|anti infective agents|protein kinase inhibitors|immunosuppressive agents|radiation sensitizing agents|steroids|immunologic factors
latrunculin b	thiazoles|sulfur compounds|porifera|marine toxins
at 7519	cyclin dependent kinases, antagonists & inhibitors
fasudil	amides|membrane transport modulators|sulfonamides|vasodilating agents|heterocyclic compounds, fused ring|peripheral vasodilators|sulfones|sulfur compounds|piperazines|calcium regulating hormones and agents|enzyme inhibitors|antiarrhythmic agents|isoquinolines|calcium channel blockers|protein kinase inhibitors|cardiovascular agents
nocodazole	mitosis modulators|benzimidazoles|antimitotic agents|antineoplastic agents|tubulin modulators|heterocyclic compounds, fused ring
piceatannol	benzene derivatives|benzylidene compounds|tyrosine kinase inhibitors
puromycin	carbohydrates|anti bacterial agents|antineoplastic agents|aminoglycoside antibacterials|agents that produce neuromuscular block (indirect)|drugs that are mainly renally excreted|nucleosides|nephrotoxic agents|antiparasitic agents|trypanocidal agents|ribonucleosides|glycosides|enzyme inhibitors|anti infective agents|nucleic acids, nucleotides, and nucleosides|noxae|heterocyclic compounds, fused ring|cinnamates|purine nucleosides|antimetabolites|protein synthesis inhibitors|acids, carbocyclic|purines|antiprotozoals|toxic actions
parecoxib	anti inflammatory agents, non steroidal|sensory system agents|central nervous system agents|musculo skeletal system|cytochrome p 450 cyp3a4 substrates|cox 2 inhibitors|nephrotoxic agents|selective cyclooxygenase 2 inhibitors (nsaids)|analgesics|agents that produce hypertension|antiinflammatory and antirheumatic products, non steroids|cytochrome p 450 enzyme inhibitors|anti inflammatory agents|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|analgesics, non narcotic|cytochrome p 450 cyp2c9 inhibitors|antirheumatic agents|cytochrome p 450 cyp3a substrates|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|cyclooxygenase inhibitors
dorsomorphin	protein kinase inhibitors|enzyme inhibitors|amp activated protein kinases, antagonists & inhibitors
tributyltin	organotin compounds|organometallic compounds
triclosan	antiseptics and disinfectants|hypolipidemic agents|phenols|dermatologicals|miscellaneous local anti infectives|phenol and derivatives|toxic actions|anti infective agents, local|medicated dressings|ethers|benzene derivatives|anti infective agents|lipid regulating agents|medicated dressings with antiinfectives|noxae|phenyl ethers|fatty acid synthesis inhibitors
thiamphenicol	glycols|nitro compounds|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|nitrobenzenes|anti infective agents|benzene derivatives|propylene glycols|amphenicols|alcohols
thiorphan	amino acids, peptides, and proteins|protease inhibitors|n substituted glycines|amino acids, sulfur|peptides|amino acids|sulfur compounds|enzyme inhibitors|peptoids
tnp 470	growth substances|angiogenesis inhibitors|antibiotics, antineoplastic|sesquiterpenes|cyclohexanes|cycloparaffins|growth inhibitors|antineoplastic agents|terpenes|angiogenesis modulating agents
y 27632	muscle relaxants|antihypertensive agents|muscle relaxants, centrally acting agents|peripheral nervous system agents|central nervous system agents|enzyme inhibitors|central nervous system depressants|neuromuscular agents|cardiovascular agents
diloxanide	dichloroacetamide derivatives|amebicides|anti infective agents|antiprotozoals|antiparasitic agents|antiparasitic products, insecticides and repellents
antazoline	antiallergic agents, excl. corticosteroids|histamine agents|imidazoles|nasal preparations|moderate risk qtc prolonging agents|anti allergic agents|antihistamines for systemic use|neurotransmitter agents|histamine antagonists|qtc prolonging agents|histamine h1 antagonists
chloropyramine	substituted ethylene diamines|antihistamines for topical use|histamine agents|diamines|dermatologicals|polyamines|antihistamines for systemic use|neurotransmitter agents|histamine antagonists|amines|histamine h1 antagonists|antipruritics, incl. antihistamines, anesthetics, etc.
roxatidine acetate	histamine agents|gastric acid lowering agents|alimentary tract and metabolism|gastrointestinal agents|histamine h2 antagonists|histamine antagonists|neurotransmitter agents|acid reducers|anti ulcer agents|drugs for peptic ulcer and gastro oesophageal reflux disease (gord)|drugs for acid related disorders
dichloroacetic acid	acetates|acids, acyclic|chloroacetates|hydrocarbons, halogenated|fatty acids, volatile|fatty acids|hydrocarbons, chlorinated|lipids
triflusal	antiplatelet agents|phenols|hydroxy acids|anticoagulants|hematologic agents|acids, carbocyclic|hydroxybenzoates|platelet aggregation inhibitors excl. heparin|benzene derivatives|benzoates|blood and blood forming organs
deferiprone	ugt1a6 substrate|compounds used in a research, industrial, or household setting|iron chelating activity|pyridines|pyridones|chelating agents|iron chelating agents|drugs that are mainly renally excreted|sequestering agents|heavy metal antagonists
spaglumic acid	antiallergic agents, excl. corticosteroids|nasal preparations|sensory organs|ophthalmologicals|mast cell stabilizers|decongestants and antiallergics
serotonin	fluids and secretions|enzymes|toxins, biological|tryptamines|venoms|peptide hydrolases|amines|indoles|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|snake venoms|central nervous system depressants|hydrolases|neurotransmitter agents|viper venoms|antidepressive agents|bodily secretions|autacoids|enzymes and coenzymes|biogenic monoamines|endopeptidases|serine proteases|biological factors|heterocyclic compounds, fused ring|inflammation mediators|biogenic amines|complex mixtures|serotonin receptor agonists
tyramine	agents producing tachycardia|membrane transport modulators|sympathomimetics|peripheral nervous system agents|neurotransmitter uptake inhibitors|adrenergic agents|agents that produce hypertension|biogenic amines|biogenic monoamines|autonomic agents|neurotransmitter agents|amines
ellagic acid	benzopyrans|oat1/slc22a6 substrates|cytochrome p 450 enzyme inhibitors|heterocyclic compounds, fused ring|cytochrome p 450 cyp2e1 inhibitors|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|pyrans|oat1/slc22a6 inhibitors|oat3/slc22a8 substrates
pitavastatin	ugt1a3 substrates|oatp1b3 substrates|hydroxymethylglutaryl coa reductase inhibitors|lipid regulating agents|ugt2b7 substrates|p glycoprotein substrates|lipid modifying agents|oatp1b1/slco1b1 inhibitors|bcrp/abcg2 substrates|hypolipidemic agents indicated for hyperlipidemia|oatp1b1/slco1b1 substrates|agents causing muscle toxicity|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c9 substrates|lipid modifying agents, plain|heterocyclic compounds, fused ring|hypolipidemic agents|bsep/abcb11 substrates|anticholesteremic agents|toxic actions|cytochrome p 450 cyp2c8 substrates
crizotinib	aminopyridines|antineoplastic and immunomodulating agents|cytochrome p 450 cyp2b6 inhibitors (strength unknown)|antineoplastic agents|kinase inhibitor|receptor tyrosine kinase inhibitors|amines|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|tyrosine kinase inhibitors|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp3a5 inhibitors|oct2 inhibitors|qtc prolonging agents|pyridines|cytochrome p 450 cyp2b6 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a4 inhibitors (moderate)|moderate risk qtc prolonging agents|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|piperidines|enzyme inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a inhibitors|protein kinase inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|organic cation transporter 1 inhibitors|narrow therapeutic index drugs|cytochrome p 450 cyp3a5 inhibitors (strength unknown)|p glycoprotein substrates with a narrow therapeutic index
ruxolitinib	cytochrome p 450 cyp3a substrates|antineoplastic and immunomodulating agents|protein kinase inhibitors|myelosuppressive agents|antineoplastic agents|cytochrome p 450 substrates|narrow therapeutic index drugs|drugs that are mainly renally excreted|kinase inhibitor|janus kinases, antagonists & inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|immunosuppressive agents|cytochrome p 450 cyp3a4 substrates|tyrosine kinase inhibitors
vemurafenib	cytochrome p 450 cyp2c8 inhibitors|drugs causing inadvertant photosensitivity|antineoplastic and immunomodulating agents|bcrp/abcg2 inhibitors|antineoplastic agents|kinase inhibitor|cytochrome p 450 cyp2b6 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|tyrosine kinase inhibitors|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp2d6 inhibitors (weak)|indoles|photosensitizing agents|sulfones|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|cytochrome p 450 cyp1a2 inhibitors (moderate)|bcrp/abcg2 substrates|cytochrome p 450 cyp2b6 inducers|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|amides|cytochrome p 450 enzyme inhibitors|sulfonamides|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|gynecological antiinfectives and antiseptics|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp1a2 inhibitors|protein kinase inhibitors|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|highest risk qtc prolonging agents|genito urinary system and sex hormones|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|sulfur compounds
tofacitinib	cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp3a substrates|biologics for rheumatoid arthritis treatment|antineoplastic and immunomodulating agents|cytochrome p 450 cyp2c19 substrates|janus kinase inhibitor|myelosuppressive agents|disease modifying antirheumatic agents|selective immunosuppressants|cytochrome p 450 substrates|janus kinase inhibitors|enzyme inhibitors|protein kinase inhibitors|immunosuppressive agents|antirheumatic agents|bradycardia causing agents|janus kinase 3, antagonists & inhibitors
enzalutamide	cytochrome p 450 cyp2c8 inhibitors|antineoplastic and immunomodulating agents|cytochrome p 450 cyp2b6 inhibitors (strength unknown)|cytochrome p 450 cyp2c9 inducers (moderate)|antineoplastic agents|drugs that are mainly renally excreted|androgen receptor antagonists|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|cytochrome p 450 cyp2c8 inhibitors (moderate)|cytochrome p 450 cyp3a inducers (strong)|cytochrome p 450 cyp3a5 inducers (strong)|cytochrome p 450 cyp2c19 inducers|antiandrogens|hydantoins|cytochrome p 450 cyp3a4 inducers (strong)|thyroxine binding globulin substrates|cytochrome p 450 cyp2b6 inhibitors|cytochrome p 450 enzyme inhibitors|androgen receptor inhibitor|imidazoles|antiandrogens, non steroidal|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 enzyme inducers|endocrine therapy|hormone antagonists and related agents|cytochrome p 450 cyp2c19 inducers (moderate)|cytochrome p 450 cyp2c9 inducers|cytochrome p 450 cyp3a5 inducers|imidazolidines|cytochrome p 450 cyp2c8 substrates
ponatinib	cytochrome p 450 cyp2c8 inhibitors|antineoplastic and immunomodulating agents|bcrp/abcg2 inhibitors|antineoplastic agents|kinase inhibitor|hepatotoxic agents|cytochrome p 450 cyp3a4 substrates|tyrosine kinase inhibitors|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp2d6 substrates with a narrow therapeutic index|bcrp/abcg2 substrates|myelosuppressive agents|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|protein kinase inhibitors|immunosuppressive agents|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|cytochrome p 450 cyp2c8 substrates with a narrow therapeutic index|cytochrome p 450 cyp2c8 substrates
formestane	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|androstenes|antineoplastic and immunomodulating agents|gonadal steroid hormones|adrenal cortex hormones|estrogen antagonists|androstanes|antineoplastic agents|drugs that are mainly renally excreted|cytochrome p 450 cyp3a4 inducers|fused ring compounds|ketosteroids|testosterone congeners|steroid synthesis inhibitors|aromatase inhibitors|enzyme inhibitors|cytochrome p 450 cyp3a inducers|17 ketosteroids|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|steroids|endocrine therapy|hormone antagonists and related agents|hormones|gonadal hormones
trametinib	cytochrome p 450 cyp2c8 inhibitors|antineoplastic and immunomodulating agents|pyrimidines|antineoplastic agents|drugs that are mainly renally excreted|kinase inhibitor|cytochrome p 450 cyp3a4 inducers|pyridines|cytochrome p 450 enzyme inhibitors|enzyme inhibitors|map kinase kinase 1, antagonists & inhibitors|protein kinase inhibitors|cytochrome p 450 cyp3a inducers|map kinase kinase 2, antagonists & inhibitors|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|narrow therapeutic index drugs|cytochrome p 450 cyp2c8 inhibitors (strong)
dabrafenib	cytochrome p 450 cyp2c8 inhibitors|drugs causing inadvertant photosensitivity|antineoplastic and immunomodulating agents|cytochrome p 450 cyp2c9 inducers (strong)|oatp1b3 inhibitors|bcrp/abcg2 inhibitors|antineoplastic agents|cytochrome p 450 cyp2c9 inducers|kinase inhibitor|cytochrome p 450 cyp2b6 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers|amines|cytochrome p 450 cyp3a4 substrates|p glycoprotein substrates|proto oncogene proteins b raf, antagonists & inhibitors|organic anion transporter 1 inhibitors|photosensitizing agents|oat3/slc22a8 inhibitors|cytochrome p 450 cyp2c19 inducers|oatp1b1/slco1b1 inhibitors|bcrp/abcg2 substrates|cytochrome p 450 cyp2b6 inducers|qtc prolonging agents|hydroxylamines|cytochrome p 450 enzyme inhibitors|hyperglycemia associated agents|cytochrome p 450 cyp2c8 inducers|cytochrome p 450 substrates|enzyme inhibitors|oat1/slc22a6 inhibitors|organic anion transporting polypeptide 1b1 inhibitors|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp2c8 inducers (weak)|potential qtc prolonging agents|protein kinase inhibitors|cytochrome p 450 cyp3a4 inducers (moderate)|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|organic anion transporting polypeptide 1b3 inhibitors|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index|cytochrome p 450 cyp2c8 inhibitors (strong)|cytochrome p 450 cyp2c8 substrates with a narrow therapeutic index|breast cancer resistance protein inhibitors|cytochrome p 450 cyp2c8 substrates
afatinib	quinazolines|amides|p glycoprotein inhibitors|p glycoprotein substrates|antineoplastic and immunomodulating agents|heterocyclic compounds, fused ring|bcrp/abcg2 inhibitors|antineoplastic agents|enzyme inhibitors|kinase inhibitor|protein kinase inhibitors|bcrp/abcg2 substrates|tyrosine kinase inhibitors
perospirone	cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp3a substrates|neurotoxic agents|heterocyclic compounds, fused ring|psychotropic drugs|central nervous system agents|tranquilizing agents|antipsychotic agents|cytochrome p 450 substrates|sulfur compounds|central nervous system depressants|dopamine antagonists|antipsychotic agents (second generation [atypical])|cytochrome p 450 cyp2c8 substrates|dopamine d2 receptor antagonists
amperozide	neurotoxic agents|serotonin 5 ht2a receptor antagonists|psychotropic drugs|serotonin agents|central nervous system agents|serotonin receptor antagonists|tranquilizing agents|antipsychotic agents|central nervous system depressants|serotonin 5 ht2 receptor antagonists|neurotransmitter agents|antidepressive agents
chlorcyclizine	piperazine derivatives|antihistamines for systemic use|histamine antagonists|potential qtc prolonging agents|qtc prolonging agents|histamine h1 antagonists
isoxsuprine	propanolamines|agents producing tachycardia|adrenergic agents|tocolytic agents|amines|peripheral vasodilators|hypotensive agents|agents that produce hypertension|neurotransmitter agents|cardiovascular agents|sympathomimetics|vasodilating agents|adrenergic agonists|propanols|ethylamines|2 amino 1 phenylethanol derivatives|adrenergic beta agonists|peripheral nervous system agents|reproductive control agents|amino alcohols|autonomic agents|phenethylamines|alcohols
isoxicam	nephrotoxic agents|thiazines|anti inflammatory agents, non steroidal|peripheral nervous system agents|agents causing hyperkalemia|anti inflammatory agents|central nervous system agents|analgesics|sensory system agents|sulfur compounds|agents that produce hypertension|non cox 2 selective nsaids|analgesics, non narcotic|antirheumatic agents
iopanoic acid	compounds used in a research, industrial, or household setting|hydrocarbons, halogenated|hydrocarbons, iodinated|diagnostic uses of chemicals|contrast media|watersoluble, hepatotropic x ray contrast media|x ray contrast media, iodinated|benzene derivatives|iodobenzenes
iopamidol	x ray contrast activity|compounds used in a research, industrial, or household setting|iodobenzoates|diagnostic uses of chemicals|acids, carbocyclic|contrast media|iodinated contrast agents|triiodobenzoic acids|benzene derivatives|benzoates|x ray contrast media, iodinated|radiographic contrast agent|roentgenography|watersoluble, nephrotropic, low osmolar x ray contrast media
indoprofen	anti inflammatory agents, non steroidal|sensory system agents|central nervous system agents|musculo skeletal system|nephrotoxic agents|analgesics|agents that produce hypertension|non cox 2 selective nsaids|antiinflammatory and antirheumatic products, non steroids|isoindoles|phenylpropionates|anti inflammatory agents|enzyme inhibitors|analgesics, non narcotic|antirheumatic agents|heterocyclic compounds, fused ring|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|propionates|acids, carbocyclic|cyclooxygenase inhibitors
ifenprodil	excitatory amino acid antagonists|adrenergic alpha antagonists|adrenergic antagonists|receptors, n methyl d aspartate|vasodilating agents|nmda receptor antagonists|adrenergic agents|peripheral vasodilators|anti parkinson drugs|agents that produce hypertension|anticonvulsants|central nervous system depressants|neurotransmitter agents|experimental unapproved treatments for covid 19|cardiovascular agents|excitatory amino acid agents
hexetidine	antifungal agents|antiinfectives and antiseptics for local oral treatment|alimentary tract and metabolism|pyrimidines|genito urinary system and sex hormones|anti infective agents, local|stomatological preparations|anti infective agents|gynecological antiinfectives and antiseptics
hexamethonium	nicotinic antagonists|muscle relaxants|ganglion blockers|amines|quaternary ammonium compounds|anticholinergic agents|ammonium compounds|central nervous system depressants|neurotransmitter agents|cardiovascular agents|cholinergic agents|onium compounds|nitrogen compounds|hexamethonium compounds|antihypertensive agents|peripheral nervous system agents|bis trimethylammonium compounds|autonomic agents|muscle relaxants, peripherally acting agents
fursultiamine	growth substances|thiazoles|micronutrients|pyrimidines|sulfur compounds|food|vitamin b complex|diet, food, and nutrition|vitamins|food and beverages|physiological phenomena
flumequine	topoisomerase inhibitors|antibacterials for systemic use|anti bacterial agents|anti infective agents, urinary|antineoplastic agents|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|fluoroquinolones|quinolines|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|quinolones|enzyme inhibitors|anti infective agents|potential qtc prolonging agents|cytochrome p 450 cyp1a2 inhibitors|heterocyclic compounds, fused ring|antiinfectives for systemic use|topoisomerase ii inhibitors|renal agents
flubendazole	acids, acyclic|benzimidazoles|heterocyclic compounds, fused ring|antinematodal agents|carbamates|benzimidazole derivatives|anthelmintics|anti infective agents|antiparasitic agents|antiparasitic products, insecticides and repellents
fenspiride	respiratory system agents|anti asthmatic agents|peripheral nervous system agents|bronchodilator agents|autonomic agents|asthma|drugs for obstructive airway diseases
fendiline	membrane transport modulators|calcium regulating hormones and agents|amines|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|antiarrhythmic agents|phenylalkylamine derivatives|calcium channel blockers|cardiovascular agents|qtc prolonging agents|vasodilating agents|moderate risk qtc prolonging agents|cytochrome p 450 substrates|ethylamines|non selective calcium channel blockers|cytochrome p 450 cyp3a substrates|agents causing hyperkalemia|phenethylamines
fenbufen	anti inflammatory agents, non steroidal|sensory system agents|central nervous system agents|musculo skeletal system|nephrotoxic agents|analgesics|agents that produce hypertension|non cox 2 selective nsaids|antiinflammatory and antirheumatic products, non steroids|anti inflammatory agents|enzyme inhibitors|analgesics, non narcotic|antirheumatic agents|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|propionates|acids, carbocyclic|cyclooxygenase inhibitors
etofenamate	anti inflammatory agents, non steroidal|antiinflammatory preparations, non steroids for topical use|central nervous system agents|sensory system agents|benzoates|musculo skeletal system|amines|aminobenzoates|nephrotoxic agents|analgesics|agents that produce hypertension|non cox 2 selective nsaids|thyroxine binding globulin substrates|topical products for joint and muscular pain|anti inflammatory agents|analgesics, non narcotic|antirheumatic agents|aniline compounds|peripheral nervous system agents|agents causing hyperkalemia|acids, carbocyclic|ortho aminobenzoates|benzene derivatives|fenamates
etilefrine	agents producing tachycardia|adrenergic agents|amines|vasoconstrictor agents|protective agents|agents that produce hypertension|neurotransmitter agents|cardiovascular agents|cardiac stimulants excl. cardiac glycosides|sympathomimetics|adrenergic agonists|adrenergic beta 1 receptor agonists|adrenergic alpha agonists|adrenergic beta agonists|ethanolamines|compounds used in a research, industrial, or household setting|peripheral nervous system agents|cardiotonic agents|adrenergic and dopaminergic agents|amino alcohols|autonomic agents|cardiac therapy|alcohols
etamivan	respiratory system agents|amides|acids, carbocyclic|benzene derivatives|benzoates
epirizole	nephrotoxic agents|anti inflammatory agents, non steroidal|peripheral nervous system agents|agents causing hyperkalemia|anti inflammatory agents|central nervous system agents|analgesics|pyrazoles|pyrimidines|sensory system agents|agents that produce hypertension|non cox 2 selective nsaids|analgesics, non narcotic|antirheumatic agents
diosmin	benzopyrans|flavonoids|heterocyclic compounds, fused ring|flavones|pyrans|capillary stabilizing agents|chromones|vasoprotectives
cloperastine	cough and cold preparations
clobutinol	respiratory system agents|antitussive agents|cough and cold preparations|central nervous system agents|amines|alcohols
articaine	amides|anesthetics, local|nervous system|peripheral nervous system agents|hyperglycemia associated agents|sensory system agents|central nervous system agents|sulfur compounds|local anesthetics (amide)|thiophenes|central nervous system depressants|anesthetics|local anesthesia
carmofur	fluoropyrimidines|pyrimidine analogues|antineoplastic and immunomodulating agents|antimetabolites|pyrimidines|antineoplastic agents|pyrimidinones
canrenoic acid	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|diuretics|agents causing hyperkalemia|potassium sparing diuretics|pregnanes|steroids|natriuretic agents|pregnadienes|cardiovascular agents|mineralocorticoid receptor antagonists|fused ring compounds
bromhexine	respiratory system agents|aniline compounds|cough and cold preparations|cyclohexanes|cycloparaffins|expectorants|amines|cyclohexylamines
bisacodyl	phenols|enemas|cresols|alimentary tract and metabolism|gastrointestinal agents|increased large intestinal motility|laxatives|drugs for constipation|contact laxatives|benzene derivatives|stimulation large intestine fluid/electrolyte secretion
benfluorex	appetite depressants|anti obesity agents|hypolipidemic agents|drugs used in diabetes|alimentary tract and metabolism|toxic actions|blood glucose lowering agents|ethylamines|lipid regulating agents|phenethylamines|noxae|amines
benactyzine	agents producing tachycardia|cholinergic agents|hydroxy acids|parasympatholytics|peripheral nervous system agents|psychotropic drugs|central nervous system agents|anticholinergic agents|acids, carbocyclic|phenylacetates|benzilates|central nervous system depressants|autonomic agents|diphenylacetic acids|antidepressive agents|neurotransmitter agents|muscarinic antagonists
aliskiren	renin inhibitors|acids, acyclic|agents acting on the renin angiotensin system|cytochrome p 450 cyp3a substrates|p glycoprotein substrates|antihypertensive agents|agents causing hyperkalemia|hypotensive agents|cytochrome p 450 substrates|methyl ethers|ethers|benzene derivatives|antihypertensive agents indicated for hypertension|dicarboxylic acids|cytochrome p 450 cyp3a4 substrates
ibrutinib	cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|antineoplastic and immunomodulating agents|myelosuppressive agents|antineoplastic agents|cytochrome p 450 substrates|kinase inhibitor|protein kinase inhibitors|immunosuppressive agents|cytochrome p 450 cyp3a4 substrates|tyrosine kinase inhibitors
idelalisib	cytochrome p 450 cyp2c8 inhibitors|antineoplastic and immunomodulating agents|cytochrome p 450 cyp3a7 substrates with a narrow therapeutic index|oatp1b3 inhibitors|antineoplastic agents|cytochrome p 450 cyp3a4 inhibitors (strong)|kinase inhibitor|hepatotoxic agents|cytochrome p 450 cyp2b6 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp3a7 inhibitors (strength unknown)|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp3a5 inhibitors|ugt1a4 inhibitors|oatp1b1/slco1b1 inhibitors|bcrp/abcg2 substrates|cytochrome p 450 cyp2b6 inducers|cytochrome p 450 cyp3a7 substrates|class ia phosphatidylinositol 3 kinase, antagonists & inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|heterocyclic compounds, fused ring|immunosuppressive agents|quinazolines|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a7 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 cyp2c8 inhibitors (weak)|cytochrome p 450 enzyme inducers|narrow therapeutic index drugs|cytochrome p 450 cyp3a5 inhibitors (strength unknown)|p glycoprotein substrates with a narrow therapeutic index|ugt1a4 substrates|cytochrome p 450 cyp3a4 substrates (strength unknown)
acipimox	hypolipidemic agents|nicotinic acid and derivatives|agents causing muscle toxicity|toxic actions|lipid modifying agents|lipid regulating agents|noxae|lipid modifying agents, plain
ciprofibrate	acids, acyclic|carcinogens|lipid regulating agents|butyrates|fatty acids|lipid modifying agents|ethers|isobutyrates|phenols|agents causing muscle toxicity|fatty acids, volatile|phenyl ethers|noxae|lipid modifying agents, plain|hypolipidemic agents|peroxisome proliferators|lipids|benzene derivatives|fibric acids|toxic actions
trimetazidine	vasodilating agents|piperazines|cardiac therapy|cardiovascular agents
tibolone	anabolic agents|hormones, hormone substitutes, and hormone antagonists|hormone antagonists|norsteroids|norpregnanes|steroids|hormones|estrogens|genito urinary system and sex hormones|estrogens,antiestrogens,estrogen agonist antagonists|sex hormones and modulators of the genital system|cardiovascular agents|antineoplastic agents, hormonal|fused ring compounds|estrogen receptor modulators
palbociclib	antineoplastic and immunomodulating agents|bcrp/abcg2 inhibitors|antineoplastic agents|cytochrome p 450 cyp3a4 inhibitors (weak)|kinase inhibitor|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|p glycoprotein substrates|myelosuppressive agents|bcrp/abcg2 substrates|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|enzyme inhibitors|cyclin dependent kinases, antagonists & inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a inhibitors|protein kinase inhibitors|immunosuppressive agents|oct1 inhibitors|cytochrome p 450 cyp3a substrates|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index
olaparib	antineoplastic and immunomodulating agents|bcrp/abcg2 inhibitors|antineoplastic agents|poly(adp ribose) polymerase inhibitors|cytochrome p 450 cyp3a4 inhibitors (weak)|cytochrome p 450 cyp2b6 inducers (strength unknown)|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|p glycoprotein substrates|pyridazines|myelosuppressive agents|cytochrome p 450 cyp2b6 inducers|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|enzyme inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a inhibitors|immunosuppressive agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 enzyme inducers|narrow therapeutic index drugs|p glycoprotein substrates with a narrow therapeutic index
nintedanib	p glycoprotein inhibitors|oct1 inhibitors|cytochrome p 450 cyp3a substrates|p glycoprotein substrates|antineoplastic and immunomodulating agents|tyrosine kinase inhibitors|heterocyclic compounds, fused ring|antineoplastic agents|cytochrome p 450 substrates|enzyme inhibitors|kinase inhibitor|antifibrotic agents|oct1 substrates|protein kinase inhibitors|ugt1a1 substrates|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp3a4 substrates (strength unknown)
idebenone	antioxidants|nervous system|compounds used in a research, industrial, or household setting|quinones|enzymes and coenzymes|benzoquinones|psychoanaleptics|psychostimulants, agents used for adhd and nootropics|protective agents|drugs that are mainly renally excreted|coenzymes
benzydamine	anti inflammatory agents, non steroidal|antiinflammatory preparations, non steroids for topical use|drugs that are mainly renally excreted|stomatological preparations|musculo skeletal system|nephrotoxic agents|antiinflammatory products for vaginal administration|pyrazoles|agents that produce hypertension|non cox 2 selective nsaids|antiinflammatory and antirheumatic products, non steroids|topical products for joint and muscular pain|throat preparations|anti inflammatory agents|heterocyclic compounds, fused ring|antiinflammatory and antirheumatic products|agents causing hyperkalemia|alimentary tract and metabolism|genito urinary system and sex hormones|mouthwashes and gargles|indazoles
tetracaine	anesthetics, local|sensory system agents|central nervous system agents|ophthalmologicals|benzoates|aminobenzoates|local anesthesia|antipruritics, incl. antihistamines, anesthetics, etc.|antipruritics and local anesthetics|anesthetics, general|central nervous system depressants|nervous system|esters of aminobenzoic acid|para aminobenzoates|anesthetics for topical use|dental agents|vasoprotectives|anesthetics|local anesthetics (ester)|peripheral nervous system agents|dermatologicals|acids, carbocyclic|sensory organs|agents for treatment of hemorrhoids and anal fissures for topical use|benzene derivatives
eugenol	solvents|compounds used in a research, industrial, or household setting|increased histamine release|caffeic acids|acids, carbocyclic|anti infective agents|cinnamates|cell mediated immunity|standardized chemical allergen
trimebutine	agents producing tachycardia|hydroxybenzoate ethers|drugs that are mainly renally excreted|benzoates|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|hydroxybenzoates|anticholinergic agents|synthetic anticholinergics, esters with tertiary amino group|antiarrhythmic agents|ethers|calcium channel blockers|qtc prolonging agents|phenols|parasympatholytics|gastrointestinal agents|cytochrome p 450 substrates|prokinetic agents|phenyl ethers|potential qtc prolonging agents|drugs for functional gastrointestinal disorders|muscarinic antagonists|antimuscarinics antispasmodics|cytochrome p 450 cyp3a substrates|hydroxy acids|peripheral nervous system agents|agents causing hyperkalemia|alimentary tract and metabolism|acids, carbocyclic|autonomic agents|benzene derivatives
xanthinol	pyridines|vasodilating agents|alkaloids|peripheral vasodilators|purinones|nicotinic acids|purines|cardiovascular agents|purine derivatives|heterocyclic compounds, fused ring
chlortetracycline	antibacterials for systemic use|anti bacterial agents|agents that produce neuromuscular block (indirect)|ophthalmologicals|stomatological preparations|tetracyclines|antiparasitic agents|naphthacenes|antiinfectives and antiseptics for local oral treatment|antibiotics for topical use|enzyme inhibitors|anti infective agents|antiinfectives for systemic use|dermatologicals|alimentary tract and metabolism|protein synthesis inhibitors|sensory organs|antiprotozoals
somatostatin	hormones, hormone substitutes, and hormone antagonists|amino acids, peptides, and proteins|cytochrome p 450 cyp3a4 inhibitors (weak)|p glycoprotein substrates|peptides|pituitary hormone release inhibiting hormones|cytochrome p 450 enzyme inhibitors|hypothalamic hormones|pancreatic hormones|peptide hormones|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a inhibitors|neuropeptides|nerve tissue proteins|hormones|somatostatin, agonists|proteins|pituitary and hypothalamic hormones and analogues|systemic hormonal preparations, excl. sex hormones and insulins|somatostatin and analogues
elvitegravir	cytochrome p 450 cyp3a4 inhibitors (strong)|cytochrome p 450 cyp3a4 substrates|antivirals for systemic use|human immunodeficiency virus integrase strand transfer inhibitor|quinolines|hiv integrase inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|hiv integrase|cytochrome p 450 substrates|antiviral agents|cytochrome p 450 cyp3a inhibitors|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|antiinfectives for systemic use|cytochrome p 450 enzyme inducers|direct acting antivirals|cytochrome p 450 cyp2c9 inducers|ugt1a1 substrates|ugt1a4 substrates
stiripentol	drugs causing inadvertant photosensitivity|central nervous system agents|cytochrome p 450 cyp3a4 inhibitors (strong)|drugs that are mainly renally excreted|photosensitizing agents|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|cytochrome p 450 cyp2c19 substrates|anticonvulsants|central nervous system depressants|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|miscellaneous anticonvulsants|cytochrome p 450 cyp2d6 inhibitors|nervous system|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strong)|cytochrome p 450 cyp1a2 inhibitors|cytochrome p 450 cyp2c19 inhibitors|dioxoles|cytochrome p 450 cyp1a2 substrates
ioversol	x ray contrast activity|compounds used in a research, industrial, or household setting|iodobenzoates|diagnostic uses of chemicals|acids, carbocyclic|contrast media|drugs that are mainly renally excreted|iodinated contrast agents|x ray contrast media, iodinated|benzene derivatives|benzoates|radiographic contrast agent|roentgenography|watersoluble, nephrotropic, low osmolar x ray contrast media
sonidegib	cytochrome p 450 cyp3a substrates|antineoplastic and immunomodulating agents|smoothened receptor antagonists|antineoplastic agents|cytochrome p 450 substrates|narrow therapeutic index drugs|benzene derivatives|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|hedgehog pathway inhibitor|cytochrome p 450 cyp3a4 substrates
iopromide	x ray contrast activity|compounds used in a research, industrial, or household setting|iodobenzoates|diagnostic uses of chemicals|acids, carbocyclic|contrast media|drugs that are mainly renally excreted|iodinated contrast agents|triiodobenzoic acids|benzene derivatives|benzoates|x ray contrast media, iodinated|radiographic contrast agent|roentgenography|watersoluble, nephrotropic, low osmolar x ray contrast media
dosulepin	adrenergic uptake inhibitors|agents producing tachycardia|membrane transport modulators|psychoanaleptics|central nervous system agents|adrenergic agents|serotonin receptor antagonists|thiepins|cytochrome p 450 cyp2d6 inhibitors (weak)|serotonin 5 ht1 receptor antagonists|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|anticholinergic agents|cytochrome p 450 cyp2b6 substrates|cytochrome p 450 cyp2d6 substrates with a narrow therapeutic index|dibenzothiepins|agents that produce hypertension|serotonin 5 ht1a receptor antagonists|serotonin modulators|tertiary amine tricyclic antidepressants|central nervous system depressants|cytochrome p 450 cyp2b6 substrates with a narrow therapeutic index|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|cytochrome p 450 cyp1a2 inhibitors (moderate)|antidepressive agents|neurotransmitter agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|nervous system|agents that reduce seizure threshold|antidepressive agents, tricyclic|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 substrates|non selective monoamine reuptake inhibitors|serotonin 5 ht2 receptor antagonists|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp1a2 inhibitors|potential qtc prolonging agents|heterocyclic compounds, fused ring|muscarinic antagonists|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp2c19 inhibitors|neurotoxic agents|cytochrome p 450 cyp2d6 inhibitors (moderate)|combined inhibitors of serotonin/norepinephrine reuptake|neurotransmitter uptake inhibitors|serotonin 5 ht2a receptor antagonists|psychotropic drugs|narrow therapeutic index drugs|sulfur compounds|histamine antagonists|histamine h1 antagonists
viloxazine	adrenergic uptake inhibitors|membrane transport modulators|psychoanaleptics|central nervous system agents|adrenergic agents|drugs that are mainly renally excreted|oxazines|antidepressive agents, second generation|central nervous system depressants|neurotransmitter agents|antidepressive agents|nervous system|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp1a2 inhibitors (weak)|cytochrome p 450 cyp1a2 inhibitors|neurotransmitter uptake inhibitors|psychotropic drugs|morpholines
nisoxetine	adrenergic uptake inhibitors|norepinephrine, antagonists & inhibitors|propylamines|central nervous system depressants|antidepressive agents|amines
ciglitazone	cytochrome p 450 cyp2c8 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 enzyme inhibitors|thiazoles|thiazolidinediones|sulfur compounds|cytochrome p 450 substrates|blood glucose lowering agents|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp2c8 substrates
cirazoline	respiratory system agents|agents producing tachycardia|adrenergic agonists|vasoconstrictor agents|adrenergic agents|agents that produce hypertension|nasal decongestants|adrenergic alpha 1 receptor agonists|adrenergic alpha agonists|neurotransmitter agents|cardiovascular agents
synephrine	agents producing tachycardia|adrenergic agents|sympathomimetics used as decongestants|ophthalmologicals|amines|vasoconstrictor agents|agents that produce hypertension|neurotransmitter agents|cardiovascular agents|decongestants and antiallergics|cardiac stimulants excl. cardiac glycosides|sympathomimetics|adrenergic agonists|nasal decongestants|biogenic monoamines|adrenergic alpha agonists|respiratory system agents|ethanolamines|peripheral nervous system agents|sensory organs|adrenergic and dopaminergic agents|biogenic amines|amino alcohols|autonomic agents|cardiac therapy|alcohols
moxisylyte	dimethylamines|miotics|adrenergic agents|drugs that are mainly renally excreted|amines|adrenergic antagonists|methylamines|peripheral vasodilators|agents that produce hypertension|neurotransmitter agents|cardiovascular agents|urologicals|drugs used in erectile dysfunction|vasodilating agents|cholinesterase substrates|adrenergic alpha antagonists|peripheral nervous system agents|genito urinary system and sex hormones|autonomic agents|sympatholytics
piracetam	acids, acyclic|psychoanaleptics|central nervous system agents|drugs that are mainly renally excreted|acetamides|fatty acids|protective agents|pyrrolidines|amides|nervous system|fatty acids, volatile|psychostimulants, agents used for adhd and nootropics|pyrrolidinones|acetates|neuroprotective agents|compounds used in a research, industrial, or household setting|nootropic agents|lipids
loxoprofen	nephrotoxic agents|anti inflammatory agents, non steroidal|peripheral nervous system agents|agents causing hyperkalemia|anti inflammatory agents|central nervous system agents|analgesics|sensory system agents|acids, carbocyclic|agents that produce hypertension|non cox 2 selective nsaids|analgesics, non narcotic|antirheumatic agents|ugt2b7 substrates
dexketoprofen	anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|antiinflammatory preparations, non steroids for topical use|central nervous system agents|sensory system agents|drugs that are mainly renally excreted|musculo skeletal system|propylene glycols|nephrotoxic agents|analgesics|agents that produce hypertension|non cox 2 selective nsaids|antiinflammatory and antirheumatic products, non steroids|nervous system|phenylpropionates|topical products for joint and muscular pain|anti inflammatory agents|analgesics, non narcotic|antirheumatic agents|glycols|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|propionates|acids, carbocyclic|alcohols
tolfenamic acid	hormones, hormone substitutes, and hormone antagonists|membrane transport modulators|hormone antagonists|anti inflammatory agents, non steroidal|sensory system agents|central nervous system agents|serotonin receptor antagonists|calcium regulating hormones and agents|benzoates|musculo skeletal system|aminobenzoates|bradycardia causing agents|cytochrome p 450 cyp3a4 substrates|nephrotoxic agents|serotonin agents|analgesics|agents that produce hypertension|non cox 2 selective nsaids|antiarrhythmic agents|central nervous system depressants|neurotransmitter agents|calcium channel blockers|cardiovascular agents|antiinflammatory and antirheumatic products, non steroids|anti inflammatory agents|cytochrome p 450 substrates|analgesics, non narcotic|prostaglandin antagonists|antirheumatic agents|cytochrome p 450 cyp3a substrates|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|acids, carbocyclic|migraine disorders, drug therapy|benzene derivatives|fenamates
nicorandil	nitric acid|acids|micronutrients|drugs that are mainly renally excreted|food|food and beverages|electrolytes|ions|anions|vasodilators used in cardiac diseases|antiarrhythmic agents|cardiovascular agents|pyridines|vasodilating agents|nitrogen compounds|nitrates|diet, food, and nutrition|acids, noncarboxylic|physiological phenomena|growth substances|antihypertensive agents|agents causing hyperkalemia|nicotinic acids|cardiac therapy
melperone	central nervous system agents|tranquilizing agents|drugs that are mainly renally excreted|psycholeptics|antipsychotic agents|antiarrhythmic agents|central nervous system depressants|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|nervous system|cytochrome p 450 enzyme inhibitors|moderate risk qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|dopamine d2 receptor antagonists|antipsychotic agents (second generation [atypical])|ketones|butyrophenone derivatives|neurotoxic agents|psychotropic drugs|dopamine antagonists
benidipine	membrane transport modulators|calcium regulating hormones and agents|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|antiarrhythmic agents|calcium channel blockers|selective calcium channel blockers with mainly vascular effects|cardiovascular agents|qtc prolonging agents|pyridines|cytochrome p 450 enzyme inhibitors|vasodilating agents|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp3a4 inhibitors (moderate)|moderate risk qtc prolonging agents|cytochrome p 450 substrates|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|agents causing hyperkalemia|dihydropyridines|dihydropyridine derivatives
cilnidipine	dihydropyridine derivatives|membrane transport modulators|cytochrome p 450 cyp3a substrates|pyridines|vasodilating agents|agents causing hyperkalemia|hypotensive agents|cytochrome p 450 substrates|calcium regulating hormones and agents|antiarrhythmic agents|calcium channel blockers|selective calcium channel blockers with mainly vascular effects|cardiovascular agents|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents
lacidipine	membrane transport modulators|calcium regulating hormones and agents|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|hypotensive agents|antiarrhythmic agents|calcium channel blockers|selective calcium channel blockers with mainly vascular effects|cardiovascular agents|qtc prolonging agents|pyridines|vasodilating agents|cytochrome p 450 substrates|mutagens|potential qtc prolonging agents|cytochrome p 450 cyp3a substrates|antihypertensive agents|agents causing hyperkalemia|dihydropyridine derivatives
niguldipine	membrane transport modulators|antineoplastic agents|calcium regulating hormones and agents|adrenergic alpha 1 receptor antagonists|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|p glycoprotein inhibitors|adrenergic antagonists|antiarrhythmic agents|calcium channel blockers|cardiovascular agents|qtc prolonging agents|pyridines|vasodilating agents|cytochrome p 450 substrates|potential qtc prolonging agents|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|antihypertensive agents|agents causing hyperkalemia
methylene blue	phenothiazines|cytochrome p 450 cyp2c8 inhibitors|drugs causing inadvertant photosensitivity|cytochrome p 450 cyp2b6 inhibitors (strength unknown)|miscellaneous therapeutic agents|diagnostic agents|drugs that are mainly renally excreted|cytochrome p 450 cyp1a2 inducers (strength unknown)|mate 2 inhibitors|mate 1 inhibitors|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp1a2 inducers|photosensitizing agents|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|cytochrome p 450 cyp3a5 inhibitors|serotonergic drugs shown to increase risk of serotonin syndrome|antipsychotic agents|agents that produce hypertension|tests for gastric secretion|oct2 inhibitors|central nervous system depressants|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|ugt1a4 inhibitors|ugt1a9 inhibitors|antidepressive agents|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 cyp2d6 inhibitors|oxidation reduction agent|cytochrome p 450 cyp2b6 inhibitors|agents that reduce seizure threshold|cytochrome p 450 enzyme inhibitors|antidotes|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|enzyme inhibitors|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp3a inhibitors|monoamine oxidase inhibitors|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp1a2 inhibitors|heterocyclic compounds, fused ring|mate inhibitors|cytochrome p 450 cyp2c19 inhibitors|gastric function|neurotoxic agents|cytochrome p 450 enzyme inducers|sulfur compounds|cytochrome p 450 cyp3a5 inhibitors (strength unknown)
moxonidine	agents producing tachycardia|antihypertensive agents|adrenergic agonists|hypotensive agents|imidazoline receptor agonists|agents that produce hypertension|adrenergic alpha 2 receptor agonists|adrenergic alpha agonists|sympatholytics|cardiovascular agents|antiadrenergic agents, centrally acting
pirlindole	agents that reduce seizure threshold|indoles|serotonin 5 ht1 receptor antagonists|heterocyclic compounds, fused ring|psychotropic drugs|central nervous system agents|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin 5 ht1a receptor antagonists|serotonin agents|serotonin receptor antagonists|agents that produce hypertension|drugs that are mainly renally excreted|enzyme inhibitors|central nervous system depressants|monoamine oxidase a inhibitors  for interaction with monoamine oxidase a substrates|antidepressive agents|monoamine oxidase inhibitors
tegafur	antineoplastic and immunomodulating agents|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|pyrimidines|thyroxine binding globulin inducers|antineoplastic agents|drugs that are mainly renally excreted|cytochrome p 450 cyp2a6 substrates|cytochrome p 450 cyp2a6 substrates with a narrow therapeutic index|pyrimidinones|cytochrome p 450 cyp3a5 substrates with a narrow therapeutic index|cytochrome p 450 substrates|noxae|pyrimidine analogues|cytochrome p 450 cyp2e1 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|fluoropyrimidines|antimetabolites|cytochrome p 450 cyp2e1 substrates|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs|fluorouracil and prodrugs|cytochrome p 450 cyp2c8 substrates with a narrow therapeutic index|toxic actions|cytochrome p 450 cyp2c8 substrates
doxofylline	agents producing tachycardia|anti asthmatic agents|central nervous system agents|phosphodiesterase inhibitors|adrenergic beta 2 receptor agonists|purinones|agents that produce hypertension|phosphodiesterase 5 inhibitors|vasodilating agents|adrenergic agonists|alkaloids|cytochrome p 450 substrates|enzyme inhibitors|xanthine derivatives|adrenergic beta agonists|heterocyclic compounds, fused ring|drugs for obstructive airway diseases|respiratory system agents|antitussive agents|peripheral nervous system agents|bronchodilator agents|cytochrome p 450 cyp1a2 substrates|purines|autonomic agents
artesunate	acids, acyclic|reactive oxygen species|antineoplastic agents|antiplatyhelmintic agents|cytochrome p 450 cyp2a6 substrates|ugt2b7 substrates|dicarboxylic acids|antiparasitic products, insecticides and repellents|schistosomicides|p glycoprotein substrates|electrolytes|ions|oat3/slc22a8 inhibitors|anions|oxides|peroxides|anthelmintics|oatp1b1/slco1b1 inhibitors|bcrp/abcg2 substrates|antiparasitic agents|artemisinins|artemisinin and derivatives, plain|cytochrome p 450 substrates|anti infective agents|antiviral agents|antimalarials|oxygen compounds|ugt1a9 substrates|terpenes|antiprotozoals|free radicals
molsidomine	vasodilating agents|sydnones|oxazoles|oxazines|vasodilators used in cardiac diseases|cardiac therapy|morpholines|nitric oxide donors|cardiovascular agents|oxadiazoles
trapidil	antiplatelet agents|vasodilating agents|hematologic agents|pyrimidines|triazoles|vasodilators used in cardiac diseases|enzyme inhibitors|cardiac therapy|cardiovascular agents|phosphodiesterase inhibitors
pipamperone	central nervous system agents|serotonin receptor antagonists|tranquilizing agents|psycholeptics|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|hypotensive agents|antipsychotic agents|central nervous system depressants|neurotransmitter agents|antidepressive agents|nervous system|dopamine d2 receptor antagonists|ketones|butyrophenone derivatives|neurotoxic agents|psychotropic drugs|dopamine antagonists
tianeptine	psychoanaleptics|central nervous system agents|thiepins|cytochrome p 450 cyp3a4 substrates|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|analgesics|serotonin modulators|agents that produce hypertension|central nervous system depressants|antidepressive agents|azepines|nervous system|agents that reduce seizure threshold|antidepressive agents, tricyclic|agents causing muscle toxicity|cytochrome p 450 substrates|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a substrates|neurotoxic agents|psychotropic drugs|narrow therapeutic index drugs|sulfur compounds
talniflumate	nephrotoxic agents|selective cyclooxygenase 2 inhibitors (nsaids)|anti inflammatory agents, non steroidal|agents causing hyperkalemia|anti inflammatory agents|heterocyclic compounds, fused ring|agents that produce hypertension|niflumic acid and prodrugs
silibinin	oatp1b3 inhibitors|antineoplastic agents|benzyl compounds|flavonolignans|flavonoids|ugt1a1 inhibitors|oat1/slc22a6 substrates|protective agents|oatp1b1/slco1b1 inhibitors|benzopyrans|antineoplastic agents, phytogenic|lignans|oat1/slc22a6 inhibitors|heterocyclic compounds, fused ring|compounds used in a research, industrial, or household setting|pyrans|chromones|benzene derivatives|oat3/slc22a8 substrates
kitasamycin	macrolides|cytochrome p 450 enzyme inhibitors|polyketides|anti bacterial agents|cytochrome p 450 cyp3a4 inhibitors|leucomycins|anti infective agents|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|lactones
ioxaglic acid	x ray contrast activity|compounds used in a research, industrial, or household setting|iodobenzoates|diagnostic uses of chemicals|acids, carbocyclic|contrast media|triiodobenzoic acids|benzene derivatives|benzoates|x ray contrast media, iodinated|radiographic contrast agent|watersoluble, nephrotropic, low osmolar x ray contrast media
sulbactam	amides|antiinfectives for systemic use|antibacterials for systemic use|heterocyclic compounds, fused ring|sulfur compounds|drugs that are mainly renally excreted|enzyme inhibitors|beta lactams|anti infective agents|beta lactam antibacterials|beta lactamase inhibitors|lactams
propoxycaine	anesthetics, local|phenols|hydroxy acids|para aminobenzoates|peripheral nervous system agents|sensory system agents|central nervous system agents|benzoates|acids, carbocyclic|hydroxybenzoates|hydroxybenzoate ethers|central nervous system depressants|ethers|benzene derivatives|anesthetics|phenyl ethers|aminobenzoates
pramocaine	anesthetics, local|antipruritics and local anesthetics|peripheral nervous system agents|dermatologicals|sensory system agents|central nervous system agents|anesthetics for topical use|central nervous system depressants|vasoprotectives|agents for treatment of hemorrhoids and anal fissures for topical use|anesthetics|oxazines|antipruritics, incl. antihistamines, anesthetics, etc.
sulfabenzamide	amides|sulfones|sulfur compounds
noretynodrel	norsteroids|adrenal cortex hormones|cytochrome p 450 cyp3a4 substrates|hormonal contraceptives for systemic use|fused ring compounds|contraceptives, oral, synthetic|sex hormones and modulators of the genital system|norpregnenes|norpregnanes|progestins|contraceptives, oral|cytochrome p 450 substrates|contraceptive agents, female|combination contraceptives (with estrogen and derivatives)|cytochrome p 450 cyp3a substrates|progestin contraceptives|steroids|reproductive control agents|genito urinary system and sex hormones
norgestrel	norsteroids|adrenal cortex hormones|contraceptives, postcoital|cytochrome p 450 cyp3a4 substrates|hormonal contraceptives for systemic use|fused ring compounds|progestogens and estrogens, sequential preparations|contraceptives, oral, synthetic|sex hormones and modulators of the genital system|norpregnenes|norpregnanes|progestins|contraceptives, oral|cytochrome p 450 substrates|contraceptive agents, female|combination contraceptives (with estrogen and derivatives)|cytochrome p 450 cyp3a substrates|progestin contraceptives|steroids|reproductive control agents|genito urinary system and sex hormones
isosorbide	carbohydrates|adrenal cortex hormones|contraceptive agents, male|sugar alcohols|hormonal contraceptives for systemic use|antianginal agents|cardiovascular agents|diuretics, osmotic|vasodilating agents|diuretics|natriuretic agents|noxae|organic nitrates|sesquiterpenes|reproductive control agents|terpenes|toxic actions|alcohols
iocetamic acid	hydrocarbons, halogenated|hydrocarbons, iodinated|contrast media|watersoluble, hepatotropic x ray contrast media|x ray contrast media, iodinated|benzene derivatives
meglumine	carbohydrates|amino sugars|compounds used in a research, industrial, or household setting|iodobenzoates|benzoates|diagnostic uses of chemicals|acids, carbocyclic|contrast media|triiodobenzoic acids|benzene derivatives|sugar alcohols|hexosamines|alcohols
glycerol	increased igg production|carbohydrates|osmotic laxatives|triose sugar alcohols|non standardized chemical allergen|cytochrome p 450 cyp2e1 inducers (strength unknown)|drugs for constipation|sugar alcohols|cryoprotective agents|cell mediated immunity|solvents|other cold and cough preparations|protective agents|laxatives|other diagnostics|basic ointments and protectants|cytochrome p 450 cyp2e1 inducers|irrigating solutions|compounds used in a research, industrial, or household setting|enemas|increased histamine release|cytochrome p 450 enzyme inducers|alimentary tract and metabolism|alcohols
enalaprilat	amino acids, peptides, and proteins|drugs causing inadvertant photosensitivity|drugs that are mainly renally excreted|antihypertensive agents indicated for hypertension|dipeptides|photosensitizing agents|peptides|hypotensive agents|cardiovascular agents|agents causing angioedema|oligopeptides|enzyme inhibitors|agents acting on the renin angiotensin system|protease inhibitors|angiotensin converting enzyme inhibitors|antihypertensive agents|decreased blood pressure|agents causing hyperkalemia
thonzonium	onium compounds|nitrogen compounds|ammonium compounds|amines
ixazomib	cytochrome p 450 cyp2c19 substrates with a narrow therapeutic index|amino acids, peptides, and proteins|antineoplastic and immunomodulating agents|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|antineoplastic agents|drugs that are mainly renally excreted|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp2b6 substrates|cytochrome p 450 cyp2d6 substrates with a narrow therapeutic index|amino acids|cytochrome p 450 cyp2b6 substrates with a narrow therapeutic index|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp3a substrates|protease inhibitors|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs|cytochrome p 450 cyp2c9 substrates with a narrow therapeutic index|cytochrome p 450 cyp2c8 substrates with a narrow therapeutic index|proteasome inhibitors|cytochrome p 450 cyp2c8 substrates
oat	cell mediated immunity|non standardized food allergenic extract|increased histamine release
homosalate	phenols|compounds used in a research, industrial, or household setting|hydroxy acids|dermatologicals|household products|radiation protective agents|protective agents|acids, carbocyclic|hydroxybenzoates|sunscreen agents|benzene derivatives|benzoates|cosmetics
resorcinol	phenols|anti acne preparations for topical use|dermatologicals|root canal filling materials|anti acne preparations|sensory organs|drugs that are mainly renally excreted|ophthalmologicals|benzene derivatives|anti infective agents
allantoin	thyroxine binding globulin substrates|imidazolidines|imidazoles|dermatologicals|basic ointments and protectants|herbs and natural products|hydantoins
benzethonium	antiseptics and disinfectants|throat preparations|quaternary ammonium compounds|dermatologicals|onium compounds|miscellaneous local anti infectives|nitrogen compounds|ammonium compounds|anti infective agents, local|benzylammonium compounds|anti infective agents|amines
butamben	anesthetics, local|para aminobenzoates|peripheral nervous system agents|sensory system agents|central nervous system agents|benzoates|acids, carbocyclic|cholinesterase substrates|drugs that are mainly renally excreted|central nervous system depressants|benzene derivatives|anesthetics|aminobenzoates
pyrantel	tetrahydropyrimidine derivatives|neuromuscular depolarizing agents|peripheral nervous system agents|antinematodal agents|pyrimidines|neuromuscular blocking agents|sulfur compounds|thiophenes|drugs that are mainly renally excreted|anthelmintics|central nervous system depressants|anti infective agents|neuromuscular agents|antiparasitic agents|antiparasitic products, insecticides and repellents
homatropine	parasympatholytics|peripheral nervous system agents|mydriatics and cycloplegics|alkaloids|anticholinergic agents|aza compounds|azabicyclo compounds|ophthalmologicals|sensory organs|autonomic agents|muscarinic agonists|muscarinic antagonists
pentoxyverine	respiratory system agents|antitussive agents|cough and cold preparations|central nervous system agents|cycloparaffins
arbutin	carbohydrates|glucosides|glycosides
dioxybenzone	sunscreen agents|benzene derivatives|ketones
hexylresorcinol	phenols|throat preparations|resorcinols|anti infective agents, local|anthelmintics|anti infective agents|benzene derivatives|miscellaneous anti infectives|antiparasitic agents
polydatin	carbohydrates|glycosides|drugs, chinese herbal|benzene derivatives|benzylidene compounds
piceid	carbohydrates|glycosides|drugs, chinese herbal|benzene derivatives|benzylidene compounds
diethyltoluamide	amides|compounds used in a research, industrial, or household setting|agrochemicals|benzamides and benzamide derivatives|protective agents|ectoparasiticides, incl. scabicides, insecticides and repellents|acids, carbocyclic|pesticides|benzene derivatives|benzoates|toxic actions|insecticides and repellents|insect repellents|antiparasitic products, insecticides and repellents
kinetin	growth substances|cytokinins|plant growth regulators|purines|heterocyclic compounds, fused ring
guaiacol	phenols|catechols|methyl ethers|ethers|benzene derivatives|phenyl ethers
pidotimod	glutamates|acids, acyclic|amino acids, peptides, and proteins|thiazoles|antineoplastic and immunomodulating agents|amino acids, cyclic|adjuvants, immunologic|amino acids, acidic|amino acids, dicarboxylic|imines|pyrrolidines|amino acids|sulfur compounds|drugs that are mainly renally excreted|pyrrolidinones|imino acids|immunologic factors
roquinimex	growth substances|angiogenesis inhibitors|antineoplastic and immunomodulating agents|adjuvants, immunologic|heterocyclic compounds, fused ring|growth inhibitors|antineoplastic agents|angiogenesis modulating agents|quinolines|immunologic factors
alfaxalone	nervous system|anesthetics, general|steroids|pregnanes|central nervous system agents|central nervous system depressants|anesthetics|fused ring compounds
altrenogest	hormones, hormone substitutes, and hormone antagonists|estrenes|adrenal cortex hormones|progesterone congeners|hormones|progestins|steroids|estranes|fused ring compounds
azaperone	hypnotics and sedatives|neurotoxic agents|psychotropic drugs|antipsychotic agents (first generation [typical])|central nervous system agents|dopamine agents|tranquilizing agents|antipsychotic agents|central nervous system depressants|neurotransmitter agents|dopamine antagonists|dopamine d2 receptor antagonists|ketones|butyrophenones
carbarsone	arsenicals|organometallic compounds
chloroform	solvents|nervous system|compounds used in a research, industrial, or household setting|anesthetics, general|hydrocarbons, halogenated|hydrocarbons, chlorinated|anesthetics|trihalomethanes
clorsulon	amides|aniline compounds|sulfonamides|sulfones|sulfur compounds|antiplatyhelmintic agents|anthelmintics|anti infective agents|amines|antiparasitic agents
deracoxib	amides|sulfones|sulfur compounds
enrofloxacin	cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|anti bacterial agents|heterocyclic compounds, fused ring|quinolones|fluoroquinolones|anti infective agents|quinolines|cytochrome p 450 cyp1a2 inhibitors
fenbendazole	acids, acyclic|benzimidazoles|heterocyclic compounds, fused ring|antinematodal agents|carbamates|benzimidazole derivatives|anthelmintics|anti infective agents|antiparasitic agents|antiparasitic products, insecticides and repellents
florfenicol	nitro compounds|anti bacterial agents|nitrobenzenes|benzene derivatives|anti infective agents|propylene glycols|glycols|alcohols
lasalocid	membrane transport modulators|compounds used in a research, industrial, or household setting|anti bacterial agents|ionophores|antiprotozoals|anti infective agents|coccidiostats|antiparasitic agents|furans
marbofloxacin	anti bacterial agents|quinolones|anti infective agents|quinolines|heterocyclic compounds, fused ring
medetomidine	hypnotics and sedatives|agents producing tachycardia|peripheral nervous system agents|imidazoles|adrenergic agonists|sensory system agents|central nervous system agents|adrenergic agents|analgesics|agents that produce hypertension|central nervous system depressants|adrenergic alpha 2 receptor agonists|adrenergic alpha agonists|neurotransmitter agents|analgesics, non narcotic
monensin	acids, acyclic|membrane transport modulators|p glycoprotein inhibitors|p glycoprotein substrates|fatty acids|coccidiostats|antiparasitic agents|furans|valerates|fatty acids, volatile|enzyme inhibitors|anti infective agents|uncoupling agents|compounds used in a research, industrial, or household setting|proton ionophores|sodium ionophores|ionophores|lipids|antiprotozoals
oxfendazole	benzimidazoles|heterocyclic compounds, fused ring|antinematodal agents|anthelmintics|anti infective agents|antiparasitic agents
phenothiazine	agents that reduce seizure threshold|heterocyclic compounds, fused ring|sulfur compounds|antiprotozoals|anti infective agents|antiparasitic agents
rotenone	insecticides|benzopyrans|flavonoids|compounds used in a research, industrial, or household setting|heterocyclic compounds, fused ring|agrochemicals|pyrans|chromones|enzyme inhibitors|pesticides|uncoupling agents|isoflavones|toxic actions
roxarsone	organometallic compounds|anti bacterial agents|arsenicals|antiprotozoals|anti infective agents|coccidiostats|antiparasitic agents
selamectin	macrolides|cytochrome p 450 enzyme inhibitors|polyketides|anti bacterial agents|cytochrome p 450 cyp3a4 inhibitors|anti infective agents|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|lactones|antiparasitic agents
sulfachlorpyridazine	amides|aniline compounds|sulfonamides|anti infective agents, urinary|renal agents|sulfones|sulfur compounds|anti infective agents|sulfanilamides|amines
sulfaquinoxaline	amides|aniline compounds|sulfonamides|sulfones|sulfur compounds|anti infective agents|antiprotozoals|sulfanilamides|amines|antiparasitic agents
thiostrepton	amino acids, peptides, and proteins|peptides, cyclic|anti bacterial agents|peptides|anti infective agents
metrifonate	insecticides|cholinergic agents|compounds used in a research, industrial, or household setting|cholinesterase inhibitors|organophosphonates|agrochemicals|organophosphorus compounds|organophosphorous compounds|antitrematodals|enzyme inhibitors|anthelmintics|pesticides|anti infective agents|neurotransmitter agents|toxic actions|antiparasitic agents|antiparasitic products, insecticides and repellents
tylosin	macrolides|cytochrome p 450 enzyme inhibitors|polyketides|anti bacterial agents|cytochrome p 450 cyp3a4 inhibitors|anti infective agents|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|lactones
xylazine	hypnotics and sedatives|agents producing tachycardia|thiazines|muscle relaxants|sensory system agents|central nervous system agents|adrenergic agents|muscle relaxants, centrally acting agents|analgesics|agents that produce hypertension|central nervous system depressants|adrenergic alpha 2 receptor agonists|neuromuscular agents|neurotransmitter agents|adrenergic agonists|adrenergic alpha agonists|peripheral nervous system agents|sulfur compounds
zeranol	hormones, hormone substitutes, and hormone antagonists|phenols|toxins, biological|zearalenone|hormones|resorcinols|mycotoxins|estrogens|estrogens, non steroidal|benzene derivatives|lactones|biological factors
sarafloxacin	cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|anti bacterial agents|heterocyclic compounds, fused ring|potential qtc prolonging agents|quinolones|fluoroquinolones|quinolines|cytochrome p 450 cyp1a2 inhibitors|qtc prolonging agents
butacaine	anesthetics, local|peripheral nervous system agents|sensory system agents|central nervous system agents|benzoates|acids, carbocyclic|central nervous system depressants|benzene derivatives|anesthetics
dihydrostreptomycin	carbohydrates|nephrotoxic agents|anti bacterial agents|sensory organs|glycosides|agents that produce neuromuscular block (indirect)|aminoglycoside antibacterials|drugs that are mainly renally excreted|ophthalmologicals|anti infective agents
diperodon	
flunixin	nephrotoxic agents|veterinary drugs|pyridines|anti inflammatory agents, non steroidal|peripheral nervous system agents|agents causing hyperkalemia|anti inflammatory agents|central nervous system agents|analgesics|sensory system agents|agents that produce hypertension|non cox 2 selective nsaids|nicotinic acids|antipyretics|analgesics, non narcotic|antirheumatic agents
fluprostenol	prostaglandins|prostaglandins, synthetic|eicosanoids|biological factors|luteolytic agents|reproductive control agents|fatty acids|inflammation mediators|lipids|fatty acids, unsaturated|abortifacient agents|autacoids
isoflupredone	steroids, fluorinated|steroids|pregnanes|pregnadienes|pregnadienetriols|fused ring compounds
masitinib	antineoplastic and immunomodulating agents|sulfur compounds|antineoplastic agents|protein kinase inhibitors
melengestrol	hormones, hormone substitutes, and hormone antagonists|corticosteroids for systemic use|cytochrome p 450 cyp3a substrates|adrenal cortex hormones|pregnanes|hormones|steroids|corticosteroids|cytochrome p 450 substrates|pregnadienes|immunosuppressive agents|cytochrome p 450 cyp3a4 substrates|fused ring compounds
tiletamine	anesthetics, dissociative|anesthetics, general|central nervous system agents|cyclohexanes|cyclohexanones|cycloparaffins|sulfur compounds|thiophenes|anticonvulsants|central nervous system depressants|anesthetics|anesthetics, intravenous|ketones
bicuculline	gaba antagonists|central nervous system stimulants|gaba a receptor antagonists|heterocyclic compounds, fused ring|central nervous system agents|alkaloids|benzylisoquinolines|gaba agents|isoquinolines|neurotransmitter agents|convulsants
thiocolchicoside	muscle relaxants|muscle relaxants, centrally acting agents|alkaloids|central nervous system depressants|musculo skeletal system
thiomersal	antiseptics and disinfectants|compounds used in a research, industrial, or household setting|increased histamine release|organometallic compounds|dermatologicals|preservatives, pharmaceutical|alkylmercury compounds|mercurial products|pharmaceutic aids|organomercury compounds|pharmaceutical preparations|ethylmercury compounds|cell mediated immunity|standardized chemical allergen
pirarubicin	carbohydrates|naphthacenes|antineoplastic and immunomodulating agents|antineoplastic agents|glycosides|anthracyclines|cytotoxic antibiotics and related substances|immunosuppressive agents|anthracyclines and related substances
gestrinone	hormones, hormone substitutes, and hormone antagonists|norsteroids|adrenal cortex hormones|norpregnatrienes|cytochrome p 450 cyp3a4 substrates|hormonal contraceptives for systemic use|fused ring compounds|sex hormones and modulators of the genital system|norpregnanes|progestins|contraceptives, oral|cytochrome p 450 substrates|contraceptive agents, female|cytochrome p 450 cyp3a substrates|progestin contraceptives|steroids|reproductive control agents|hormones|genito urinary system and sex hormones|antigonadotropins and similar agents
dehydrocholic acid	steroids|gastrointestinal agents|laxatives|cholanes|fused ring compounds|cholic acids|cholagogues and choleretics|bile acids and salts
dehydrocholate	steroids|gastrointestinal agents|laxatives|cholanes|fused ring compounds|cholic acids|cholagogues and choleretics|bile acids and salts
nomegestrol	cytochrome p 450 cyp3a substrates|adrenal cortex hormones|pregnanes|progesterone congeners|progestins|progestogens and estrogens, sequential preparations|hormonal contraceptives for systemic use|genito urinary system and sex hormones|cytochrome p 450 substrates|steroids|pregnadienes|sex hormones and modulators of the genital system|pregnadien derivatives|antineoplastic agents, hormonal|cytochrome p 450 cyp3a4 substrates|fused ring compounds
dap	potassium channel blockers|membrane transport modulators|nervous system|pyridines|aminopyridines|peripheral nervous system agents|iodine radioisotopes|moderate risk qtc prolonging agents|potassium channel antagonists|cardiovascular agents|miscellaneous central nervous system agents|amines|qtc prolonging agents
rebamipide	antioxidants|amino acids, peptides, and proteins|compounds used in a research, industrial, or household setting|heterocyclic compounds, fused ring|alimentary tract and metabolism|gastrointestinal agents|protective agents|amino acids|enzyme inhibitors|quinolines|anti ulcer agents|drugs for peptic ulcer and gastro oesophageal reflux disease (gord)|drugs for acid related disorders
buparlisib	phosphatidylinositol 3 kinase, antagonists & inhibitors|oxazines|amines|pyridines
curcumin	heptanes|sensory system agents|central nervous system agents|antineoplastic agents|catechols|cytochrome p 450 cyp3a4 inhibitors (strong)|p glycoprotein inhibitors|p glycoprotein substrates|diarylheptanoids|cytochrome p 450 cyp2b6 inhibitors (moderate)|analgesics|coloring agents|cytochrome p 450 cyp1a2 inhibitors (moderate)|cytochrome p 450 cyp2d6 inhibitors|hydrocarbons, acyclic|cytochrome p 450 cyp2b6 inhibitors|phenols|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp2c9 inhibitors (strong)|anti inflammatory agents|cytochrome p 450 cyp3a4 inhibitors|enzyme inhibitors|analgesics, non narcotic|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp1a2 inhibitors|antirheumatic agents|compounds used in a research, industrial, or household setting|cytochrome p 450 cyp2d6 inhibitors (moderate)|peripheral nervous system agents|alkanes|benzene derivatives
equol	benzopyrans|flavonoids|hormones, hormone substitutes, and hormone antagonists|heterocyclic compounds, fused ring|hormones|pyrans|estrogens|estrogens, non steroidal|chromones|isoflavones|phytoestrogens
mosapride	drugs for functional gastrointestinal disorders|amides|propulsives|alimentary tract and metabolism|serotonergic drugs shown to increase risk of serotonin syndrome|gastrointestinal agents|serotonin agents|oxazines|acids, carbocyclic|central nervous system depressants|benzene derivatives|benzoates|antidepressive agents|neurotransmitter agents|anti ulcer agents|serotonin receptor agonists
selumetinib	ugt1a1 substrates|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|p glycoprotein substrates|cytochrome p 450 cyp2c19 substrates|cytochrome p 450 cyp2e1 substrates|heterocyclic compounds, fused ring|cytochrome p 450 cyp1a2 substrates|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|bcrp/abcg2 substrates|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp2c8 substrates|tyrosine kinase inhibitors
racecadotril	neprilysin, antagonists & inhibitors|amino acids, peptides, and proteins|protease inhibitors|n substituted glycines|amino acids, sulfur|alimentary tract and metabolism|peptides|gastrointestinal agents|amino acids|sulfur compounds|enzyme inhibitors|antidiarrheals|peptoids|antidiarrheals, intestinal antiinflammatory/antiinfective agents
tropisetron	indoles|peripheral nervous system agents|heterocyclic compounds, fused ring|alimentary tract and metabolism|central nervous system agents|gastrointestinal agents|serotonin agents|serotonin receptor antagonists|drugs that are mainly renally excreted|antiemetics|antiarrhythmic agents|antiemetics and antinauseants|autonomic agents|central nervous system depressants|antidepressive agents|neurotransmitter agents|serotonin 5 ht3 receptor antagonists
latrepirdine	alzheimer disease|heterocyclic compounds, fused ring
rilmenidine	agents producing tachycardia|antihypertensive agents|peripheral nervous system agents|adrenergic agonists|adrenergic agents|imidazoline receptor agonists|agents that produce hypertension|adrenergic alpha 2 receptor agonists|adrenergic alpha agonists|autonomic agents|neurotransmitter agents|cardiovascular agents|sympatholytics|oxazoles|antiadrenergic agents, centrally acting
mk 1775	enzyme inhibitors
benfotiamine	compounds used in a research, industrial, or household setting|thiazoles|adjuvants, immunologic|alimentary tract and metabolism|pyrimidines|sulfur compounds|sequestering agents|vitamin b complex|vitamins|immunologic factors
clobetasol	hormones, hormone substitutes, and hormone antagonists|adrenal cortex hormones|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|corticosteroids|corticosteroids, very potent (group iv)|cytochrome p 450 cyp3a5 inducers (strength unknown)|steroids, fluorinated|hyperglycemia associated agents|anti inflammatory agents|pregnanes|cytochrome p 450 substrates|pregnadienetriols|cytochrome p 450 cyp3a inducers|corticosteroid hormone receptor agonists|immunosuppressive agents|cytochrome p 450 cyp3a substrates|glucocorticoids|cytochrome p 450 cyp3a4 inducers (strength unknown)|dermatologicals|cytochrome p 450 enzyme inducers|steroids|corticosteroids, dermatological preparations|hormones|thyroxine binding globulin inhibitors|pregnadienes|cytochrome p 450 cyp3a5 inducers
pevonedistat	enzyme inhibitors|cycloparaffins
pazufloxacin	cytochrome p 450 enzyme inhibitors|topoisomerase inhibitors|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|heterocyclic compounds, fused ring|potential qtc prolonging agents|antituberculosis agents|topoisomerase ii inhibitors|quinolones|fluoroquinolones|enzyme inhibitors|anti infective agents|cytochrome p 450 cyp1a2 inhibitors (moderate)|quinolines|cytochrome p 450 cyp1a2 inhibitors|qtc prolonging agents
danusertib	amides|acids, carbocyclic|benzene derivatives|benzoates|protein kinase inhibitors
danoprevir	amides|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|sulfones|sulfur compounds|cytochrome p 450 cyp3a4 inhibitors (strong)|cytochrome p 450 cyp3a inhibitors
tosedostat	amino acids, peptides, and proteins|hydroxylamines|hydroxy acids|amino acids|enzyme inhibitors|amines
npy	amino acids, peptides, and proteins|neuropeptides|neuropeptide y, drug effects|nerve tissue proteins|peptides|proteins|neuropeptide y, antagonists & inhibitors
tivozanib	receptors, vascular endothelial growth factor, antagonists & inhibitors|antineoplastic and immunomodulating agents|antineoplastic agents|benzene derivatives|protein kinase inhibitors|heterocyclic compounds, fused ring
saracatinib	cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|heterocyclic compounds, fused ring|dioxoles|antineoplastic agents|enzyme inhibitors|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|tyrosine kinase inhibitors
targinine	amino acids, peptides, and proteins|nitric oxide synthase, antagonists & inhibitors|amino acids, diamino|amino acids|amino acids, basic|arginine|enzyme inhibitors|amino acids, essential
nifurtimox	trypanocidal agents|thiazines|nitrofuran derivatives|nitro compounds|nitrofurans|sulfur compounds|anti infective agents|antiprotozoals|bcrp/abcg2 substrates|agents against leishmaniasis and trypanosomiasis|antiparasitic agents|furans|antiparasitic products, insecticides and repellents
neratinib	p glycoprotein inhibitors|cytochrome p 450 cyp3a substrates|antineoplastic and immunomodulating agents|protein kinase inhibitors|heterocyclic compounds, fused ring|antineoplastic agents|cytochrome p 450 substrates|narrow therapeutic index drugs|kinase inhibitor|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp3a4 substrates|tyrosine kinase inhibitors
mocetinostat	amides|histone deacetylase inhibitors|moderate risk qtc prolonging agents|antineoplastic agents|acids, carbocyclic|enzyme inhibitors|benzene derivatives|benzoates|qtc prolonging agents
entinostat	amides|histone deacetylase inhibitors|antineoplastic and immunomodulating agents|moderate risk qtc prolonging agents|antineoplastic agents|acids, carbocyclic|enzyme inhibitors|benzene derivatives|benzoates|qtc prolonging agents
3,3' diindolylmethane	compounds used in a research, industrial, or household setting|anticarcinogenic agents|protective agents|heterocyclic compounds, fused ring
deflazacort	corticosteroids for systemic use|adrenal cortex hormones|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|corticosteroids|cytochrome p 450 cyp3a5 inducers (strength unknown)|corticosteroids for systemic use, plain|hyperglycemia associated agents|anti inflammatory agents|cytochrome p 450 substrates|cytochrome p 450 cyp3a inducers|corticosteroid hormone receptor agonists|immunosuppressive agents|cytochrome p 450 cyp3a substrates|glucocorticoids|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|steroids|cytochrome p 450 cyp3a5 inducers|systemic hormonal preparations, excl. sex hormones and insulins
brivanib	amino acids, peptides, and proteins|amino acids
gsk 1059615	
diacerein	cytochrome p 450 cyp2c9 inhibitors|musculo skeletal system|cytochrome p 450 enzyme inhibitors|quinones|antiinflammatory and antirheumatic products|anti inflammatory agents|cytochrome p 450 cyp2e1 inhibitors|cytochrome p 450 cyp2e1 inhibitors (strength unknown)|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|antiinflammatory and antirheumatic products, non steroids|cytochrome p 450 cyp1a2 inhibitors|anthracenes|cytochrome p 450 cyp2d6 inhibitors
fostamatinib	phosphodiesterase 5 inhibitors|ugt1a1 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 enzyme inhibitors|vasodilating agents|cytochrome p 450 cyp3a4 inhibitors|ugt1a9 substrates|hemostatics|bcrp/abcg2 inhibitors|cytochrome p 450 substrates|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|blood and blood forming organs|cytochrome p 450 cyp3a4 substrates|tyrosine kinase inhibitors
ozagrel	acids, acyclic|histamine agents|thromboxane a synthase, antagonists & inhibitors|hematologic agents|enzyme inhibitors|neurotransmitter agents|acrylates|cardiovascular agents|fibrin modulating agents
triptolide	alkylating drugs|adrenal cortex hormones|reproductive control agents|contraceptive agents, male|antineoplastic agents|antineoplastic agents, alkylating|antispermatogenic agents|ethers, cyclic|terpenes|ethers|tripterygium|immunosuppressive agents|noxae|toxic actions|hormonal contraceptives for systemic use|immunologic factors
serdemetan	indoles|radiation sensitizing agents|biogenic amines|biogenic monoamines|amines|heterocyclic compounds, fused ring
icariin	benzopyrans|pyrans|chromones|drugs, chinese herbal|heterocyclic compounds, fused ring
bms 777607	amines|pyridines
orteronel	
orantinib	acids, acyclic|fatty acids, volatile|heterocyclic compounds, fused ring|fatty acids|lipids|enzyme inhibitors|protein kinase inhibitors
enobosarm	amides|amines|aniline compounds
naftopidil	antiplatelet agents|membrane transport modulators|adrenergic agents|calcium regulating hormones and agents|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|adrenergic antagonists|agents that produce hypertension|antiarrhythmic agents|neurotransmitter agents|calcium channel blockers|cardiovascular agents|vasodilating agents|hematologic agents|cytochrome p 450 substrates|cytochrome p 450 cyp3a substrates|adrenergic alpha antagonists|antihypertensive agents|agents causing hyperkalemia
tetrahydropalmatine	membrane transport modulators|sensory system agents|central nervous system agents|adrenergic agents|benzylisoquinolines|tranquilizing agents|calcium regulating hormones and agents|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|analgesics|antipsychotic agents|antiarrhythmic agents|central nervous system depressants|neurotransmitter agents|calcium channel blockers|cardiovascular agents|qtc prolonging agents|vasodilating agents|alkaloids|cytochrome p 450 substrates|isoquinolines|analgesics, non narcotic|potential qtc prolonging agents|dopamine d2 receptor antagonists|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|neurotoxic agents|antihypertensive agents|peripheral nervous system agents|agents causing hyperkalemia|psychotropic drugs|dopamine agents|dopamine antagonists
mk 212	serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|central nervous system depressants|neurotransmitter agents|antidepressive agents|serotonin receptor agonists
vinpocetine	psychoanaleptics|central nervous system agents|phosphodiesterase inhibitors|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|indoles|protective agents|indole alkaloids|anticonvulsants|antiarrhythmic agents|central nervous system depressants|calcium channel blockers|cardiovascular agents|nervous system|vasodilating agents|alkaloids|psychostimulants, agents used for adhd and nootropics|cytochrome p 450 substrates|enzyme inhibitors|heterocyclic compounds, fused ring|neuroprotective agents|compounds used in a research, industrial, or household setting|cytochrome p 450 cyp3a substrates|agents causing hyperkalemia|nootropic agents|secologanin tryptamine alkaloids
diphencyprone	cycloparaffins
secoisolariciresinol	hormones, hormone substitutes, and hormone antagonists|hormones|estrogens, non steroidal|benzyl compounds|benzene derivatives|glycols|alcohols|phytoestrogens
dalcetrapib	hypolipidemic agents|sulfur compounds|anticholesteremic agents|lipid regulating agents|noxae|toxic actions
obatoclax	enzyme inhibitors
tivantinib	pyrrolidines|heterocyclic compounds, fused ring|proto oncogene proteins c met, antagonists & inhibitors
canrenone	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|diuretics|agents causing hyperkalemia|potassium sparing diuretics|pregnanes|steroids|natriuretic agents|pregnadienes|cardiovascular agents|mineralocorticoid receptor antagonists|fused ring compounds
temefos	insecticides|organothiophosphates|organophosphates|compounds used in a research, industrial, or household setting|agrochemicals|organothiophosphorus compounds|organophosphorus compounds|sulfur compounds|toxic actions|pesticides|potential qtc prolonging agents|qtc prolonging agents
azd 7762	sulfur compounds
edaravone	antioxidants|nervous system|neuroprotective agents|compounds used in a research, industrial, or household setting|oat1/slc22a6 substrates|pyrazolones|central nervous system agents|pyrazoles|protective agents|free radical scavengers|miscellaneous central nervous system agents|oat3/slc22a8 substrates
triclabendazole	cytochrome p 450 cyp2c8 inhibitors|cytochrome p 450 cyp2b6 inhibitors (strength unknown)|antiplatyhelmintic agents|cytochrome p 450 cyp3a4 substrates|antiparasitic products, insecticides and repellents|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|cytochrome p 450 cyp2c19 substrates|antitrematodals|cytochrome p 450 cyp2a6 inhibitors (strength unknown)|anthelmintics|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|antiparasitic agents|qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 cyp2b6 inhibitors|cytochrome p 450 enzyme inhibitors|benzimidazoles|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|anti infective agents|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp1a2 inhibitors|cytochrome p 450 cyp2c9 inhibitors|potential qtc prolonging agents|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp1a2 substrates|cytochrome p 450 cyp2a6 inhibitors
abt 751	amides|aniline compounds|phenols|sulfones|sulfur compounds|benzene derivatives|amines
ecopipam	neurotoxic agents|heterocyclic compounds, fused ring|psychotropic drugs|central nervous system agents|dopamine agents|tranquilizing agents|antipsychotic agents|central nervous system depressants|neurotransmitter agents|dopamine antagonists
tacedinaline	
nefopam	nervous system|peripheral nervous system agents|sensory system agents|central nervous system agents|analgesics|analgesics, non narcotic|oxazocines|azocines
cp 724714	receptor, erbb 2, antagonists & inhibitors|heterocyclic compounds, fused ring
foretinib	receptors, vascular endothelial growth factor, antagonists & inhibitors|amides|aniline compounds|amines|heterocyclic compounds, fused ring|tyrosine kinase inhibitors
trehalose	carbohydrates|glucans|polysaccharides|compounds used in a research, industrial, or household setting|disaccharides|oligosaccharides|polymers|biopolymers|macromolecular substances
benzbromarone	benzofurans|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 enzyme inhibitors|preparations increasing uric acid excretion|heterocyclic compounds, fused ring|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|renal agents|bsep/abcb11 substrates|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|uricosuric agents|oatp1b1/slco1b1 inhibitors|antigout preparations|musculo skeletal system|cytochrome p 450 cyp2c9 inhibitors|antirheumatic agents
salvinorin a	hallucinogens|psychotropic drugs|central nervous system agents|diterpenes|terpenes|central nervous system depressants|salvia
cantharidin	benzofurans|compounds used in a research, industrial, or household setting|irritants|enzyme inhibitors|noxae|toxic actions|heterocyclic compounds, fused ring
rucaparib	cytochrome p 450 cyp1a2 inducers (moderate)|cytochrome p 450 cyp2c8 inhibitors|antineoplastic and immunomodulating agents|cytochrome p 450 cyp1a2 substrates with a narrow therapeutic index|oatp1b3 inhibitors|bcrp/abcg2 inhibitors|antineoplastic agents|poly(adp ribose) polymerase inhibitors|mate 2 inhibitors|cytochrome p 450 cyp3a4 inhibitors (weak)|mate 1 inhibitors|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp3a7 inhibitors (strength unknown)|p glycoprotein inhibitors|ugt1a1 inhibitors|p glycoprotein substrates|cytochrome p 450 cyp1a2 inducers|oat3/slc22a8 inhibitors|cytochrome p 450 cyp3a5 inhibitors|cytochrome p 450 cyp2d6 substrates with a narrow therapeutic index|cytochrome p 450 cyp2c19 inhibitors (weak)|cytochrome p 450 cyp2c9 inhibitors (strength unknown)|oatp1b1/slco1b1 inhibitors|bcrp/abcg2 substrates|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp1a2 inhibitors (weak)|cytochrome p 450 substrates|enzyme inhibitors|oat1/slc22a6 inhibitors|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 substrates with a narrow therapeutic index|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp1a2 inhibitors|heterocyclic compounds, fused ring|mate inhibitors|cytochrome p 450 cyp2d6 substrates|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a7 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2d6 inhibitors (moderate)|oct1 inhibitors|cytochrome p 450 cyp2c8 inhibitors (weak)|cytochrome p 450 enzyme inducers|cytochrome p 450 cyp1a2 substrates|narrow therapeutic index drugs|cytochrome p 450 cyp3a5 inhibitors (strength unknown)|p glycoprotein substrates with a narrow therapeutic index
navitoclax	amides|sulfones|antineoplastic agents|sulfur compounds|amines
indirubin	compounds used in a research, industrial, or household setting|antibiotics, antineoplastic|heterocyclic compounds, fused ring|antineoplastic agents|leukemia, myelogenous, chronic, bcr abl positive|coloring agents|protein kinase inhibitors
10 hydroxycamptothecin	alkaloids|antineoplastic agents, phytogenic|antineoplastic agents
osi 027	
bromperidol	butyrophenone derivatives|nervous system|neurotoxic agents|psychotropic drugs|central nervous system agents|tranquilizing agents|antipsychotic agents|central nervous system depressants|psycholeptics|ketones|butyrophenones
triciribine	carbohydrates|nucleic acids, nucleotides, and nucleosides|glycosides|nucleosides
sulforaphane	compounds used in a research, industrial, or household setting|isocyanates|anticarcinogenic agents|protective agents|antineoplastic agents|sulfur compounds
alvespimycin	amides|quinones|hsp90 heat shock proteins|lactams
nadifloxacin	anti acne preparations for topical use|topoisomerase inhibitors|topoisomerase ii inhibitors|dermatologicals|anti bacterial agents|anti acne preparations|heterocyclic compounds, fused ring|quinolones|enzyme inhibitors|anti infective agents|antiinfectives for treatment of acne|quinolines
ketanserin	antiplatelet agents|quinazolines|quinazolinones|antihypertensive agents|heterocyclic compounds, fused ring|serotonergic drugs shown to increase risk of serotonin syndrome|hematologic agents|serotonin agents|serotonin receptor antagonists|piperidines|central nervous system depressants|neurotransmitter agents|antidepressive agents|cardiovascular agents
lynestrenol	norsteroids|adrenal cortex hormones|cytochrome p 450 cyp3a4 substrates|hormonal contraceptives for systemic use|fused ring compounds|cytochrome p 450 cyp2c19 substrates|progestogens and estrogens, sequential preparations|contraceptives, oral, synthetic|sex hormones and modulators of the genital system|norpregnenes|cytochrome p 450 enzyme inhibitors|norpregnanes|cytochrome p 450 cyp2c19 inhibitors (strength unknown)|progestins|contraceptives, oral|cytochrome p 450 substrates|contraceptive agents, female|cytochrome p 450 cyp2c9 substrates|combination contraceptives (with estrogen and derivatives)|cytochrome p 450 cyp2c19 inhibitors|cytochrome p 450 cyp3a substrates|progestin contraceptives|steroids|reproductive control agents|genito urinary system and sex hormones|estren derivatives
piribedil	nervous system|nonergot derivative dopamine receptor agonists|anti parkinson agents (dopamine agonist)|central nervous system agents|dopamine agents|anti parkinson drugs|anti dyskinesia agents|piperazines|neurotransmitter agents|dopamine agonists
betulinic acid	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|anti inflammatory agents, non steroidal|sensory system agents|central nervous system agents|antineoplastic agents|analgesics|agents that produce hypertension|non cox 2 selective nsaids|anti retroviral agents|antiparasitic agents|antineoplastic agents, phytogenic|anti inflammatory agents|anti infective agents|antiviral agents|antimalarials|analgesics, non narcotic|prostaglandin antagonists|antirheumatic agents|peripheral nervous system agents|anti hiv agents|terpenes|antiprotozoals
raclopride	amides|neurotoxic agents|psychotropic drugs|central nervous system agents|benzamides and benzamide derivatives|dopamine agents|tranquilizing agents|antipsychotic agents|acids, carbocyclic|central nervous system depressants|benzene derivatives|benzoates|neurotransmitter agents|dopamine antagonists|chlorobenzoates|dopamine d2 receptor antagonists
mizolastine	histamine agents|cytochrome p 450 enzyme inhibitors|heterocyclic compounds, fused ring|moderate risk qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|histamine h1 antagonists, non sedating|antihistamines for systemic use|neurotransmitter agents|histamine antagonists|qtc prolonging agents|histamine h1 antagonists|cytochrome p 450 cyp2d6 inhibitors
oxetacaine	anesthetics, local|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|vasoprotectives|agents for treatment of hemorrhoids and anal fissures for topical use|anesthetics|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 inhibitors (strength unknown)
idazoxan	adrenergic alpha antagonists|adrenergic antagonists|imidazoles|heterocyclic compounds, fused ring|adrenergic agents|adrenergic alpha 2 receptor antagonists|agents that produce hypertension|neurotransmitter agents|dioxanes
fluocinolone	steroids, fluorinated|adrenal cortex hormones|pregnanes|steroids|pregnadienes|fused ring compounds
mebeverine	drugs for functional gastrointestinal disorders|agents producing tachycardia|parasympatholytics|peripheral nervous system agents|agents causing muscle toxicity|alimentary tract and metabolism|central nervous system agents|anticholinergic agents|synthetic anticholinergics, esters with tertiary amino group|ethylamines|autonomic agents|amines|muscarinic antagonists
mk 5108	cyclohexanes|cycloparaffins|acids, carbocyclic|sulfur compounds|protein kinase inhibitors
piperine	hydrocarbons, acyclic|amides|p glycoprotein inhibitors|cytochrome p 450 enzyme inhibitors|piper nigrum|udpglucose 4 epimerase, antagonists & inhibitors|cytochrome p 450 cyp3a4 inhibitors|heterocyclic compounds, fused ring|dioxoles|alkenes|alkynes|enzyme inhibitors|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|chemically induced disorders
azd 1480	janus kinase 2, antagonists & inhibitors
sisomicin	carbohydrates|nephrotoxic agents|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|gentamicins|protein synthesis inhibitors|narrow therapeutic index drugs|glycosides|agents that produce neuromuscular block (indirect)|aminoglycoside antibacterials|drugs that are mainly renally excreted|drugs that are mainly renally excreted with a narrow therapeutic index|anti infective agents|enzyme inhibitors
ebselen	anti inflammatory agents, non steroidal|sensory system agents|central nervous system agents|anti ulcer agents|selenium compounds|analgesics|protective agents|agents that produce hypertension|anti inflammatory agents|gastrointestinal agents|enzyme inhibitors|analgesics, non narcotic|antirheumatic agents|antioxidants|neuroprotective agents|compounds used in a research, industrial, or household setting|peripheral nervous system agents|cyclooxygenase inhibitors
pf 477736	benzazepines|heterocyclic compounds, fused ring
pu h71	heterocyclic compounds, fused ring|dioxoles|antineoplastic agents
givinostat	acids, acyclic|histone deacetylase inhibitors|antineoplastic agents|potential qtc prolonging agents|qtc prolonging agents
ghrh	tests for pituitary function|diagnostic agents
urapidil	peripheral alpha 1 blockers|adrenergic alpha antagonists|adrenergic antagonists|antihypertensive agents|vasodilating agents|serotonin agents|adrenergic agents|agents that produce hypertension|antiadrenergic agents, peripherally acting|adrenergic alpha 1 receptor antagonists|central nervous system depressants|neurotransmitter agents|antidepressive agents|cardiovascular agents|serotonin receptor agonists
isoquercetin	benzopyrans|flavonoids|carbohydrates|heterocyclic compounds, fused ring|pyrans|glycosides|flavonols|chromones
prothionamide	pyridines|antiinfectives for systemic use|anti bacterial agents|drugs for treatment of tuberculosis|antimycobacterials|antituberculosis agents|isonicotinic acids|thiocarbamide derivatives|anti infective agents
pha 793887	cyclin dependent kinases, antagonists & inhibitors
ritanserin	central nervous system agents|pyrimidines|serotonin receptor antagonists|tranquilizing agents|hypoglycemia associated agents|selective serotonin reuptake inhibitors|antidepressive agents, second generation|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|serotonin modulators|antipsychotic agents|central nervous system depressants|neurotransmitter agents|antidepressive agents|pyrimidinones|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|piperidines|neurotoxic agents|cytochrome p 450 cyp2d6 inhibitors (moderate)|psychotropic drugs|anti anxiety agents
phenethyl isothiocyanate	compounds used in a research, industrial, or household setting|isocyanates|anticarcinogenic agents|protective agents|antineoplastic agents|sulfur compounds|enzyme inhibitors|carcinogens|noxae|toxic actions|aldehyde dehydrogenase, antagonists & inhibitors
etanidazole	nitro compounds|imidazoles|radiation sensitizing agents|antineoplastic agents|nitroimidazoles
amuvatinib	
gsk 690693	oxazoles
abc 294640	cycloparaffins
hydroxytyrosol	antiplatelet agents|antioxidants|compounds used in a research, industrial, or household setting|hematologic agents|protective agents|anti infective agents|alcohols
azd 8055	oxazines
benserazide	aromatic l amino acid decarboxylase inhibitors|central nervous system agents|dopamine agents|hydrazines|anti parkinson drugs|anti dyskinesia agents|drugs that are mainly renally excreted|enzyme inhibitors|neurotransmitter agents
dinoprost	prostaglandins|eicosanoids|abortifacient agents, nonsteroidal|biological factors|prostaglandins f|fatty acids|inflammation mediators|reproductive control agents|genito urinary system and sex hormones|uterotonic agents|lipids|fatty acids, unsaturated|abortifacient agents|autacoids
decafluorobutane	transition elements|compounds used in a research, industrial, or household setting|organometallic compounds|electrolytes|hydrocarbons, halogenated|ions|anions|diagnostic uses of chemicals|oxygen compounds|hydrocarbons, fluorinated|metals|contrast media|iron compounds|elements|metals, heavy
gabexate	amidines|guanidines|protease inhibitors|anticoagulants|hematologic agents|serine protease inhibitors|enzyme inhibitors
secnidazole	nitro compounds|antiinfectives for systemic use|antibacterials for systemic use|imidazoles|nitroimidazole antimicrobial|nitroimidazole derivatives|nitroimidazoles|anti infective agents|antiprotozoals|antiparasitic agents|antiparasitic products, insecticides and repellents
pyroxamide	hydroxylamines|hydroxy acids|amines|pyridines
pf 04217903	
benperidol	butyrophenone derivatives|nervous system|neurotoxic agents|psychotropic drugs|central nervous system agents|dopamine agents|tranquilizing agents|antipsychotic agents|central nervous system depressants|neurotransmitter agents|psycholeptics|dopamine antagonists|ketones|butyrophenones
eliprodil	receptors, neurotransmitter|neuroprotective agents|excitatory amino acid antagonists|compounds used in a research, industrial, or household setting|central nervous system agents|protective agents|neurotransmitter agents|excitatory amino acid agents
buthionine sulfoximine	amino acids, peptides, and proteins|compounds used in a research, industrial, or household setting|amino acids, neutral|radiation sensitizing agents|antimetabolites|amino acids, sulfur|radiation protective agents|protective agents|amino acids|antineoplastic agents|sulfur compounds|enzyme inhibitors|noxae|toxic actions|amino acids, essential
quizartinib	thiazoles|antineoplastic and immunomodulating agents|antineoplastic agents|sulfur compounds|benzene derivatives|protein kinase inhibitors|heterocyclic compounds, fused ring
indole 3 carbinol	compounds used in a research, industrial, or household setting|anticarcinogenic agents|protective agents|antineoplastic agents|heterocyclic compounds, fused ring
dihydrexidine	nonergot derivative dopamine receptor agonists|dopamine agents|neurotransmitter agents|dopamine agonists|heterocyclic compounds, fused ring
zstk 474	
opipramol	membrane transport modulators|psychoanaleptics|central nervous system agents|adrenergic agents|serotonergic drugs shown to increase risk of serotonin syndrome|agents that produce hypertension|central nervous system depressants|neurotransmitter agents|antidepressive agents|dibenzazepines|nervous system|agents that reduce seizure threshold|antidepressive agents, tricyclic|cytochrome p 450 substrates|non selective monoamine reuptake inhibitors|heterocyclic compounds, fused ring|cytochrome p 450 cyp2d6 substrates|neurotoxic agents|neurotransmitter uptake inhibitors|psychotropic drugs|narrow therapeutic index drugs
fenobam	
hypericin	radiation sensitizing agents|benz(a)anthracenes|psychotropic drugs|central nervous system agents|antineoplastic agents|enzyme inhibitors|central nervous system depressants|protein kinase c, antagonists & inhibitors|anti infective agents|phenalenes|antidepressive agents|immunosuppressive agents|immunologic factors
tiapride	central nervous system agents|tranquilizing agents|drugs that are mainly renally excreted|benzoates|psycholeptics|amines|antipsychotic agents|central nervous system depressants|neurotransmitter agents|amides|nervous system|ethylamines|dopamine d2 receptor antagonists|neurotoxic agents|psychotropic drugs|dopamine agents|benzamides and benzamide derivatives|acids, carbocyclic|benzene derivatives|dopamine antagonists
ornidazole	nitro compounds|antiinfectives for systemic use|antibacterials for systemic use|imidazoles|nitroimidazole derivatives|radiation sensitizing agents|amebicides|genito urinary system and sex hormones|nitroimidazoles|anti infective agents|antiprotozoals|antitrichomonal agents|gynecological antiinfectives and antiseptics|imidazole derivatives|antiparasitic agents|antiparasitic products, insecticides and repellents
fau	carbohydrates|pyrimidine nucleosides|ribonucleosides|nucleosides|pyrimidines|glycosides|nucleic acids, nucleotides, and nucleosides|arabinonucleosides
foxy 5	
gossypol	adrenal cortex hormones|reproductive control agents|sesquiterpenes|contraceptive agents, male|terpenes|hormonal contraceptives for systemic use
pac 1	
irsogladine	compounds used in a research, industrial, or household setting|anticarcinogenic agents|gastrointestinal agents|protective agents|radiation protective agents|anti ulcer agents
parthenolide	magnoliaceae|increased histamine release|peripheral nervous system agents|anti inflammatory agents|sensory system agents|central nervous system agents|analgesics|terpenes|asteraceae|nf kappa b, antagonists & inhibitors|analgesics, non narcotic|cell mediated immunity|antirheumatic agents|standardized chemical allergen
meclocycline	anti acne preparations for topical use|naphthacenes|tetracyclines|dermatologicals|anti bacterial agents|anti acne preparations|anti infective agents|antiinfectives for treatment of acne
chromanol	antioxidants|benzopyrans|compounds used in a research, industrial, or household setting|protective agents|pyrans|heterocyclic compounds, fused ring
jnj 38877605	
artemisinin	reactive oxygen species|cytochrome p 450 cyp2b6 inducers (strength unknown)|artemisia|antiparasitic products, insecticides and repellents|electrolytes|ions|anions|cytochrome p 450 cyp2b6 substrates|oxides|peroxides|cytochrome p 450 cyp2b6 inducers|artemisinin and derivatives, plain|cytochrome p 450 substrates|antimalarials|anti infective agents|oxygen compounds|cytochrome p 450 enzyme inducers|sesquiterpenes|terpenes|antiprotozoals|free radicals
levalbuterol	agents producing tachycardia|oatp1b3 substrates|drugs that are mainly renally excreted|agents to treat airway disease|amines|adrenergic beta 2 receptor agonists|agents that produce hypertension|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 cyp2d6 inhibitors|oatp1b1/slco1b1 substrates|cytochrome p 450 enzyme inhibitors|adrenergic agonists|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|ethylamines|cytochrome p 450 cyp3a inhibitors|adrenergic beta agonists|ethanolamines|amino alcohols|phenethylamines|alcohols
parachlorophenol	chlorobenzenes|phenols|oatp1b3 substrates|hydrocarbons, halogenated|hydrocarbons, chlorinated|anti infective agents, local|drugs that are mainly renally excreted|benzene derivatives|anti infective agents
esculin	benzopyrans|carbohydrates|heterocyclic compounds, fused ring|glucosides|pyrans|glycosides|coumarins
nandrolone	hormones, hormone substitutes, and hormone antagonists|gonadal steroid hormones|ophthalmologicals|estranes|fused ring compounds|nandrolone and esters|testosterone congeners|anabolic agents|anabolic steroids|estrenes|steroids|alimentary tract and metabolism|hormones|gonadal hormones|estren derivatives|sensory organs|thyroxine binding globulin inhibitors|anabolic agents for systemic use|androgens
tunicamycin	carbohydrates|pyrimidine nucleosides|anti bacterial agents|nucleosides|pyrimidines|glycosides|anti infective agents|nucleic acids, nucleotides, and nucleosides
troleandomycin	cytochrome p 450 cyp2c8 inhibitors|antibacterials for systemic use|anti bacterial agents|cytochrome p 450 cyp3a4 inhibitors (strong)|cytochrome p 450 cyp3a4 substrates|p glycoprotein inhibitors|cytochrome p 450 cyp3a5 inhibitors|macrolides, lincosamides and streptogramins|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp3a4 inhibitors|cytochrome p 450 substrates|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|anti infective agents|cytochrome p 450 cyp3a inhibitors|macrolides|cytochrome p 450 cyp3a7 inhibitors|cytochrome p 450 cyp3a7 inhibitors (strong)|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 inhibitors (strong)|antiinfectives for systemic use|polyketides|lactones
daidzein	benzopyrans|flavonoids|hormones, hormone substitutes, and hormone antagonists|topoisomerase inhibitors|topoisomerase ii inhibitors|heterocyclic compounds, fused ring|hormones|growth inhibitors|pyrans|antineoplastic agents|estrogens, non steroidal|chromones|enzyme inhibitors|phytoestrogens
oxolamine	respiratory system agents|antitussive agents|cough and cold preparations|central nervous system agents|oxazoles
fentiazac	acids, acyclic|anti inflammatory agents, non steroidal|antiinflammatory preparations, non steroids for topical use|central nervous system agents|sensory system agents|musculo skeletal system|nephrotoxic agents|analgesics|fatty acids|agents that produce hypertension|non cox 2 selective nsaids|acetic acid derivatives and related substances|antiinflammatory and antirheumatic products, non steroids|topical products for joint and muscular pain|anti inflammatory agents|fatty acids, volatile|analgesics, non narcotic|antirheumatic agents|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|sulfur compounds|lipids
dibenzepin	nervous system|agents that reduce seizure threshold|neurotoxic agents|antidepressive agents, tricyclic|heterocyclic compounds, fused ring|psychoanaleptics|central nervous system agents|psychotropic drugs|serotonergic drugs shown to increase risk of serotonin syndrome|narrow therapeutic index drugs|agents that produce hypertension|central nervous system depressants|non selective monoamine reuptake inhibitors|antidepressive agents
tribenoside	carbohydrates|peripheral nervous system agents|anti inflammatory agents|sensory system agents|central nervous system agents|analgesics|capillary stabilizing agents|vasoprotectives|agents for treatment of hemorrhoids and anal fissures for topical use|analgesics, non narcotic|antirheumatic agents
suxibuzone	nephrotoxic agents|topical products for joint and muscular pain|anti inflammatory agents, non steroidal|peripheral nervous system agents|pyrazolones|agents causing hyperkalemia|anti inflammatory agents|antiinflammatory preparations, non steroids for topical use|analgesics|central nervous system agents|pyrazoles|sensory system agents|agents that produce hypertension|non cox 2 selective nsaids|analgesics, non narcotic|musculo skeletal system|antirheumatic agents
alaproclate	amino acids, peptides, and proteins|membrane transport modulators|nervous system|selective serotonin reuptake inhibitors|neurotransmitter uptake inhibitors|psychotropic drugs|psychoanaleptics|central nervous system agents|serotonergic drugs shown to increase risk of serotonin syndrome|serotonin agents|serotonin modulators|amino acids|central nervous system depressants|neurotransmitter agents|antidepressive agents|hypoglycemia associated agents
cymarin	strophanthins|carbohydrates|compounds used in a research, industrial, or household setting|steroids|strophanthus glycosides|cardenolides|protective agents|cardiotonic agents|glycosides|antiarrhythmic agents|fused ring compounds|cardiac therapy|cardiac glycosides|cardiovascular agents|cardanolides
bucladesine	cardiac stimulants excl. cardiac glycosides|carbohydrates|nucleotides|purine nucleotides|ribonucleotides|heterocyclic compounds, fused ring|glycosides|cyclic amp|nucleotides, cyclic|purines|cardiac therapy|phosphodiesterase inhibitors|nucleic acids, nucleotides, and nucleosides|adenine nucleotides
phthalylsulfathiazole	amides|aniline compounds|sulfonamides|thiazoles|alimentary tract and metabolism|sulfones|genito urinary system and sex hormones|intestinal antiinfectives|sulfur compounds|sulfanilamides|gynecological antiinfectives and antiseptics|amines|antidiarrheals, intestinal antiinflammatory/antiinfective agents
octopamine	agents producing tachycardia|adrenergic agents|amines|vasoconstrictor agents|agents that produce hypertension|neurotransmitter agents|cardiovascular agents|cardiac stimulants excl. cardiac glycosides|adrenergic agonists|biogenic monoamines|ethylamines|adrenergic alpha agonists|ethanolamines|adrenergic and dopaminergic agents|biogenic amines|amino alcohols|phenethylamines|cardiac therapy|alcohols
aceclidine	peripheral nervous system agents|miotics|sensory organs|ophthalmologicals|autonomic agents|antiglaucoma preparations and miotics|parasympathomimetics
cefatrizine	amides|nephrotoxic agents|thiazines|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|cephalosporins|heterocyclic compounds, fused ring|sulfur compounds|first generation cephalosporins|beta lactams|anti infective agents|lactams
meticrane	sulfonamides|diuretics|low ceiling diuretics, excl. thiazides|genito urinary system and sex hormones|gynecological antiinfectives and antiseptics
pimethixene	sulfur compounds|xanthenes|antihistamines for systemic use|heterocyclic compounds, fused ring
atracurium	cholinergic agents|nicotinic antagonists|muscle relaxants|peripheral nervous system agents|heterocyclic compounds, fused ring|alkaloids|anticholinergic agents|benzylisoquinolines|neuromuscular blocking agents|neuromuscular blocking agents (nondepolarizing)|central nervous system depressants|isoquinolines|neuromuscular agents|muscle relaxants, peripherally acting agents|neurotransmitter agents|musculo skeletal system|neuromuscular nondepolarizing blockade
proscillaridin	carbohydrates|compounds used in a research, industrial, or household setting|scilla glycosides|steroids|bufanolides|protective agents|cardiotonic agents|glycosides|enzyme inhibitors|fused ring compounds|cardiac therapy|cardiac glycosides|cardiovascular agents|cardanolides
benproperine	cough and cold preparations|benzene derivatives
trichloroethylene	solvents|nervous system|compounds used in a research, industrial, or household setting|anesthetics, general|hydrocarbons, halogenated|central nervous system agents|hydrocarbons, chlorinated|agents that produce hypertension|anesthetics, inhalation|central nervous system depressants|anesthetics
picotamide	antiplatelet agents|hematologic agents|acids, carbocyclic|platelet aggregation inhibitors excl. heparin|blood and blood forming organs
pyrithyldione	hypnotics and sedatives|nervous system|piperidinedione derivatives|pyridines|central nervous system depressants|psycholeptics
suloctidil	propanolamines|vasodilating agents|propanols|peripheral vasodilators|amino alcohols|ethylamines|phenethylamines|cardiovascular agents|amines|alcohols
dihydroergocristine	ergot alkaloids and derivatives|cytochrome p 450 cyp3a substrates|adrenergic antagonists|vasodilating agents|heterocyclic compounds, fused ring|alkaloids|adrenergic agents|ergotamines|peripheral vasodilators|agents that produce hypertension|cytochrome p 450 substrates|bsep/abcb11 substrates|neurotransmitter agents|cardiovascular agents|cytochrome p 450 cyp3a4 substrates|cytochrome p 450 cyp3a4 substrates (strength unknown)
bufexamac	acids, acyclic|anti inflammatory agents, non steroidal|anti inflammatory agents, non steroidal (non selective)|antiinflammatory preparations, non steroids for topical use|central nervous system agents|sensory system agents|antineoplastic agents|benzeneacetamides|musculo skeletal system|amines|acetamides|nephrotoxic agents|analgesics|fatty acids|non cox 2 selective nsaids|acetic acid derivatives and related substances|hydroxamic acids|antiinflammatory and antirheumatic products, non steroids|amides|hydroxylamines|topical products for joint and muscular pain|anti inflammatory agents|fatty acids, volatile|analgesics, non narcotic|antirheumatic agents|acetates|hydroxy acids|histone deacetylase inhibitors|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|lipids|benzene derivatives
piperidolate	drugs for functional gastrointestinal disorders|agents producing tachycardia|alimentary tract and metabolism|anticholinergic agents|acids, carbocyclic|phenylacetates|synthetic anticholinergics, esters with tertiary amino group|muscarinic antagonists
phenprobamate	acids, acyclic|muscle relaxants|muscle relaxants, centrally acting agents|carbamic acid esters|central nervous system depressants|musculo skeletal system
vincamine	antihypertensive agents|indoles|vasodilating agents|heterocyclic compounds, fused ring|alkaloids|peripheral vasodilators|antineoplastic agents|indole alkaloids|vinca alkaloids|cardiovascular agents|secologanin tryptamine alkaloids
merbromin	antiseptics and disinfectants|organometallic compounds|dermatologicals|mercurial products|organomercury compounds
emetine	peripheral nervous system agents|agents causing muscle toxicity|emetics|heterocyclic compounds, fused ring|alkaloids|antinematodal agents|central nervous system agents|amebicides|gastrointestinal agents|protein synthesis inhibitors|enzyme inhibitors|anti infective agents|antiprotozoals|autonomic agents|isoquinolines|antiparasitic agents|antiparasitic products, insecticides and repellents
terguride	ergot alkaloids and derivatives|cytochrome p 450 cyp3a substrates|ergolines|prolactine inhibitors|heterocyclic compounds, fused ring|alkaloids|dopamine agents|genito urinary system and sex hormones|agents that produce hypertension|cytochrome p 450 substrates|neurotransmitter agents|cytochrome p 450 cyp3a4 substrates
nifenazone	anti inflammatory agents, non steroidal|antiinflammatory preparations, non steroids for topical use|central nervous system agents|sensory system agents|musculo skeletal system|nephrotoxic agents|pyrazoles|analgesics|agents that produce hypertension|non cox 2 selective nsaids|pyridines|nervous system|topical products for joint and muscular pain|pyrazolones|anti inflammatory agents|analgesics, non narcotic|antirheumatic agents|peripheral nervous system agents|agents causing hyperkalemia|nicotinic acids
lofepramine	nervous system|agents that reduce seizure threshold|neurotoxic agents|antidepressive agents, tricyclic|heterocyclic compounds, fused ring|psychoanaleptics|central nervous system agents|cytochrome p 450 cyp2b6 substrates|psychotropic drugs|serotonergic drugs shown to increase risk of serotonin syndrome|agents that produce hypertension|cytochrome p 450 substrates|central nervous system depressants|non selective monoamine reuptake inhibitors|antidepressive agents|dibenzazepines
pentylenetetrazol	respiratory system agents|gaba antagonists|central nervous system stimulants|central nervous system agents|gaba agents|neurotransmitter agents|convulsants|azepines
troxipide	alimentary tract and metabolism|drugs for peptic ulcer and gastro oesophageal reflux disease (gord)|drugs for acid related disorders
proglumide	amino acids, peptides, and proteins|amino acids, neutral|alimentary tract and metabolism|amino acids, diamino|gastrointestinal agents|amino acids|amino acids, basic|glutamine|anti ulcer agents|drugs for peptic ulcer and gastro oesophageal reflux disease (gord)|drugs for acid related disorders
citiolone	liver therapy, lipotropics|alimentary tract and metabolism|liver therapy|sulfur compounds|expectorants|bile and liver therapy
esatenolol	cytochrome p 450 cyp2d6 substrates|beta blocking agents, selective|adrenergic antagonists|antihypertensive agents|agents causing hyperkalemia|adrenergic beta antagonists|cytochrome p 450 substrates|bradycardia causing agents
bephenium	antinematodal agents|anthelmintics|antiparasitic agents|antiparasitic products, insecticides and repellents
deptropine	histamine agents|alkaloids|aza compounds|azabicyclo compounds|antihistamines for systemic use|neurotransmitter agents|histamine antagonists|histamine h1 antagonists
lanatoside c	carbohydrates|digitalis glycosides|steroids|cardenolides|glycosides|fused ring compounds|cardiac therapy|cardiac glycosides|cardanolides
meptazinol	nervous system|narcotics|peripheral nervous system agents|sensory system agents|central nervous system agents|analgesics|serotonergic drugs shown to increase risk of serotonin syndrome|opioid antagonists|opioids|central nervous system depressants|azepines
tenidap	anti inflammatory agents, non steroidal|sensory system agents|central nervous system agents|musculo skeletal system|nephrotoxic agents|indoles|analgesics|agents that produce hypertension|indole alkaloids|non cox 2 selective nsaids|antiinflammatory and antirheumatic products, non steroids|anti inflammatory agents|alkaloids|enzyme inhibitors|analgesics, non narcotic|antirheumatic agents|heterocyclic compounds, fused ring|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia|cyclooxygenase inhibitors
etamsylate	arylsulfonates|coagulants|hematologic agents|acids|hemostatics|benzenesulfonates|sulfonic acids|sulfur compounds|arylsulfonic acids|benzene derivatives|blood and blood forming organs|acids, noncarboxylic|sulfur acids
cefsulodin	amides|nephrotoxic agents|thiazines|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|cephalosporins|heterocyclic compounds, fused ring|sulfur compounds|third generation cephalosporins|beta lactams|anti infective agents|lactams
buflomedil	antiplatelet agents|adrenergic alpha antagonists|adrenergic antagonists|vasodilating agents|peripheral vasodilators|agents that produce hypertension|cardiovascular agents
clebopride	drugs for functional gastrointestinal disorders|amides|propulsives|peripheral nervous system agents|alimentary tract and metabolism|central nervous system agents|benzoates|gastrointestinal agents|acids, carbocyclic|antiemetics|autonomic agents|benzene derivatives|dopamine antagonists
pranoprofen	acids, acyclic|anti inflammatory agents, non steroidal|sensory system agents|central nervous system agents|ophthalmologicals|nephrotoxic agents|analgesics|fatty acids|agents that produce hypertension|non cox 2 selective nsaids|antigout preparations|anti inflammatory agents|fatty acids, volatile|analgesics, non narcotic|antirheumatic agents|heterocyclic compounds, fused ring|peripheral nervous system agents|agents causing hyperkalemia|pyrans|sensory organs|lipids
metergoline	ergot alkaloids and derivatives|ergolines|prolactine inhibitors|ergot derivative dopamine receptor agonists|heterocyclic compounds, fused ring|alkaloids|dopamine agents|serotonin agents|serotonin receptor antagonists|genito urinary system and sex hormones|agents that produce hypertension|dopamine agonists|central nervous system depressants|neurotransmitter agents|antidepressive agents|serotonin receptor agonists
chlormadinone	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|adrenal cortex hormones|steroids, chlorinated|pregnadien derivatives|cytochrome p 450 cyp3a4 substrates|hormonal contraceptives for systemic use|fused ring compounds|progestogens and estrogens, sequential preparations|contraceptives, oral, synthetic|sex hormones and modulators of the genital system|antiandrogens|pregnanes|progestins|contraceptives, oral|cytochrome p 450 substrates|contraceptive agents, female|combination contraceptives (with estrogen and derivatives)|cytochrome p 450 cyp3a substrates|progestin contraceptives|steroids|reproductive control agents|genito urinary system and sex hormones|pregnadienes
cyclopenthiazide	gynecological antiinfectives and antiseptics|amides|membrane transport modulators|sulfonamides|antihypertensive agents|benzothiadiazines|diuretics|heterocyclic compounds, fused ring|hyperglycemia associated agents|sulfones|natriuretic agents|genito urinary system and sex hormones|low ceiling diuretics and potassium sparing agents|sodium chloride symporter inhibitors|sulfur compounds|cardiovascular agents|thiazides
bifemelane	nervous system|psychotropic drugs|psychoanaleptics|central nervous system agents|serotonergic drugs shown to increase risk of serotonin syndrome|central nervous system depressants|benzene derivatives|antidepressive agents
acefylline	heterocyclic compounds, fused ring|alkaloids|purinones|cytochrome p 450 cyp1a2 substrates|cytochrome p 450 substrates|purines|xanthine derivatives|drugs for obstructive airway diseases
heptaminol	vasodilators used in cardiac diseases|amino alcohols|cardiac therapy|amines|alcohols
bietaserpine	antihypertensive agents|indoles|heterocyclic compounds, fused ring|alkaloids|indole alkaloids|cardiovascular agents|antiadrenergic agents, centrally acting|secologanin tryptamine alkaloids
succinylsulfathiazole	amides|aniline compounds|sulfonamides|thiazoles|alimentary tract and metabolism|sulfones|intestinal antiinfectives|sulfur compounds|sulfanilamides|amines|antidiarrheals, intestinal antiinflammatory/antiinfective agents
mephenesin	muscle relaxants|muscle relaxants, centrally acting agents|peripheral nervous system agents|central nervous system agents|propylene glycols|central nervous system depressants|neuromuscular agents|musculo skeletal system|glycols|alcohols
gallamine	nicotinic antagonists|muscle relaxants|musculo skeletal system|amines|quaternary ammonium compounds|anticholinergic agents|ammonium compounds|central nervous system depressants|neuromuscular agents|neurotransmitter agents|cholinergic agents|onium compounds|nitrogen compounds|neuromuscular blocking agents (nondepolarizing)|neurotoxic agents|peripheral nervous system agents|neuromuscular blocking agents|muscle relaxants, peripherally acting agents
naftidrofuryl	vasodilating agents|serotonin agents|serotonin receptor antagonists|peripheral vasodilators|central nervous system depressants|neurotransmitter agents|antidepressive agents|cardiovascular agents|furans
moroxydine	antiinfectives for systemic use|direct acting antivirals|anti infective agents|antiviral agents|oxazines|antivirals for systemic use
ipriflavone	benzopyrans|bone remodeling|flavonoids|heterocyclic compounds, fused ring|drugs for treatment of bone diseases|pyrans|drugs affecting bone structure and mineralization|chromones|musculo skeletal system
oxolinic acid	topoisomerase inhibitors|antibacterials for systemic use|anti bacterial agents|anti infective agents, urinary|antineoplastic agents|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|4 quinolones|fluoroquinolones|quinolines|qtc prolonging agents|cytochrome p 450 enzyme inhibitors|quinolones|enzyme inhibitors|anti infective agents|potential qtc prolonging agents|cytochrome p 450 cyp1a2 inhibitors|heterocyclic compounds, fused ring|antiinfectives for systemic use|topoisomerase ii inhibitors|renal agents
alcuronium	nicotinic antagonists|muscle relaxants|central nervous system agents|benzylisoquinolines|tetrahydroisoquinolines|musculo skeletal system|adjuvants, anesthesia|amines|quaternary ammonium compounds|anticholinergic agents|ammonium compounds|central nervous system depressants|neuromuscular agents|neurotransmitter agents|cholinergic agents|onium compounds|alkaloids|nitrogen compounds|neuromuscular blocking agents (nondepolarizing)|isoquinolines|heterocyclic compounds, fused ring|toxiferine|peripheral nervous system agents|curare alkaloids|neuromuscular blocking agents|muscle relaxants, peripherally acting agents
niridazole	thiazoles|imidazoles|amebicides|sulfur compounds|schistosomicides|antiplatyhelmintic agents|antitrematodals|anthelmintics|anti infective agents|antiprotozoals|antiparasitic agents|antiparasitic products, insecticides and repellents
ipidacrine	nervous system|cholinesterase inhibitors|psychoanaleptics|anti dementia drugs|quinolines|heterocyclic compounds, fused ring
oxantel	tetrahydropyrimidine derivatives|antinematodal agents|pyrimidines|sulfur compounds|thiophenes|anthelmintics|anti infective agents|antiparasitic agents|antiparasitic products, insecticides and repellents
dexchlorpheniramine	cytochrome p 450 cyp2d6 substrates|agents that reduce seizure threshold|histamine agents|cytochrome p 450 enzyme inhibitors|pyridines|stereoisomerism|substituted alkylamines|moderate risk qtc prolonging agents|cytochrome p 450 cyp2d6 inhibitors (strength unknown)|cytochrome p 450 substrates|antihistamines for systemic use|neurotransmitter agents|histamine antagonists|qtc prolonging agents|histamine h1 antagonists|cytochrome p 450 cyp2d6 inhibitors
quinisocaine	anesthetics, local|peripheral nervous system agents|dermatologicals|heterocyclic compounds, fused ring|sensory system agents|central nervous system agents|anesthetics for topical use|central nervous system depressants|anesthetics|antipruritics, incl. antihistamines, anesthetics, etc.
dilazep	vasodilating agents|vasodilators used in cardiac diseases|cardiac therapy|cardiovascular agents|azepines
hydroquinine	parasympatholytics|peripheral nervous system agents|heterocyclic compounds, fused ring|alkaloids|quinuclidines|antiarrhythmic agents|cinchona alkaloids|autonomic agents|quinolines|cardiovascular agents|musculo skeletal system
diphemanil	respiratory system agents|drugs for functional gastrointestinal disorders|agents producing tachycardia|parasympatholytics|anti asthmatic agents|peripheral nervous system agents|alimentary tract and metabolism|anticholinergic agents|bronchodilator agents|autonomic agents|synthetic anticholinergics, quaternary ammonium compounds|muscarinic antagonists
sulfaguanidine	amidines|amides|aniline compounds|guanidines|sulfonamides|alimentary tract and metabolism|sulfones|intestinal antiinfectives|sulfur compounds|anti infective agents|sulfanilamides|amines|antidiarrheals, intestinal antiinflammatory/antiinfective agents
halometasone	hormones, hormone substitutes, and hormone antagonists|adrenal cortex hormones|cytochrome p 450 cyp3a4 inducers|fused ring compounds|corticosteroids, potent (group iii)|corticosteroids|cytochrome p 450 cyp3a5 inducers (strength unknown)|steroids, fluorinated|anti inflammatory agents|pregnanes|pregnadienetriols|cytochrome p 450 cyp3a inducers|immunosuppressive agents|glucocorticoids|cytochrome p 450 cyp3a4 inducers (strength unknown)|dermatologicals|cytochrome p 450 enzyme inducers|steroids|corticosteroids, dermatological preparations|hormones|pregnadienes|cytochrome p 450 cyp3a5 inducers
bemegride	respiratory system agents|central nervous system stimulants|pyridones|central nervous system agents|convulsants|pyridines
piromidic acid	pyridines|cytochrome p 450 enzyme inhibitors|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|potential qtc prolonging agents|anti infective agents, urinary|renal agents|quinolones|nicotinic acids|anti infective agents|cytochrome p 450 cyp1a2 inhibitors|qtc prolonging agents
peruvoside	carbohydrates|compounds used in a research, industrial, or household setting|steroids|protective agents|cardiotonic agents|glycosides|fused ring compounds|cardiac therapy|cardiac glycosides|cardiovascular agents|cardanolides
meclofenoxate	acetates|acids, acyclic|glycolates|compounds used in a research, industrial, or household setting|hydroxy acids|nervous system|neuroprotective agents|fatty acids, volatile|psychoanaleptics|central nervous system agents|fatty acids|protective agents|nootropic agents|psychostimulants, agents used for adhd and nootropics|lipids|phenoxyacetates
fenpiverinium	agents producing tachycardia|alimentary tract and metabolism|anticholinergic agents|synthetic anticholinergics, quaternary ammonium compounds|drugs for functional gastrointestinal disorders|muscarinic antagonists
lidoflazine	membrane transport modulators|non selective calcium channel blockers|cytochrome p 450 cyp3a substrates|qtc prolonging agents|vasodilating agents|agents causing hyperkalemia|cytochrome p 450 substrates|piperazines|calcium regulating hormones and agents|antiarrhythmic agents|calcium channel blockers|cardiovascular agents|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents
rufloxacin	cytochrome p 450 enzyme inhibitors|topoisomerase inhibitors|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|heterocyclic compounds, fused ring|potential qtc prolonging agents|topoisomerase ii inhibitors|quinolones|fluoroquinolones|enzyme inhibitors|quinolines|cytochrome p 450 cyp1a2 inhibitors|qtc prolonging agents
sulfamethoxypyridazine	amides|aniline compounds|sulfonamide antibacterial|sulfonamides|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|sulfonamides and trimethoprim|long acting sulfonamides|sulfones|sulfur compounds|anti infective agents|sulfanilamides|amines
xamoterol	cardiac stimulants excl. cardiac glycosides|propanolamines|agents producing tachycardia|adrenergic agonists|propanols|adrenergic agents|adrenergic beta 1 receptor agonists|agents that produce hypertension|alcohols|amino alcohols|morpholines|neurotransmitter agents|cardiac therapy|adrenergic beta agonists|oxazines|phenoxypropanolamines|amines
acemetacin	anti inflammatory agents, non steroidal|sensory system agents|central nervous system agents|ugt2b7 substrates|musculo skeletal system|nephrotoxic agents|indoles|analgesics|agents that produce hypertension|non cox 2 selective nsaids|acetic acid derivatives and related substances|antigout preparations|antiinflammatory and antirheumatic products, non steroids|anti inflammatory agents|analgesics, non narcotic|antirheumatic agents|heterocyclic compounds, fused ring|peripheral nervous system agents|antiinflammatory and antirheumatic products|agents causing hyperkalemia
dropropizine	respiratory system agents|antitussive agents|cough and cold preparations|central nervous system agents|glycols|alcohols
fipexide	nervous system|psychostimulants, agents used for adhd and nootropics|psychoanaleptics
penfluridol	central nervous system agents|tranquilizing agents|psycholeptics|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents|antipsychotic agents|antiarrhythmic agents|central nervous system depressants|neurotransmitter agents|calcium channel blockers|qtc prolonging agents|nervous system|moderate risk qtc prolonging agents|cytochrome p 450 substrates|piperidines|dopamine d2 receptor antagonists|cytochrome p 450 cyp3a substrates|neurotoxic agents|agents causing hyperkalemia|psychotropic drugs|dopamine agents|diphenylbutylpiperidine derivatives|dopamine antagonists
clopamide	amides|sulfonamides|diuretics|low ceiling diuretics, excl. thiazides|sulfones|natriuretic agents|sulfur compounds|piperidines|cardiovascular agents
vinburnine	indoles|vasodilating agents|alkaloids|peripheral vasodilators|indole alkaloids|cardiovascular agents|secologanin tryptamine alkaloids|heterocyclic compounds, fused ring
linopirdine	potassium channel blockers|membrane transport modulators|nervous system|compounds used in a research, industrial, or household setting|neuroprotective agents|psychoanaleptics|central nervous system agents|psychostimulants, agents used for adhd and nootropics|protective agents|cardiovascular agents|heterocyclic compounds, fused ring
mebhydrolin	pyridines|indoles|antihistamines for systemic use|heterocyclic compounds, fused ring
talampicillin	amides|penicillins with extended spectrum|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|heterocyclic compounds, fused ring|penicillin g|sulfur compounds|penicillins|beta lactams|anti infective agents|beta lactam antibacterials|lactams
pipemidic acid	pyridines|cytochrome p 450 enzyme inhibitors|antiinfectives for systemic use|antibacterials for systemic use|anti bacterial agents|potential qtc prolonging agents|anti infective agents, urinary|renal agents|cytochrome p 450 cyp1a2 inhibitors (weak)|piperazines|fluoroquinolones|nicotinic acids|anti infective agents|cytochrome p 450 cyp1a2 inhibitors|qtc prolonging agents
methylatropine	drugs for functional gastrointestinal disorders|parasympatholytics|peripheral nervous system agents|belladonna alkaloids, semisynthetic, quaternary ammonium compounds|alimentary tract and metabolism|alkaloids|solanaceous alkaloids|aza compounds|azabicyclo compounds|tropanes|belladonna alkaloids|autonomic agents|belladonna and derivatives, plain
gamma linolenic acid	linolenic acids|fatty acids, essential|agents that reduce seizure threshold|fatty acids, omega 6|dermatologicals|fatty acids|lipids|fatty acids, unsaturated
gla	linolenic acids|fatty acids, essential|agents that reduce seizure threshold|fatty acids, omega 6|dermatologicals|fatty acids|lipids|fatty acids, unsaturated
nifuroxazide	phenols|hydroxy acids|nitro compounds|alimentary tract and metabolism|benzoates|acids, carbocyclic|intestinal antiinfectives|anti infective agents|benzene derivatives|antidiarrheals, intestinal antiinflammatory/antiinfective agents|furans
ethynodiol	norsteroids|cytochrome p 450 cyp3a substrates|adrenal cortex hormones|norpregnanes|norpregnenes|progestins|steroids|hormonal contraceptives for systemic use|genito urinary system and sex hormones|cytochrome p 450 substrates|estren derivatives|sex hormones and modulators of the genital system|cytochrome p 450 cyp3a4 substrates|fused ring compounds
fluticasone	cytochrome p 450 cyp2c8 inhibitors|anti asthmatic agents|androstenes|adrenal cortex hormones|androstanes|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|p glycoprotein substrates|cytochrome p 450 cyp3a5 inhibitors|corticosteroids, potent (group iii)|corticosteroids|cytochrome p 450 cyp3a5 inducers (strength unknown)|oatp1b1/slco1b1 inhibitors|androstadienes|cytochrome p 450 cyp3a4 inhibitors (strength unknown)|cytochrome p 450 cyp3a7 substrates|cytochrome p 450 enzyme inhibitors|hyperglycemia associated agents|anti inflammatory agents|cytochrome p 450 cyp3a4 inhibitors|anti allergic agents|cytochrome p 450 substrates|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a inhibitors|corticosteroid hormone receptor agonists|drugs for obstructive airway diseases|immunosuppressive agents|respiratory system agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|glucocorticoids|dermatologicals|cytochrome p 450 enzyme inducers|nasal preparations|corticosteroids, dermatological preparations|bronchodilator agents|peripheral nervous system agents|steroids|cytochrome p 450 cyp3a5 inhibitors (strength unknown)|thyroxine binding globulin inhibitors|autonomic agents|cytochrome p 450 cyp2c8 inhibitors (strong)|cytochrome p 450 cyp3a5 inducers
iniparib	amides|antineoplastic agents|acids, carbocyclic|poly(adp ribose) polymerase inhibitors|enzyme inhibitors|benzene derivatives|benzoates
candesartan	ugt1a3 substrates|cytochrome p 450 cyp2c8 inhibitors|cytochrome p 450 cyp2c9 inhibitors (weak)|angiotensin ii receptor blockers (arbs), plain|angiotensin 2 receptor blocker|p glycoprotein inhibitors|oatp1b1/slco1b1 inhibitors|cardiovascular agents|cytochrome p 450 enzyme inhibitors|angiotensin ii receptor blockers (arbs) and diuretics|angiotensin ii type 2 receptor blockers|cytochrome p 450 substrates|angiotensin ii receptor blockers (arbs) and calcium channel blockers|cytochrome p 450 cyp2c8 inhibitors (strength unknown)|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp2c9 inhibitors|heterocyclic compounds, fused ring|agents acting on the renin angiotensin system|antihypertensive agents|agents causing hyperkalemia|cytochrome p 450 cyp2c8 inhibitors (weak)|angiotensin receptor antagonists
relcovaptan	antiplatelet agents|hormones, hormone substitutes, and hormone antagonists|hormone antagonists|hematologic agents|heterocyclic compounds, fused ring
estradiol benzoate	hormones, hormone substitutes, and hormone antagonists|gonadal steroid hormones|adrenal cortex hormones|bcrp/abcg2 inhibitors|estranes|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|hormonal contraceptives for systemic use|p glycoprotein substrates|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|cytochrome p 450 cyp2c19 substrates|oct2 inhibitors|oatp1b1/slco1b1 inhibitors|cytochrome p 450 cyp3a7 substrates|cytochrome p 450 enzyme inhibitors|estrogens|cytochrome p 450 substrates|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp1a2 inhibitors|oct1 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|estrenes|cytochrome p 450 enzyme inducers|reproductive control agents|hormones|steroids|estradiol congeners|cytochrome p 450 cyp1a2 substrates|gonadal hormones|ugt1a1 substrates|cytochrome p 450 cyp2c8 substrates
estradiol cypionate	hormones, hormone substitutes, and hormone antagonists|gonadal steroid hormones|adrenal cortex hormones|thyroxine binding globulin inducers|bcrp/abcg2 inhibitors|drugs that are mainly renally excreted|estranes|estrogen contraceptives|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|hormonal contraceptives for systemic use|p glycoprotein substrates|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|cytochrome p 450 cyp2c19 substrates|oct2 inhibitors|oatp1b1/slco1b1 inhibitors|cytochrome p 450 cyp3a7 substrates|cytochrome p 450 enzyme inhibitors|estrogens|cytochrome p 450 substrates|contraceptive agents, female|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp1a2 inhibitors|oct1 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|estrenes|cytochrome p 450 enzyme inducers|reproductive control agents|hormones|steroids|estradiol congeners|cytochrome p 450 cyp1a2 substrates|gonadal hormones|ugt1a1 substrates|cytochrome p 450 cyp2c8 substrates
estradiol valerate	hormones, hormone substitutes, and hormone antagonists|gonadal steroid hormones|adrenal cortex hormones|thyroxine binding globulin inducers|bcrp/abcg2 inhibitors|drugs that are mainly renally excreted|estranes|estrogen contraceptives|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|hormonal contraceptives for systemic use|p glycoprotein substrates|cytochrome p 450 cyp1a2 inhibitors (strength unknown)|cytochrome p 450 cyp2c19 substrates|oct2 inhibitors|oatp1b1/slco1b1 inhibitors|cytochrome p 450 cyp3a7 substrates|estradiol, agonists|cytochrome p 450 enzyme inhibitors|estrogens|cytochrome p 450 substrates|contraceptive agents, female|cytochrome p 450 cyp2c9 substrates|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp1a2 inhibitors|oct1 inhibitors|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|estrenes|cytochrome p 450 enzyme inducers|steroids|hormones|estradiol congeners|cytochrome p 450 cyp1a2 substrates|gonadal hormones|ugt1a1 substrates|cytochrome p 450 cyp2c8 substrates
1,2 dichlorobenzene	insecticides|compounds used in a research, industrial, or household setting|hydrocarbons, halogenated|cytochrome p 450 cyp2e1 substrates|agrochemicals|hydrocarbons, chlorinated|cytochrome p 450 substrates|pesticides|benzene derivatives|toxic actions
nomegestrol acetate	norsteroids|adrenal cortex hormones|cytochrome p 450 cyp3a4 substrates|hormonal contraceptives for systemic use|fused ring compounds|antineoplastic agents, hormonal|norpregnanes|pregnanes|progesterone congeners|progestins|contraceptives, oral|cytochrome p 450 substrates|contraceptive agents, female|combination contraceptives (with estrogen and derivatives)|cytochrome p 450 cyp3a substrates|progestin contraceptives|steroids|pregnadienes
sb 269970	amides|sulfones|sulfur compounds|benzene derivatives
pentetic acid	acetates|acids, acyclic|compounds used in a research, industrial, or household setting|lead chelating activity|antidotes|fatty acids, volatile|fatty acids|protective agents|lead chelator|chelating agents|iron chelating agents|drugs that are mainly renally excreted|lipids|polyamines|sequestering agents|amines
clinafloxacin	topoisomerase inhibitors|anti bacterial agents|cytochrome p 450 cyp2c9 inhibitors (weak)|hypoglycemia associated agents|cytochrome p 450 cyp2d6 inhibitors (weak)|cytochrome p 450 cyp2c19 inhibitors (weak)|quinolines|cytochrome p 450 cyp2d6 inhibitors|cytochrome p 450 enzyme inhibitors|cytochrome p 450 cyp1a2 inhibitors (strong)|quinolones|enzyme inhibitors|anti infective agents|cytochrome p 450 cyp2c9 inhibitors|cytochrome p 450 cyp1a2 inhibitors|heterocyclic compounds, fused ring|cytochrome p 450 cyp2c19 inhibitors|topoisomerase ii inhibitors
palmitoylethanolamide	hormones, hormone substitutes, and hormone antagonists|agents producing tachycardia|sensory system agents|central nervous system agents|amines|analgesics|fatty acids|neurotransmitter agents|anti inflammatory agents|anti infective agents|analgesics, non narcotic|antirheumatic agents|peripheral nervous system agents|hormones|cannabinoids and similars|lipids|amino alcohols|alcohols
asiatic acid	terpenes|triterpenes
hycanthone	p glycoprotein inhibitors|heterocyclic compounds, fused ring|thioxanthenes|sulfur compounds|antiplatyhelmintic agents|xanthenes|anthelmintics|anti infective agents|antiparasitic agents|schistosomicides
lomerizine	membrane transport modulators|p glycoprotein inhibitors|cytochrome p 450 cyp3a substrates|agents causing hyperkalemia|cytochrome p 450 substrates|calcium regulating hormones and agents|antiarrhythmic agents|calcium channel blockers|cardiovascular agents|cytochrome p 450 cyp3a4 substrates|bradycardia causing agents
imidazolidinyl urea	increased histamine release|pharmaceutic aids|cell mediated immunity|standardized chemical allergen
il1a	amino acids, peptides, and proteins|peptides|intercellular signaling peptides and proteins|proteins|monokines|interleukin 1|interleukins|cytokines|biological factors
asiaticoside	terpenes|anti infective agents
catechin	benzopyrans|flavonoids|catechin|heterocyclic compounds, fused ring|pyrans|chromones|chromans
dimercaptosuccinic acid	chelating agents|compounds used in a research, industrial, or household setting|metal chelator
linoleic acid	fatty acids, omega 6|fatty acids, essential|linoleic acids|fatty acids|lipids|fatty acids, unsaturated
cardamonin	zingiberaceae|benzopyrans|flavonoids|propiophenones|pyrans|chromones|ketones|heterocyclic compounds, fused ring
tenofovir	organophosphorus compounds|hepatitis b virus nucleoside analog reverse transcriptase inhibitor|drugs that are mainly renally excreted|cytochrome p 450 cyp3a4 substrates|nephrotoxic agents|p glycoprotein substrates|organophosphonates|anti retroviral agents|nucleoside reverse transcriptase inhibitors|reverse transcriptase inhibitors|tenofovir and prodrugs|nucleic acid synthesis inhibitors|cytochrome p 450 substrates|human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor|enzyme inhibitors|anti infective agents|antiviral agents|heterocyclic compounds, fused ring|cytochrome p 450 cyp3a substrates|anti hiv agents|purines|oat3/slc22a8 substrates|cytochrome p 450 cyp3a4 substrates (strength unknown)
nadide	carbohydrates|nucleotides|purine nucleotides|ribonucleotides|enzymes and coenzymes|heterocyclic compounds, fused ring|glycosides|purines|coenzymes|nucleic acids, nucleotides, and nucleosides|adenine nucleotides
bfgf	amino acids, peptides, and proteins|peptides|intercellular signaling peptides and proteins|proteins|fibroblast growth factors|fibroblast growth factor 2, antagonists & inhibitors|biological factors
ginsenoside	carbohydrates|saponins|glycosides|terpenes|triterpenes
isoeugenol	increased histamine release|caffeic acids|acids, carbocyclic|cell mediated immunity|cinnamates|standardized chemical allergen
cobalt(ii) chloride	transition elements|compounds used in a research, industrial, or household setting|antimutagenic agents|protective agents|metals|elements|metals, heavy
hydrocortisone acetate	hormones, hormone substitutes, and hormone antagonists|adrenal cortex hormones|pregnenediones|cytochrome p 450 cyp2c8 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers|aerosols|cytochrome p 450 cyp3a4 substrates|fused ring compounds|11 hydroxycorticosteroids|corticosteroids|hydroxycorticosteroids|cytochrome p 450 cyp3a7 substrates|17 hydroxycorticosteroids|administration, topical|hydrocortisone and derivatives|anti inflammatory agents|pregnanes|cytochrome p 450 cyp2c8 inducers|cytochrome p 450 substrates|cytochrome p 450 cyp3a inducers|immunosuppressive agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|pregnenes|hormones|steroids
hydrocortisone phosphate	hormones, hormone substitutes, and hormone antagonists|adrenal cortex hormones|pregnenediones|cytochrome p 450 cyp2c8 inducers (strength unknown)|cytochrome p 450 cyp3a4 substrates|fused ring compounds|11 hydroxycorticosteroids|hydroxycorticosteroids|cytochrome p 450 cyp3a7 substrates|17 hydroxycorticosteroids|hydrocortisone and derivatives|pregnanes|cytochrome p 450 cyp2c8 inducers|cytochrome p 450 substrates|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 enzyme inducers|pregnenes|hormones|steroids
hydrocortisone valerate	hormones, hormone substitutes, and hormone antagonists|adrenal cortex hormones|pregnenediones|cytochrome p 450 cyp2c8 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|11 hydroxycorticosteroids|corticosteroids|hydroxycorticosteroids|cytochrome p 450 cyp3a7 substrates|17 hydroxycorticosteroids|hydrocortisone and derivatives|anti inflammatory agents|pregnanes|cytochrome p 450 cyp2c8 inducers|cytochrome p 450 substrates|cytochrome p 450 cyp3a inducers|immunosuppressive agents|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|pregnenes|hormones|steroids
loteprednol	androstenes|adrenal cortex hormones|anti inflammatory agents|steroids|androstanes|anti allergic agents|corticosteroids|sensory organs|ophthalmologicals|androstadienes|corticosteroid hormone receptor agonists|fused ring compounds
prednisolone hemisuccinate	cytochrome p 450 cyp3a5 inducers|hormones, hormone substitutes, and hormone antagonists|glucocorticoids|cytochrome p 450 cyp3a4 inducers (strength unknown)|adrenal cortex hormones|cytochrome p 450 enzyme inducers|hormones|pregnanes|steroids|corticosteroids|cytochrome p 450 cyp3a5 inducers (strength unknown)|pregnadienes|pregnadienetriols|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a4 inducers|fused ring compounds
isoflupredone acetate	steroids, fluorinated|steroids|pregnanes|pregnadienes|pregnadienetriols|fused ring compounds
lypressin	hormones, hormone substitutes, and hormone antagonists|amino acids, peptides, and proteins|antidiuretic agents|vasopressins|vasopressin and analogues|peptides|vasoconstrictor agents|posterior pituitary lobe hormones|cardiovascular agents|peptide hormones|coagulants|oligopeptides|hematologic agents|hemostatics|natriuretic agents|neuropeptides|nerve tissue proteins|hormones|proteins|pituitary and hypothalamic hormones and analogues|pituitary hormones, posterior|pituitary hormones|systemic hormonal preparations, excl. sex hormones and insulins
dexamethasone acetate	bsep/abcb11 inducers|bcrp/abcg2 inhibitors|cytochrome p 450 cyp2e1 inducers (strength unknown)|cytochrome p 450 cyp3a4 inhibitors (weak)|cytochrome p 450 cyp2c8 inducers (strength unknown)|cytochrome p 450 cyp3a5 inducers (moderate)|cytochrome p 450 cyp2b6 inducers (strength unknown)|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds|p glycoprotein inhibitors|p glycoprotein substrates|cytochrome p 450 cyp2a6 inducers|cytochrome p 450 cyp2c19 inducers|p glycoprotein inducers|cytochrome p 450 cyp2b6 inducers|cytochrome p 450 cyp3a7 substrates|steroids, fluorinated|cytochrome p 450 enzyme inhibitors|anti inflammatory agents|cytochrome p 450 cyp3a4 inhibitors|pregnanes|cytochrome p 450 cyp2c8 inducers|cytochrome p 450 substrates|cytochrome p 450 cyp3a7 inducers (strength unknown)|pregnadienetriols|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a inhibitors|cytochrome p 450 cyp3a4 inducers (moderate)|cytochrome p 450 cyp2e1 inducers|cytochrome p 450 cyp3a substrates|cytochrome p 450 cyp2c19 inducers (strength unknown)|cytochrome p 450 cyp3a5 substrates|cytochrome p 450 enzyme inducers|steroids|pregnadienes|cytochrome p 450 cyp3a7 inducers|cytochrome p 450 cyp3a5 inducers|oat3/slc22a8 substrates
chlorphenesin carbamate	alcohols|propylene glycols|glycols
cortisone	hormones, hormone substitutes, and hormone antagonists|corticosteroids for systemic use|adrenal cortex hormones|ophthalmologicals|cytochrome p 450 cyp3a4 inducers|fused ring compounds|corticosteroids|cytochrome p 450 cyp3a5 inducers (strength unknown)|hydroxycorticosteroids|corticosteroids for systemic use, plain|17 hydroxycorticosteroids|anti inflammatory agents|pregnanes|cytochrome p 450 cyp3a inducers|corticosteroid hormone receptor agonists|glucocorticoids|cytochrome p 450 cyp3a4 inducers (strength unknown)|cytochrome p 450 enzyme inducers|pregnenes|hormones|steroids|sensory organs|cytochrome p 450 cyp3a5 inducers|systemic hormonal preparations, excl. sex hormones and insulins
dextrorphan	neuroprotective agents|compounds used in a research, industrial, or household setting|excitatory amino acid antagonists|heterocyclic compounds, fused ring|phenanthrenes|central nervous system agents|alkaloids|protective agents|neurotransmitter agents|opiate alkaloids|morphinans|excitatory amino acid agents
pik3ca	
azd 6482	class ia phosphatidylinositol 3 kinase, antagonists & inhibitors|pyrimidines|acids, carbocyclic|benzene derivatives|benzoates|aminobenzoates
hydroquinidine	parasympatholytics|peripheral nervous system agents|antiarrhythmics, class i|heterocyclic compounds, fused ring|alkaloids|quinuclidines|antiarrhythmics, class ia|antiarrhythmic agents|cinchona alkaloids|autonomic agents|cardiac therapy|quinolines|cardiovascular agents
biochanin a	benzopyrans|flavonoids|hormones, hormone substitutes, and hormone antagonists|compounds used in a research, industrial, or household setting|anticarcinogenic agents|heterocyclic compounds, fused ring|hormones|protective agents|pyrans|antineoplastic agents|estrogens|estrogens, non steroidal|chromones|isoflavones|phytoestrogens
xanthohumol	benzopyrans|pyrans|chromones|ketones|heterocyclic compounds, fused ring
bms 754807	
eticlopride	amides|dopamine agents|neurotransmitter agents|dopamine antagonists
prednisolone acetate	cytochrome p 450 cyp3a substrates|p glycoprotein substrates|cytochrome p 450 cyp3a4 inducers (strength unknown)|anti inflammatory agents|adrenal cortex hormones|cytochrome p 450 enzyme inducers|pregnanes|steroids|prodrugs|corticosteroids|cytochrome p 450 substrates|pregnadienes|pregnadienetriols|cytochrome p 450 cyp3a inducers|cytochrome p 450 cyp3a4 inducers|cytochrome p 450 cyp3a4 substrates|fused ring compounds
luteolin	benzopyrans|flavonoids|heterocyclic compounds, fused ring|flavones|pyrans|chromones
ursolic acid	anti inflammatory agents, non steroidal|antineoplastic agents, phytogenic|peripheral nervous system agents|anti inflammatory agents|sensory system agents|central nervous system agents|analgesics|antineoplastic agents|terpenes|enzyme inhibitors|anti infective agents|analgesics, non narcotic|antirheumatic agents|cyclooxygenase inhibitors
aminopentamide	benzene derivatives
tff2	peptides|amino acids, peptides, and proteins|trefoil factors
chlormadinone acetate	hormones, hormone substitutes, and hormone antagonists|hormone antagonists|adrenal cortex hormones|pregnanes|reproductive control agents|steroids|contraceptives, oral, synthetic|hormonal contraceptives for systemic use|contraceptives, oral|contraceptive agents, female|pregnadienes|antiandrogens|steroids, chlorinated|fused ring compounds
anethole	food ingredients|phenols|compounds used in a research, industrial, or household setting|food additives|methyl ethers|pharmaceutic aids|ethers|benzene derivatives|food|phenyl ethers|diet, food, and nutrition|pharmaceutical preparations|physiological phenomena|food and beverages|flavoring agents
carbaryl	insecticides|acids, acyclic|cholinergic agents|compounds used in a research, industrial, or household setting|cholinesterase inhibitors|agrochemicals|carbamates|enzyme inhibitors|pesticides|neurotransmitter agents|toxic actions|naphthalenes
clemizole	heterocyclic compounds, fused ring
strychnine	central nervous system stimulants|compounds used in a research, industrial, or household setting|indoles|heterocyclic compounds, fused ring|poisons|central nervous system agents|alkaloids|glycine agents|indole alkaloids|neurotransmitter agents|convulsants|noxae|toxic actions|secologanin tryptamine alkaloids
desoxycortone	hormones, hormone substitutes, and hormone antagonists|corticosteroids for systemic use|systemic hormonal preparations, excl. sex hormones and insulins|adrenal cortex hormones|pregnanes|hormones|pregnenediones|pregnenes|steroids|corticosteroids|hydroxycorticosteroids|mineralocorticoids|corticosteroids for systemic use, plain|fused ring compounds
homochlorcyclizine	piperazines
nifekalant	cardiovascular agents|antiarrhythmic agents|pyrimidines
levosulpiride	amides|nervous system|benzamides and benzamide derivatives|antipsychotic agents|acids, carbocyclic|central nervous system depressants|benzene derivatives|benzoates|psycholeptics
bi 2536	antimitotic agents|heterocyclic compounds, fused ring
tak 715	amides|p38 mitogen activated protein kinases, antagonists & inhibitors|tumor necrosis factor alpha (tnf α) inhibitors|acids, carbocyclic|sulfur compounds|benzene derivatives|benzoates
